DNA Methylation in Rectal Cancer by Dbeis, Rachel
	 1	
	
DNA Methylation in Rectal 
Cancer: A Genome Wide Study 
 
 
Rachel Dbeis 
 
 
Submitted by Rachel Dbeis to the University of Exeter 
as a thesis for the degree of Masters by Research in 
Medical Studies (MbyRes), July 2017 
 
 
This thesis is available for Library use on the understanding that it is copyright 
material and that no quotation from the thesis may be published without proper 
acknowledgement.  
 
 
 
I certify that all material in this thesis which is not my own work has been identified 
and that no material has previously been submitted and approved for the award 
of a degree by this or any other University.  
 
 
 
 
Signature:  
	 2	
Abstract 
Rectal cancer differs from colon cancer in terms of its underlying biological 
behaviour, clinical course, genetic and epigenetic aetiology. Epigenetic 
mechanisms modify gene expression independently of DNA sequence. DNA 
methylation is the most studied epigenetic mechanism, known to play a role in 
colorectal cancer. The role of DNA methylation specific to rectal cancer 
however, is poorly understood. Here we present the results from a DNA 
methylation study of 45 individuals with rectal cancer.  
A total of 45 patients (>18 years) diagnosed with rectal adenocarcinoma (stages 
II and III) who underwent or were undergoing treatment were recruited. Matched 
rectal tumour and adjacent normal mucosal samples (n=90) were obtained from 
each patient and processed fresh frozen (n=32) or embedded in paraffin (n=58). 
DNA was extracted and checked for quality and quantity, treated with sodium 
bisulfite and run on the Illumina Infinium HumanMethylation 450 Beadchip. Only 
samples that passed the Quality Control were subsequently analysed (n=30).  
A combined linear regression analysis of all 408,652 probes showed that global 
levels of DNA methylation are decreased in rectal cancer samples compared 
with normal unaffected samples. In total, 176 differentially methylated probes 
and 828 differentially methylated regions were identified in rectal cancer vs 
normal tissue. All the genes identified underwent gene ontology analysis to 
assess whether they are biologically meaningful. 
In summary, our study focused on the discovery of de novo epigenetic changes 
associated with rectal cancer, using a genome wide approach and novel 
bioinformatics approaches. These findings improve our understanding of the 
epigenetics of this disease. Furthermore, they have the potential to be used as 
biomarkers for detection, prognosis and monitoring treatment response in 
patients with rectal cancer. 
 
The work presented in this thesis was funded by the Jean Shanks Foundation, the Royal 
College of Surgeons and Bowel Cancer West.  
Approximate word count: 38,000  
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1.1 THE COLON 
1.1.1 Anatomy: 
The large intestine is divided into the caecum, colon, rectum and anal canal. 
The colon extends superiorly from the caecum and is subdivided into four parts: 
the ascending, transverse, descending and sigmoid colon (Warwick et al., 1985) 
(Figure 1.1). The blood supply to the proximal colon arises from the superior 
mesenteric artery, whereas the distal colon gets its blood supply from the 
inferior mesenteric artery. The proximal and distal divide is marked by the 
splenic flexure, situated at the junction of the transverse and descending parts 
of the colon, where the anastomosis between the two vascular territories occurs 
(Warwick et al., 1985).  
 
 
The extrinsic and the intrinsic nerves supply colonic innervation. Extrinsic 
innervation involves the sympathetic and parasympathetic pathways, which are 
responsible for colonic motility and sensation. Intrinsic innervation arises from 
the poorly understood enteric nervous system (Szmulowicz and Hull, 2011). 
The parasympathetic supply to the proximal colon arises from the vagus nerve 
whereas fibres from S2-S4 innervate the distal colon and the rectum (Li and Lai, 
2009, Szmulowicz and Hull, 2011). 
	 18	
 
Figure 1.1 The large intestine. This picture shows the different parts of the 
large intestine and its anatomical subdivisions. Adapted from Blausen (2014). 
 
 
1.1.2 Physiology and function: 
Absorption of nutrients and water along with faecal storing are the main 
functions of the colon (Li and Lai, 2009). Various complex carbohydrates and to 
a lesser extent proteins, are processed in the proximal segment of the colon, 
where nutrients from these products are salvaged via fermentation. The residual 
products of fermentation and dietary fats that reach the colon are then expelled 
with the stool (Szmulowicz and Hull, 2011). The enteric nervous system is 
responsible for colorectal contraction and is under the influence of gut 
hormones. The varying circulating concentrations of these hormones affect the 
contractile activity. For example, after meals, the motility of the colon rises 
	 19	
considerably due to cholecystokinin secretion, whereas sleep reduces colonic 
activity and a high fibre diet helps to retain water and increase the faecal bulk, 
thus aiding in defecation (Irving and Catchpole, 1992). 
The colon is also integral to maintaining appropriate hydration and electrolyte  
balance through absorption and secretion of water and electrolytes. Sodium and 
water absorption are greatest in the caecum and decrease progressively 
towards the rectum. The majority of colonic activity is centred on promoting the 
salvage of water and electrolytes. Periodically this activity shifts to allow for 
expulsion of stool through colonic contractions (Szmulowicz and Hull, 2011). 
Figure 1.2 illustrates some of the physiological functions of the colon.  
 
 
Figure 1.2 Physiological functions of the colon. Adapted from Mulroney 
and Myers (2015). 
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1.2 Colorectal Cancer 
1.2.1 Epidemiology 
Colorectal cancer (CRC) is any cancer that starts in the colon or the rectum. It is 
the second leading cause of cancer-related death in the USA (Siegel et al., 
2017) and one of the most common cancers in the United Kingdom (U.K.) after 
lung and breast (NICE, 2014). The incidence of the disease is increasing 
globally, with over one million new cases diagnosed worldwide and 
approximately 40,000 new cases registered in the U.K. yearly (NICE, 2014, 
Siegel et al., 2017). By gender worldwide, CRC is the second most common 
cancer in women (9.2%) and the third in men (10%) (IARC, 2014). The 
occurrence of CRC is strongly correlated with age, with approximately three 
quarters of cases occurring in people aged 65 years or older (NICE, 2014). The 
median age of diagnosis in 70 years in developed countries (Siegel et al., 
2017). The prognosis of CRC is slowly improving with improvements in care. 5-
year relative survival has reached almost 65% in high-income countries but 
remains less than 50% in low-income countries. Stage at diagnosis remains the 
most important prognostic factor (Brenner et al., 2014). There isn’t a single risk 
factor that accounts for most cases of CRC, but several risk factors have been 
identified such as: family history of CRC, obesity, excessive alcohol 
consumption, inflammatory bowel disease, smoking, high consumption of red 
meat and diabetes. Preventative factors include Aspirin, physical activity and 
hormone replacement therapy (Brenner et al., 2014). 
 
1.2.2 Aetiology 
1.2.2.1 Histology 
On a cellular level, CRC is thought to originate in multi-potential stem cells 
found in the intestinal crypts. These stem cells reside at the base of the 
intestinal glands and give rise to 'transient-amplifying' cells (that become 
increasingly differentiated with successive rapid divisions, finally giving rise to 
terminally differentiated cells). At the mouth of the crypts, these cells 
differentiate into three types: goblet, enteroendocrine and Paneth cells. These 
differentiated cells eventually undergo apoptosis to the lumen after 3-5 days. 
Any imbalance in the proliferation, differentiation or apoptosis process within the 
crypts can lead to aberrant crypt foci, which may progress to adenoma 
	 21	
(Hammoud et al., 2013). The histological progression of these mucosal cells 
from benign adenomas to malignant carcinomas is characterised by underlying 
genetic and epigenetic alterations, affecting oncogenes, tumour suppressor 
genes and DNA repair genes (Coppedè, 2014). The initiation and progression 
of CRC is therefore considered a multistep tumourigenesis process known as 
the adenoma-carcinoma sequence (Fearon, 2011).  
 
1.2.2.2 Genetics  
Sporadic CRCs, which are likely due to random mutations and devoid of any 
familial or inherited predisposition, account for approximately 70% of all CRC 
cases. The second type of CRC is the familial type. In affected families, CRC 
develops too frequently to be considered sporadic, but does not follow a pattern 
consistent with an inherited syndrome. The third type is the inherited genetic 
CRCs, which include: familial adenomatous polyposis (FAP), Gardner 
Syndrome (a variant of FAP), attenuated FAP (aFAP), Lynch syndrome 
(hereditary non-polyposis colorectal cancer or HNPCC), MUTYH-associated 
polyposis (MAP). The rarer ones include hamartomatous polyposis conditions 
(Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS) and others) 
and hyperplastic polyposis (Migliore et al., 2011, Coppedè, 2014, Nojadeh et 
al., 2018, Lee et al., 2014). CRC is therefore considered a heterogeneous 
malignancy with several subtypes, each characterised by different genetic, 
cytogenetic and epigenetic changes (Migliore, 2011, Perea et al., 2015).  
 
1.2.2.3 Cytogenetics 
Genomic instability is considered a key hallmark in CRC. There are three 
recognised major molecular subtypes: the chromosomal instability (CIN) 
pathway, the microsatellite instability (MSI) pathway and the recently identified 
epigenetic CpG island methylator phenotype (CIMP) (Lengauer et al., 1997, 
Toyota et al., 1999, Migliori, 2011, Perea et al., 2015).  
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The CIN pathway 
CIN is the most common type of genomic instability, occurring in 80%-85% of 
CRCs (Grady and Carethers, 2008). CIN refers to an accelerated rate of gains 
or losses – in large portions or in whole chromosomes – that leads to variability 
in the karyotypes of cells. This causes an imbalance in chromosome number 
and a high frequency of loss of heterozygosity. The mechanisms underlying CIN 
include telomere dysfunction, alterations in chromosome segregation and DNA 
damage response (Marmol et al., 2017). CIN tumours are characterised by 
mutations in tumour suppressor genes and oncogenes that activate pathways 
critical for CRC initiation and progression (Lengauer et al., 1997, Migliori, 2011). 
 
The MSI pathway  
Microsatellites are stretches of repetitive DNA sequences, which are normally 
stable. MSI (or replication error positive RER+), the second major pathway, is 
defined as a relatively frequent change of the length of these loci, due to either 
insertion or deletion of repeated units (Wheeler, 2005). This change makes 
them prone to slippage during DNA replication, resulting in a small loop in either 
the template or the DNA strand. This is usually repaired under normal 
conditions. However, in the absence of efficient mismatch repair function, the 
‘loops’ may become permanent and alleles of different sizes will propagate at 
subsequent rounds of replication. If a cancer has silenced or mutated mismatch 
repair genes, then different sized alleles will accumulate over several 
generations. MSI is seen when such alleles are formed relatively frequently at 
microsatellite loci in tumour DNA compared with normal DNA (Wheeler, 2005). 
DNA mutations in mismatch repair genes are found in all HNPCC (Lynch 
syndrome) contributing to MSI (Grady and Carethers, 2008, Aaltonen, 1993).  
 
The CIMP Pathway 
Epigenetic instability, which is responsible for the CIMP, is also thought to play 
a part in CRC carcinogenesis. CIMP tumours are characterised by 
hypermethylation or hypomethylation of oncogene promoters, leading to genetic 
silencing and loss of protein expression (Marmol et al., 2017, Migliori, 2011). 
The CIMP pathway is explored further in Section 1.6.3.2.  
 
	 23	
1.2.3 Symptoms and clinical presentation 
Patients with CRC may present in three different ways: 1) suspicious symptoms 
and signs 2) asymptomatic individuals discovered through routine screening 
and 3) emergency admission with acute intestinal obstruction, peritonitis or 
gastrointestinal bleed (Macrae and Bendell, 2017). Most CRCs (70-90% of all 
cases) are diagnosed after the onset of symptoms, the most frequent of which 
being: rectal bleeding, abdominal pain, anaemia or a change in bowel habit 
(Hamilton et al., 2013, Macrae and Bendell, 2017). Change in bowel habits, due 
to the progressive narrowing of the bowel lumen by tumour, is a more common 
symptom of left sided cancers. However, the majority of CRC patients who 
present with iron deficiency anaemia are more commonly found to have right-
sided lesions (Kanellos et al., 2004, Thrumurthy et al., 2016). Abdominal pain 
can occur with tumours arising at all sites, due to partial obstruction, peritoneal 
dissemination or intestinal perforation. Patients may also present with 
symptoms of metastatic disease related to the any of metastatic sites of CRC, 
such as the lung, liver and peritoneum (Macrae and Bendell, 2017) 
 
 
1.2.4 Diagnosis, staging and grading  
Diagnosis 
Colonoscopy is still the most accurate test for CRC screening and diagnosing. 
The National Institute for Health and Care Excellence (NICE) recommends 
offering a colonoscopy to patients without major comorbidity to confirm the 
diagnosis of CRC (Poston et al., 2011, NICE, 2014). A biopsy of any suspicious 
lesions is then taken during the procedure for histological proof of malignancy. 
Histologically, the majority of cancers arising in the colon and rectum are 
adenocarcinoma (Macrae and Bendell, 2017). If a cancer is detected, complete 
visualisation of the whole colon is required pre or post-operatively, as 
synchronous cancers occur in 5% of patients. Computed Tomography (CT) 
colonography (CTC) is offered in circumstances where colonoscopy cannot be 
completed, or where the patient expresses a preference not to undergo invasive 
diagnostic tests. CTC still requires significant bowel preparation and may not be 
suitable for patients with extensive comorbidities (Poston et al., 2011, Macrae 
and Bendell, 2017, Thrumurthy et al., 2016). In cases of major comorbidities or 
in elderly frail patients, conventional colonic imaging tests may be difficult to 
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perform due to immobility and poor tolerance of the bowel preparation. In such 
cases, minimal preparation plain CT is considered (Mahmoud et al., 2017). A 
plain CT of the abdomen (without prior bowel preparation) has a sensitivity of 
88% to 94% for detection of colon cancer (Kealey et al., 2017). 
 
Staging 
Staging of the disease and complete visualisation of the colon are required 
once the diagnosis of CRC is made. All patients are offered enhanced CT scan 
of the chest, abdomen and pelvis to estimate the stage of the disease. All 
patients with rectal cancer are offered MRI to assess the risk of local recurrence 
(Poston et al., 2011) (see Section 1.4.4). The TNM system for tumour (T), node 
(N) and metastases (M) represents the stages of CRC progression. These 
stages are then combined into an overall stage definition, which guides 
therapeutic decisions (Brenner et al., 2014). TNM is the staging system that is 
most commonly used, as defined by the American Joint Committee on Cancer 
(AJCC) (Edge et al., 2010). It describes the depth of invasion through the bowel 
wall, the extent of the involvement of nearby lymph nodes and the presence or 
absence of distant metastases (Migliore et al., 2011) (Figure 1.3). Clinicians 
also still use the Dukes’ staging system: named after Cuthbert Dukes who, in 
1929, proposed a classification designed to represent a step wise progression 
of local and regional invasion by rectal cancer. The classification has been 
modified on several occasions to increase its prognostic value, with the 
commonly used modification produced by Astler and Coller (1954, Mahmoud et 
al., 2017). Table 1.1 and Table 1.2 describe the AJCC, Dukes’ and modified 
Dukes’ staging systems. 
 
Grading 
CRC can be graded according to the cancer cell differentiation into four different 
categories: grade 1 (low grade) if the cancer cells are well differentiated, grade 
2 (moderate grade) if the cancer cells are moderately differentiated, grade 3 
(high grade) if the cancer cells are poorly differentiated and grade 4 
(high grade) for undifferentiated cells (Figure 1.4). Histological grade is 
considered a stage-independent prognostic factor in CRC, with high tumour 
grade associated with adverse prognosis (Compton, 2003).  
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Figure 1.3 The illustrated stages of colorectal cancer. This picture shows 
different tumour sizes and invasion of anatomical layers of the large intestine. 
Adapted from the National Cancer Institute, illustrator Terese Winslow (2005). 
 
 
 
Figure 1.4 Differentiation states of colorectal cancer. Grade 1 (G1), Grade 2 
(G2) and Grade 3 (G3) show the grading states during tumour genesis and H 
represents histological sample of healthy colon with normal cells. Adapted from 
Kuepper et al. (2016). 
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T for Tumour: How far the main/primary tumour has grown into the 
wall of the rectum 
 
Tx: primary tumour cannot be assessed 
T0: no evidence of primary tumour 
Tis: carcinoma in situ: intraepithelial or invasion of lamina propria 
T1: tumour invades submucosa 
T2: tumour invades muscularis propria 
T3: tumour invades through the muscularis propria into the subserosa or 
into non-peritonealised peri-rectal tissues 
T3a: tumour extends <1 mm beyond muscularis propria 4 
T3b: tumour extends 1-5 mm beyond muscularis propria 4 
T3c: tumour extends 5-15 mm beyond muscularis propria 4 
T3d: tumour extends 15 mm beyond muscularis propria 4 
T4: tumour invades directly into other organs or structures and/or 
perforates visceral peritoneum 
T4a: tumour penetrates to the surface of the visceral peritoneum 
T4b: tumour directly invades or is adherent to other organs or structures 
 
N describes the extend of the spread to regional (nearby) lymph 
nodes 
Nx: regional nodes not assessed 
N0: no regional lymph nodes 
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    Table 1.1 TNM classification of colorectal cancer (Edge et al., 2010). 
 
 
 
 
 
 
 
 
N1: metastasis in 1-3 regional (peri-rectal) lymph nodes 
N1a: metastasis in one regional lymph node 
N1b: metastasis in 2-3 regional lymph nodes 
N1c: tumour deposit(s) in the subserosa, mesentery, or non-
peritonealised pericolic or perirectal tissues without regional nodal 
metastasis 
N2: metastasis in 4 or more regional lymph nodes 
N2a: metastasis in 4-6 regional lymph nodes 
N2b: metastasis in 7 or more regional lymph nodes 
 
M describes whether there is spread to other parts of the body – 
Metastases 
Mx: cannot be assessed 
M0: no distant metastasis 
M1: distant metastasis 
M1a: metastasis confined to one organ or site (for example, liver, lung, 
ovary, non-regional node) 
M1b: metastases in more than one organ/site or the peritoneum 
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AJCC Stage TNM Classification DUKE’S MAC* 
    
0 Tis               N0                    M0 - - 
I 
 
T1                N0                    M0 A A 
T2                N0                    M0 A B1 
IIA T3                N0                    M0 B B2 
IIB T4a              N0                    M0 B B2 
IIC T4b              N0                    M0 B B3 
IIIA T1-T2           N1/N1c             M0 C C1 
T1                N2a                  M0 C C1 
IIIB T3-T4a         N1/N1c             M0 C C2 
T2-T3           N2a                  M0 C C1/C2 
T1-T2           N2b                  M0 C C1 
IIIC T4a              N2a                  M0 C C2 
T3a-T4a       N2b                  M0 C C2 
T4b              N1-N2              M0 C C3 
IVA Any T          Any N              M1a - - 
IVB Any T          Any N              M1b - - 
 
 
 
Table 1.2 Colon cancer anatomic stage and prognostic groups. According 
to the AJCC Staging, TNM classification, Dukes’ and Astler-Coller 
classifications. (Edge et al., 2010, Astler and Coller, 1954, Mahmoud et al., 
2017).  
*Modified Astler-Coller classification 
 
 
1.2.5 Treatment and prognosis 
CRC survival is correlated with stage at the time of diagnosis. The 5-year 
survival rates are 82.9% for early stage disease and 64.4% for late stage 
disease (Tsikitis et al., 2009). The curative treatment options available at 
present for high-risk colorectal tumours is complete surgical excision with 
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adjuvant (postoperative) therapy (Morley-Bunker et al., 2016) or a long course 
of chemoradiotherapy (CRT). In colon cancer surgery, the tumour and 
corresponding lymph nodes are removed. The extent and type of surgery is 
determined by the tumour localisation and the supplying blood vessels. For 
patients who have undergone a potentially curative resection of colon cancer, 
the goal of adjuvant chemotherapy is to reduce disease recurrence rate and 
increase cure rate by eradicating micro-metastases (Rodriguez-Bigas and 
Grothey, 2017). Despite this, a significant proportion of patients with stage II 
and stage III CRC suffer recurrence, with risk of recurrence ranging between 
15-50% (Brenner et al., 2014).  Adjuvant chemotherapy is recommended to 
patients with stage III colon cancers after surgical resection (Brenner et al., 
2014), however, the risk of toxicity may increase in older patients and those with 
comorbidities, therefore the benefits of the therapy vs the risks should be 
considered in these cases. A Cochrane review (Figueredo et al., 2008) looking 
at adjuvant therapy for completely resected stage II colon cancer showed that 
chemotherapy improves Disease Free Survival (DFS) but had no effect on 
Overall Survival (OS). Therefore, adjuvant chemotherapy in Stage II is only 
recommended for patients with high risk of relapse (Brenner et al., 2014) but is 
usually discussed with individual patients. Most adjuvant chemotherapy involves 
a combination of several drugs, given intravenously in a specific timeline and 
order. A six-month course of Oxaliplatin containing regime is usually 
recommended for the majority of patients (Rodriguez-Bigas and Grothey, 2017). 
The benefits of Oxaliplatin however are controversial in the elderly and 
chemotherapy regimens are continuously evolving. Data for the role of 
neoadjuvant (preoperative) therapy in colon cancer is rare. A recent pilot study 
showed that preoperative chemotherapy was feasible for patients with locally 
advanced tumours (FOxTROT, 2012), however further validation in larger 
cohorts is needed for definitive conclusions. Similarly, adjuvant radiation 
therapy is not considered a routine component of treatment for patients with 
completely resected colon cancer.  
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1.3 THE RECTUM 
1.3.1 Anatomy  
Anatomical landmarks of the rectum are important for tumour staging, grading 
and treatment planning. The rectum is the direct continuation of the sigmoid 
colon and commences at the level of S2-S3. The rectum starts at the recto-
sigmoid junction (Mahadevan, 2017) and ends distally at the muscular anorectal 
ring or junction, which is situated 4 cm anterior to the tip of the coccyx (Jorge 
and Habr-Gama, 2014). The upper third of the rectum in located 
intraperitoneally, the middle third is partly located in the peritoneum and the 
lower third (the ampulla) lies in the extraperitoneal plane (Salerno et al., 2006). 
The rectum measures 15-20 cm in total length in adults depending upon 
definitions used. Located in the narrow pelvis, it is surrounded by numerous 
vital structures such as large vessels, nerves, bladder, internal genital organs 
and sacrum (Tamas et al., 2017). Fibres from S2-S4 innervate the rectum whilst 
branches from the inferior mesenteric arteries provide its blood supply (Li and 
Lai, 2009). The venous drainage of the upper rectum carries blood via the 
superior rectal vein to the inferior mesenteric vein to enter the portal venous 
system. The mid and lower rectum drains via the inferior rectal veins, which 
drain into the internal iliac veins then the inferior vena cava (Mahadevan, 2017). 
This distinction is important for clinical presentations of metastatic rectal cancer.  
The rectum is directly surrounded by a layer of fat along its length, known as the 
perirectal fat. A distinct circumferential layer, known as the fascia propria of the 
rectum, surrounds the perirectal fat. The fascia propria is an extension of the 
pelvic fascia and it encloses the rectum, perirectal fat, nerves, blood, lymph 
nodes and lymphatic vessels (Jorge and Habr-Gama, 2014). The fascia propria 
with its contents along with the perirectal fat is known as the mesorectum 
(Mahadevan, 2017). Most of the rectum is surrounded by the mesorectum. This 
is an important anatomical landmark as the mesorectum or mesorectal fascia 
forms the circumferential resection margin (CRM) in rectal cancer surgery 
(MERCURY, 2006) (Figure 1.5). 
The visceral fascia that surrounds the mesorectum is reflected on the parietal 
pelvic fascia at the level of the pelvic floor. Loose connective tissue provides an  
	 31	
interface between the visceral and parietal fasciae, which facilitates dissection 
and forms bloodless cavities filled with air. This forms the surgical plane of 
rectal surgery (Salerno et al., 2006) (Figure 1.6). 
 
 
 
Figure 1.5 Rectal anatomy and important landmarks for rectal cancer 
treatment. Adapted from Apgar et al (2008). 
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Figure 1.6 Anatomical surgical plane for rectal surgery. Adapted from 
Kuipers et al. (2015). 
 
1.3.2 Differences between the rectum and colon 
The colon and the rectum have different embryonic origins: the rectum arises 
from the hindgut and the colon from the midgut (Tamas et al., 2017, Li and Lai, 
2009). Cancers arising from these two different locations in the large bowel 
therefore have distinctive features. From an anatomical perspective, the 
proximal and distal colons are located within the peritoneal cavity whilst the 
rectum lies within the pelvis, the location of which is not easily accessible (Li 
and Lai, 2009). Differences between adult proximal colonic mucosa and rectal 
mucosa have also been reported for the expression of glycoconjugates. Rectal 
mucosa expresses acidic mucin whilst proximal colonic mucosa expresses 
neutral mucin (Iacopetta, 2002).  
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Additionally, the rectum and colon are exposed to different faecal matter and 
serve different functions. The faecal matter in the rectum is more concentrated 
than in the colon. Furthermore, as undigested matter travels through the colon it 
becomes progressively more coated with alkaline mucus (Wei et al., 2004). This 
means that there are varying levels of pH between the rectum and colon that 
create varying environments, making the rectum more susceptible to different 
environmental and risk factors than other parts of the colon.  
 
 
1.4 Rectal Cancer 
1.4.1 Epidemiology  
Rectal cancer is defined as a tumour with its lower edge within 15 cm from the 
anal verge (Brown and Daniels, 2005, MERCURY, 2006). For most 
epidemiological studies, rectal cancers have been considered as part of CRCs 
(see Section 1.2). Rectal cancers account for one third of all colorectal 
malignancies, which in 2008 corresponded to approximately 450,000 new cases 
worldwide and 15,000 in the UK (Tamas et al., 2017). They are the second 
most common cancers in the large intestine after proximal colon cancers 
(Siegel et al., 2017). There is a male predominance for the disease worldwide 
(30-50% higher than in women) (Tardivo et al., 2005). The risk increases with 
age, with 70 years being median age at diagnosis in most European countries 
(Glimelius et al., 2013).  
1.4.2 Aetiology  
Rectal cancer has largely been studied under the banner of CRC with the two 
combined as one entity. Hence, its aetiology is similar to that of CRC (Section 
1.2.2). The molecular pathways involved in the aetiology of this disease were 
highlighted in Section 1.2.2.3. The two main genetic syndromes, FAP and 
HNPCC or Lynch syndrome, constitute the inherited form of CRC and therefore 
rectal cancer. FAP is associated with mutations in the adenomatous polyposis 
coli (APC) tumour suppressor genes, whilst HNPCC results from inactivating 
mutations in DNA mismatch repair genes. In patients with FAP, tumours 
develop in the distal colon in approximately 60% of cases and in the rectum in 
25% (Tamas et al., 2017). As for patients with HNPCC, 55% of tumours are 
present in the proximal colon and 15% in the rectum.  
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1.4.3 Symptoms and clinical presentation 
Rectal bleeding is the most common presentation of rectal cancer. In later 
stages, symptomatic patients may present with: tenesmus, rectal pain, 
diminished calibre of stools, incomplete stool evacuation, cramping, pelvic pain 
and even obstructive symptoms (Macrae and Bendell, 2017, Fazeli and 
Keramati, 2015). Adjacent soft tissue organ invasion can occur into the uterus, 
vagina, anal sphincter complex, bladder, prostate, sigmoid colon or small bowel 
and rarely into the sacrum (Salerno et al., 2006). Patients suffering with 
metastatic cancer may present with symptoms related to their sites of 
metastases. In rare situations, rectal cancer can present as an emergency with 
intestinal obstruction, acute gastrointestinal bleeding or peritonitis if the tumour 
perforates the peritoneal cavity. Other rare presentations include fistula 
formation into adjacent organs, bacteraemia or sepsis (Macrae and Bendell, 
2017). 
 
 
1.4.4 Diagnosis, staging and grading  
Diagnosis and Staging  
Rectal cancer staging defines the local and distant extent of the disease (Wu, 
2007). Exact local staging at the time of diagnosis is essential and is the basis                                              
for determining whether a patient undergoes neoadjuvant treatment (Brenner et 
al., 2014). Similar to CRC, all patients are offered enhanced CT scan of the 
chest, abdomen and pelvis (see Section 1.2.4).  
Endoscopic ultrasonography is accurate for determining the T stage of the 
disease and is the method of choice for regional tumours or early (T1 or T2) 
rectal tumours (Wu, 2007). For more advanced rectal cancers, the CRM, the 
integrity of the mesorectal fascia (MRF) and the remaining lateral and inferior 
borders of the mesorectum are important landmarks for staging purposes. 
Although not included in the TNM staging system (Section 1.2.4), local tumour 
staging in rectal cancer currently includes tumour proximity to the MRF along 
with depth of tumour penetration and lymph node metastases (Kosinski et al., 
2012). 
The ability to identify these parameters by dedicated pelvic MRI as well as 
predicting the degree of extramural vascular invasion (EMVI), was the basis for 
the Magnetic Resonance Imaging and Rectal Cancer European Equivalence 
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(MERCURY) trial (MERCURY, 2006). Following the MERCURY study, MRI 
(thin section, high resolution, phased array coil MRI of the pelvis) became the 
preferred method for T3 and T4 tumours. Table 1.3 compares the T staging 
criteria of the AJCC vs MERCURY trial for rectal cancer. 
The risk of local recurrence is also assessed using MRI as determined by 
anticipated resection margin, tumour and lymph node staging which is offered to 
all patients unless there is contraindication (Poston, 2011), and should be done 
prior to neoadjuvant therapy as the changes induced by radiation make local 
staging less reliable (Brenner, 2014).  
 
Grading 
The grading of rectal tumours is similar to that of CRCs (see Section 1.2.4). 
Histopathological examination should include surgical specimen with proximal, 
distal and circumferential margins, regional lymph nodes and vascular invasion. 
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 AJCC T CATEGORY 
CRITERIA 
MERCURY TRIAL "T" STAGING 
CRITERIA 
Tis In situ carcinoma No corresponding value. 
T0 No evidence of viable tumour 
cells. 
No evidence of primary tumour. 
 
T1 
 
Tumour invades submucosa 
Tumour invades submucosa. Low 
signal in submucosal layer or 
replacement of submucosal layer by 
abnormal signal not extending into 
circular muscle layer. 
 
 
 
T2 
 
 
 
Tumour invades into but not 
through 
muscularis propria. 
Tumour invades into but not through 
muscularis propria. Intermediate 
signal intensity (higher signal than 
muscle, lower signal than 
submucosa) in muscularis propria; 
outer muscle coat replaced by 
tumour of intermediate signal 
intensity that does not extend 
beyond outer muscle into perirectal 
fat. 
 
T3 
 
Tumour invades through 
muscularis 
propria into 
mesorectal/subserosal fat. 
Tumour invades through muscularis 
propria into mesorectal/subserosal 
fat. Broad-based bulge or nodular 
projection (not fine spiculation) of 
intermediate signal intensity 
projecting beyond outer muscular 
coat 
T3a No equivalent category Tumour extends < 1 mm beyond 
muscularis propria 
T3b No equivalent category Tumour extends 1 to 5 mm beyond 
muscularis propria 
T3c No equivalent category Tumour extends > 5 - 15 mm beyond 
muscularis propria 
T3d No equivalent category Tumour extends > 15 mm beyond 
muscularis propria 
 
T4 
  Tumour invades other organs. 
Extension of abnormal signal into 
adjacent organ; extension of tumour 
signal through peritoneal reflection. 
 
T4a 
Tumour involves serosal 
surface. 
No equivalent category 
 
T4b 
Tumour invades adjacent 
structures/organs. 
See T4 
 
Table 1.3 AJCC vs MERCURY trial for T staging criteria in rectal cancer 
(Sizer et al., 2006, Beets-Tan et al., 2001, Kosinski et al., 2012).  
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1.4.5 Treatment and prognosis 
1.4.5.1 Introduction 
In recent decades, improved surgical techniques, advances in imaging and the 
introduction of radiotherapy (RT) and chemotherapy have led to improvements 
in loco-regional control of rectal cancer, but not in survival (Glimelius et al., 
2012). The goal in rectal cancer treatment therefore is to optimise DFS and OS 
whilst minimising the risk of local recurrence and metastases and avoiding 
treatment toxicity from radiation and systemic therapy (Schrag, 2013, Biondo et 
al., 2016). Choosing the optimal treatment depends on the risk of local 
occurrence, the tumour status (T), the nodal status (N) and the surgical CRM 
(Tamas et al., 2017). The treatment is based on surgery, chemotherapy and RT 
in different time frames (Petersen et al., 2012, DeSantis et al., 2014, Biondo et 
al., 2016). 
Disagreements and controversies arise when trying to categorise rectal cancer 
into distinct groups for treatment purposes. Prior to the introduction of MRI 
staging of rectal cancer and the planning of individualised care through the 
multidisciplinary team (MDT), the main aim of treatment was to avoid an 
incomplete resection — an involved CRM (CRM+) — as this is associated with 
high levels of local recurrence (Burton et al., 2006, MERCURY Study Group, 
2006, Quirke et al., 1986). The recognition that preoperative CRT in selected 
cases and the resultant down-staging of disease through MRI-directed care has 
led to improvements in OS and a reduction in CRM+ rates. However, selecting 
the cases that would benefit from CRT, the locally advanced cases, was 
challenging. In recent decades, there has been an increase in what is 
considered locally advanced rectal cancer (LARC) with a paralleled increase in 
improved treatment outcomes. This has created further debate with regards to 
the nomenclature and treatment of the clinical subgroups of rectal cancer. 
Currently, treatment decisions are influenced by the four distinct T stage groups 
(T1, T2, T3, T4) as well as with other relevant factors: tumour height; closeness 
to the CRM (see Section 1.4.4); clinical N stage; EMVI and nerve invasion. 
Therefore, it is not possible to define these subgroups based on T and N stages 
only. Following the MERCURY study (MERCURY Study Group, 2006), the 
positive experiences of using a dedicated MRI protocol for rectal cancer 
imaging resulted in the division of rectal cancer patients into three groups for 
preoperative staging and treatment planning: the good, the bad and the ugly. 
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1.4.5.2 The good, the bad and the ugly 
The good group includes patients with early, clearly resectable tumours, with no 
bad prognostic factors on MRI, neither for the risk of local or systemic failure 
(Table 1.4). The slightly more advanced tumours, with MRI features suggesting 
increased risk for distant metastasis (little challenge to sphincter preservation, 
limited lymph node metastases), constitute the bad group. Finally, the ugly 
group included the cases with MRI features suggestive of increased risk for 
distant metastasis (threatened CRM or CRM+, poor prognostic factors such as 
lymph node metastases or EMVI) (Kosinski et al., 2012).  
Recently, adjusted definitions of the three categories have been widely adopted 
(Blomqvist and Glimelius, 2008), emphasizing the risk of local failure: a 'good' 
group has a low risk of failing locally, a 'bad' group has higher risk of failing 
locally and an 'ugly' group has the worst risk of local failure. Most international 
groups tend to refer to the 'bad' and the 'ugly' as LARC.  
There is an agreement that for the 'good' rectal cancer, surgery is the mainstay 
treatment with low risk of failure and good survival (Leong et al., 2011). For 
LARC, curative management focuses on the complete surgical removal of the 
tumour and prevention of local recurrence and metastases based on surgery, 
chemotherapy and RT (Petersen et al., 2012, DeSantis et al., 2014). See Figure 
1.7 for a summary of the definitions and treatments of the good, the bad, the 
ugly as described in Blomqvist and Glimelius (2009). 
 
Risk of Local 
recurrence                                      
Characteristics of rectal tumours as predicted by 
MRI
High A threatened (<1mm) or breached resection margin 
OR low tumours encroaching on the inter-sphincteric 
plane or with levator involvement 
 
Moderate Any cT3b or greater, in which the surgical margin 
isn’t threatened OR any suspicious lymph node not 
threatening the surgical margin OR the presence of 
extramural vascular invasion 
Low cT1 or cT2 or cT3 
AND no lymph node involvement  
 
Table 1.4 Risk of local recurrence for rectal tumours as predicted by MRI 
(NICE, 2014). 
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Figure 1.7. The good, the bad, the ugly: definitions and treatment. Adapted 
from Kosinski et al (2012) and Blomqvist and Glimelius (2009). 
 
 
1.4.5.3 Surgery 
Total Mesorectal Excision (TME) surgery is one of the main components of 
improvement in current management. For the last twenty years, low anterior 
resection with TME has been a gold standard surgical treatment for rectal 
cancer (Dulskas et al., 2016). TME refers to the removal of the rectum together 
with the mesorectum around the surrounding envelope, the mesorectal fascia. 
Achieving a clear lateral or circumferential margin is important for the overall 
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outcome of the procedure. A clear CRM is defined as a distance greater than 
1mm between the tumour border and the resection margin, as tumours within 1 
mm of the CRM strongly predicts local recurrence and poor survival (Brown and 
Daniels, 2005). Therefore, an incomplete cancer resection — identified by the 
involvement of the histopathological CRM (CRM+) — results in increased local 
recurrence and poor oncological outcomes (Battersby et al., 2015). 
Due to the close relationship between the rectum and the pelvic nerves, the 
bladder, bowel and sexual function are commonly affected following TME 
(Dulskas et al., 2016). It is therefore important to follow the narrow surgical 
plane in the pelvis (see Section 1.3.1) to excise the rectum with its 
lymphovascular supply intact (Brown and Daniels, 2005). The surgical 
management is therefore technically challenging for the surgeon and local 
recurrence is a common result of treatment failure (Birbeck et al., 2002). 
 
 
1.4.5.4 Adjuvant and neoadjuvant therapy 
Before the introduction of TME, chemotherapy and RT were adjuncts to 
surgery, either together or individually. However local recurrence in rectal 
cancer was common and toxicity of postoperative treatment established. By the 
late 1970s, the benefits of neoadjuvant chemoradiotherapy (nCRT) became 
more apparent but so did the risks and side effects. Major randomised trials 
looking at neoadjuvant treatment demonstrated decreased local recurrence 
rates with neoadjuvant radiotherapy (nRT) or nCRT vs surgery alone or surgery 
followed by RT (Kosinski et al., 2012). nRT was also found to have more 
advantages to postoperative RT, related to tumour response and sparing of 
normal tissue (Section 1.4.5.5).  
The introduction of nCRT for patients with LARC reduced the local recurrence 
rate from a historical 30% or more, to less than 10% in recent cohorts. It also 
reduced distant metastases rates and reduced the potential CRM involvement, 
optimised DFS and OS (Biondo et al., 2016). The main downside of 
neoadjuvant therapies is the possibility of over-treating patients who may not 
benefit from it. 
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1.4.5.5 Radiotherapy and chemotherapy 
RT treatment shrinks the tumour in rectal cancer, increasing the likelihood of 
achieving a pathological clear resection margin and reducing the risk of local 
recurrence. The target areas in planning for RT treatment are the rectum, anus, 
sigmoid and mesorectum. RT fields should include the tumour with a 2-5 cm 
margin, the presacral and internal iliac nodes. External iliac nodes and inguinal 
nodes are usually included for T4 tumours invading anterior structures and the 
distal anal canal respectively (Kye and Cho, 2014). 
Tumour response depends on sensitivity to RT. Irradiating tissue that is 
surgically-naïve and therefore better oxygenated may increase sensitivity to RT. 
Additionally, reducing the volume of tumour pre-operatively through RT may aid 
the surgical resection and increase the success of sphincter-sparing 
procedures. Preoperative RT may also avoid postsurgical RT-induced injury to 
the small bowel (which may be stuck in the pelvis due to post-surgical 
adhesions). Finally, preoperative RT may additionally target structures that will 
be resected, increasing the chances of success of surgical anastomoses with a 
healthy colon (Kye and Cho, 2014, Sauer et al., 2004, Wagman et al., 1998, 
Kachnic, 2007). 
 
There are two main options for neoadjuvant treatment: a short course of RT or a 
long course of CRT. Unlike long course radiation combined with chemotherapy, 
i.e., CRT, short course of RT cannot be safely combined with concurrent doses 
of systemic chemotherapy. Therefore, the value of choosing a neoadjuvant 
short course of RT vs CRT is up for debate. In a recent meta-analysis (Chen et 
al., 2015) looking at neoadjuvant RT for rectal cancer, short course RT was 
found to reduce the risk of local recurrence compared with surgery alone or 
surgery with postoperative RT +/- Chemotherapy. The effect was deemed 
comparable to the local control established with CRT. Short course RT has 
advantages compared to longer term CRT: it is less expensive, more 
convenient and has better patient compliance. However, surgery is ideally 
delayed following short course RT, as cancer cells sterilised by radiation require 
time to undergo necrosis (Kosinski et al., 2012). On the other hand, a 6-8 week 
interval following neoadjuvant CRT is standard practice, allowing tumours to 
undergo necrosis. Nevertheless, a delayed interval to surgery is a reasonable 
option, especially in elderly patients or patients with comorbidities, who are 
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often unfit to undergo CRT in locally advanced rectal cancer, prior to surgical 
resection. 
The best regimen for neoadjuvant treatment therefore is not yet fully 
established, due to lack of consistent differences in terms of local recurrence 
between different regimes (Biondo et al., 2016). Whilst short course RT (5 Gy 
per day for 5 days) has been adopted as the standard neoadjuvant treatment in 
some countries, in others, long course CRT (45-50 Gy over 5 weeks with 
concomitant chemotherapy) is preferred (Dbeis et al., 2016). Other regimens 
have used induction chemotherapy prior to CRT, such as in the EXPERT-C 
trial, by adding Cetuximab in follow up arms (Dewdney et al., 2012). 
Follow-up data from important randomised controlled trials looking at different 
regimes of CRT is yet to be published. Meanwhile, concomitant radiation 
therapy plus chemotherapy agents that are thought to be radiosensitisers 
(agents that make the tumour more vulnerable to radiation), such as 
Fluorouracil (5-FU), Capecitabine or Oxaliplatin is a recognised regime (De 
Felice et al., 2014, Brenner et al., 2014). 
 
 
 1.4.5.6 Treatment response  
The response of rectal cancer patients after nCRT may be associated with 
oncological outcomes. Preoperative treatment response could serve as an 
indicator of prognosis and of subsequent response to treatment (Kye and Cho, 
2014). The work of Dr Habr-Gamma et al. (2004) in Brazil on the non-operative 
management of rectal cancer following CRT, led to a desire to identify patients 
who may respond completely to, thus avoiding surgery, CRT management 
which is known as 'watch and wait'. Rates of complete clinical response (cCR), 
disappearance of signs of cancer, and radiological response have been 
reported as high as 15% in selected U.K. series. Additionally, a group of 
patients who achieve a complete pathological response (pCR) — no evidence 
of remaining tumour in the histopathological specimen — has also been 
identified (Dalton et al., 2012, Renehan et al., 2017).  
The role, importance and validity of re-staging rectal cancer after nCRT has 
been uncertain until recently. The results of the MERCURY study showed that 
post-CRT MRI assessment of tumour regression grade correlate with DFS and 
OS, therefore with prognosis. It also gave information regarding the risk of local 
	 43	
recurrence (MERCURY Study Group, 2006, Patel, 2011). The ability to assess 
local recurrence and prognosis following the initial nCRT enables for a more 
tailored treatment and ultimately better outcomes (Taylor et al., 2012).  
The response of tumours to therapy is often described as tumour regression 
and measured by tumour regression grades (TRG), which refers to the 
pathological ratio of residual viable tumour to scar after nRT or nCRT (Kosinski 
et al., 2012). There is currently no gold standard system to measure TRG, but 
most examine the tumour specimen histologically. See Table 1.5 for the 
commonly used pathological systems reported for TRG in LARC. MRI has also 
been shown to have a role in assessing the response to nCRT (Patel et al., 
2011, Battersby et al., 2015) and CT may be used for re-staging.  
 
The high variability in response of patients to the treatment of rectal cancer is 
attributed to genetic, epigenetic, environmental and patient related factors. The 
molecular heterogeneity of rectal cancer for example, is believed to be one of 
the factors responsible for the variability in treatment response among patients 
with the same stage of cancer (Bettoni et al., 2017). Tumour heterogeneity 
refers to the differences between tumours of the same type in different patients, 
or between cancer cells within the same tumour. Both can lead to different 
responses to therapy, even targeted therapy (Buczacki and Davies, 2014). This 
may explain why some tumour cells remain present in the patient after 
completion of cancer treatment. Therefore, single biopsy specimens of primary 
tumours may not represent the full genetically diverse malignant picture. 
Similarly, analysis techniques may not be sensitive enough to detect the lower 
frequency changes in tumour sub clones. Polymorphisms, activation of growth 
receptor factors and mutations in DNA repair genes may also play a role in the 
variation in treatment outcomes (Sebio et al., 2015). 
Additionally, patient related factors such as sex, age and comorbidities, may 
influence response to targeted therapies. Certain drugs for example, such as 
Aspirin and Non-steroidal anti-inflammatory drugs (NSAIDs), are thought to 
have a potential impact on acute toxicity and pCR. The cyclooxygenase-2 
(COX2) pathway is overexpressed in 90% of rectal tumours compared to 20% 
in colonic tumours (Feng Yin, 2009). COX2 has been hypothesised to inhibit 
apoptosis, to promote angiogenesis and modulation of cell differentiation and 
even more to improve cancer aggressiveness and metastasising potential. It is 
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also associated with chemoradioresistance in rectal cancer (Sakurai et al., 
2007, Del Gobbo and Ferrero, 2017). Both Aspirin and NSAIDs inhibit the 
COX2 pathway.  
Other medications may also be responsible in the variation of treatment 
response: in a multivariate analysis, Katz et al. (2005) found that Statin use is 
associated with an improved pCR rate after nCRT for rectal cancer. Similarly, 
Morris et al. (2016) found that the use of ACE Inhibitor and Alpha Receptor 
Blocker medications among patients with rectal cancer is associated with 
increased rates of pCR after neoadjuvant treatment. 
There are currently no biomarkers to predict treatment response in rectal 
cancer. However potential candidates are being studied with special focus on 
methylated genes, which are showing promising results as biomarkers (see 
Section 1.6.5)  
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Table 1.5 Common tumour regression grade systems for locally advanced 
rectal cancer after treatment. Adapted from Kim et al. (2016). 
 
 
 Mandard Ryan *AJCC Modified 
Dvorak 
(pT+pN) 
 
Complete 
regression 
No 
residual 
cancer 
cells (TRG 
1) 
No viable 
cancer cells, 
or single 
cells, or small 
groups of 
cancer cells 
(TRG 1) 
No viable 
cancer cells 
(TRG 0) 
No tumour 
cells  
(TRG 4) 
Near 
complete 
regression 
Rare 
residual 
cancer 
cells (TRG 
2) 
- Single or small 
groups of 
tumour cells 
(TRG 1: 
moderate 
response) 
Fibrosis > 
50% of 
tumour 
mass  
(TRG 3) 
Moderate 
regression 
Predomina
nt fibrosis 
with 
increased 
number of 
residual 
cancer 
cells (TRG 
3) 
Residual 
cancer 
outgrown by 
fibrosis (TRG 
2) 
Residual 
cancer 
outgrown by 
fibrosis (TRG 2: 
minimal 
response) 
Dominantly 
fibrotic 
changes 
(25-50%) of 
tumour 
mass  
(TRG 2) 
Minimal 
regression 
Residual 
cancer 
outgrowing 
fibrosis 
(TRG 4) 
Significant 
fibrosis 
outgrown by 
cancer, or no 
fibrosis with 
extensive 
residual 
cancer  
(TRG 3) 
Minimal or no 
tumour cells 
killed (TRG 3: 
poor response) 
Dominant 
tumour cell 
mass (> 
50%) with 
fibrosis or no 
regression 
(TRG 1) 
No 
regression 
No 
regressive 
change 
(TRG 5) 
 
 
- - - 
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1.4.6 Differences between rectal and colon cancer 
Rectal cancer was usually discussed under the banner of colon cancer in the 
terms of ‘colorectal’ cancer. Recently, it has become increasingly clear that the 
concept of CRC should be divided into proximal colon cancer, distal colon 
cancer and rectal cancer. Several biological and clinical hallmarks suggest that 
rectal cancer is different from colon cancer. The rectum and the colon have 
different embryological origin, anatomy and function (Iacopetta, 2002 and Li and 
Lai, 2009) (see Section 1.3.2).   
Anatomically, colonic tumours extend directly to the serosal surface whilst 
advanced rectal cancers cannot gain direct access to the peritoneal cavity (Li 
and Lai, 2009). The rectum is surrounded by numerous vital structures due to 
its confined location in the pelvis (see Section 1.3.1). Therefore, the local 
treatment for rectal cancer is more aggressive than for colon cancer. Rectal 
cancer has a propensity to recur locally. Additionally, it is more likely to 
metastasise to the lungs whereas tumours in other parts of the colon are more 
likely to metastasise to the liver (Tamas et al., 2017). This is due to the 
difference in anatomical venous return between the rectum and the colon 
(Section 1.3.2).  
The staging of colon and rectal cancer are assessed using different methods. 
The former is assessed with CT scanning but the latter with CT for distant 
disease staging and endoscopic ultrasound and/or MRI for local staging (see 
Section 1.2.4 and Section 1.4.4). Historically, the prognosis of rectal cancer was 
worse than that of colon cancers (Enblad et al, 1988). However, this has 
changed in the last few years, with worse prognosis more frequently applied to 
colon cancer patients. This improvement in rectal cancer outcomes is attributed 
to the evolution of treatment, the standardisation of rectal cancer surgery (TME) 
leading to a reduction in local occurrence and a steady improvement in survival 
(Hohenberger et al., 2009, Folkesson et al., 2005). 
The incidence of cancer in the colon is similar for both males and females. 
However, there is male predominance in rectal cancer (30-50% higher than in 
women) (Tardivo et al., 2005). Other epidemiological differences are also 
present between rectal cancer and cancers arising in the rest of the colon (see 
Section 1.2.1 and Section 1.4.1). For example, there has been an increase in 
the incidence of proximal colon cancer but a decrease in that of rectal cancer in  
	 47	
a number of countries such as Canada, New Zealand, Australia and the United 
States of America (Tamas et al., 2017). Furthermore, in several epidemiological 
studies, physical activity was shown to decrease the risk of colon cancer but not 
of rectal cancer (Samad et al., 2005, Harriss et al., 2009, Wolin et al., 2009). 
Additionally, behavioural factors, such as physical activity, diet, smoking and 
BMI, were stronger mediators of risk for colon cancer than for rectal cancer 
(Doubeni et al., 2012).  
There are also genetic differences underlying the two cancers. In contrast to 
CRC, it has been observed that MSI is rare in rectal cancer whilst the incidence 
of CIN is high. Yet, compared with colon cancer, the number of mutations 
detected in rectal cancer is significantly higher (Frattini et al, 2004). Kapiteijn et 
al (2001) demonstrated that rectal cancers showed significantly more nuclear  
β-catenin than colon cancers, which is a critical mediator of the WNT signalling 
pathway - a critical pathway for colon carcinogenesis.  
Furthermore, the COX2 pathway, which plays a major role in influencing the 
development of CRC, is overexpressed in 90% of rectal tumours compared to 
20% in colonic tumours (Li and Lai, 2009). Indeed, a recent prospective cohort 
study of 134,365 men and women concluded that some risk factors, including 
family history, physical activity and possibly height, differ in their association 
with colon and rectal cancer (Wei et al., 2004). Therefore, cancers arising from 
the colon and the rectum have been shown to be different in their biological 
behaviours, clinical course and genetic mechanisms.  
Finally, the molecular heterogeneity of CRC is believed to be one of the factors 
responsible for the variability of treatment response in patients with the same 
stage of cancer (Bettoni et al., 2016, Buczacki and Davies, 2014) (see Section 
1.4.5.6). This also might account for the difference in behaviour and treatment 
response between tumours originating in different sites of the colon as well as 
the rectum.  
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1.5 Epigenetics 
 
 
 
Figure 1.8 Epigenetic landscape. This image shows a cell represented as a 
marble. The cell is initially phenotypically plural, but becomes increasingly 
differentiated as it traverses the landscape. This landscape describes the way in 
which cell-lineage commitments are made during development (Waddington, 
1942). 
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1.5.1 Introduction to epigenetics  
1.5.1.1 About the epigenome 
One of the challenges of modern science is to understand the mechanisms 
behind the development of a complex multicellular organism from a single 
genetic blueprint. A fertilised egg contains a full complement of genetic 
information, yet, only part of this genetic material is required at all times or by all 
cells: only half of the ~25,000 protein coding genes within the mammalian 
genome are thought to be expressed in any cell type (Romanoski et al., 2015). 
As an organism develops, establishing and maintaining cell-specific genomic 
regulation becomes necessary: adequate control of genomic functions, such as 
gene expression and DNA replication, is required for cellular growth and 
differentiation. 
During transcription, a coding portion of DNA (i.e. a protein coding gene) is 
used as a template (by the enzyme RNA polymerase) to generate messenger 
RNA (mRNA) molecule. mRNA contains introns, which are sequences that are 
removed before the mature mRNA leaves the nucleus in a process called 
splicing. The exons, the remaining regions of the transcripts with the protein-
coding regions, are spliced together to produce mature mRNA. After the mature 
mRNA leaves the nucleus, it is used as a template to synthesise proteins in a 
process called translation.  
The fine-scale control of gene transcription (DNA to RNA) is regulated by the 
factors known as transcription factors as well as by epigenetic marks. These 
epigenetic marks also play an essential role in the regulation of developmental 
processes and their dysregulation has been associated with many diseases, 
such as cancer (Section 1.5.6). 
 
 
1.5.1.2 Epigenetics 
The term ‘epigenetics’, was first introduced by the embryologist Conrad 
Waddington in 1942, as the emerging branch of biology that “...studies the 
causal interactions between genes and their products which bring the 
phenotype into being...” (Waddington, 1942). Waddington famously illustrated 
his concept as an ‘Epigenetic Landscape’ (Figure 1.8), which shows a cell 
represented as a marble that is initially phenotypically plural, but becomes  
 
	 50	
increasingly differentiated as it traverses the landscape (Waddington, 1957).  
Recent usage of the term epigenetics refers to the study of mitotically heritable, 
but reversible, changes in gene expression that occur independently of the 
genomic DNA sequence (Henikoff and Matzke, 1997). Subsequently, epigenetic 
mechanisms are essential for normal cellular development, tissue differentiation 
and the long-term regulation of gene function. For a glossary of key epigenetic 
terms used in this thesis see Table 1.6. 
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Chromatin (Berger, 2007) DNA-protein complex that constitutes the 
chromosomes. The structure of chromatin can be 
altered through modifications made to the DNA or 
the proteins associated with it (histones). This 
facilitates movement between condensed 
(heterochromatic) and open (euchromatic) states.  
CpG island (Gardiner-
Garden and Frommer, 
1987) 
Typically defined as 200 to 500 base pairs (bp) in 
length with a C and G content of more than 50% 
and an observed/expected CpG frequency of 0.6. 
DNA Methylation 
(Jaenisch and Bird, 2003) 
Addition of a methyl group to carbon 5 of the 
cytosine pyrimidine ring at palindromic CpG 
dinucleotides. DNA methylation in certain CpG-rich 
promoter regions acts to repress gene expression 
by disrupting the binding of transcription factors 
and recruitment of proteins associated with 
chromatin compaction. 
Epigenetics (Henikoff and 
Matzke, 1997) 
Heritable, but reversible, regulation of genomic 
functions occurring independently of the DNA 
sequence. Primarily mediated by alteration of 
chromatin structure and DNA modifications. 
Epigenetic inheritance 
(Richards, 2006) 
Epigenetic modifications are mitotically heritable 
and can therefore be maintained across cell 
division to contribute to cell line establishment. It is 
less clear whether epigenetic marks are inherited 
transgenerationally through meiosis. 
Histone Modifications 
(Berger, 2007) 
Post-translational, covalent additions made to N-
terminal histone tails that modulate chromatin 
structure. Modifications include acetylation, 
methylation and phosphorylation. 
Genomic imprinting 
(Davies et al., 2005) 
Monoallelic expression of genes in a parent-of-
origin specific manner, regulated by allele-specific 
epigenetic marks established in the germline. 
Fundamental to normal mammalian development. 
Non-coding RNA 
(Kapranov et al., 2007) 
RNA molecules that are not translated into protein 
that can have structural or regulatory roles. 
Nucleosome 
(Luger et al., 1997) 
DNA-histone complex consisting of 147 base pairs 
of DNA wrapped around eight histone proteins. 
 
Table 1.6 Key epigenetic terms. 
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1.5.2 Epigenetic mechanisms  
1.5.2.1 Introduction 
A focus on identifying genetic aberrations has dominated aetiological research 
in cancer. Over the last decade however, attention has been focused on 
epigenetic mechanisms: the mechanisms that modify gene expression 
independently of DNA sequence (Virani et al., 2012, Goel and Boland, 2012). 
Epigenetic mechanisms are integral to normal cellular differentiation and play a 
key role in the regulation of gene expression in normal tissue (Avner and Heard, 
2001), in genomic imprinting (Morison et al., 2005) and tissue differentiation 
(Sharma et al., 2010). Once established during development, the epigenetic 
marks that determine cellular phenotype are mitotically inherited. However, 
epigenetic alterations can also arise across the life span due to environmental 
influences (Egger et al., 2004). Therefore, epigenetic modifications can be 
environmentally induced, tissue specific and can have similar effects to 
pathogenic mutations: they can silence, increase or decrease the expression of 
a gene. 
In 1982, aberrant epigenetic alterations were discovered in CRC (Feinberg and 
Vogelstein, 1983). Since, research into epigenetics has revealed a landscape of 
epigenetic mechanisms controlling gene expression, in both normal and 
cancerous tissues. Proteins that control gene expression require access to DNA 
to initiate gene transcription. The accessibility of DNA largely depends on the 
condensation state of chromatin. An “open” or relaxed chromatin state gives 
proteins access to DNA for gene transcription, whereas a “closed” or 
condensed chromatin state prevents gene transcription (Lao and Grady, 2011 
and Sharma et al., 2010) (Figure 1.9). The epigenetic landscape is partially a 
reflection of the factors that determine the condensation state of the chromatin 
and therefore partly controls gene transcription.  
The mechanisms through which epigenetic changes induce their effects include:  
1) DNA modification, most commonly DNA methylation; 2) histone modification 
and 3) microRNAs (Lao and Grady, 2011) (Figure 1.9). 
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Figure 1.9 Epigenetic mechanisms. The accessibility of DNA largely depends 
on the condensation state of chromatin. An “open” relaxed chromatin state 
gives proteins access to DNA for gene transcription, whereas a “closed” or 
condensed chromatin state prevents gene transcription. Epigenetic 
mechanisms are affected by several factors including environmental chemicals, 
drugs and pharmaceuticals, aging and diet. DNA methylation is what occurs 
when methyl groups tag DNA and activate or repress genes. Histones are 
proteins around which DNA can wind for compaction and gene regulation. 
Histone modification occurs when the binding of epigenetic factors to histone 
“tails” alters the extent to which DNA is wrapped around histones and the 
availability of genes in the DNA to be activated. Adapted from the National 
Institutes of Health (2005).  
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1.5.2.2 DNA methylation  
On a molecular level, four bases compose the primary sequence of DNA: 
adenine, guanine, cytosine and thymidine. However, DNA that has replicated 
itself in a dividing cell, known as post-replicative DNA, can undergo a covalent 
modification producing a ‘fifth base’. This modification is characterised by the 
addition of a methyl group to the cytosine ring, forming methyl cytosine, the 
‘fifth base’ in DNA. This reaction uses S-adenosyl-methionine as a methyl donor 
and is catalysed by enzymes known as DNA methyltransferases (DNMTs) 
(Figure 1.10).   
 
 
 
 Figure 1.10 Schematic representation of DNA methylation: Methylation 
converts cytosine to 5’methyl-cytosine via the actions of DNA methyltransferase 
(DNMT). Adapted from Zakhari (2013).  
 
This stable, non-mutagenic modification is mitotically heritable and contributes 
to a diverse range of cellular activities, including the regulation of gene 
expression (Razin and Cedar, 1991, Bird and Wolffe, 1999), the regulation of 
alternative splicing (Shukla et al., 2011), the control of transcription from 
alternative promoters within gene bodies (Maunakea et al., 2010), the regulation 
of genomic imprinting (Sasaki et al., 1992) and the silencing of repetitive DNA 
elements in the genome (Yoder et al., 1997). This is DNA methylation: the most 
extensively studied epigenetic mechanism to date. It is the most stable 
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epigenetic modification modulating the transcription of mammalian genome and 
will be the focus of this thesis. In vertebrates, DNA methylation predominantly 
occurs at cytosines that precede a guanine in the DNA sequence (Yi and Kim, 
2015). The two base pairs are linked by a phosphodiester bond therefore known 
as CpG. Mammalian genomes possess conserved regions with a high density 
of CpG sites known as “CpG islands” (Table 1.6). 
 
CpG islands are often usually sequences greater than 200-500 bases in length 
and more than 50% of guanine and cytosine in content (Gardiner-Garden, 
1987). CpG islands are usually unmethylated if the gene is expressed, and are 
associated with 60%-70% of gene promoters (Bird, 1986, Williamson et al., 
2015) (Figure 1.11). CpG islands have been the focus of much epigenetic 
research to date. DNA methylation in other genomic regions however,  
such as inter-genic CpG island shores (Irizarry et al., 2009) and intra-genic CpG 
islands (Deaton et al., 2011), is increasingly being recognised as functionally 
important (Figure 1.12). 60% to 70% of the CpG sites in the genome are usually 
methylated. Methylation is usually associated with the repression of gene 
expression via physical inhibition of transcription factor and regulator binding 
(Watt and Molloy, 1988) and through the recruitment of methyl-CpG binding 
proteins that remodel chromatin into a compact state (Hendrich and Bird, 1998) 
(Figure 1.9). However, a more nuanced relationship between DNA methylation 
and transcription, dependent on genomic and cellular context, has recently 
been revealed (Jones, 2012); DNA methylation at promoter regulatory regions 
is often associated with repressed gene expression whereas DNA methylation 
in the gene body is positively correlated with expression (Maunakea 
et al., 2010). 
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Figure 1.11 Genic location of DNA methylation. A) DNA methylation patterns 
represented across a chromosome. Repetitive elements and an example of a 
gene with a CGI-promoter are shown. B) DNA methylation pattern across a 
genomic region containing three genes and three interspersed repeat classes. 
Exons are shown in dark blue. The bottom line of each figure represents the 
DNA methylation state of the DNA; white circles represent unmethylated CpGs 
and black circles represent methylated CpGs. Blue arrows indicate active 
transcription and red colour indicates repressed transcription. Adapted from 
(Zampieri et al., 2015). 
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Figure 1.12 Schematic diagram of gene regions and CpG island regions. 
Adapted from Huang et al. (2015) 
 
 
1.5.2.3 Histone Modifications 
The nucleus of each cell in the genome contains two meters of densely 
compact DNA. This organisation and compaction of DNA is achieved through 
the formation of chromatin, the repeating unit of which is a nucleosome (Figure 
1.13). Each nucleosome consists of a section of DNA around a positively 
charged histone octamer that contains two of each of the canonical core 
histones; H2A, H2B, H3 and H4 (Luger et al., 1997). The N-terminal tails of the 
histone particles extend out from the nucleosome (Spencer and Davie, 1999).  
Changes in chromatin structure are mediated in part through post-synthetic, 
covalent modifications made to these N-terminal. The modifications can 
influence chromatin compaction state through several mechanisms including; 
altering nucleosome structure, introducing chemical groups recognised by 
regulatory or structural proteins, or through the disruption of higher-order 
chromatin structure (Strahl and Allis, 2000). A full review of histone 
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modifications is beyond the scope of this thesis, but for a more detailed review 
see Kouzarides (2007). 
These modifications have been hypothesised to form a complex, combinatorial 
‘histone code’ which plays a role in gene expression regulation via alterations in 
chromatin structure (Berger, 2007). These alterations affect the access of the 
cell’s transcriptional machinery to the DNA in a similar fashion to DNA 
methylation: in the condensed chromatin state (heterochromatin), in which the 
DNA and histone proteins are tightly packed, the access to DNA of transcription 
factors and other co-factors is blocked, repressing transcription. Conversely, an 
open chromatin state (euchromatin) allows the transcriptional machinery to 
access DNA and drive transcription (Section 1.5.2 and Section 1.5.3).  
 
 
Figure 1.13 The nucleosome, the most basic level of chromatin 
organisation. The “beads on a string” structure folds into a fibre 30 nm in 
diameter, which is then folded in to higher-order chromatin structures Adapted 
from (Felsenfeld and Groudine, 2003). 
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1.5.2.4 Non-coding RNAs 
It is a central dogma in biology that DNA makes RNA and RNA makes protein. 
However, recent data has shown that most transcripts do not code for proteins. 
(ENCODE_Project_Consortium, 2012). Those are known as the non-coding 
RNAs (ncRNA). Notably, the human genome contains more ncRNAs than 
protein coding genes (Xie et al., 2014). 
Structural ncRNAs are typically required for normal cellular function, and include 
ribosomal RNAs (rRNAs), transfer RNAs (tRNAs), small nuclear (snRNAs), and 
telomerase RNA. They can be subdivided according to length: short ncRNA 
(including microRNA) medium ncRNA and long ncRNA (Prasanth and Spector, 
2007). ncRNAs play diverse roles in regulating gene expression, epigenetic 
processes and defence against viruses. For example, miRNAs contribute to the 
regulation of gene expression through binding and destabilising target mRNA 
molecules (Bartel, 2009) and long ncRNAs contribute to the regulation of gene 
expression through interfering with transcription and inducing chromatin 
remodelling (Mercer et al., 2009). 
 
 
1.5.3 Interrogating the methylome 
Due to the primary focus on DNA modifications in this thesis, this section will 
give a brief overview of methods for quantifying DNA methylation. 
DNA methylation is erased by standard molecular biology approaches, including 
the polymerase chain reaction (PCR). Therefore, the detection of DNA 
methylation requires exposure of DNA to a methylation sensitive pre-treatment 
prior to DNA sequence analysis, of which the most commonly used is sodium 
bisulfite conversion (see Chapter 2 Section 2.4.1 for details). Whole genome 
bisulfite sequencing is considered the gold standard technique to profile DNA 
methylation, allowing the coverage of ~28 million CpG sites across the human 
genome. However, the high read depth needed to quantify the small DNA 
methylation changes makes it economically unfeasible due to a high cost of 
usage (Ziller et al., 2013).  
At present, the Illumina Infinium HumanMethylation450 BeadChip which targets 
>450,000 (450K) methylation sites, and more recently the Illumina EPIC array 
are the most commonly used methods for the analysis of genome-wide 
methylation in humans (see Chapter 2 Section 2.5).  
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This approach is particularly popular as it represents the best compromise 
between coverage and cost, and therefore enables DNA methylation to be 
quantified across the genome in a large number of samples. Further, the 
widespread use of the 450K array has driven development of many novel 
bioinformatic methods and pipelines specific for this platform. 
 
 
 
1.6 Epigenetic landscape of colon and rectal cancer 
1.6.1 Introduction 
Epigenetic mechanisms, including DNA methylation, histone modifications and 
ncRNAs, are known to play a role in carcinogenesis, in the initiation, 
progression and metastasis of cancer. DNA methylation remains the most 
studied of these mechanisms for its role in cancer.   
DNA methylation was the first epigenetic hallmark to be associated with cancer 
through altering normal gene regulation and expression (Feinberg and 
Vogelstein, 1983). It alters gene expression directly by interfering with 
transcription factor binding and/or indirectly by inducing histone modification 
leading to a more compacted and repressive chromatin state (Williamson et al., 
2015). There are three types of alterations in DNA methylation that have been 
associated with cancer: hypermethylation, hypomethylation and loss of 
imprinting. DNA hypermethylation refers to the gain of methylation at specific, 
normally unmethylated, sites in the genome. DNA hypomethylation refers to the 
loss of DNA methylation in genome wide regions. Loss of imprinting is defined 
as the loss of parental allele specific monoallelic expression of genes due to 
aberrant hypomethylation profiles at one of the two parent alleles (Yi and Kim, 
2015). The focus of this review will be on DNA hypomethylation and 
hypermethylation.  
Following the discovery of global DNA hypomethylation in cancer, it was 
discovered that CpG islands were aberrantly methylated as well. Genome wide 
studies have shown that 1%-10% of CpG islands are differentially methylated in 
cancer, amounting to thousands of hypermethylated gene promoters (Costello 
et al., 2000). Recent studies have discovered a new site for abnormally 
methylated sites in cancer: the CpG island shores, which refer to areas of less 
dense CpG dinucleotides located within two kilobases upstream of a CpG island 
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(Lao and Grady, 2011). Just like CpG islands, the methylation of the CpG island 
shores is associated with transcriptional inactivation.  
 
 
1.6.2 Epigenetics of colorectal cancer  
The classic view of cancer is that it arises because of the accumulation of 
mutations in genes or oncogenes, which ultimately causes normal cells to 
transform into cancer cells. Therefore, genetic aberrations have dominated 
CRC research and established our understanding of the role of molecular 
alterations in CRC. Over the last decade, this has led to a shift in research 
focus on the epigenetic mechanisms in CRC (Virani et al., 2012).  
Epigenetic alterations and gene mutations cooperate to drive the progression of 
normal cells to cancer cells, with the aberrant hypermethylation of genes acting 
as common molecular mechanism for silencing tumour suppressor genes 
(Section 1.5). Epigenetic alterations contribute to the heterogeneity of CRC. 
This is highlighted by the identification of a subtype of CRC with a distinct 
epigenome and a high frequency of methylated genes (Lao and Grady, 2011) 
(Section 1.2.2.3). Apart from DNA methylation, histone modifications and non-
coding RNAs have also been found to play a role in CRC (Migliore et al., 2011). 
However, DNA methylation remains the most extensively studied mechanism in 
CRC. Table 1.7 lists the most frequently methylated genes in CRC, with their 
known function and the changes in function following aberrant methylation.   
 
 
1.6.3 DNA methylation in colorectal cancer 
1.6.3.1 Background 
DNA methylation plays a large role in cancer of the colon. In the average 
genome of CRC, many more genes are affected by aberrant DNA methylation 
than by mutation. Furthermore, aberrant DNA methylation is the only 
mechanism observed for silencing certain genes. When gene expression is 
altered through DNA methylation, it is usually due to either hypomethylation of 
global DNA or hypermethylation of promoters.   
Nearly three decades ago, Feinberg and Vogesltein (1983) showed extensive  
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loss of 5’-methylcytosine content in colon cancers compared to normal colon. 
The global loss of DNA methylation or hypomethylation, appeared to 
predominantly affect CpG nucleotides found in repetitive sequences of DNA. 
Later studies showed a causal link between DNA hypomethylation and genetic 
instability (Costello et al., 2001, Feinberg and Tycko, 2004). Associations 
between global hypomethylation and aneuploidy in CRC cell lines were also 
described (Lengauer et al, 1997). Matsuzaki et al (2005) reported that 
hypomethylation of LINE sequences correlate with loss of heterozygosity on 
chromosomal loci in CRC. This global hypomethylation was also found in the 
colon in an age dependent manner as well as in the early steps of the polyp to 
cancer progression events (Feinberg, 2004, Ehrlich, 2002). Subsequently, 
global DNA hypomethylation was shown to be an early event in the process of 
CRC, contributing to cancer formation through inducing genomic instability or 
loss of imprinting (Lao and Grady, 2011) (Figure 1.14). 
In 1999, Toyota and Issa (1999) showed that some CRCs have a high 
frequency of methylated genes with unique molecular pathogenesis. They 
named them CIMP cancers. CIMP is characterised by DNA hypermethylation 
and suppression of key genes, which are differentially methylated between 
normal and malignant cells and are important in controlling cell growth and 
transcription (Williamson, 2015). The methylation of the CpG islands within the 
promoter region is generally correlated with silencing of transcription, however, 
in CRC it appears that decreased gene expression is only characteristic of 
certain methylated genes (Hinoue et. al, 2012). Additionally, CpG island shores, 
which tend to be tissue specific, are altered in CRC (Lao and Grady, 2011). 
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Figure 1.14 Aberrant methylation in colorectal cancer. Aberrant methylation 
in CRC leads to genomic instability, compared with normal colonic epithelium. 
Adapted from Lao and Grady (2011). 
 
1.6.3.2 CIN, MSI and CIMP pathways 
DNA methylation affects CRC through playing a role in the two main molecular 
pathways for colorectal carcinogenesis, CIN and MSI, as well through the CIMP 
pathway, which constitutes a distinct subset of CRC.   
CIN is one of the main pathways for colorectal carcinogenesis (Section 1.2.2.2). 
Global DNA hypomethylation is typically observed in the CIN pathway. A pattern  
of hypomethylation in pericentromic regions of tumour cells may influence 
neoplastic progression by making chromosomes more susceptible to breakage. 
Furthermore, hypomethylation may cause a disruption in the normal structure of 
genes, resulting in chromosomal instability. These mechanisms may contribute 
to the chromosomal instability in CRC (Matsubara, 2012). 
The MSI pathway (Section 1.2.2.2) is the second main molecular pathway in 
colorectal carcinogenesis, which occurs due to dysfunction of mismatch genes 
characterised by the accumulation to numerous mutations targeting DNA 
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microsatellites (Matsubara, 2012). However, in sporadic CRC with MSI, it is 
thought that methylation plays an important role in the MSI process. 
Hypermethylation of the promoter region of hMLH1 for example, causes lack of 
hMLH1 protein expression and therefore microsatellite instability (Wheeler, 
2005). The MLH1 gene is a DNA mismatch repair gene and germline mutations 
in MLH1 account for around 40% Lynch Syndrome, a hereditary CRC (Boland 
and Goel, 2010). The loss of MLH1 expression, which occurs where there is 
biallelic inactivation of the MLH1 genes for example, creates the distinctive 
mutational signature found in MSI. However, it was also discovered that most of 
CRCs with MSI that are not attributable to the hereditary Lynch syndrome, 
known as sporadic CRCs with MSI, have hypermethylation of the MLH1 gene 
(Weisenberger et al., 2006). This leads to the silencing of MLH1 which leads to 
the development of MSI. Both types of tumours are characterised by MSI and 
loss of MLH1, yet germline mutation plays a role in one and DNA 
hypermethylation in the other making them fundamentally distinct (Boland and 
Goel, 2010).  
Currently, a third subset of CRCs is being recognised and distinguished by the 
status of DNA methylation at several promoter loci: the CIMP pathway subset. 
CIMP is characterised by DNA hypermethylation and subsequently a 
suppression of key groups of genes that are differentially methylated between 
tumour and normal cells. These genes are normally important for cell growth 
and survival (Williamson et al, 2015). The panel of marker promoters is used to 
classify cancers as CIMP positive (CIMP +ve) or CIMP negative (CIMP -ve) 
(Matsubara, 2012). The first suggested CIMP panel included the following 
promoter gene regions: MLH1, p16, MINT1, MINT2 and MINT31 (Toyota et al, 
1999). Since, several more CIMP panels have been suggested. For example, a  
commonly used panel as defined by Weisenberg et al includes NEUROG1, 
SOCS1, RUNX3, IGF2 and CACNA1G (2006). The panel of genes for defining 
CIMP remains to be standardised and the panel that can be used to classify the 
CIMP status of colorectal tumours is yet to be determined. 
In an extension of the CIMP classification, different CRC epigenotypes have 
been proposed. These include different classes of CIMP, including CIMP low 
and CIMP high, which are determined by the proportion of methylated marker 
loci detected (Lao and Grady, 2011). However, the clinical utility of these 
designations is hindered, both by lack of a universally accepted definition of 
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CIMP panel and lack of validation of the accuracy of methylated gene panels 
which distinguish the different epigenotypes. 
 
 
1.6.3.3 Initiation, progression and metastasis  
Several genes appear to be more commonly methylated in the multi-step 
process from normal colonic epithelium leading to adenocarcinoma. 
At least six genes CDH13, CRBP1, RUNX3, SFRP1, SFRP2, SLC5A8 and two 
loci MINT1 and MINT31 have been consistently hypermethylated in the 
transition from normal colonic epithelium to an aberrant crypt focus (Coppedè, 
2014, Rashid et al., 2001, Chan et al., 2002, Li et al., 2003, Qi et al., 2006, Kim 
et al, 2006). 
Other examples of genes, such p14, HLTF, ITGA4, CDH1 and ESR1 were 
found to be frequently methylated in the passage from an aberrant crypt focus 
to polyp/adenoma (Lao and Grady, 2011). The progression of colon adenomas 
to adenocarcinomas is also likely to be a consequence of epigenetic alterations, 
as well as genetic mutations. For example, the hypermethylation of CXCL12, a 
chemokine ligand, has been found to promote the metastasis of CRC cell lines 
(Wendt et al., 2006).  
Other genes such as TIMP3, ID4 and IRF8, are more frequently methylated in 
colon cancer and metastases vs adenomas, suggesting that the inactivation of 
these genes by hypermethylation may lead to a clonal growth advantage (Kim 
et al, 2006, Kim et al, 2010). For a summary of the commonly cited genes 
involved in the polyp-> cancer sequence, see Table 1.7 and Figure 1.15. 
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Figure 1.15 Commonly methylated genes involved in the progression of 
normal colon to adenocarcinoma.  Adapted from Lao and Grady (2011)
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 Table 1.7 The m
ost frequently differentially m
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1.6.4 D
N
A
 m
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ent response.  
A literature review
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ith relationship to treatm
ent response is highlighted in Table 1.8. 
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1.6.5 Clinical biomarkers 
A biomarker is a biological characteristic that can be objectively measured and 
evaluated as an indicator of normal biological process, pathogenic process, or 
pharmacological response to a therapeutic intervention (Naylor, 2003). 
Biomarkers can be used at any stage of a disease and can be associated with 
its cause (risk biomarkers), onset (diagnostic biomarkers), clinical course 
(prognostic biomarkers), or response to treatment (predictive biomarkers) 
(Strimbu and Tavel, 2010).  
Epigenetic biomarkers can be used in cancer for diagnosis, prognosis and 
prediction of response to treatment therefore treatment planning. In fact, 
epigenetic biomarkers are already in use CRC, and several are being 
developed for early detection, prognosis and treatment response prediction in 
CRC as well as breast and lung cancers (Lao and Grady, 2011). Cell free DNA 
hypermethylation, released from the tumour into the blood and stools, is 
considered a potential cancer biomarker, due to its potential high sensitivities 
and specificities in tissue studies in CRC (Schwarzenbach et al., 2011).  
Discovery of markers specific for rectal cancers has been hampered by the lack 
of studies addressing rectal tumours as an independent entity and studies using 
limited numbers of candidate genes.  
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1.7 Aim of this study  
Key epigenetic features are useful for understanding the molecular subgroups 
of rectal cancer, the environmental and genetic features that lead to it, as well 
as predicting the natural history of tumours and the response to different 
treatment regimens. One of the goals of present and future research is to 
identify biomarkers that could allow a feasible, cost-effective and non-invasive 
screening and diagnosis of rectal cancer, as well as to understand which panel 
of biomarkers can be used to better define patient’s prognosis and the best 
choice of available treatments. 
The discovery of DNA methylation patterns and epigenetic markers specific for 
rectal cancer has been hampered by the lack of studies addressing rectal 
tumours as an independent entity and studies using limited numbers of 
candidate genes. Although recent technological advances have facilitated new 
approaches for identifying DNA methylation changes across the whole genome, 
to our knowledge, ours is the second study worldwide to use these advances 
and adopt a genome wide approach in rectal cancer.  
 
Therefore, there are two aims to our study:  
 
Aim 1: To use and validate methods used in CRC studies, for isolating and 
processing tumour cells from rectal cancer tissues.  
 
Aim 2: To identify methylomic variation associated with rectal cancer across the 
whole of the genome using the Illumina Infinium 450K array platform.  
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Chapter 2 - Materials and Methods 
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2.1 Pre-sample collection 
2.1.1 Introduction 
The National Institute for Health Research (NIHR) Exeter Clinical Research 
Facility (ExeterCRF) is a joint venture between the Royal Devon and Exeter 
(RDE) NHS Foundation Trust and the University of Exeter. It provides staff and 
facilities to support a variety of mechanistic and translation clinical research 
projects. One of its key resources is the ethically approved RDE Tissue Bank 
(RDETB) which was set up to proactively collect and store ‘spare’ tissue 
available from routine clinical procedures. Part of the ethical approval of the 
RDE enables the RDETB steering committee to provide ethical approval on a 
project by project basis. An application is required to build up a collection and/or 
access these or previously collected samples. Samples remaining after analysis 
are returned to the tissue bank for as a resource for future use by others.  The 
RDETB supersedes the original Exeter Tissue Bank (ETB) which collected 
spare bowel, bladder, kidney and prostate tissue on an ad hoc basis. Access to 
these stored samples required researchers to obtain full ethical approval for 
their project prior to application to the ETB. These historic samples were 
transferred to the RDETB to enable their continued availability for research use.  
Prior to any sample collection or patient involvement, I completed the Good 
Clinical Practice course, underwent appropriate training for gaining consent for 
recruitment of patients into trials. I additionally underwent all appropriate IT, 
health and safety, administrative and clinical trainings. Template application 
form and Good Clinical Practice certificate can be found in Appendix (1-2). 
 
 
2.1.2 Patient and public involvement  
Prior to the current study, the clinical members of the research team had regular 
discussions, during routine clinical care with patients, on potential treatment 
options and the benefits of each to the individual. From these discussions, it 
was clear that patients were keen for any research which could help identify the 
right treatment option for them. This led directly to the development of the 
current biomarker studies. In keeping with the National Health Service (NHS) 
Patient Carer and Public Involvement strategy, the ExeterCRF invites user 
representatives to contribute to the development of various projects within its 
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portfolio. These individuals have agreed to maintain contact and regular 
meetings have been established at which researchers discuss the development 
of current projects within the ExeterCRF. The research team also had access to 
this group during the project development phase.  
 
 
2.1.3 Study design 
This is a retrospective study using matched samples of rectal cancer and 
adjacent normal mucosa, from patients with rectal adenocarcinoma, 
interrogating the differences in genome wide methylation between the two pairs 
of tissue. Two separate cohorts were included, the historical samples and 
freshly collected samples as described in Section 2.1.4.  
 
 
2.1.4 Tissue bank applications 
2.1.4.1 Historical samples 
Preliminary discussions with the RDETB management team identified a number 
of existing samples that would be suitable for study. The samples identified 
were rectal adenocarcinoma, collected between 2004 and 2007, fresh frozen 
(FF) and stored in the ETB freezers for future use. A total of 58 samples from 
29 patients were located. Two matched pairs of fresh tissue samples had been 
previously collected: a tumour sample and an adjacent normal mucosal sample 
from each patient.  An application to the RDETB for use of these samples was 
subsequently made and approved (Appendix 3). 
 
 
2.1.4.2 Freshly collected samples 
More recently collected samples were available form a currently approved 
RDETB project from rectal cancer patients recruited as part of the Risk 
Stratification for Rectal Cancer Treatment project (RIST-
pilot/protocol/Vs1/300914). 
 
2.1.5 Ethical approval and information protection 
Ethical approval for the current use of samples was provided by the RDETB  
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steering committee. All samples held by the RDETB are held in a link-
anonymised format. RDETB data and samples are given a unique study/sample 
ID number. Personal identifiable data is only accessible by RDETB staff with the 
appropriate data protection training. Project specific consent and paper data 
collection forms are stored in locked filing cabinets within the controlled access 
ExeterCRF, for the duration of the projects. Data is transferred onto a project 
specific RDETB database and stored on a password protected NHS database.  
Anonymised samples and data were provided to the research team. 
 
 
2.1.6 Data collection and recording 
2.1.6.1 General information 
As part of the RDETB data quality procedures, data collected and recorded are 
screened and reviewed for discrepancies and missing data prior to analysis. All 
biological samples are stored in line with the Human Tissue Authority (HMGov, 
2004) and Medical Research Council guidelines (MRC, 2001) on the handling 
and storage of human tissues. 
Permission is obtained for a member of the RDETB team to access medical 
notes relevant to the study where appropriate on behalf of the research team. 
This anonymised data is then provided to the research team as required.   
 
2.1.6.2 Historical samples 
Historical colorectal samples collected from 2004-2007 were stored in the ETB 
database. Clinicians collected all samples during hospital procedures and 
subsequently fresh froze them in liquid nitrogen. Matched rectal 
adenocarcinoma samples and adjacent normal mucosa samples were 
identified, appropriately labelled in tubes and placed in specific locations in the 
ETB freezers according to date of collection and specific ETB IDs. Consent with 
the same reference ID numbers as the samples had been obtained from each 
patient prior to the collection and signed consent forms stored in the ETB 
database. A trained research clinician, research nurse or ETB officer obtained 
consent. An application to the RDETB for the use of these historic samples was  
subsequently made (reference JMRD/Vs1/290116) and approved. The samples 
were then transferred to the research laboratory freezers for dissection and 
processing.  
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2.1.6.3 Freshly collected samples 
Participants were identified by clinicians and recruited through the RDETB. 
Consent with an appropriate RDETB study ID was obtained from each patient 
prior to the collection of samples. Signed consent forms were stored in the ETB 
database. Consent was obtained by a delegated member of the RDETB. For 
each patient recruited, matched pairs of fresh tissue samples were obtained 
from the tumour and the adjacent normal mucosa. The samples were taken 
either during rigid sigmoidoscopy in outpatient clinic or prior to surgery at the 
time of de-functioning stoma formation or rectal resection. Samples were 
obtained between June 2015 and April 2016. They were then transported 
immediately in labelled tubes to the NIHR ECRF, which is located on the same 
premises of the hospital, flash frozen in liquid nitrogen and stored appropriately 
in the RDETB freezers. The tubes containing the samples were transferred at a 
later date to the research laboratory freezers for dissection and processing. The 
consent forms were stored within the RDETB (see Section 2.1.1). 
 
 
2.1.6.4 Adverse effects:  
This was a low risk study. No participants were subject to any adverse events 
from taking part in the study. A standard procedure is in place for reporting and 
recording adverse events: The Chief Investigator will be informed of any 
adverse effects within 24 hours and they will be reported following local NHS 
RDE SOPs with a copy of any adverse event form stored in the project site file.  
 
 
2.1.6.5 Study specific sample labelling 
Each sample had a unique RDETB ID code corresponding to the patient it was 
collected from which started with the letters ‘TB’ followed by numbers. 
Additionally, each sample had a unique sample code, different from the 
participant ID code. To differentiate between the matched pairs either tumour 
(T) or normal (N) was added to this sample ID. 
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2.2 Rectal patients sample processing 
2.2.1 Stored historical samples 
2.2.1.1 Patient selection 
Patients with a rectal adenocarcinoma (high, mid and low rectal tumours) were 
selected and included in the study. Patients had to be to be over 18 years of 
age, able and willing to provide consent and not pregnant. A summary of 
exclusion and inclusion criteria is provided in Table 2.1. 
 
Inclusion Criteria Exclusion Criteria 
  
Ø 18 years of age Pregnant 
Diagnosis of rectal adenocarcinoma or high-grade 
dysplasia  
Unable or unwilling to 
provide informed 
consent  
Undergoing treatment with curative intent at the 
RDE (either surgery or CRT) 
 
Able and willing to provide informed consent  
 
Table 2.1 Summary of exclusion and inclusion criteria for patient 
recruitment. 
 
 
2.2.1.2 Specimen retrieval 
Tissue specimens from 2004-2007 had been previously collected from patients 
undergoing rectal surgery for rectal adenocarcinoma. Matched samples were 
collected from the RDE and subsequently stored in the ETB freezers at -80°C.  
 
 
2.2.1.3 Paraffin embedding and histological assessment  
Prior to submitting an ETB application for the retrieval of the tissues, dissection 
and paraffin treatment of a few initial samples was required to justify the release 
of all of the required rectal samples. This was to verify the content and quality of 
the historical samples, and assess the tumour cells for integrity and 
heterogeneity prior to processing them in the lab. Subsequently, six matched 
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samples (three tumours and three adjacent normal mucosa) were supplied from 
the TB freezers, transported in formalin to the RDE Pathology lab where they 
were paraffin embedded. Thin sections of the fresh frozen paraffin embedded 
(FFPE) tissues were sliced onto slides. Pathology consultant Dr Ian Chandler 
reviewed the slides. Dr Chandler confirmed normal colonic mucosa 
histologically in the normal tissues and the presence of cancer cells in the rectal 
tumour tissues. Additionally, Dr Chandler estimated a percentage of tumour in 
each of the three cancer slides reviewed (Figure 2.1). This allowed us to have 
an approximation of tumour content in each of the cells. 
Following the TB application approval, the rest of the historical rectal samples 
were transferred from the TB freezers to the epigenetics’ group -80°C freezers. 
Sections of these samples were cut, placed in microcassettes and immediately 
fixed in formalin. The non-dissected part of each sample remained unused and 
was returned in its original collection tube to the -80°C freezers. The dissection 
was done speedily to avoid any thawing of the samples, which may affect the 
quality of the DNA. The microcassettes were then labelled as per TB and study 
IDs, transported to the RDE Pathology laboratories where they were paraffin 
embedded together to minimise batch effect. Similar to the test samples, one 
section of each FFPE sample was transferred onto a slide. The sections were 
stained with haematoxylin and eosin and reviewed by pathology registrar Dr 
Sarah Saunders who identified normal colonic mucosa and tumour tissues. Dr 
Saunders provided an estimate of percentage tumour cells in each cancer 
sample and confirmed the integrity of normal colonic cells in the normal 
adjacent mucosal samples. A summary of the histological findings is provided in 
Section 3.2. All slides and respective paraffin embedded cassettes were 
labelled with their TB and study code and returned to the epigenetics lab 
(Figure 2.2).  
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Figure 2.1 FFPE histology slides. Slides from the preliminary histological 
assessment of the rectal cancer historical samples. They are showing tumour 
cells, inflamed stroma surrounding the glands and scattered inflammatory cells. 
Tumour content is different in each of the two slides.  
 
 
Figure 2.2 Paraffin embedded cassettes of the FFPE tissues. The historical 
samples lined up for dissection and DNA extraction 
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2.2.2 Fresh sample collection 
2.2.2.1 Patient selection 
Clinicians identified patients recruited into the study during clinical visits and 
treatment, over 18 years of age, with a diagnosis of rectal adenocarcinoma or 
high-grade dysplasia, not pregnant and able and willing to provide consent. A 
summary of exclusion and inclusion criteria is provided in Table 2.1.  
 
 
2.2.2.2. Specimen retrieval 
Following appropriate consent, colonic rectal tissues (tumour and adjacent 
normal mucosa) were collected from surgically removed rectal segments from 
consecutive patients at the RDE Hospital, Exeter, Devon, during the period of 
March 2015 to April 2016. Consultant surgeons collected all samples from the 
operating room, either before or immediately after the surgical resection. In 
collaboration with the surgical staff, the samples were collected from the 
operating theatre and transported to the TB facilities in the RILD, which is 
located on the same premises, either by a TB officer, research nurse or myself. 
The transfer was done as rapidly as possible to minimise warm ischaemic time 
and maintain DNA integrity. The samples were immediately snap frozen in liquid 
nitrogen at the CRF and placed in --80°C freezers.  The transfer was done 
swiftly to reduce DNA degradation.  
 
 
2.3 Nucleic acid extraction 
DNA was isolated from human rectal samples, tumour and adjacent normal 
mucosal tissue. Two DNA extraction kits were used for the extraction, one for 
the historical samples which were FFPE and the other for the FF samples 
recruited for this study. The protocol for each of these extractions is highlighted 
in the respective sections below (Section 2.3.1 and Section 2.3.2). 
 
 
2.3.1 Paraffin embedded historical samples 
DNA was extracted using the QIAamp DNA FFPE Tissue Kit (QIAGEN GmbH, 
QIAGEN Strasse 1, 40724 Hilden, GERMANY) optimised for purification of DNA 
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from paraffin tissue (Figure 2.3). The procedure consisted of six steps 
summarised in Table 2.2 and briefly described below:  
Deparaffinisation:  The paraffin tissue was removed from the cassette using a 
sterile scalpel, placed on a dish where excess paraffin was dissected off the 
sample block. The sample was then cut into 5-10 very small sections and 
immediately placed in 1 ml of xylene. This was vortexed for 10 seconds then 
centrifuged for 10 minutes then washed with ethanol to remove excess xylene. 
DNA isolation was undertaken as described in the manufacturer’s protocol with 
a minor adjustment - the xylene wash was repeated again, as outlined above, 
before proceeding to the next step to remove the excess paraffin that was 
present in the tubes following the first wash.  
Lysis of the samples: 180μl of lysis buffer ATL and 20μl of proteinase K were 
added to the samples, mixed thoroughly and homogenised using a stator-rotor 
homogeniser. The tubes were incubated at 56°C overnight rather than the one 
hour standard incubation period, as colonic tissue is hard to lyse. During the 24-
hour period, the samples were intermittently vortexed and defragmented using a 
pestle and mortar, to encourage complete lysis. 
Heating: The samples were then incubated in 90°C to reverse formaldehyde 
modification of nucleic acids and inactivate proteinase K.  
Binding of DNA: The DNA was washed in 200μl of Buffer AL and 200μl of 
Ethanol, and the entire lysate was transferred to the QIAamp MinElute column, 
which was placed in a collection tube.  
Washing the DNA: Residual contaminants were washed away using 500μl of 
AW1 and 500μl of AW2, the wash buffers, in two distinct steps. 
Eluting the DNA: Pure concentrated DNA was eluted from the membrane by 
adding 40μl of the buffer ATE in total, in two washing steps. The final product 
consisted of 40μl of DNA.   
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Figure 2.3 DNA extraction from FFPE tissue:  Procedure overview 
Adapted from the QIAamp DNA FFPE tissue handbook 2012 (QIAamp, 2012).  
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Remove paraffin Paraffin is dissolved in xylene and 
removed 
Lyse  The sample is lysed with proteinase K 
under denaturing conditions 
Heat Incubating the samples at 90°C to 
reverse formalin crosslinking 
Bind DNA binds to the membrane in the 
column and the contaminants flow 
through 
Wash Residual contaminants are washed 
away 
Elute DNA which is pure concentrated is 
eluted from the membrane 
 
Table 2.2 The QIAamp 6 step procedure for DNA extraction from FFPE 
tissues. Adapted from the QIAamp DNA FFPE tissue handbook 2012 
(QIAamp, 2012).  
 
 
2.3.2 Fresh frozen samples:  
DNA was extracted using QIAGEN AllPrep DNA/RNA Mini Kit (50) (QIAGEN 
GmbH, QIAGEN STRASSE 1, 4072 HILDEN, GERMANY). The procedure 
consisted of four steps summarised in Table 2.3 and Figure 2.4 and briefly 
described below: 
 
Lysing and homogenising: An appropriate size section (approx. 3mm cube) 
was cut from each fresh frozen sample on dry ice. Lysis buffer RLT was added 
to each tube and the tissue initially disrupted with a pestle and mortar then 
lysed and homogenised with a rotor stator homogeniser. The time spent 
homogenising the samples was longer than suggested in the kit due to the 
dense fibrous nature of colonic tissue.  
Binding DNA: The homogenised lysate was transferred to the AllPrep DNA 
Spin column placed in a collection tube and centrifuged for 30 seconds at 
10,000 g. This allows the binding of the DNA onto the membrane of the column.  
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The spin column is then placed in a new collection tube. 
Washing DNA: 500μl of the wash buffer AW1 is added to the spin column. The 
column and collection tubes are then centrifuged at full speed for 2 minutes to 
wash the spin column membrane. The same step is repeated with AW2, a 
second wash buffer.  
Eluting DNA: The Allprep DNA spin column is placed in a new collection tube 
and 25μl of buffer EB (preheated at 70°C) is added directly to the spin column 
membrane. Following a few minutes of incubation, the spin column and 
collection tube are centrifuged for 1 minute at 10,000g. This procedure is 
repeated with another 25μl l of buffer EB. The final product consists of 50μl of 
pure eluted concentrated DNA in the collection tubes.  
                                       
 
               
 
Lyse The sample is disrupted then lysed 
  
Bind  DNA binds to the membrane and the 
contaminants flow through 
Wash Residual contaminants are washed 
away 
Elute DNA which is pure concentrated is 
eluted from the membrane 
 
Table 2.3 The QIAGEN Allprep DNA/RNA mini kit (50) 4 step procedure for 
DNA extraction from FF tissues. Adapted from the QIAGEN Allprep 
DNA/RNA mini kit handbook 2012 (QIAGEN, 2012) 
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Figure 2.4 DNA extraction from FF tissues. Procedure overview (QIAGEN, 
2012) 
 
 
2.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis is a commonly used technique to separate DNA 
fragments by their size. DNA is negatively charged at neutral pH due to its 
phosphate backbone. Therefore, when an electrical potential is present, the 
DNA molecules will move towards the positive pole in the agarose gel. This gel 
consists of Tris-borate EDTA (TBE) buffer solution (maintains the adequate pH 
and salt concentration) with 0.75% to 2% agarose added. The agarose forms a 
porous lattice in the solution, which allows the DNA to slip through the holes as 
it travels towards the positive poles. The rate at which DNA travels in the gel is 
determined by the fragments’ size: shorter molecules move faster and migrate 
further. The separated DNA is then viewed using a stain, most commonly and in 
our case Ethidium Bromide, which integrated in to the structure of the pre-
stained DNA allowing it to be visualised under UV light. UV light is absorbed by 
the Ethidium Bromide and re-emitted as visible light. This allows the fragments 
of the DNA to be observed. The DNA ladder or molecular weight marker is a set 
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of DNA fragments of a known molecular size that are used as a standard to 
determine the sizes of the unknown fragments placed in the gel. This is usually 
added first to the gel allowing for approximate assessment of the size of DNA 
fragments. The application of agarose gel electrophoresis includes assessing 
the quality and quantity of DNA and determining their size. This technique was 
used in this thesis to assess the quality of genomic DNA extracted and inspect 
PCR amplification products (Section 2.4.3). Extracted DNA was run on a 
concentration of 1.5% and PCR products was run on higher concentration using 
a 2% gel due to the expectation of larger DNA fragments. The gel was then 
assessed for the presence of DNA bands, the absence of ‘smear’ of degraded 
DNA indicating high quality DNA appropriate for downstream application (Figure 
2.5). The protocol used for the production and running of an agarose gel is 
outlined in Table 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.4. Agarose gel protocol 
1. 1.5 g of agarose was added to 100 ml of 1 x TBE buffer 
2. The solution was then warmed in a microwave, with intermitted 
mixing, until the agarose dissolved.  
3. 1 μl Ethidium Bromide was then added to the mixture once the 
solution cooled at room temperature and the whole lot mixed 
thoroughly.  
4. The gel was poured into a tank and combs added. This was left to set 
for about 25 minutes at room temperature.  
5. Once the solution set, the gel was placed in a solution of TBE buffer 
in a gel tank.   
6. The combs were removed gently, leaving wells in the gel.  
7. DNA ladder was added to the first well to allow estimation of DNA 
fragment sizes.  
8. 5μl of DNA from samples were added subsequently to other wells 
with 2μl of orange G loading buffer.  
9. The gel was run at 110 volts for 1 hour approximately.  
10.The gel was visualised under UV light and photographs were taken.  
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Figure 2.5 Agarose gel (1.5%) used to assess quality of extracted DNA 
from FF and FFPE samples. An example of 3 samples that show clear bands, 
absence of smear of degraded DNA indicating successful DNA extraction 
suitable for downstream applications.  
 
 
2.3.4 Spectrophotometry 
A spectrophotometer was used to assess the quality and quantity of DNA 
extracted. It is a device that consists of two instruments, a spectrometer for 
producing light and a photometer for measuring the intensity of the light 
wavelength. The DNA liquid is placed between the spectrometer beam and 
photometer. The photometer delivers a voltage signal, which changes as the 
amount of light absorbed by the liquid changes. DNA can absorb light at 260nm. 
RNA also has a great absorbance of light at 260nm and amino acids present in 
protein absorb light at 280nm, both considered contaminants in DNA. 
Furthermore, strong absorbance around 230nm can indicate that salts or 
organic compounds are present in the purified DNA. Therefore, a ratio of 260nm 
to 230nm can help evaluate the level of salt carried over in the purified DNA and 
a ratio of 260nm to 280nm the level of protein.  
A NandoDrop (ND-1000 Thermo Scientific, USA) was used to determine the 
concentration (ng/μl) and purity of extracted samples. Subsequently, DNA was 
considered pure if the 260/280 ratios were between 1.7-2.0 and the 260/230 
ratio was between 1.8 – 2.2 (Figure 2.6). Lower measurements would indicate 
the presence of co-purified contaminants such as protein. 
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Following quantification, an aliquot of each sample was diluted to a 
concentration of 25 ng/μl and stored at -20°C. Stock sample solutions were 
preserved at -80°C.   
 
Figure 2.6 Nanodrop samples. Six nucleic acid samples with a characteristic 
profile, ratios, and concentration.  
 
 
2.3.5 Dilutions 
Manual Dilutions 
All samples with a very high concentration of DNA (>500 ng/μl) were diluted in 
TE buffer to approximately 100 ng/μl in preparation for robotic dilutions 
 
Robotic dilutions 
Using an Eppendorf Epmotion Robot all samples were diluted to an exact level 
of 50 ng/μl prior to Sodium Bisulfite conversion, the next step. 
 
 
2.4 DNA modification for methylation analysis 
2.4.1 Bisulfite modification of DNA 
Commonly used sequencing technologies are unable to distinguish between 
methylated and unmethylated cytosine residues due to their similar base-pairing  
characteristics. Sodium Bisulfite (NaHSO3) is a chemical that alters the 
sequence of DNA. It converts unmethylated cytosines to uracils through 
deamination of these cytosines. Uracil is later replaced by thymine during 
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downstream procedures. Methylated cytosines are protected from deamination 
and therefore remain as cytosines (Figure 2.7) (Wang et al., 1980, Paul and 
Clark, 1996). This is necessary as sequencing technologies are unable to 
distinguish between methylated and unmethylated cytosines due to their similar 
base pairing characteristics. A range of technologies can be subsequently used 
to quantify this genetic alteration allowing determination of DNA methylation 
status through comparison of expected and observed DNA sequences 
(Frommer et al., 1992). 
 
Figure 2.7 DNA sodium bisulfite treatment. Taken from New England Biolabs 
(Ipsqhich, MA, USA) webpage (New England Biolabs, 2016) (www.neb.com). 
 
 
Sodium Bisulfite conversion was carried out on the genomic DNA samples, FF 
and FFPE, at the same time. 500ng of DNA from each sample was treated with 
sodium bisulfite using the EZ-96 DNA Methylation-Gold Kit (Zymo Research, 
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Irvine, CA, USA), according to manufacturer’s instructions. In brief, the ‘CT’ 
conversion reagent was added to 20μl of each DNA sample in a conversion 
plate. This was then heated under different temperatures. 400μl of Binding 
buffer was then mixed followed by a wash buffer. 200μl of desulfonation buffer 
was added, followed by a wash buffer. Finally, the 30μl of treated DNA was 
eluted for each sample. Figure 2.8 shows an overview of the experimental 
procedure. The detailed steps of the procedure are shown in Table 2.5. Sodium 
bisulfite treated DNA was aliquoted and stored at -20ºC. 
 
Figure 2.8 Overview of the sodium bisulfite treatment procedure 
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Step 1 Add 130 µl of the CT Conversion Reagent to 20 µl of each DNA 
sample in a Conversion Plate. Mix the samples by pipetting up 
and down.  
 
Step 2 Seal the plate with the provided film.  Transfer 
the Conversion Plate to a thermal cycler and perform the following 
steps:  
1.   98°C for 10 minutes 
2.   64°C for 2.5 hours 
3.   4°C storage up to 20 hours 
Step 3 Add 400 µl of M-Binding Buffer to the wells of Silicon-A™ Binding 
Plate mounted on a Collection Plate.   
Step 4 Transfer the samples from the Conversion Plate (Step 2) to the 
wells of the Silicon-A™ Binding Plate and mix.  
Step 5 Centrifuge at ≥ 3,000 x g (5,000 x g max.) for 5 minutes.  Discard the 
flow-through. 
Step 6 Add 400 µl of M-Wash Buffer to each well of the plate.  Centrifuge 
at  
≥ 3,000 x g for 5 minutes. 
Step 7 Add 200 µl of M-Desulfonation Buffer to each well and allow the 
plate to stand at room temperature for 15-20 minutes.  After the 
incubation, centrifuge at ≥ 3,000 x g for 5 minutes.  Discard the flow-
through. 
Step 8 Add 400 µl of M-Wash Buffer to each well of the plate.  Centrifuge 
at  
≥ 3,000 x g for 5 minutes.  Discard the flow-through.  Add another 
400 µl of M-Wash Buffer and centrifuge for 10 minutes. 
Step 9 Place the Silicon-A™ Binding Plate onto an Elution Plate.  Add 30 
µl of M-Elution Buffer directly to each well.  After 5 minutes, 
centrifuge at ≥ 3,000 x g for 3 minutes to elute the DNA. 
 
 
Table 2.5 Bisulfite treatment steps. Adapted from the EZ-96 DNA 
Methylation-Gold Kit booklet (Zymo Research, Irvine, CA, USA).  
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2.4.2 Polymerase chain reaction  
PCR was used to confirm the sodium bisulfite conversion. PCR is a technique 
commonly used to amplify a single or several copies of a piece of DNA, 
generating millions of copies of a particular DNA sequence. PCR uses a mix of 
components that are combined together and subject to cycles of heating and 
cooling in a thermocycler. During the first PCR step the mix is heated to a high 
temperature to activate the heat- sensitive polymerase taq. Three steps follow 
this:  
. 1) A denaturation step, where the mix is heated to 95°C to denature the 
double-stranded DNA;  
. 2) An annealing step where the mix is cooled to a primer-specific temperature 
(usually between 50°C and 65°C) to allow the primers to anneal with high 
specificity to the correct annealing sequence in the DNA;  
. 3) An elongation step at 72°C to allow the taq polymerase to synthetize the 
complementary strand of DNA using the deoxynucleotides (dNTPs).  
These three steps are repeated for a number of cycles to allow the synthesis of 
an exponential number of DNA amplicons. The final number of amplicons will 
be 2n, where n is the number of cycles. A final step at 72°C is added to allow a 
final extension.  
 
A PCR assay was performed to confirm sodium bisulfite conversion on a 
randomly selected sample of the genomic DNA (n=32), which includes both FF 
and FFPE tissues.  Seven FFPE samples and 21 FF samples were randomly 
selected. The assay used primers designed to specifically target sodium 
bisulfite converted DNA in the CTCF binding site 3 region of the imprinting 
control region upstream of H19 (Chr11: 1979977 – 1980267). The forward 
primer used had the following sequence = 5’ – 
TTTTAGGGTGTATTATTGAGGGTTA – 3’, and reverse primer = 5’ – 
CCCCATCCAAAAAAAACTTAAACTA – 3’.  
The reaction components used in this thesis, their functions and volumes are 
detailed in Table 2.6. The heating and cooling cycles used are outlined in Table 
2.7.  
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Table 2.6 Standard PCR reagents  
 
 
Component  Function  PCR reagent 
(concentration)  
Quantity (μl)  
Genomic DNA  Single-stranded bisulfite-
treated* genomic DNA 
provides the reaction 
template  
Bisulfite converted 
DNA  
(10 ng/μl)  
1  
Taq polymerase  Heat-resistant enzyme 
that extends primers to 
synthesise new strands 
of DNA complementary 
to the target sequence 
using DNA nucleotides 
Qiagen HotStar Taq 
polymerase  
(5 units/μl) (Qiagen, 
Venlo, Holland) 
0.05  
DNA Primers  Short, single-stranded 
oligonucleotides 
complementary to the 
target DNA sequence  
Forward and reverse 
primer mix  
(10μM)  
1  
DNA 
Nucleotides  
Nucleotide bases 
required for the 
synthesis of the new 
DNA strands  
dNTPs  
(2.5mM)  
0.2  
PCR buffer  Maintains optimum 
reaction pH  
10 x reaction buffers  1  
Magnesium 
chloride (MgCl2)  
Required for Taq 
polymerase function  
Magnesium chloride  
(25 mM)  
0.2  
RNAse/DNAse 
free water  
Ensures consistent 
reaction volume  
Water to 10 μl final 
volume  
6.55  
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Step  Function  Temperature 
(°C)  
Time  
1. Initiation  DNA mix is heated to activate 
the Taq. Hot-start Taq reduces 
mispriming and primer-dimer 
formation  
95  15 
minutes  
2. Denaturation  High temperatures denature the 
double stranded DNA into single 
stranded DNA  
95  20 
seconds  
3. Annealing  Lower temperatures allow the 
primers to anneal. Annealing 
temperature is selected carefully 
- too high and the primers are 
unable to anneal, too low and 
non-specific amplification 
occurs.  
50 - 65  30 
seconds  
4. Extension  Taq polymerase uses dNTPs to 
build the complementary DNA 
strand  
72  1 minute  
 
Repeat steps 2 to 4 between 20 and 40 times  
 
Up to 40 repeats  
5. Final 
extension  
Remaining single stranded DNA 
is fully extended  
72  3 minutes  
6. Finish  Products are kept at low 
temperatures  
4  ∞  
 
Table 2.7 Chosen PCR thermocycle.  
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2.4.3 Bisulfite DNA electrophoresis 
PCR amplification was confirmed using agarose gel electrophoresis (Section 
2.3.3) (Figure 2.9). There was a difference in general band intensity of bisulfite 
treated DNA between FFPE and FF samples on the gel electrophoresis images, 
with the FFPE samples generally lower in intensity. However, the presence of 
bands throughout indicated successful bisulfite conversion of genomic DNA.  
 
 
 
Figure 2.9 Agarose gel (2%) used to inspect PCR amplification products of 
random FF and FFPE samples. All samples amplified successfully during PCR 
except for FFPE sample 2 and FF sample 10. Top left shows 200bp ladder, 8 
FFPE samples, 6 FF samples, water (negative control). Bottom left shows 
200bp ladder, 14 FF samples. Whilst FFPE samples have amplified (except 
sample 2), it is noticeable that the intensity of FFPE samples is less than FF, 
indicating partially degraded/fragmented DNA in FFPE treated tissues.  
 
 
2.4.4 QUBIT fluorometric quantitation 
To ensure sufficient DNA concentration for downstream processing in the 
Illumina Infinium HumanMethylation450 Beadchip (Section 2.5), the 
concentration of genomic DNA in the samples was assessed with the QUBIT 
BR dsDNA assay using the QUBIT fluorometer (Life Technologies, Thermo 
Fisher Scientific). The QUBIT fluorometer is a small instrument that is used for 
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quantification of DNA, RNA and protein. It uses fluorescent dyes to quantify the 
concentration of nucleic acids and proteins in a sample. The dyes have low 
fluorescence until they bind to their targets, in this case the DNA. Once the dye 
binds to the DNA, it becomes intensely fluorescent. The fluorometer picks up 
the fluorescence signal and translates it into DNA concentration measurement.   
By using target-specific fluorescence, such as DNA, this method is more 
accurate than UV based methods for quantifying DNA concentration, such as 
the nanodrop. Table 2.8 illustrates the concentration of FF and FFPE samples 
randomly chosen.  
 
Sample 
ID FF 
Concentration 
(ng/ul) 
Sample 
ID FF 
Concentration 
(ng/ul) 
Sample 
ID 
FFPE 
Concentration 
(ng/ul) 
FF1 2.35 FFPE9 1.48 FFPE1 2.37 
FF2 2.31 FFPE10 1.29 FFPE2 2.25 
FF3 1.3 FFPE11 3.4 FFPE3 0.981 
FF4 9.3 FFPE12 4.86 FFPE4 1.16 
FF5 4.77 FFPE13 0.513 FFPE5 1.52 
FF6 4.66 FFPE14 4.51 FFPE6 1.71 
FF7 7.53 FFPE15 1.82 FFPE7 0.85 
FF8 5.52 FFPE16 3.56 FFPE8 0.879 
      
 
Table 2.8 Concentration of FF and FFPE samples. As measured by the 
QUBIT fluorometer.   
 
 
2.5 Genome-wide DNA methylation profiling 
2.5.1 Introduction 
Genome wide DNA methylation was quantified with the Illumina Infinium 
HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA) with arrays 
run on the HiScan System (Illumina, San Diego, Cam USA). The samples were 
processed across 16 BeadChips. The Illumina HumanMethylation450 BeadChip 
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(450K array) profiles the DNA methylation status of 485,577 sites per sample. 
This method was selected for the quantification of DNA methylation status 
because it offers a range of advantages over alternative approaches; relatively 
low DNA input, simple sample preparation, high sample throughput, lower 
running costs and simpler data storage. Furthermore, the widespread use of 
this array within the epigenetics research community enables cross-study 
comparison of research findings. Finally, the extensive use of this technology 
has led to development of a wide variety of freely available bioinformatic tools 
that can be used to extend data analysis and aid interpretation.  
Both FF and FFPE samples were examined using the Illumina 
HumanMethylation450 Beadchip. Due to the suboptimal quality of FFPE tissue 
and the chemistry, coverage and protocol of the 450K array, the final protocol 
was altered to input 7ul of the final eluate into the Infinium 450K array. The 
450K arrays were then processed following the manufacturer’s instructions.  
The key features of the Illumina Infinium HumanMethylation450 Beadchip will 
be briefly outlined in the section below (Section 2.5.2). 
 
2.5.2 Illumina HumanMethylation 450 BeadChip 
chemistry 
The Illumina Infinium I Whole Genome Genotyping assay was originally 
developed for Single Nucleotide Polymorphism (SNP) genotyping (Steemers et 
al., 2006). The 450K array used in this project to quantify DNA is an adaptation 
of the Illumina Infinium I. The nucleotide variant produced by sodium bisulfite 
conversion of DNA (Section 2.4.1) can be quantitatively “genotyped” using 
Illumina technology (Bibikova et al., 2009).  
The 450K array combines two assay types, Infinium I and Infinium II, to quantify 
DNA methylation status at single nucleotide resolution across the genome. The 
Infinium I assay was initially used by the predecessor of the 450K array, the 
Illumina HumanMethylation27 BeadChip (27K array). In this assay, two bead-
bound probes per CpG locus, one “methylated” and one “unmethylated”, are 
used to determine DNA methylation status (Figure 2.10). The 3’ terminus of one 
probe targets the cytosine protected by the presence of DNA methylation 
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(“methylated”), whereas the other probe targets the thymine that would result 
from bisulfite conversion and whole genome amplification of unmethylated DNA 
(“unmethylated”). DNA hybridisation is detected through a single-base 
extension with a labelled nucleotide, fluorescent staining and scanning. Each 
probe is 50 base pairs (bp) in length, therefore the design for Infinium I assays 
assumes that methylated is regionally correlated within 50 bp span. This 
assumption of regional correlation is supported by a study that found over 90% 
of CpG sites within 50 bases had the same DNA methylation status (Eckhardt et 
al., 2006), and the finding that methylation at adjacent sites tends to be 
correlated (Shoemaker et al., 2010).  
The Infinium II assay was introduced on the 450K array. This assay uses one 
probe per CpG locus rather than two, which enables increased genomic 
coverage, as more beads can be included on the array. In this assay, the 3’ 
terminus of the 50 bp probe complements the base directly upstream of the 
query site. The single base extension results in the incorporation of either a 
labelled G or A base, complementary to either the ‘methylated’ C or 
“unmethylated” T. The methylated and unmethylated signals are distinguished 
through use of different dye colours (green and red, respectively) (Figure 2.10). 
Additionally, the Infinium II probes are designed without the assumption that 
nearby CpGs are methylated to the same extent as the target CpG. Instead, 
degenerate bases (“R”) are included at CpG sites to allow assessment of 
methylation status at the query site independently of other CpG sites. However, 
a maximum of three R bases can be included in a probe sequence without data 
compromise, therefore the 450K array also includes a number of Infinium I 
probes to allow assessment of regions of DNA with high CpG density, such as 
promoter CpG islands.  
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Figure 2.10 Infinium I and Infinium II chemistry. A) Infinium I employs two 
bead types per CpG locus, one ‘methylated’ and one ‘unmethylated’ B) Infinium 
II design uses one bead per locus. The methylation state is determined at the 
single base extension step after hybridisation. 
 
2.5.3 Genomic coverage of the Illumina HumanMethylation450 
BeadChip  
The Illumina 450K BeadChip combines Infinium I and Infinium II assay 
chemistries for greater depth of coverage, enabling DNA methylation 
quantification at single nucleotide resolution at 485,577 sites across the  
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genome (n = 135,501 Infinium I; n = 350,076 Infinium II) (Section 2.5.2). By 
allowing the selection of specific target sequences through probe design, this 
technology avoids the bias that is inherent in capture methods, which typically 
miss regions of low CpG density, for example. However, the array only allows 
the investigation of a pre-designed probe set, which introduces the challenge of 
selecting appropriate CpG sites for inclusion on the array. A consortium of 
epigenetics researchers guided the selection of CpG sites to be interrogated by 
the 450K array (Bibikova et al., 2011). Emphasis was placed on covering CpG 
islands and RefSeq genes. Consequently 96% of CpG islands are interrogated 
and an average of 17 CpG sites across the 5’UTR, first exon, gene body and 
3’UTR of 99% of RefSeq genes (Bibikova et al., 2011). Additional sites covered 
by the array include CpG sites outside CpG islands, non-CpG sites identified in 
human stem cells, miRNA promoter regions and approximately 90% of all sites 
covered by the Illumina 27K array (482,421 CpG sites, 3091 non-CpG sites, 65 
control SNPs).  
 
 
2.6 Statistical analysis  
2.6.1 Quality control pipeline 
2.6.1.1 DNA data pre-processing  
Following the genome wide DNA methylation using the Illumina 450K BeadChip 
Array, signal intensities for each probe were extracted using the Illumina 
GenomeStudio Software (Illumina, San Diego, CA, USA). Data from 45 unique 
individuals (90 matched samples) entered our Quality Control (QC) pipeline, 
which was performed in the R (www.r-project.org) statistical programming 
environment 
(www.bioconductor.org/packages/release/bioc/html/methylumi.html) package. 
The wateRmelon package (Pidsley et al, 2013) was used for quality control and 
pre-processing of the data as described below.  
 
 
2.6.1.2 Sample and probe removal  
DNA Methylation levels reported as β values, are calculated from mean 
methylated (m) and unmethylated (u) signal intensities for each locus for each 
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sample. Therefore, the first step in the QC pipeline was to stringently filter the 
unnormalised Illumina 450K data using the pfilter function from the wateRmelon 
package (Pidsley et al, 2013). This function was used to filter CpG loci and 
samples by bead count and detection P-Values. This assessed the signal 
intensities of the samples. There was a marked difference in signal intensities 
between FF and FFPE tissues. FF samples demonstrated higher signal 
intensities than FFPE samples (Figures 2.11). Then the efficiency of bisulfite 
conversion was examined to exclude samples with conversion score <80. Four 
FFPE samples were found to have a conversion score <80.   
                                                                                                                      
 
 
 
A 
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D 
 
 
Figure 2.11 Methylated and unmethylated signal intensities across all 
samples. A) shows the methylated intensities of the FFPE samples, with the 
red line representing the cut off threshold of 2000. B) In contrast to A, the 
majority of the FFPE sample intensities in B were below the threshold. The 
same applies to the unmethylated intensities of FFPE samples in C) vs 
unmethylated intensities of FF samples in D). 
C 
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2.6.1.3 Principle component analysis 
To visually assess similarities and differences between the two types of 
samples and determine whether they can be grouped, principle component 
analysis (PCA) algorithm was applied to the samples. PCA executed on the 
whole data set showed a clustering of samples based on treatment method (FF 
and FFPE) (Figure 2.12). A second PCA of all samples against median 
methylation intensities showed a clustering of the FF samples (with the 
exception of one sample) above 2000, and a clustering of FFPE samples (with 
the exception of three samples) <2000 (Figure 2.13). 
 
 
         
Figure 2.12 PCA of all samples. This shows the clustering of samples based 
on treatment method: the FF samples are clustered in blue to the left of the 
graph, whereas the FFPE samples are clustered to the right of the graph in red.  
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Figure 2.13 PCA of all samples against M median. This shows a clustering of 
most of the FF samples (except one) above the 2000 threshold of median 
methylation intensity (in blue). The majority of FFPE samples are clustered in 
red below 2000.  
 
2.6.1.4 Selecting samples that passed QC 
Following the QC checks, in the light of the low signal intensities of the FFPE 
samples and the clustering of samples using PCA graphs, samples with both 
the median methylated ‘M’ and unmethylated ‘U’ intensities <2000 and their 
matched counterparts (matched cancer or normal mucosal) were excluded from 
subsequent analysis. Therefore, all FFPE samples and two FF samples were 
excluded.  
A final dataset comprising of n = 30 samples remained following implementation 
of QC procedures. These were all FF matched rectal tumour and adjacent 
normal mucosa samples from 15 individuals. Therefore, the term FF in the rest 
of this section will refer to the FF samples that passed our stringent QC 
methods and the rest of the data analysis was only performed on those 
samples.  
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2.6.1.5 Data normalisation  
Following QC checks, normalisation of data is necessary to remove systematic 
differences between samples and reduce undesirable variation between arrays. 
This ensures maximum sensitivity to detect differential methylation between 
experimental groups. Here, data were normalised using quantile-normalisation 
(QN). QN is a non-linear transformation that produces identical array-wide 
distributions by replacing each intensity score with the mean of the features with 
the same rank from each array. This is a well-established approach within gene 
expression analysis, where it has been found to perform well (Irizarry et al., 
2003). Specifically, the “dasen” method was utilised for data normalisation. This 
approach, defined by Pidsley et al., involves background adjustment of 
methylated and unmethylated intensities, followed by separate QN of 
methylated Type I, unmethylated Type I, methylated Type II and unmethylated 
Type II intensities. Using three performance metrics (utilising known DNA 
methylation patterns associated with genomic imprinting, X-chromosome 
inactivation and SNP genotyping assays included on the array) this 
normalisation scheme was quantitatively determined to be optimal (Pidsley et 
al., 2013).  
 
 
2.6.1.6 Gender check 
The cohort was assessed using multi-dimensional scaling (MDS) to graphically 
visualise the similarity of individuals within a dataset. The concordance between 
the expected sample sex (collected data), and the reported sample sex (DNA 
methylation data) was assessed through MDS visualisation of the DNA 
methylation status of Y-chromosome and X-chromosome CpG sites, which are 
expected to display sex differences due to the process of X-chromosome 
inactivation in females. There were no discrepancies in the reported gender and 
sex chromosomes in any of the samples that passed QC (Figure 2.14). 
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Figure 2.14 Multi-dimensional scaling for gender check. No discrepancies 
between reported and detected gender were found. 
 
2.6.1.7 Sample identity check 
In addition to examining predicted and reported sex, sample identity was further 
validated by examining the genotype correlation between the two types of 
tissues: rectal tumour and normal mucosa. There are 65 SNPs included on the 
450k methylation array that can be used to generate a DNA "fingerprint" of 
samples as an added level of QC. This is done by plotting the beta values from 
the 65 SNPs methylation profile in a scatter plot. Samples from the same 
individual have the SNP results fall along the identity line in a scatter plot 
whereas samples from different persons scatter into the 9 different possible 
spots, based on their genotypes (Figure 2.15). SNP results of the samples that 
did not pass the QC would not be expected to pass the sample identity 
validation.  
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Figure 2.15 Scatter plots of SNP results from three samples. A) The graph 
shows good correlation with SNP results from the same individual falling along 
the identity line. B) and C) show a scattering of the results with dots more 
spread out across the nine quadrants. B) represents a FFPE sample. C) 
represents a FF sample – the only FF sample to fail the QC test.  
 
A 
B 
C 
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2.6.1.8 DNA methylation age calculation 
DNA methylation values for the FF samples were uploaded to the DNA 
methylation online age calculator (Hovrath, 2013) to estimate DNA methylation 
age for each sample and obtain tissue prediction information. The DNA age 
calculator was developed using 8,000 samples from a broad range of healthy 
tissues, cancer tissues and cell lines. The calculator allows the estimation of 
DNA methylation age from a complete 450k dataset, using a weighted average 
data from 353 ‘clock CpGs’, which is then transformed to DNA methylation age 
using a calibration function. DNA methylation age for each FF sample is 
presented in Supplementary Table 1 (Appendix 4). 
 
 
2.6.2 Data analysis 
2.6.2.1 Paired t-test  
Following successful QC, data was analysed using a t-test for group mean 
differences in DNA methylation between the normal and tumour samples. 
Global methylation difference was reported.  
For each CpG site a β-value was generated by calculating the ratio of the 
normalised signal from the methylated probe to the sum of the normalised 
signals of the methylated and unmethylated probes. Consequently, the β-value 
is a measurement ranging continuously from zero (unmethylated) to one (fully 
methylated).  
 
 
2.6.2.2 Top probes selection 
To identify rectal cancer associated DNA methylation differences at the 
individual probe level across all samples, I performed a linear regression using 
the pre-processed and normalised DNA methylation β values as the dependent 
variable and tissue type, cancer vs normal, as the independent variable. Other 
phenotypical factors such as medication, smoking status and gender were not 
included due to incomplete data.  
DNA methylation differences are frequently auto-correlated across the genome, 
therefore probe-wise multiple testing corrections are often overly stringent, 
which can make data-interpretation challenging. To account for concordance of  
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DNA methylation effect across genomic regions, the command line tool comb-p 
was used to identify spatially correlated DNA methylation-phenotype 
associations. Illumina probe-site chromosomal coordinates and respective P-
values for the effects of interest were output from the linear regression 
performed as described above. This data was then manipulated using the 
program comb-p to (1) calculate auto-correlations (2) combine adjacent P 
values (3) perform false discovery adjustment (4) find regions of enrichment and 
(5) assign significance to those regions. 
 
 
2.6.2.3 Top regions selection 
Because DNA methylation is often correlated across adjacent CpG sites across 
broad genomic regions we also sought to identify differentially methylated 
regions (DMRs) associated with rectal cancer in our samples. Although several 
approaches exist to identify DMRs, we used the Python module, Comb-P, to 
detect spatially correlated P-values (Pedersen et al, 2012) and group spatially 
correlated differentially methylated probes (seed P-value < 1.00E-3, minimum of 
5 probes) in each region. The regions’ p-values were corrected for multiple 
testing using Sidak correction (Sidak, 1967), which corrects the combined P for 
na/nr test, where na is the total number of probes tested in the initial EWAS and 
nr the number of probes in the given region.   
 
 
2.6.2.4 Gene ontology analysis  
An enrichment analysis on Gene Ontology (GO) terms was performed next, to 
test for a significant enrichment of particular GO terms (Ashburner et al., 2000). 
A logistic regression model developed by our group was used, as described in 
Lunnon et al. (2016), to test if genes in each module predicted pathway 
membership, while controlling for the number of probes in each network 
annotated to each gene. Pathways were downloaded from the GO website 
(Gene Ontology Consortium, 2015) and mapped to genes including all parent 
ontology terms. All genes with at least one 450k probe annotated and mapped 
to at least one GO pathway were considered. Pathways were filtered to those 
containing between 10 and 2000 genes. After applying this method to all 
pathways, the list of significant pathways (P < 0.05) was refined by grouping 
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related pathways to control for the effect of overlapping genes. This was 
achieved by taking the most significant pathway, and retesting all remaining  
significant pathways while controlling additionally for this best term. If the test 
genes no longer predicted the pathway, the term was said to be explained by 
the more significant pathway, and hence these pathways were grouped 
together. This algorithm was repeated, taking the next most significant term, 
until all pathways were considered as the most significant or found to be 
explained by a more significant term.  
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Chapter 3 - Results 
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3.1 Methodological overview 
Matched tumour and normal adjacent mucosal colorectal samples were 
collected and DNA isolated using methods described (Section II). Genomic 
DNA was treated with sodium bisulfite in duplicate using the EZ-96 DNA 
methylation-gold kit (Zymo Research, Irvine, CA, USA) and DNA methylation 
profiled using the Infinium HumanMethylation450 BeadChip (Illumina, San 
Diego, CA, USA) processed on an Illumina HiScan System (Illumina) using an 
adjusted protocol (Section 2.5.1). All samples were randomised within and 
between arrays to avoid potential batch effects. In total, 90 FF and FFPE 
matched rectal samples, of normal mucosa and adjacent tumour, entered the 
QC pipeline. The majority (> 90%) of the FFPE samples and one FF sample 
failed the QC test. Therefore, all FFPE samples (n= 62) and two FF samples 
(the tumour sample that failed the QC test and its matched normal sample 
counterpart) were excluded. In total, 30 matched samples, all FF, passed the 
stringent QC tests. The data from these samples was subsequently analysed.  
In summary, we assessed genome wide patterns of DNA methylation in 30 
human matched rectal tumour and adjacent normal mucosal samples (7 males 
and 8 females, age range 45-79 years). The results obtained from the QC 
analysis of the FFPE samples will be presented first, followed by the results of 
the FF samples and the methylation data obtained.  
 
 
3.2 FFPE tissues 
3.2.1 Clinical and histopathological characteristics  
Historical CRC samples were collected from 2004-2007 and stored in the ETB 
database. Sections of these samples were cut, placed in micro-cassettes, 
immediately fixed in formalin and treated with paraffin. Paraffin embedding 
allows for histological verification of the content and quality of the historical 
samples, and assesses the integrity and heterogeneity of the tumour cells. All 
historical samples were thought to be adenocarcinoma tumours taken from the 
colonic epithelium. However, the results of the histological examination showed 
not all adjacent mucosal samples were biopsied from the colonic epithelium and 
tumour samples contained varied cancer content (visually estimated in 
percentage terms). Table 3.1 shows a summary of the histological findings. 
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Sample  Type of tissue collected 
adjacent to the tumour  
Cancer % in rectal tumour 
tissue collected 
1 Colonic epithelium  20% 
2 Colonic epithelium  100% 
3 Colonic epithelium  90% 
4 Muscle sample 35% 
5 Ischemic sample 0% (Ischemic sample) 
6 Dysplastic sample 100% 
7 Colonic epithelium  90% 
8 Colonic epithelium  30% 
9 Colonic epithelium  10% Tumour + Necrosis 
10 Colonic epithelium  50% Tumour + Necrosis 
11 Colonic epithelium  90% 
12 Colonic epithelium  55% 
13 Colonic epithelium  90% 
14 Dysplastic sample 50% 
15 Muscle Sample 20% 
16 Colonic epithelium  45% 
17 Colonic epithelium  90% 
18 Colonic epithelium  0% (Dysplastic sample) 
19 Colonic epithelium  90% 
20 Colonic epithelium  70% 
21 Colonic epithelium  30% 
22 Colonic epithelium  80% 
23 Colonic epithelium  80% 
24 Colonic epithelium  90% 
25 Colonic epithelium  35% 
26 Colonic epithelium  40% 
27 Colonic epithelium  50% 
28 Colonic epithelium  0% (Dysplastic sample) 
29 Colonic epithelium  0% (Dysplastic sample) 
 
Table 3.1 Type of tissue in FFPE mucosal samples and quantification of 
cancer in tumour samples. 
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3.2.2 QC and exclusion from methylation analysis  
Before proceeding with the Illumina 450K microarray protocol, it was necessary 
to sodium bisulfite convert all the samples (n=90). Genomic DNA (500ng) from 
each individual was treated with sodium bisulfite using the Zymo EZ DNA 
MethGold Kit according to the manufacturer's protocol (Section 2.4.1). 
The first QC step assessed the methylation intensity profiles of all the samples. 
Prior to methylation quantification using Illumina 450K, a PCR assay on a 
portion of the samples was performed to confirm the success of the sodium 
bisulfite conversion. Seven FFPE samples and 21 FF samples were randomly 
selected. PCR amplification was confirmed using agarose gel electrophoresis. 
There was a difference in general band intensity of bisulfite treated DNA 
between FFPE and FF samples on the gel electrophoresis images, with the 
FFPE samples generally lower in intensity. The presence of clear bands 
throughout however, indicated successful bisulfite conversion of genomic DNA 
(Section 2.4.3) (Figure 2.9). To ensure sufficient DNA concentration for 
downstream processing in the Illumina Infinium HumanMethylation450 Bead 
Chip, the concentration of genomic DNA in the samples was assessed with the 
QUBIT BR dsDNA assay using the QUBIT Fluorometer (Life Technologies, 
Thermo Fisher Scientific). This method is more accurate than UV based 
methods such as the nanodrop, for quantifying DNA concentration. QUBIT 
Fluorometric Quantification showed that the DNA concentration of FFPE 
samples was overall lower than the FF samples (DNA concentration mean for 
FF samples = 4.71, DNA concentration mean for FFPE samples = 2.02), yet 
sufficient to proceed with downstream processing (Section 2.4.4). Both FF and 
FFPE samples were examined using the Illumina HumanMethylation450 
BeadChip. Due to the suboptimal quality of FFPE tissue and their slightly lower 
DNA concentration, and due to the chemistry, coverage and protocol of the 
450K array, the final protocol was altered to input 7ul of the final FFPE elute, 
more than the standard protocol, into the Infinium 450K array. The 450K arrays 
were then processed following the manufacturer’s instructions. 
Following the genome wide DNA methylation using the Illumina 450K BeadChip 
Array, signal intensities for each probe were extracted using the Illumina 
GenomeStudio Software (Illumina, San Diego, CA, USA). Data from 45 unique 
individuals (90 matched samples) entered our Quality Control (QC) pipeline, 
which was performed in the R (www.r-project.org) statistical programming 
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environment. QC tests returned suboptimal results on the FFPE samples. The 
first QC step was to measure the signal intensities of the samples. DNA 
Methylation levels reported as β-values, are calculated from mean methylated 
(m) and unmethylated (u) signal intensities for each locus for each sample. 
There was a marked difference in signal intensities between FF and FFPE 
tissues. FF samples demonstrated higher signal intensities than FFPE samples 
(Figure 2.11). In addition to examining predicted and reported sex, sample 
identity validation is another important QC measure. Sample identity was 
validated by examining the genotype correlation between the two types of 
tissues: rectal tumour and normal mucosa. There are 65 SNPs included on the 
450K methylation array that can be used to generate a DNA "fingerprint" of 
samples as an added level of quality control. This is done by plotting the β-
values from the 65 SNPs methylation profile in a scatter plot. Samples from the 
same individual have the SNP results fall along the identity line in a scatter plot, 
samples from different persons scatter into the 9 different possible spots, based 
on their genotypes (Figure 2.15). SNP results of the samples that did not pass 
the QC would not be expected to pass the sample identity validation.  
A high correlation between the two types was observed for all FF samples 
(except one sample) further confirming no sample mix-ups and success of 
detection of methylation intensities. However, a low correlation (r<0.95) 
between rectal tumour and normal mucosal tissue was found in all FFPE 
samples (Section 2.6.1.7). Finally, PCA executed on the whole data set showed 
a clustering of samples based on treatment method (FF and FFPE). A second 
PCA of all samples against median methylation intensities showed a clustering 
of the FF samples (except for one sample) above 2000, and a clustering of 
FFPE samples (except for three samples) <2000 (Figure 3.1). Following these 
results, the threshold for passing the QC check was set at median methylation 
intensity of >2000 for methylated (m) and unmethylated (u) signals. This 
threshold was set based on previously tested thresholds within the group, the 
QC tests showing suboptimal results for the FFPE samples and a further PCA 
of all samples against methylation intensities, showing a clear separation of the 
two types of tissues above and below the 2000 mark. Only three FFPE samples 
(out of 58 analysed) passed the threshold. Figure 2.11 shows the signal 
intensities of all FFPE samples. Consequently, all FFPE samples were 
excluded from further analyses. All FF samples except for one had a 
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methylation signal intensity of >2000. After exclusion of the one FF sample with 
signal intensity <2000 and its matched counterpart, 30 samples in total all 
processed as FF were included in the methylation analyses. 
 
 
Figure 3.1 PCA showing clustering of samples. A) PCA executed on the 
whole data set showed a clustering of samples based on treatment method (FF 
and FFPE). B) PCA of all samples against median methylation intensities 
showed a clustering of the FF samples (with the exception of one sample) 
above 2000, and a clustering of FFPE samples (with the exception of three 
samples) <2000. 
A 
B 
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3.3 FF samples 
3.3.1 Introduction 
Following a successful DNA extraction and bisulfite conversion, the samples 
were processed using Illumina 450K. The unnormalised Illumina 450K data was 
stringently filtered using the pfilter function of the watermelon package. This, 
filters both samples and CpG loci dependent on bead count and detection p-
values. Following data normalisation, PCA was applied to reveal the presence 
of any underlying data-structure that could be attributed to unknown variables. 
PCA executed on the FF samples included in the analysis set showed a 
clustering of samples based on pathological disease state (Tumour vs Normal), 
indicating the presence of widespread epigenetic differences associated with 
rectal cancer (Figure 3.2). Following successful QC, data was analysed using a 
t-test for group mean differences in DNA methylation between the normal and 
tumour samples. No further covariates were included in this test. A linear 
regression model was used to identify DNA methylation at individual probes 
then region-level analysis was performed by spatially combining correlated P-
values using the Python module comb-p. Finally, Gene Ontology (GO) 
enrichment analysis was performed.  
 
Figure 3.2 PCA of FF samples. PCA on all FF samples showed a clustering of 
samples based on type of tissue (Normal mucosa [RISTN] Vs Tumour [RISTT]). 
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3.3.2 Clinical and pathological characteristics of rectal cancer 
patients 
A final data set comprising of n=30 FF samples and n = 424,413 probes 
remained following implementation of QC procedures. These samples 
corresponded to rectal cancer patients and included n=7 males (age range 45-
79) and n=8 females (age range 63-79). The clinical and pathological 
characteristics are described in Table 3.2 and Table 3.3.  
 
We analysed rectal tumour tissue and matched normal adjacent mucosal tissue 
from 15 patients diagnosed with rectal tumours (adenocarcinoma n= 12, high 
grade dysplasia n= 2, low grade dysplasia n=1) at the Royal Devon and Exeter 
hospital Exeter, Devon, UK.   
The inclusion criteria were as follows: a clinical diagnosis of rectal cancer 
(histopathological initial polyp biopsies were considered unrepresentative due to 
their superficial nature. Subsequently, three samples showed dysplasia, and the 
rest (n=12) were adenocarcinoma). The median age of the patients was 71 
years (range 44.9 – 74.7 years) with 7 men and 8 women.  
Samples were taken during surgery or colonoscopy, after the purpose and 
nature of all the procedures were fully explained and written consent obtained 
from all patients. Biopsies from all 15 patients contained a sufficient amount of 
tissue for DNA extraction and downstream processes. The CRF NIHR in Exeter, 
approved the protocol of the study. 
 
 
 
 
Characteristics N % 
   
Gender   
Female 8 53.33 
Male  7 46.67 
Age   
Median 71  
Range 45-79  
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Procedure   
Surgery 15 100.00 
Type   
Adenocarcinoma 12 80.00 
High Grade Dysplasia 2 13.33 
Low Grade Dysplasia 1 6.67 
Tumour (Radiological Stage)  
T4 2 13.33 
T3 8 53.33 
T2/3 3 20.00 
T2 1 6.67 
N/R 1 6.67 
Nodes (Radiological Stage)  
N2 1 6.67 
N1 5 33.33 
N0 8 53.33 
N/R 1 6.67 
Metastasis    
No 15 100.00 
Yes 0 0.00 
Location   
High Rectum 8 53.33 
Mid Rectum 1 6.67 
Low Rectum 6 40.00 
 
 
 
Table 3.2 Summary of the clinical and histopathological characteristics of 
tumour samples. 
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3.3.3 Global hypomethylation in tumour samples 
A combined analysis of all 424,413 probes on the Illumina 450K array passing 
stringent QC metrics showed that global levels of DNA methylation are 
decreased in rectal tumour samples compared with normal unaffected samples 
(rectal tumour mean β = 0.468, normal mucosa β = 0.471, mean difference = 
0.003 P= 0.006). Therefore, global hypomethylation in rectal tumour samples vs 
normal mucosal samples was demonstrated.  For each CpG site a β-value was 
generated by calculating the ratio of the normalised signal from the methylated 
probe to the sum of the normalised signals of the methylated and unmethylated 
probes. Consequently, the β-value is a measurement ranging continuously from 
zero (unmethylated) to one (fully methylated). Plotting the density of all β-values 
for all samples showed that, as expected, the data followed a bimodal 
distribution (Figure 3.3). The methylated peak for the normal mucosal samples 
was skewed to the left of the rectal tumour samples, corresponding to the 
higher global methylation levels of the normal mucosal samples. Given the 
global DNA methylation changes observed we also tested whether there was a 
difference in derived “DNA methylation” age between tumour and normal 
samples. We did not identify a significant difference suggesting there is no 
elevated aging in the tumour tissue (p=<0.05).  
 
                                                                                 β-value 
Figure 3.3 Beta density plot for rectal tumour and adjacent mucosal 
samples. A clear shift to the left is seen for normal mucosal samples. (Note the 
shift is on sites already methylated, as expected, with no difference on 
unmethylated sites). 
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3.3.4 Identification and distribution of differentially methylated 
positions (DMPs) 
A linear regression model was used to identify DNA methylation at each probe 
associated with rectal cancer. Probes were identified as significantly associated 
if they passed a stringent threshold of P < 2E-7. We found that DNA methylation 
at autosomal sites was variable whereas overall there is a decreased global 
DNA hypomethylation in rectal cancer (Section 3.3.3).  
Out of the 424,413 probes that passed the QC pipeline, a total of 176 probes 
were differentially methylated between rectal cancer tissues and normal 
mucosa. We refer to these as differentially methylated positions (DMPs).  
The distribution of DMPs is relatively consistent across most autosomal 
chromosomes (Figure 3.4), however, one chromosome showed a notable 
enrichment of significant sites: 8.5% of CpG probes on chromosome 20 were 
identified as DMPs (enrichment = 4.12, p = 1.05E05) (Table 3.4).  
Although the DMPs are seen throughout the genome, they are not equally 
distributed with regard to annotated genetic features. The hypermethylated and 
hypomethylated DMP sites were distributed over six gene categories: TSS1500 
(15.3%), TSS200 (15.9%), 5′UTR (26.1%), 1st exon (19.9%), gene body (21%), 
3′UTR (0.57%) and intergenic regions (22.7%) (Figure 3.5). 
The distribution of the hypermethylated and hypomethylated DMPs over CpG 
islands (CGIs), CGI shores, CGI shelves and open sea regions was also 
analysed. As expected, the vast majority of CpG sites (79.0%) were located in 
the CpG islands, followed by CGI shores (10.8%), CGI Sea (9.1%) and CGI 
shelves (1.1%) (Figure 3.5). 
For categorisation,	the CpG counts were normalised by the number of CpGs in 
the same category represented on the 450K array, and the percentage of 
normalised CpG counts is indicated through the bars (Figure 3.6). 
Compared to the distribution of all probes included in the dataset, DMPs were 
significantly enriched in promoter regulatory regions including CpG islands 
(percentage of significant probes = 79%, relative enrichment = 7.9, p = 3.63E-
37), 5’ untranslated regions (5’ UTRs) (percentage of significant probes= 
26.1%, relative enrichment = 2.14, p = 3.06E-05), genic first exons (percentage 
of significant probes = 19.9%, relative enrichment = 2.69, p = 1.89E-06). 
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Conversely, DMPs were significantly underrepresented in CGI shores 
(percentage of significant probes = 10.8%, relative enrichment = 0.39, p = 
2.45E-05), CGI shelves (percentage of significant probes = 1.14%, relative 
enrichment = 0.11, p = 1.16E-05), CGI seas (percentage of significant probes = 
9.1%, relative enrichment = 0.19, p = 2.36E-15) and gene bodies (percentage of 
significant probes = 21%, relative enrichment = 0.46, p = 9.95E-06) and 3’ 
untranslated regions (percentage of significant probes = 0.57%, relative 
enrichment = 0.13, p = 0.008).  
Relative enrichment and depletion in the vicinity of annotated transcription start 
site TSS200 and TSS1500 respectively was non-significant (percentage of 
probes in TSS200 = 16%, relative enrichment = 1.19, p = 0.38 and percentage 
of probes in TSS1500 = 15.3%, relative enrichment = 0.83, p = 0.43) (Figure 
3.7). Table 3.5 and Table 3.6 show an overview of the distribution of all probes 
and DMPs across CpG and genomic features. Table 3.7 and Table 3.8 show  
the distribution of hypomethylated and hypermethylated probes, respectively, 
across CpG regions. Table 3.9 and Table 3.10 show the distribution of 
hypomethylated and hypermethylated probes, respectively, across genomic 
features.  
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Figure 3.4 Manhattan plot showing the distribution of tumour associated 
DMPs across all autosomes. The red line represents the threshold                
(P < 1.25E-7). The dots above the red line portray the DMPs and the dots below 
the line depict all the probes on each chromosome. 
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 All % Rectal % P Value Enrichment 
       
Total 424413 100 176 100   
        
Chr1 41386 9.751350689 18 10.22727273 0.799228153 1.054406535 
Chr2 30645 7.220561104 17 9.659090909 0.240852363 1.374025428 
Chr3 22400 5.277877916 6 3.409090909 0.395350087 0.63331765 
Chr4 17753 4.182953868 8 4.545454545 0.707256146 1.090815528 
Chr5 21412 5.045085801 11 6.25 0.487208025 1.254879621 
Chr6 31336 7.383374213 14 7.954545455 0.772132497 1.084051903 
Chr7 25538 6.017252063 18 10.22727273 0.025491392 1.779909941 
Chr8 18312 4.314665196 15 8.522727273 0.013491585 2.067048207 
Chr9 8625 2.032218617 3 1.704545455 1 0.835907898 
Chr10 21445 5.052861246 6 3.409090909 0.391046051 0.663102935 
Chr11 25781 6.074507614 6 3.409090909 0.156041819 0.545605772 
Chr12 21649 5.100927634 8 4.545454545 0.864719947 0.885874634 
Chr13 10700 2.521129183 7 3.977272727 0.220431718 1.601871084 
Chr14 13297 3.133033154 2 1.136363636 0.187490593 0.355282331 
Chr15 13176 3.104523188 4 2.272727273 0.666420557 0.725754703 
Chr16 18866 4.445198427 3 1.704545455 0.095782672 0.372666999 
Chr17 24506 5.774092688 6 3.409090909 0.254086598 0.575839664 
Chr18 5305 1.249961712 0 0 0.288840233 0 
Chr19 22002 5.184101335 9 5.113636364 1 0.985669098 
Chr20 9397 2.21411691 15 8.522727273 1.05E-05 4.119682271 
Chr21 3731 0.87909654 0 0 0.41387867 0 
Chr22  7286 1.71672404 0 0 0.080687631 0 
 
Table 3.4 Distribution of DMPs split by autosomal chromosomes. 
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Figure 3.5 Pie charts showing the distribution of DMPs. A) across CpG sites 
B) across genomic features. 
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Figure 3.6 Bar chart depicting the distribution of probes across CpG sites. 
Light green bars indicate the distribution of all the probes whereas adjacent 
dark green bar indicates the percentage of the significant DMP for that same 
region. Above the bars is the p value of the difference.	 
	
 Total 
Probes 
(%) DMPs  
(p < 2E-07)  
(%) P Value Enrichment  
Total 424413 100 176 100   
Shelf 39297 9.26 2 1.14 1.16E-05 0.11 
Shore 100025 23.57 19 10.80 2.45E-05 0.39 
Island 136651 32.20 139 78.98 3.63E-37 7.92 
Sea 148440 34.98 16 9.09 2.36E-15 0.19 
 
Table 3.5 Overview of the distribution of the DMPs across CpG regions.   
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Figure 3.7. Bar chart depicting the distribution of probes across genomic 
features. Light green bars indicate the distribution of all the probes whereas 
adjacent dark green bar indicates the percentage of the DMP for that same 
region. Above the bars is the p value of the difference. 
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 All Probes (%) DMPs (%) P Value Enrichment 
Total 424413 100.00 176 100   
TSS1500 76045 17.92 27 15.34 0.431496981 0.83 
TSS200 58046 13.68 28 15.91 0.380057727 1.19 
5'UTR 60213 14.19 46 26.14 3.06E-05 2.14 
1stExon 35899 8.46 35 19.89 1.89E-06 2.69 
Body 155343 36.60 37 21.02 9.95E-06 0.46 
3'UTR 17737 4.18 1 0.57 0.007827814 0.13 
Intergenic 96166 22.66 40 22.73 1 1.00 
 
Table 3.6 Overview of the distribution of the DMPS across genomic 
features.   
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A
ll 
H
ypom
ethylated 
Probes 
%
 
Significantly 
H
ypom
ethylated 
Probes 
(p< 1.25E-7) 
%
 
P Value 
Enrichm
ent 
Total 
197772 
100 
21 
100 
 
 
Shelf 
21769 
11.00711931 
1 
4.761904762 
0.72245339 
0.404225178 
Shore 
41076 
20.76937079 
2 
9.523809524 
0.284586158 
0.401521283 
Island 
48256 
24.39981393 
5 
23.80952381 
1 
0.968230273 
Sea 
86671 
43.82369597 
13 
61.9047619 
0.122858355 
2.083215505 
	Table 3.7 O
verview
 of the distribution of hypom
ethylated probes across C
pG
 regions.  
 
 A
ll  
H
yperm
ethylated  
Probes 
  %
 
 Significantly 
H
yperm
ethylated 
Probes (p< 1.25E-7) 
  %
 
  P value 
  Enrichm
ent 
 Total 
 226641 
 100 
 155 
 100 
 
 
 Shelf 
 17528 
 7.733816918 
 1 
 0.64516129 
 0.000112052 
 0.077394769 
Shore 
58949 
26.009857 
17 
10.96774194 
5.48E-06 
0.35022811 
Island 
88395 
39.00221054 
134 
86.4516129 
2.47E-34 
9.992248395 
Sea 
61769 
27.25411554 
3 
1.935483871 
2.69E-17 
0.052635237 
 	Table 3.8 O
verview
 of the distribution of hyperm
ethylated probes across C
pG
 regions.   
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A
ll 
H
ypom
ethylated 
Probes 
%
 
Significantly 
H
ypom
ethylated 
Probes (p< 1.25E-7) 
%
 
P Value 
Enrichm
ent 
 Total 
 
197772 
 
100 
 
21 
 
100 
 
 
 TSS1500 
 
30491 
 
15.42 
 3 
 
14.29 
 1 
 
0.91434221 
TSS200 
23335 
11.80 
0 
0.00 
0.164494492 
0 
5'U
TR
 
24362 
12.32 
2 
9.52 
1 
0.749249321 
1stExon 
14137 
7.15 
1 
4.76 
1 
0.649439526 
B
ody 
73231 
37.03 
5 
23.81 
0.261909754 
0.531426339 
3'U
TR
 
7947 
4.02 
0 
0.00 
1 
0 
Intergenic 
54056 
27.33 
11 
52.38 
0.014264388 
2.924888549 
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H
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ethylated 
Probes 
  %
 
Significant 
H
yperm
ethylated 
probes (p< 1.25E-7) 
  %
 
  P Value 
  Enrichm
ent 
 Total 
 226641 
 100 
 155 
 100 
 
 
 TSS1500 
 45554 
 20.10 
 24 
 15.48 
 0.161287284 
 0.728144993 
TSS200 
34711 
15.32 
28 
18.06 
0.371135895 
1.219233509 
5'U
TR
 
35851 
15.82 
44 
28.39 
9.14E-05 
2.110903761 
1stExon 
21762 
9.60 
34 
21.94 
4.03E-06 
2.64796571 
B
ody 
82112 
36.23 
32 
20.65 
3.59E-05 
0.457714581 
3'U
TR
 
9790 
4.32 
1 
0.65 
0.016079783 
0.143721678 
Intergenic 
42110 
18.58 
29 
18.71 
0.918071224 
1.008588913 
	Table 3.10 O
verview
 of the distribution of hyperm
ethylated probes across genom
ic features.
Table 3.9 O
verview
 of the distribution of hypom
ethylated probes across genom
ic features.    
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3.3.5 Identification of DMPs associated with rectal cancer 
 
The top 10 autosomal DMPs (ranked by P value) are listed in Table 3.11. They 
consist of nine hypermethylated probes (characterised by higher methylation in 
tumour samples) and one hypomethylated probe (cg18538668, characterised 
by lower DNA methylation in tumour samples). Figure 3.8 shows box plots 
demonstrating the beta value difference of the top ten probes with gene name 
and p values. Differences in DNA methylation were observed across all of the 
rectal samples (n=30) between matched normal mucosa and tumour for the top 
ranked DMPs (Figure 3.9). A complete list of all 176 DMPs is found in 
Supplementary Table 2 (Appendix 4).  
Out of the 176 DMPs, 21 were hypomethylated in tumour samples and the rest, 
155 probes, were hypermethylated. Overall there is a highly significant 
enrichment of hypermethylated autosomal DMPs compared with 
hypomethylated DMPs (hypermethylated DMPs n = 155 P <2.2e-16). Figure 
3.10 shows a heatmap of the DMPs identified. 
Some DMPs have not been annotated to genes, leaving a total of 137 DMPs 
annotated to known genes (95 genes in total, 71%).  
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  Probe 
P Value 
R
egression coefficient 
C
hr 
Position 
G
ene nam
e 
Probe location 
cg02647878 
3.66E-10 
0.45 
4 
154681197 
R
N
F175 
5'U
TR
; 
1stExon 
cg14650610 
7.30E-10 
0.48 
5 
136834492 
SPO
C
K1 
5'U
TR
 
cg13001868 
1.58E-09 
0.45 
17 
43339223 
C
17orf46; 
LO
C
100133991 
Body;  
TSS1500 
cg13895235 
2.22E-09 
0.57 
7 
752292 
PR
KAR
1B 
5'U
TR
 
cg18538668 
3.79E-09 
-0.20 
14 
103839038 
 
 
cg03061682 
4.83E-09 
0.42 
15 
28352098 
 
 
cg24847829 
6.29E-09 
0.40 
5 
136834464 
SPO
C
K1 
5'U
TR
 
cg26034516 
6.48E-09 
0.35 
17 
76228121 
LO
C
283999 
Body 
cg03576469 
6.83E-09 
0.29 
19 
46917061 
C
C
D
C
8 
TSS200 
cg18601167 
8.02E-09 
0.56 
7 
752286 
PR
KAR
1B 
5'U
TR
 
  	 Table 3.11 The top ten D
M
Ps. Table lists each probe, its chrom
osom
al position and genic location, its annotated gene, p value and 
direction of effect
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Figure 3.8 Box plots of beta values of the top ten probes. The box plots are 
showing the beta values of tumour vs non-tumour samples annotated with the 
probe name (at the top of plot) and gene name (if available) with p values in 
brackets (at the bottom of plot). One DMP (probe cg18538668) is more 
hypomethylated in tumour vs normal mucosa. All nine other DMPs are 
hypermethylated in tumour vs normal mucosa. Whiskers depict the 25 and 75% 
quartile of the data.  
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Figure 3.9 Top ten DMPs between each pair of rectal samples. Graphs 
showing the difference in DNA methylation (∆β) between each pair of matched 
rectal samples (tumour and normal mucosa) for each of the ten top-ranked 
differentially methylated positions (DMPs). Mean ∆β across all 15 pairs is 
highlighted with red bar. Consistent within each pair are differences in DNA 
methylation. Notably, sample 8 consistently showed lower (∆β) than the other 
samples across all DMPs.  
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Figure 3.10 Heatmap of DMPs. This heatmap is depicting the difference in the 
top DMPs between normal rectal samples (red) and rectal tumour (yellow). The 
sample identifications are written at the top, with N for ‘normal’ and T for 
‘tumour’.  
 
Several of our top DMPs are located in the vicinity of genes that have previously 
been implicated in cancer pathways. Of note: 
cg02647878, the top ranked DMP, was hypermethylated in rectal tumour 
compared with normal mucosa (p =3.66E-10). It is located on chromosome 4, 
189 kb downstream of the transcriptional start site (TSS) of the RNF175 gene, 
which encodes ring finger protein 175 and is involved in the prevention of 
oncogenesis (Ng et al., 2003). Also, amongst the top ten ranked DMPs is the 
hypermethylated cg03576469 probe (p= 6.83E-09) associated with the gene 
CCDC8, a regulator of microtubule dynamics and associated with metastasis of 
breast cancer (Pangeni et al., 2015). Interestingly, two of the top ten ranked  
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DMPs were in the vicinity of PRKAR1B gene. The probes cg13895235 and 
cg18601167 are located on chromosome 7 downstream of the TSS of 
PRKAR1B gene (p = 2.22E-09 and p = 8.02E-09 respectively). Similarly, 
SPOCK1 gene was associated with two top ten-ranked DMPs: cg14650610 and 
cg24847829 (p = 7.30E-10 and p = 6.29E-09 respectively), located on 
chromosome 5 downstream of the TSS of SPOCK1. Both SPOCK1 and 
PRKAR1B play a role in cancer pathways (Miao et al., 2013) (Naviglio et al., 
2009). Table 3.12 lists all of the DMPs (p < 2E-7) identified in the analysis that 
have previously been found to play a role in cancer, along with the genes they 
are annotated to
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   Probe(s) 
G
enom
ic 
Position 
Illum
ina 
G
ene A
n-
notation 
G
enic 
R
egion 
D
N
A
 
M
ethylation 
D
ifference 
(%
) 
P Value 
G
ene Function 
Literature 
Finding 
  
  
  
  
  
  
  
  
cg20295442 
C
hr8:67344665 
AD
H
FE1 
TSS200 
47.80 
1.37E-07 
Encodes 
hydroxyacid-
oxoacid 
transhydrogenase  
  
Frequently 
m
ethylated in C
R
C
. 
M
ethylation-m
ediated 
dow
n expression 
of A
D
H
FE1 and 
proliferation of C
R
C
 
cells alcohol induced 
(M
oon et al., 2014) 
  
cg20912169 
C
hr8:67344720 
AD
H
FE1; 
AD
H
FE1 
5'U
TR
; 
1stExon 
47.99 
1.64E-07 
cg26328335 
C
hr12:50354840 
AQ
P5 
TSS1500 
44.60 
3.26E-08 
Encodes 
Aquaporin 5, a 
w
ater channel 
protein.  
      
A
ssociated w
ith C
R
C
 
m
etastasis (K
ang et 
al., 2008) and w
ith 
tum
our TN
M
 stage, 
lym
ph node and 
distant m
etastases 
(Shan et al., 2014) 
    
cg08266366 
C
hr12:50354998 
AQ
P5 
TSS1500 
37.51 
3.38E-08 
cg03020208 
C
hr12:50354962 
AQ
P5 
TSS1500 
30.40 
3.85E-08 
cg15336765 
C
hr12:50355307 
AQ
P5; 
AQ
P5 
1stExon; 
5'U
TR
 
42.95 
5.15E-08 
cg13850380 
C
hr1:1475143 
C
1orf70 
Body 
31.76 
1.60E-07 
Encodes 
C
hrom
osom
e 1 
open reading 
fram
e 70  
  
M
ethylated in C
R
C
 
(N
aum
ov et al., 2013) 
cg16306898 
C
hr1:1475675 
C
1orf70 
1stExon 
47.78 
1.83E-07 
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cg17170568 
C
hr7:156433406 
C
7orf13;  
TSS200; 
 
17.71 
5.05E-08 
Encodes 
C
hrom
osom
e 7 
open reading 
fram
e 13 
M
ethylation levels 
im
plicated in 
expression levels 
and clinical 
outcom
es in 
glioblastom
a 
(Etcheverry et al., 
2010) 
cg13405887 
C
hr9:132382812 
C
9orf50 
1stExon 
42.46 
4.37E-08 
Encodes 
C
hrom
osom
e 9 
open reading 
fram
e 50  
  
N
ovel blood based 
D
N
A
 m
ethylation 
biom
arker for C
R
C
 
early detection 
(N
aum
ov et al., 2013) 
  
cg14015706 
C
hr9:132382433 
C
9orf50 
1stExon 
50.26 
1.30E-07 
cg03576469 
C
hr19:46917061 
C
C
D
C
8 
TSS200 
29.07 
6.83E-09 
A regulator of 
m
icrotubule 
dynam
ics 
A
ssociated w
ith 
m
etastasis of breast 
cancer (Pangeni et 
al., 2015) 
cg08516516 
C
hr5:115152492 
C
D
O
1 
TSS200 
30.09 
1.50E-07 
Encodes C
ysteine 
dioxygenase type 
1 w
hich is involved 
in m
etabolic 
pathw
ays of 
hypotaurine and 
pyruvate 
M
ethylation plays a 
role in C
R
C
, is a 
prom
ising biom
arker 
for C
R
C
 detection 
(Yam
ashita et al., 
2014)  
cg11573679 
C
hr2:68546467 
C
N
R
IP1 
1stExon 
47.54 
1.03E-07 
Encodes a protein 
that interacts w
ith 
the C
-term
inal tail 
of cannabinoid 
receptor 1. 
  
M
ethylated C
N
R
1P1 
w
as recently 
included in a novel 
com
bined biom
arker 
panel for detection of 
C
R
C
 and 
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cg24171907 
C
hr2:68546579 
C
N
R
IP1; 
C
N
R
IP1 
 
1stExon; 
5'U
TR
 
 
44.70 
1.32E-07 
prem
alignant 
m
elanom
as (Lind et 
al., 2011) 
  
cg21938148 
C
hr13:11095897
7 
C
O
L4A1; 
C
O
L4A1 
Body; 
TSS1500 
47.95 
4.01E-08 
Encodes a type IV 
collagen alpha 
protein. 
M
ethylated in 
peripheral blood D
N
A
 
in C
R
C
 cancer cases 
(M
itchell et al., 2014) 
cg11751707 
C
hr2:38302587 
C
YP1B1 
5'U
TR
 
27.31 
3.85E-08 
Encodes 
cytochrom
e P450 
1B1 
M
ethylation levels 
involved in 
developm
ent of som
e 
C
R
C
s and altered 
response to 
chem
otherapy in 
C
R
C
 (H
abano et al., 
2009) 
cg17393267 
C
hr3:192127356 
FG
F12; 
FG
F12 
TSS1500
; Body 
28.74 
6.15E-08 
Encodes 
Fibroblast grow
th 
factor 12  
  
H
yperm
ethylated in 
C
R
C
, prom
ising early 
detection biom
arker 
(Li et al., 2012) 
  
cg16366473 
C
hr3:192126849 
FG
F12; 
FG
F12 
TSS200; 
Body 
41.24 
1.88E-07 
cg26958524 
C
hr16:86613067 
FO
XL1 
1stExon 
33.70 
2.90E-08 
Encodes Forkhead 
box protein L1 
H
yperm
ethylated in 
adenoid cystic 
carcinom
a of salivary 
gland (B
ell et al., 
2012)  
cg03424342 
C
hr3:120169783 
FSTL1; 
FSTL1 
5'U
TR
; 
1stExon 
27.91 
8.35E-08 
Encodes 
Follistatin-related 
protein 1 
R
eduction in D
N
A
 
m
ethylation after 
treatm
ent w
ith 
C
elecoxib in 
oesophageal 
carcinom
a (Liu JF, 
2016) 
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cg24820783 
C
hr10:26504969 
G
AD
2 
TSS1500 
24.71 
1.41E-08 
Encodes 
G
lutam
ate 
D
ecarboxylase 2 
    
H
yperm
ethylated in 
C
R
C
 (Li et al., 2012) 
    
cg11903130 
C
hr10:26506751 
G
AD
2 
Body 
34.81 
1.82E-07 
cg11328303 
C
hr10:26505440 
G
AD
2; 
G
AD
2 
5'U
TR
; 
1stExon; 
27.11 
1.94E-08 
cg13389502 
C
hr17:1961440 
H
IC
1 
Body 
16.17 
1.72E-07 
G
row
th regulatory 
and tum
our 
suppressor gene  
H
yperm
ethylated in 
C
R
C
, the loss of a 
single H
IC
1 allele 
w
as found to 
accelerate polyp 
form
ation in m
ice 
w
ith A
PC
 gene 
m
utation 
(M
oham
m
ad et al., 
2011) 
H
yperm
ethylation 
w
as also found to 
play an im
portant 
role in the initiation 
of the disease 
(W
ahab et al., 2011) 
cg18607529 
C
hr7:50343869 
IKZF1 
TSS1500 
40.88 
3.47E-08 
Encodes IKAR
O
S 
Fam
ily Zinc Finger 
1 protein 
  
M
ethylated in several 
cancers, potential to 
be used as a blood 
biom
arker in the 
detection of C
R
C
 
recurrence (Pedersen 
et al., 2015) 
  
cg07589773 
C
hr7:50343883 
IKZF1 
TSS1500 
37.26 
3.80E-08 
cg26415547 
C
hr12:66583048 
IR
AK3; 
IR
AK3 
1stExon; 
5'U
TR
 
31.99 
4.82E-08 
Encodes 
interleukin-1 
receptor-
M
ethylated in 
hepatocellular 
carcinom
a tissues, 
associated w
ith 
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associated kinase 
3 protein 
tum
our stage and 
poor prognosis (K
uo 
et al., 2015) 
cg17228900 
C
hr6:391764 
IR
F4; 
IR
F4 
5'U
TR
; 
1stExon 
45.37 
9.42E-08 
Belongs to the 
Interferon 
R
egulatory factor 
fam
ily of 
transcription 
factors w
hich 
contribute to the 
regulation of the 
interferon 
signalling pathw
ay 
IFN
 
Plays a role in rectal 
cancer (Slattery et 
al., 2011) 
cg25024074 
C
hr2:182322501 
ITG
A4 
1stExon 
31.15 
2.94E-08 
Encodes Integrin 
Alpha 4 receptor 
for fibronectin 
    
Frequently 
m
ethylated in C
R
C
 
and adenom
a tissues 
(Zhang et al., 2015) 
    
cg11947981 
C
hr2:182322749 
ITG
A4 
Body 
39.48 
6.39E-08 
cg06952671 
C
hr2:182322268 
ITG
A4; 
ITG
A4 
5'U
TR
; 
1stExon 
47.21 
2.55E-08 
cg20415809 
C
hr2:182321855 
ITG
A4; 
ITG
A4 
5'U
TR
; 
1stExon 
38.61 
3.92E-08 
cg21995919 
C
hr2:182322279 
ITG
A4; 
ITG
A4 
5'U
TR
; 
1stExon 
41.46 
9.27E-08 
cg05447008 
C
hr6:73331114 
KC
N
Q
5 
TSS1500 
40.04 
9.87E-09 
 Encodes 
Potassium
 
Voltage-G
ated 
C
hannel Subfam
ily 
Q
 M
em
ber 5 
H
yperm
ethylated in 
C
R
C
 (A
shktorab et 
al., 2013) 
cg04377145 
C
hr6:73331191 
KC
N
Q
5 
TSS1500 
32.90 
2.72E-08 
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cg23977631 
C
hr2:100938799 
LO
N
R
F2; 
LO
N
R
F2 
5'U
TR
; 
1stExon 
45.66 
1.30E-08 
Encodes LO
N
 
Peptidase N
-
Term
inal D
om
ain 
and R
ing Finger 2 
H
yperm
ethylation 
thought to contribute 
to tum
ourigenesis or 
rectal cancer (H
ua  et 
al., 2017) 
cg27200446 
C
hr6:41606439 
M
D
FI 
5'U
TR
 
57.21 
1.62E-07 
Encodes M
yoD
 
Fam
ily Inhibitor 
H
yperm
ethylated in 
C
R
C
 (Lin et al., 2014) 
cg16964348 
C
hr7:24323799 
N
PY 
TSS200 
39.09 
1.65E-08 
Encodes 
N
europeptide Y 
protein 
    
H
yperm
ethylated in 
C
R
C
 and prom
ising 
biom
arker (R
operch 
et al., 2013) 
    
cg24242823 
C
hr7:24323675 
N
PY 
TSS200 
37.21 
6.79E-08 
cg25884711 
C
hr7:24323840 
N
PY 
5'U
TR
; 
1stExon 
41.79 
2.52E-08 
cg04366687 
C
hr8:145107199 
O
PLAH
 
Body 
35.31 
7.26E-08 
Encodes 5-
oxoprolinase, an 
enzym
e 
responsible for 
glutathione 
synthesis and 
degradation 
H
yperm
ethylated in 
C
R
C
 (N
aum
ov et al., 
2013) 
cg13895235 
C
hr7:752292 
PR
KAR
1B 
5'U
TR
; 
TSS200 
56.92 
2.22E-09 
A regulatory 
subunit of cyclic 
AM
P dependent 
protein kinase A 
(PKA) 
      
Involved in the 
cA
M
P/PK
A
 signalling 
pathw
ay w
hich is 
altered in different 
cancers and m
ay be 
used in cancer 
therapy and 
diagnosis (N
aviglio et 
al., 2009) 
       
cg18601167 
C
hr7:752286 
PR
KAR
1B 
5'U
TR
; 
TSS200 
55.98 
8.02E-09 
cg12441126 
C
hr7:751962 
PR
KAR
1B 
5'U
TR
 
41.41 
6.21E-08 
cg20381963 
C
hr7:752238 
PR
KAR
1B 
5'U
TR
; 
TSS200 
50.90 
6.48E-08 
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cg24645214 
C
hr8:54789978 
R
G
S20 
Body 
30.08 
1.45E-07 
R
egulator of G
 
protein signalling 
U
pregulated in a 
variety of tum
ours, 
m
ay prom
ote 
m
etastasis of tum
our 
cells (Yang  et al., 
2016) 
cg02647878 
C
hr4:154681197 
R
N
F175; 
R
N
F175 
5'U
TR
; 
1stExon 
44.94 
3.66E-10 
Encodes ring 
finger protein 175 
    
Involved in the 
ubiquitination 
pathw
ay, thought to 
contribute to the 
aetiology of tum
ours 
(H
oeller et al., 2006) 
    
cg18355902 
C
hr4:154681128 
R
N
F175; 
R
N
F175 
5'U
TR
; 
1stExon 
40.11 
7.28E-08 
cg01440841 
C
hr4:154681066 
R
N
F175; 
R
N
F175 
5'U
TR
; 
1stExon 
35.12 
1.06E-07 
cg25645268 
C
hr4:154710598 
SFR
P2 
TSS1500 
30.58 
7.81E-08 
Encodes secreted 
frizzled-related 
protein 2  
Frequently 
m
ethylated in C
R
C
 
and adenom
a tissues 
(Zhang et al., 2015) 
cg03064067 
C
hr12:85306916 
SLC
6A15 
TSS1500 
39.48 
1.70E-07 
A disintegrin-like 
and 
m
etallopeptidase 
(reprolysin type) 
w
ith 
throm
bospondin 
type 1 m
otif)  
H
yperm
ethylated in 
C
R
C
 (K
im
 et al., 2011) 
cg14658804 
C
hr5:168728213 
SLIT3 
TSS200 
33.08 
1.92E-07 
Encodes Slit 
G
uidance  
Ligand 3 
  
Frequently 
m
ethylated in C
R
C
 
and significantly 
associated w
ith TN
M
 
stage, lym
ph node 
m
etastasis and 
differentiation 
(H
uang et al., 2015) 
cg09073398 
C
hr5:168727762 
SLIT3; 
SLIT3 
5'U
TR
; 
1stExon 
38.52 
1.20E-07 
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cg24190603 
C
hr6:84418433 
SN
AP91; 
SN
AP91 
Body; 
5'U
TR
 
35.53 
5.05E-08 
Encodes 
Synaptosom
e 
Associated Protein 
91 
 
D
ow
nregulated due 
to prom
oter 
hyperm
ethylation in 
around 60%
 of 
colorectal cancer and 
m
ay be associated 
w
ith treatm
ent 
resistance (B
eggs et 
al., 2013) 
cg09296001 
C
hr7:127672564 
SN
D
1 
Body 
52.17 
8.21E-08 
Staphylococcal 
nuclease 
hom
ology  
dom
ain 1 
  
Frequently up-
regulated in hum
an 
colon cancers 
(N
aum
ov et al., 2013)  
  
cg12628196 
C
hr7:127672458 
SN
D
1;  
LR
R
C
4 
Body; 
TSS1500 
40.31 
4.87E-08 
cg14650610 
C
hr5:136834492 
SPO
C
K1 
5'U
TR
 
48.50 
7.30E-10 
Encodes the 
protein core of a 
sem
inal plasm
a 
proteoglycan 
containing 
chondroitin- and 
heparan-sulfate 
chains. 
Prom
otes tum
our 
grow
th and 
m
etastasis in 
prostate cancer 
(C
hen et al., 2016), 
contributes to 
m
etastases of 
recurrent 
glioblastom
a (Yu et 
al., 2016) and plays a 
role in gallbladder 
and lung cancers 
(M
iao et al., 2013) 
cg24847829 
C
hr5:136834464 
SPO
C
K1 
5'U
TR
 
39.69 
6.29E-09 
cg12619536 
C
hr1:108508067 
VAV3 
TSS1500 
41.58 
1.49E-07 
A m
em
ber of the 
VAV gene fam
ily 
O
verexpressed in 
C
R
C
 and is 
correlated w
ith 
tum
our m
etastases 
and invasion (U
en et 
al., 2015) 
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cg25480336 
C
hr20:50720908 
ZFP64 
Body 
38.50 
1.50E-08 
Encodes Zinc 
Finger Protein 64 
M
ethylation levels 
indicate different 
m
olecular 
m
echanism
s for 
tum
ourigenesis in 
laterally spreading 
tum
ours of the 
colorectum
 (Sugai et 
al., 2016) 
cg17892556 
C
hr19:12267464 
ZN
F625; 
ZN
F625 
1stExon; 
5'U
TR
 
46.62 
1.49E-07 
Encodes Zinc 
Finger Protein 625 
H
yperm
ethylated in 
C
R
C
 (Lin et al., 2014) 
  Table 3.12 Sum
m
ary of D
M
Ps involved in rectal cancer, C
R
C
, cancer pathw
ays or colorectal diseases. 
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3.3.6 Identification of differentially methylated regions (DMRs) 
associated with rectal cancer 
Many DMPs do not represent isolated changes at specific sites but rather occur 
in clusters known as differentially methylated regions (DMRs). Region level 
analysis was performed using Comb-p (Section 2.6.2.3) to identify spatially 
correlated regions of differential DNA significantly associated with rectal cancer. 
We allowed a maximum distance 500 bp between neighbouring CpG sites, and 
only included probes with a P-value <1e-7 in the initial epigenome wide 
association scan as starting points for identifying potential DMRs. For each 
DMR, we report the combined P, which is Stouffer–Liptak–Kechris-corrected for 
regional correlation structure, and the multiple-testing-corrected Šidák P-value. 
The latter corrects the combined P for na/nr tests, where na is the total number 
of probes tested in the initial epigenome wide association scan and nr the 
number of probes in the given region.  
In total, 828 differentially DMRs were identified in rectal cancer vs normal tissue 
(P < 1E-7, number of probes >=5). The top ten ranked DMRs (ranked by Sidak-
corrected P value) are shown in Table 3.13 and the top region is shown in 
Figure 3.11. 53 of the genes annotated to DMRs were also annotated to DMPs. 
They are listed in Supplementary Table 3 (Appendix 4). A complete list of all 
significant DMRs is found in Supplementary Table 4 (Appendix 4). 
 
Six of the genes annotated to our top ten DMRs (Table 3.13) were found to be 
of interest, of note:  
 
- The top ranked DMR was annotated to the gene PRKAR1B (p<1.24E-
19) which was also listed twice in the top ten DMPs (Table 3.4), is a gene 
involved in signalling pathway which are often altered in different cancers 
and may be used in cancer therapy and diagnosis (Naviglio et al., 2009). 
- ITGA4 gene, also annotated to several DMPs, is frequently 
hypermethylated in CRC (Table 3.5). 
- Hypermethylated TBX15, has been correlated with low expression of the 
TBX15 protein and thought to play a role in the pathogenesis of ovarian 
cancer (Gozzi et al., 2016).  
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- GSTM2 methylation has previously been identified in prostate cancer, 
breast cancer and oral squamous cell carcinoma (Ashour et al., 2014, 
Rauscher et al., 2015, Li YF et al., 2015) and considered a potential 
biomarker for rectal cancer (Wei et al., 2016) 
- NPY methylation has been successfully included in a six-CpG 
methylation biomarker panel for prediction of treatment (CRT) response 
in patients with oesophageal squamous cell carcinoma (Chang et al., 
2016). 
- EYA4 promoter methylation has previously been linked to CRC and 
shown to function as a tumour suppressor gene as well as being a 
potential biomarker (Kim SJ et al., 2015) 
 
Furthermore, six genes - CDH13, RUNX3, SFRP1, SFRP2, ESR1 and ITGA4 - 
known to play a role in the in the multi-step process from normal colonic 
epithelium leading to adenocarcinoma (Section 1.6.3.3), were annotated to 
DMRs in our rectal cancer samples. Table 3.14 lists their function and Figure 
3.12 illustrates their role in the progression of normal colon to adenocarcinoma.   
 
Other DMRs identified were also in the vicinity of genes that have previously 
been implicated in colon and rectal cancer. The SEPT9 gene for example, a 
member of the Septin family of genes, is a well-studied and promising 
biomarker for CRC (Grutzman et al., 2008, Tanzer et al., 2010). Genes SFRP1, 
SFRP2 and Fli1 are also considered potential biomarkers for detection and 
monitoring of colon and rectal cancer (Zhang et al., 2007, Vymetalkova et al., 
2016, Nagaska at al., 2009, Tang et al., 2011). Table 3.15 lists all of the genes 
annotated to DMRs that have been implicated in rectal cancer or considered to 
be a potential biomarker for cancer treatment response.  
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Chromosome Start End Gene N of 
Probes 
Sidak P 
Value 
CpG 
region 
chr7 751830 752456 PRKAR1B 9 1.24E-19 island 
chr3 129693370 129694683 TRH 11 7.14E-19 island 
chr1 119526783 119528848 TBX15 14 8.02E-19 island 
chr10 118031632 118033902 GFRA1 24 8.33E-19 island 
chr2 182321489 182322841 ITGA4 11 3.88E-18 island 
chr7 24323128 24323939 NPY 10 1.82E-17 island 
chr8 69243285 69244734 C8orf34-AS1; 
C8orf34 
12 1.66E-16 island 
chr6 133561224 133562776 EYA4 41 1.76E-16 island 
chr5 134362967 134363973 PITX1 9 2.38E-16 island 
chr8 70982867 70983760 PRDM14 10 3.32E-16 island 
 
 
Table 3.13. The top ten DMRs. Chromosomal location is indicated in the first 
three columns, followed by gene name, the number of probes identified, the 
corrected Sidak p value and the CpG region in the last column. As expected, all 
methylated genes were located in the CpG islands. The table with all the DMRs 
is found in Supplementary Table 4 (Appendix 4).  
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Figure 3.11 The top ranked DMR and annotated gene (PRKAR1B). This 
graph demonstrates the percentage methylation change of the top ranked gene 
identified through the DMRs and its distribution on chromosome 7.
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 Chrom
osom
e 
G
ene 
N
am
e 
N
. 
Probes 
Sidak 
P Value 
C
pG
 
R
egion 
Function 
M
ethylated in C
R
C
 
chr16:82659960-
82660873 
C
D
H
13 
C
adherin 13 
15 
5.98E-12 
Island 
C
ell recognition and 
adhesion, anti-
apoptotic. Tum
our 
suppressor gene, 
involved in cell cycle 
regulation.  
Progression of 
norm
al colon to 
aberrant crypt foci 
(Section 1.6.3.3) 
chr1:25257505-
25258082 
R
U
N
X3 
R
unt-related 
transcription 
factor 3 
13 
2.55E-10 
Island 
Transcription factor  
Progression of 
norm
al colon to 
aberrant crypt foci 
(Section 1.6.3.3) 
chr9:41166530-
41167278 
SFR
P1 
Secreted frizzled-
related protein 1 
8 
8.79E-16 
Island 
W
nt antagonist 
Progression of 
norm
al colon to 
aberrant crypt foci 
(Section 1.6.3.3) 
chr4:154710224-
154710961 
SFPR
2 
Secreted frizzled-
related protein 2 
17 
2.07E-17 
Island 
W
nt antagonist 
Progression of 
norm
al colon to 
aberrant crypt foci 
(Section 1.6.3.3) 
chr4:154710224-
154710961 
SFPR
2 
Secreted frizzled-
related protein 2 
6 
4.21E-12 
Island 
W
nt antagonist 
Progression of 
norm
al colon to 
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 Table 3.14 The list of genes annotated to D
M
R
s know
n to play a role in the in the m
ulti-step process from
 norm
al 
colonic epithelium
 leading to adenocarcinom
a. 
   
aberrant crypt foci 
(Section 1.6.3.3) 
chr6:152128024-
152129036 
ESR
1 
O
estrogen  
receptor 1  
21 
1.84E-11 
Island 
Transcription factor  
Progression of 
Aberrant C
rypt 
Focus to 
Polyp/Adenom
a 
(Section 1.6.3.3) 
chr2:182321489-
182322841 
ITG
A4 
Integrin Alpha 
Subunit G
ene 
11 
6.02E-23 
Island 
Encodes Integrin Alpha 
4 receptor for 
fibronectin 
Progression of 
Aberrant C
rypt 
Focus to 
Polyp/Adenom
a 
(Section 1.6.3.3) 
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           Figure 3.12 The com
m
only m
ethylated genes in the progression of norm
al colon to adenocarcinom
a w
ith em
phasis 
on rectal cancer associated genes. In black are all genes previously know
n to play a role in the progression of norm
al 
epithelium
 to adenocarcinom
a. H
ighlighted in yellow
 are the genes w
e found hyperm
ethylated in rectal tum
our sam
ples 
com
pared w
ith norm
al m
ucosa. Adapted from
 Lao and G
rady (2011). 
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R
egion 
G
ene 
N
.Probes 
P Value 
Epigenetic/C
ancer Literature 
 
chr11:12869367
7-128694679 
FLI1 
9 
7.83E-07 
Prom
ising biom
arker for rectal cancer as part of a specific D
N
A 
m
ethylation signature (Vym
etalkova et al., 2016) 
chr14:23834710
-23835212 
EFS 
9 
6.24E-13 
Associated w
ith prediction of biochem
ical, local, and system
ic 
recurrence of prostate cancer (Vanaja et al., 2009) 
chr17:75368750
-75369657 
Sept9 
10 
2.21E-05 
 
U
sed com
m
ercially as a m
ethylation biom
arker for C
R
C
 detection 
(Payne SR
, 2010) 
C
hr7:19156621-
19158747 
C
hr7:19146032-
19146555 
TW
IST1 
TW
IST1 
30 
5 
4.45E-15 
1.94E-09 
 
D
ifferentially m
ethylated in rectal tum
ours (Exner at al., 2015) 
C
hr4:11153326
7-111533951 
C
hr4:11155496
6-111555503 
C
hr4:11154988
0-111550666 
PITX2 
PITX2 
PITX2 
7 5 6 
1.41E-10 
4.00E-08 
2.38E-06 
D
ifferentially m
ethylated in rectal tum
ours (Exner at al., 2015) 
C
hr11:4433090
3-44333192 
ALX4 
46 
5.56E-15 
 
H
yperm
ethylated in C
R
C
 serum
 and correlated w
ith advanced stage 
disease (Ebert et al., 2006) 
C
hr1:25257505- 
25258082 
R
U
N
X3 
13 
2.55E-10 
 
H
yperm
ethylation in serum
 a prom
ising diagnostic m
arker in C
R
C
 
(Tan et al., 2007) 
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C
hr8:97505391-
97505868 
C
hr8:97507561-
97507958 
SD
C
2 
SD
C
2 
8 5 
1.33E-11 
2.08E-11 
 
S
D
C
2 m
ethylation in serum
 is useful for diagnosis and m
onitoring of 
C
R
C
 (O
h, et al., 2013) 
C
hr4:15471022
4-154710961 
C
hr4 
154713235-
154713789 
SFR
P2 
SFR
P2 
17 
6 
2.45E-12 
6.63E-07 
 
Potential stool and serum
 biom
arker in C
R
C
 patients (N
agaska at 
al., 2009, Tang et al., 2011) 
C
hr7:93519220-
93520566 
TFPI2 
20 
2.34E-20 
 
H
yperm
ethylation is a potential biom
arker for detection of C
R
C
 
(G
lockner et al., 2009) 
C
hr20: 
23029640-
23030343 
TH
BD
 
5 
4.32E-14 
 
H
yperm
ethylation m
arker for early C
R
C
 detection (Lange et al., 
2012)  
C
hr17:1961109-
1961778 
 
H
IC
1 
 
5  
1.21E-12 
  
H
yperm
ethylated in C
R
C
 stool sam
ples (Lenhard et al., 2005) 
 
C
hr20:5817984
7-58180616 
PH
AC
TR
3 
5 
1.34E-13 
 
Found m
ethylated in C
R
C
 stool (Bosch et al., 2012) 
C
hr13:3691934
4-36919960 
 
SPG
20 
7 
1.93E-09 
 
D
etected in stool sam
ples of patients w
ith C
R
C
 (Zhang et al., 2013) 
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 Table 3.15 The list of genes annotated to D
M
R
s that are know
n to play a role in rectal cancer or show
n to have 
biom
arker potential. 
 chr9:41166530-
41167278 
SFR
P1 
8 
8.79E-16 
D
N
A stool test of hyperm
ethylation of SFR
P1 prom
oter found to be 
a good m
ethod for early detection of C
R
C
 (Zhang et al., 2007) 
C
hr4:96470053-
96471143 
C
hr4:96468962-
96469634 
 
U
N
C
5C
 
U
N
C
5C
 
12 
9 
1.93E-17 
2.51E-13 
 
Inactivation of the U
N
C
5C
 N
etrin-1 receptor is associated w
ith 
tum
our progression in colorectal m
alignancies (Bernet et al., 2007). 
U
N
C
5C
 m
ethylation w
as found to be negatively correlated w
ith 
protein expression and prognosis in C
R
C
 patients (W
u et al., 2017) 
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3.3.7 Identifying key pathways: gene ontology  
To assess whether the genes identified (Section 3.3.6) were biologically 
meaningful, GO enrichment analysis was performed on genes annotated to 
DMPs identified in the analysis using the R package. 
The logistic regression approach described by Lunnon et al. (2016) was used 
for the GO analysis. In summary, all probes were mapped to genes using the 
standard gene annotation file provided by Illumina (GRCh37/hg19). GO terms 
were downloaded and annotated to all probes based on these gene annotations 
where all parent terms were also included. Probes without genic annotation or 
without any gene ontology annotation were excluded from the subsequent 
analysis. GO Pathways were filtered to contain between 10 and 2000 genes 
each. Significant pathways (P <0.05) were then grouped together using a loop 
algorithm.   
We therefore analysed 828 genes annotated with DMRs. Our analysis revealed 
the significant enrichment of multiple modules in various GO terms. We grouped 
the GO terms into two different categories: cellular components and biological 
functions. In the cellular category, our analysis identified 46 enriched (P < 0.05) 
terms (Table 3.16). The top proteins encoded by the analysed genes in this 
category, mainly associate with neuronal functions and plasma membranes as 
expected. Although we are unable to give a full description of each of the 
significant pathways due to limited space, many are interesting in relation to 
cancer. For example, the extracellular region (GO: 0005576, p < 0.0013) and its 
GO parts including the extracellular matrix (ECM) (GO:0031012, p < 7.55151E-
08), the proteinaceous ECM (GO:0005578, p < 1.35639E-06), the ECM part 
(GO:0044420 p < 0.0017) as well as the transcription factor complex pathway 
(GO:0005667, p < 0.0004) are listed in the top categories and play a role in 
cancer (Section 4.6).  
 
Categorisation by “biological process” identified 687 enriched (p <0.05) terms, 
mainly associated with developmental, neuronal and cell differentiation 
activities. We observed that the top terms included pathways that are known to 
play a role in cancer, such as DNA cell-cell adhesion (GO:0098609), cell-cell 
adhesion via plasma-membrane adhesion molecules (GO:0098742), regulation 
of transcription regulatory region DNA binding (GO:2000677), regulation of 
transcription regulatory region DNA binding (GO:2000677) and cell fate 
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commitment (GO:0045165). Table 3.17 lists some of the terms that are relevant 
to cancer. All the enriched biological and cellular terms can be found in 
Supplementary Table 5 and Supplementary Table 6 (Appendix 4). 
 
 
 
GO Term N of 
Genes 
P-value Adjusted   
P-value 
     
GO:0044456 Synapse Part 40 1.9776E-09 6.24921E-07 
GO:0005887 Integral component 
of plasma membrane  
71 3.36109E-08 5.31052E-06 
GO:0031012 Extracellular matrix  34 7.55151E-08 7.95426E-06 
GO:0030425 Dendrite 25 1.09876E-06 8.57239E-05 
GO:0005578 Proteinaceous 
extracellular matrix  
25 1.35639E-06 8.57239E-05 
GO:0034702 Ion channel complex  24 1.38185E-05 0.0007 
GO:0045211 Postsynaptic 
membrane  
20 2.01469E-05 0.0009 
GO:1902495 Transmembrane 
transporter complex  
25 2.42697E-05 0.0010 
GO:1990351 Transporter complex 25 3.16854E-05 0.0011 
GO:0097060 Synaptic membrane  21 5.41966E-05 0.0017 
GO:0033267 Axon part  15 8.26454E-05 0.0024 
GO:0045202 Synapse  21 0.0001 0.0033 
GO:0043235 Receptor complex  22 0.0002 0.0051 
GO:0005667 Transcription factor 
complex  
21 0.0004 0.0093 
GO:0008328 Ionotropic glutamate 
receptor complex 
8 0.0004 0.0093 
GO:0030424 Axon 15 0.0006 0.0109 
GO:0042734 Presynaptic 
membrane 
7 0.0011 0.0213 
GO:0005576 Extracellular region 75 0.0013 0.0223 
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GO:0044420 Extracellular matrix 
part 
12 0.0017 0.0288 
GO:0043025 Neuronal cell body 19 0.0025 0.0402 
GO:0005614 Interstitial matrix  4 0.0028 0.0408 
GO:0044297 Cell body 21 0.0028 0.0408 
GO:0032809 Neuronal cell body 
membrane  
3 0.0045 0.0589 
GO:0044298 Cell body membrane 3 0.0045 0.0589 
GO:0031045 Dense core granule 3 0.0058 0.0715 
GO:0005604 Basement membrane  8 0.0059 0.0715 
GO:0043204 Perikaryon 6 0.0074 0.0842 
GO:0014069 Postsynaptic density 9 0.0075 0.0842 
GO:0043679 Axon terminus 5 0.0078 0.0851 
GO:0034707 Chloride channel 
complex  
6 0.0089 0.0912 
GO:0030672 Synaptic vesicle 
membrane  
4 0.0089 0.0912 
GO:0008021 Synaptic vesicle 8 0.0106 0.1048 
GO:0043195 Terminal bouton 5 0.0129 0.1225 
GO:0048786 Presynaptic active 
zone 
4 0.0132 0.1225 
GO:0005615 Extracellular space  51 0.0154 0.1387 
GO:0044306 Neuron projection 
terminus 
5 0.0199 0.1750 
GO:0097481 Neuronal 
postsynaptic density 
5 0.0284 0.2429 
GO:0031225 Anchored component 
of membrane  
10 0.0337 0.2799 
GO:0043197 Dendritic spine 6 0.0371 0.2867 
GO:0034705 Potassium channel 
complex 
6 0.0371 0.2867 
GO:0005581 Collagen trimer  7 0.0382 0.2867 
GO:0061202 Clathrin-sculpted 
gamma-aminobutyric 
2 0.0390 0.2867 
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acid transport vesicle 
membrane 
GO:0032279 Asymmetric synapse 2 0.0390 0.2867 
GO:0044309 Neuron spine  6 0.0434 0.3118 
GO:0044224 Juxtaparanode 
Region of axon  
2 0.0467 0.3207 
GO:0001527 Microfibril  2 0.0467 0.3207 
 
 
Table 3.16 GO enrichment analysis top categories grouped by cellular 
function and p value.  
 
 
 
 Term N of 
genes 
P-value Adjusted P-
value 
     
GO:0098742 Cell-cell adhesion via 
plasma-membrane 
adhesion molecules  
35 4.44464E-14 3.40564E-
11 
GO:0098609 Cell-cell adhesion 35 5.09521E-14 3.40564E-
11 
GO:0007156 Homophilic cell 
adhesion via plasma 
membrane adhesion 
molecules 
28 3.94219E-12 1.46387E-
09 
GO:0001708 Cell fate specification 17 8.08533E-10 1.93008E-
07 
GO:0010721 Negative regulation of 
cell development 
30 1.17763E-08 2.07138E-
06 
GO:0045165 Cell fate commitment 22 1.6157E-08 2.57127E-
06 
GO:0001709 Cell fate determination  12 3.11388E-07 3.05004E-
05 
																								 168	
GO:0007188 Adenylate cyclase-
modulating G-protein 
coupled receptor 
signalling pathway  
19 3.19789E-07 3.05004E-
05 
GO:0023019 Signal transduction 
involved in regulation 
of gene expression  
9 6.02994E-07 4.79811E-
05 
GO:0007193 Adenylate cyclase-
inhibiting G-protein 
coupled receptor 
signalling pathway 
13 1.3342E-06 9.09979E-
05 
GO:0007187 G-protein coupled 
receptor signalling 
pathway, coupled to 
cyclic nucleotide 
second messenger 
20 1.8803E-06 0.0001 
GO:0030855 Epithelial cell 
differentiation  
27 2.54267E-05 0.0011 
GO:0090092 Regulation of 
transmembrane 
receptor protein 
serine/threonine 
kinase signalling 
pathway  
20 2.63132E-05 0.0011 
GO:0048545 Response to steroid 
hormone 
29 0.0001 0.0037 
GO:0030510 Regulation of BMP 
signalling pathway  
11 0.0001 0.0043 
GO:0051101 Regulation of DNA 
binding  
11 0.0002 0.0064 
GO:0030178 Negative regulation of 
Wnt signalling pathway  
14 0.0003 0.0090 
GO:0043388 Positive regulation of 
DNA binding 
7 0.0004 0.0103 
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GO:0051954 Positive regulation of 
amine transport  
6 0.0004 0.0104 
GO:0030111 Regulation of Wnt 
signalling pathway  
19 0.0004 0.0108 
GO:0035235 Ionotropic glutamate 
receptor signalling 
pathway  
6 0.0005 0.0112 
GO:0045785 Positive regulation of 
cell adhesion 
16 0.0007 0.0150 
GO:0007263 Nitric oxide mediated 
signal transduction  
5 0.0007 0.0155 
GO:0034199 Activation of protein 
kinase A activity 
5 0.0007 0.0155 
GO:0090101 Negative regulation of 
transmembrane 
receptor protein 
serine/threonine 
kinase signalling 
pathway  
12 0.0008 0.0155 
GO:0045168 Cell-cell signalling 
involved in cell fate 
commitment  
6 0.0009 0.0177 
GO:0007200 Phospholipase C-
activating G-protein 
coupled receptor 
signalling pathway  
8 0.0009 0.0178 
GO:0007215 Glutamate receptor 
signalling pathway 
7 0.0010 0.0187 
 
	
 
Table 3.17 GO enrichment analysis cancer related categories grouped by 
biological function and p value.  
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Chapter 4 - Discussion 
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4.1 Introduction  
Most studies have considered colonic and rectal cancers as a single entity, 
despite the molecular, clinical and histopathological differences between them 
(see Section 1.3.2 and Section 1.4.6). Very few studies to date have looked at 
DNA methylation of rectal cancer as a separate entity. The majority of those 
that have, did not take a systematic approach across the whole of the genome 
and included a limited set of genes. To our knowledge, only two other studies 
have addressed the genome wide methylation differences between rectal 
cancer and adjacent normal mucosa.  
In this study, we assessed genome wide patterns of DNA methylation in 30 
human matched rectal tumour and adjacent normal mucosal samples (from 7 
males and 8 females, age range 45-79 years) using the Illumina Infinium 450K 
array platform. 
  
The first aim of this study was to use and validate methods used in CRC studies, 
for isolating and processing tumour cells from rectal cancer tissues.  
The second aim was to identify methylomic variation associated with rectal 
cancer across the whole of the genome using the Illumina Infinium 450K array 
platform, that may form diagnostic of prognostic signatures of primary human 
rectal carcinoma based on DNA methylation.  
The chosen methodology and the lessons learned will be presented first, then 
the findings will be discussed to shed a light on the potential of DNA methylation 
in rectal cancer.  
 
 
4.2 Methodology 
Current genome-wide methods to detect DNA-methylation in healthy and 
diseased tissue require high-quality DNA from FF samples, which provide the 
gold standard tissue quality (Ruijter et al., 2015). Therefore, the tissues we 
actively collected as part our study, were swiftly transferred in liquid nitrogen 
and stored as FF at − 80 °C to minimise nucleic acid degradation.  We obtained 
enough DNA following bisulfite conversion for downstream processing using the 
Illumina BeadChip 450. Quality control revealed the ‘success’ of the FF tissues 
as they passed our stringent QC checks (only one sample failed the QC tests 
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for unidentified reasons) (Section 3.3). Thus, we successfully replicated the 
methodology commonly used in DNA methylation studies using rectal FF 
tissues.  
We also chose to use historically stored samples, fix them in formalin and 
process them as FFPE tissues. This is a common clinical method for processing 
tissues which, unlike the FF method, allows for dissection and quantification of 
tumour content in biopsied samples.  
Whilst FF tissues are the gold standard, FFPE tissues on the other hand are 
less optimal for DNA methylation studies. First, the fixation process and storage 
of tissue embedded in paraffin can lead to fragmentation, nucleotide base 
lesions, modified bases and cross linkage (Iwamoto et al., 1996, Srinivasan et 
al., 2002). This results in DNA fragmentation and low DNA quality.  
Furthermore, the bisulfite modification required for downstream processing 
using the 450K array, degrades DNA further, making assessment of methylation 
challenging.  
With that in mind, we quantified our DNA (see Section 2.4.4) and modified the 
protocol (see Section 2.5.1) to account for the challenges of FFPE tissues. 
Unfortunately, the FFPE samples were suboptimal and did not pass our 
stringent QC testing. The DNA resulting from our FFPE isolation protocol was 
too fragmented to be used in any downstream analyses. No current approach 
(methodological or bioinformatic) would be able to overcome the technical 
limitations of using these samples. We therefore excluded them our study (see 
Section 3.2). 
We believe that the inherent suboptimal quality of FFPE tissues, the long time 
spent homogenising the thick fibrous rectal tissue with rotor–stator homogeniser 
(Section 2.3.1) — which results in greater DNA fragmentation — and the 
potential initial delays in freezing the biopsied historical samples (2004-2007) 
may have played roles in the DNA fragmentation of the samples (Section 
2.1.3.1). 
 
The poor integrity of FFPE tissues and decreased compatibility with Illumina 
HumanMethylation 450 BeadChip is recognised. New protocols, technologies 
and kits are constantly being manufactured to circumvent this problem. 
Recently, Ruijter el al. (2015), showed that FFPE tissue-derived DNA is 
successfully restored using the Illumina FFPE DNA Restoration solution kit 
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(Illumina, San Diego, USA), making it feasible for downstream processing with 
the 450K array with successful results. Although we were not able to try it as 
part of the current project, the incorporation of this restorative kit along with the 
implementation of the Illumina modified FFPE protocol (Illumina, San Diego, 
USA) are future steps that may ensure better quality DNA from FFPE tissues.  
 
One problem common to both FF and FFPE samples is tissue heterogeneity. 
CRC tissue is characterised by heterogeneity, cellular and molecular. It 
combines a mixture of normal epithelial ducts, in situ or invasive tumour cells, 
adjacent blood vessels, stroma, immune system cells and the extra cellular 
matrix (ECM) (Bahrami et al., 2017). Subsequently, cancer biopsies will 
invariably contain dysplastic cells, stromal cells and adjacent morphologically 
normal cells. Therefore, ‘contamination’ of the biopsied sample is possible, 
resulting in either higher or lower quantitative methylation results. Indeed, the 
results of the histopathological examination of our FFPE tissues showed high 
variability in tumour content, a discordance between the expected sample type 
and the actual sample type and sections of dysplasia instead of 
adenocarcinoma (Section 3.2.1). Manual microdissection can provide a solution 
to this problem. Isolating tumour cells under microscopy is a relatively easy 
method of enriching tumour cells by excluding the majority of non-tumour cells 
and ensuring tumour content is high. However, it does require the time and 
effort of a histopathologist or a trained person. Laser capture microdissection is 
also another option which offers higher resolutions and could isolate relatively 
pure individual cells (Fend and Raffeld, 2000). This technology, however, is 
expensive and not readily available. Whether such high level of cell purity is 
necessary for molecular testing in rectal cancer is debatable.  
 
In contrast to FF tissues, FFPE tissues allows for histological assessment. FF 
tissues however remain the gold standard for DNA methylation. Therefore, we 
propose a trial of the following methodology for future rectal methylation studies: 
a) obtaining a core biopsy of the tissue b) dissection of the tissue biopsy into 
four equal parts c) three parts to be embedded in paraffin and assessed 
histologically for sample type and tumour content d) the fourth part to remain 
fresh frozen and used in downstream methylation studies e) estimation of the 
tumour content of FF section from the histological assessment of the three 
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FFPE parts.  Whilst this is a more complex way of quantifying and qualifying 
tumour and mucosal tissues for methylation studies in cancer, it offers a 
potential less expensive and labour intensive solution to the tissue 
heterogeneity problem whilst allowing the use of the gold standard FF tissues 
for methylation studies.  
 
In summary, we validated previously used methodology for FF tissues in 
genome wide and specific DNA methylation gene studies for rectal cancer and 
proposed a potentially improved methodology for future studies.  
 
 
4.3 Global methylomic variation in rectal cancer 
In this study, we have demonstrated global hypomethylation in rectal tumour 
samples compared with adjacent normal mucosal samples. 
Over three decades ago, the first epigenetic alteration in cancer was described 
by Feinberg and Vogesltein (1983): global hypomethylation in colon cancer 
compared with normal colon. This loss of methylation mainly affected repetitive 
sequences of DNA and satellite repeats and appeared to be an early event in 
CRC. Since that discovery, CRC remained one of the most studied diseases in 
the field of epigenetics and DNA methylation research. Less is known however 
about the global methylation changes specific to rectal cancer, despite the two 
being increasingly recognised as separate entities.  
Global DNA hypomethylation is associated with genomic instability and 
chromosome abnormalities. It is often seen before the formation of adenomas, 
can also be observed in the healthy tissue adjacent to tumours suggesting a role 
in the initiation of disease. Furthermore, hypomethylation is thought to predispose 
to genomic instability as increasing hypomethylation is observed in the adenoma-
carcinoma sequence (Sheaffer et al., 2016). 
Global DNA methylation often occurs in repetitive elements of the genome such 
as long interspersed repeat sequences (LINE-1). Benard et al. (2013) 
investigated whether global DNA Methylation and histone modification patterns 
can be used to predict clinical outcome in rectal cancer patients enrolled in a 
clinical trial. They showed that LINE-1 methylation is an independent predictor 
of survival and recurrence in early stage rectal cancer.  
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Contrastingly, a recent study could not identify LINE-1 hypomethylation in the 
aberrant crypt foci of rectal cancer samples (Quintanilla et al., 2014). Tsang et 
al. (2014) looked at changes in global DNA methylation levels following 
treatment in rectal cancer, in a study which included 53 patients who underwent 
nCRT. They found a correlation between pretreatment DNA methylation levels  
and treatment response: patients with lower global methylation levels pre nCRT 
were more likely to achieve pCR. They were also able to predict the likelihood 
of a pCR and partial pathological response from pre-treatment global 
methylation level.  
 
We report global DNA hypomethylation in rectal tumour samples compared to 
normal mucosa. Our findings are in line with previous studies in colon cancer. It 
is possible that global DNA hypomethylation in the rectum may contribute to 
tumourigenesis similar to the colon and may play a role in the prediction of 
treatment response.  
 
 
4.4 Aberrant DNA methylation in the pathogenesis of 
rectal cancer 
The pathogenesis of rectal cancer is largely linked to that of CRC. The 
adenoma-carcinoma sequence in CRC is well established. It is characterised by 
genetic and epigenetic changes in a step wise manner and is responsible for 
the development of sporadic and familial FAP (Section 1.6.3).  
DNA methylation plays a role in CRC and several genes are known to be 
hypermethylated along different stages of the adenoma-carcinoma progression. 
We identified DMPs and DMRs annotated to some of these genes, notably: 
CDH13, RUNX3, SFRP1, SFRP2, ESR1 and ITGA4.  
CDH13, RUNX3, SFRP1 and SFRP2 have been shown to be methylated early 
in the normal colonic epithelium to aberrant crypt focus stage, whereas 
methylation of ESR1 and ITGA4 is associated with the aberrant crypt focus to 
adenoma stage. Both CDH13 and ESR1 have previously been found 
differentially methylated between rectal cancer FFPE tissues and normal 
mucosa (Leong at al., 2011, Molinari et al., 2013) further confirming our results.  
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Age may also be a risk factor in the development of CRC and thus in rectal 
cancer. Aberrant DNA methylation is observed in normal tissues of older 
individuals. Therefore, CRC in older people may have more epigenetic events 
than cancers seen in younger people. Approximately half of the genes that 
show age related methylation are the same genes that are involved in the 
pathogenesis of colon cancer (Toyota and Issa, 1999). 
Some of the genes we identified as aberrantly methylated in rectal cancer have 
been linked to age associated methylation. Changes in the methylation of ESR1 
and TUSC3 for example, occur in histologically normal colonic epithelium in an 
age-related fashion (Lao and Grady, 2015). ESR1 is often methylated in distal 
CRC and reported to show age related methylation (Iacopetta, 2002). Belshaw 
et al. (2008 and 2010) assessed age-dependent gene methylation of a panel of 
genes which include SFRP1, SFRP2 and ESR1 in normal colon mucosa. They 
found significant differences in gene methylation levels between people with 
and without colon cancer.  
Not only aberrant DNA methylation in gene promoters is seen in ageing, but 
global hypomethylation is also seen in the ageing process (Lao and Grady, 
2015). This suggests that there may be common mechanisms for age related 
and cancer related DNA methylation. However, the cause of this age related 
differential methylation remains unknown.  
 
The concept of field cancerisation has also been investigated in the context of 
epigenetic events and tumourigenesis in the colon. Studies have shown that 
epigenetic alterations may be indicators of field cancerisation in the colon, by 
creating a predisposition for specific cancer related mutations (Ramirez et al., 
2008, Worthley et al., 2010). Field cancerisation refers to the susceptibility of 
normal tissues and cells to develop cancer, possibly because of the 
environment. It was first proposed to explain the development of multiple 
primary tumours, local recurrence, abnormal tissue surrounding the cancer and 
focal areas of precancerous changes (Slaughter et al., 1953). Field 
cancerisation occurs at the molecular level of precancerous cells, which may 
have a clonal relationship to the tumour and can persist after complete 
resection of the tumour. Yet it is still unclear how far the cancer field can extend 
from the primary tumour. 
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Inactivation of the APC tumour suppressor gene represents the rate-limiting 
event in CRC formation. The loss of APC function leads to the constitutive 
activation of the canonical Wnt signal transduction pathway, which regulates the 
finely tuned equilibrium between cell proliferation, differentiation and apoptosis.  
Aberrant Wnt pathway signalling is an early progression event in the majority of 
CRCs (Fodde et al., 2001, Fodde and Tomlinson, 2010). Interestingly, the 
hypermethylation of SFRP genes are present in monoclonal aberrant crypt foci 
lacking APC mutations. This is thought to contribute to constitutive Wnt ligand 
signalling and decreased apoptosis. The constitutive activation of the pathway 
results in cellular defect such as proliferation, differentiation, cell migration and 
genetic instability, leading to the formation of the aberrant crypts - the first stage 
of the adenoma-carcinoma sequence (Reya and Clevers, 2005). This 
constitutive activation is required to complement downstream mutations for the 
evolution of CRC.  This epigenetic loss of SFPR function therefore may 
‘cancerise’ the field, rendering cells especially sensitive to further activating 
events in the Wnt pathway (Suzuki and Bird, 2004). The methylation pattern of 
SFRP genes in this case may be useful in predicting the risk of developing 
rectal cancer and further understanding field cancerisation.  
 
We also annotated several other genes to DMPs and DMRs that contribute to 
the aetiology of other cancers. One of those genes is RNF175, which encodes 
ring finger protein 175. RING-finger proteins are a large group of proteins 
concerned with apoptosis, cell-cycle control, and prevention of oncogenesis (Ng 
et al., 2003). They are also likely to be involved in the ubiquitination pathway, 
which is thought to contribute to the aetiology of different types of tumours 
(Hoeller et al., 2006). A recent study by Wang et al (2014) has found that Ring 
finger proteins, including RNF32, play a role in the progression from Barrett 
oesophagus to oesophageal carcinoma. Interestingly, RNF14 depletion 
experiments have demonstrated that it is crucial for colon cancer cell survival 
through interacting with TCF/β-catenin complexes to regulate Wnt gene 
transcription (Wu et al., 2013). More information is needed however on the role 
of ring finger proteins in rectal cancer and their effect on the Wnt pathway.  
 
The relationship between differential methylation in normal rectal mucosa and 
the susceptibility of the mucosa to undergo cancer formation is complex. Recent 
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data suggested that hypomethylation of genes that undergo age related DNA 
methylation correlates with CRCs in CIMP category (Lao and Grady, 2015, 
Worthley et al., 2010). Whether the differential methylation in normal rectal 
mucosa is indicative of a field effect or a marker of an associated phenomenon 
or exposure, such as folate status or tobacco exposure, is still to be determined. 
One hypothesis suggests that aberrant promoter CpG methylation constitutes 
an epigenetic field defect that increases the vulnerability of the colon to cancer 
with advancing age. This theory however remains largely untested. 
 
We have presented in our results several genes involved in the pathogenesis of 
colon and other cancers. It is likely that many of those play a role in the initiation 
and progression of rectal cancer, through several pathways and mechanisms, 
which require further exploration.  
 
 
4.5 Rectal cancer: CIMP subtype? 
Toyota et al. (1999) found two distinct patterns of methylation in CRC. 
Methylation ‘type A’, which is age specific and methylation ‘type C’ which is 
cancer specific. Type A refers to an increase in global methylation levels with 
age, whereas type C was called the CIMP: a subgroup of CRC with very high 
levels of DNA methylation of certain CpG islands, associated with different 
clinical features, such as age, gender and tumour location, and different 
molecular features such as BRAF mutation status (Section 1.6.3.2) 
(Weisenberger et al., 2006). The CIMP is characterised by epigenetic DNA 
hypermethylation of important cell growth and survival genes, and the 
subsequent suppression of those genes which are differentially methylated 
between malignant and normal cells (Williamson et al., 2015). 
In the initial discovery, Toyota and ISSA (1999) quantified DNA methylation in 
33 cancer genes, using combined bisulfite restriction analysis. They discovered 
that 7 of those genes were differentially methylated in a subset of cancers 
known as CIMP +ve. Several alternative methods have been used since for 
methylation analysis and several methylation panels have been proposed. 
Weisnberger et al. (20006) contributed to our knowledge by reliably identifying 
tumours with a CIMP +ve phenotype, consisting of a five-gene panel: 
CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1.  
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Further genes were added in later studies, such as CDKN2A, CRABP1, and 
promoter region of MGMT, a DNA repair gene (Ogino et al., 2007). In tumours 
where 4 out of the 5 CIMP panel genes were hypermethylated, a decrease in  
the expression of p53, p27 and COX2 and an increase in TGFBR2 mutations 
were found. It was therefore suggested that there are distinct molecular 
pathways for different CIMP tumours (CIMP high; CIMP intermediate; CIMP 
low).  
This phenotypic classification however faces certain challenges. First, a panel 
of genes for defining CIMP is yet to be standardised, therefore the definitions of 
CIMP tumours vary across studies making the generalisation of results difficult. 
Second, regardless of which panel of CIMP markers is used, CIMP cancers 
tend to occur in the right colon more than the left, in females more than males 
and tend to have a high frequency of BRAF mutations (Weisenberger et al., 
2006). Additionally, CIMP increases linearly from the rectum to the ascending 
colon, and is known to be rare in rectal cancer, associated with between 2-10% 
of cases (Williamson et al., 2015, Jo et al, 2012, Yamauchi et al., 2012). 
Previous studies looking at CIMP in rectal tumours have reported conflicting 
results (Jo et al., 2012, Kohonen-Corish et al., 2014., Williamson et al., 2015), 
which is partly due to a lack of consensus on methods for investigating 
methylation, the classification into prognostic groups and the utility of these 
groups in predicting response. 
 
The lack of large cohort size in our study and the lack of prognostic information 
on patients, some of whom are still undergoing treatment, did not allow us to 
test for statistically significant methylation signatures for subgroups of our 
tumour sets at this stage. However, the study is ongoing and long term clinical 
data is being obtained in order to allow for full CIMP panel testing at a later 
stage. Meanwhile, in our DMRs list, two differentially methylated annotated 
genes (RUNX3 and IGF2) which are part of the CIMP panel were identified.  
 
RUNX3 refers to the runt-related transcription factor 3 tumour suppressor gene, 
located downstream of transforming growth factor-β (TGF-β). This gene 
regulates the growth and differentiation of epithelial cells and its apoptotic 
functions are correlated with tumourigenesis and cancer progression (He et al., 
2015). RUNX3 protein deficiencies can affect the TGF-β1 signalling pathway by 
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blocking TGF-β1-induced cell growth inhibition therefore decreasing the 
sensitivity to apoptosis. Consequently, β-catenin accumulates in the cytoplasm 
resulting in cell proliferation and apoptosis imbalance. The genetically unstable 
cell clonal expansion is thought to promote tumourigenesis (Miyazono et al., 
2004).  Indeed, RUNX3 is involved in the pathogenesis of numerous cancers, 
such as breast (Chen LF, 2012), ovarian (Lee et al., 2011), head and neck 
(Tsunematsu et al., 2009) and gastric cancers (Freidrich et al., 2006).      
RUNX3 CpG island methylation was also found in colon cancer compared to 
normal mucosa. Subramaniam et al., (2009) concluded that the inactivation of 
the gene in colorectal polyps due to promoter hypermethylation is an early 
event in CRC progression. In a large cohort of both colon and rectal cancers, a 
strong association between RUNX3 and the risk of colon and rectal cancer was 
demonstrated (Slattery et al., 2011). Interestingly, in recent a study looking at 
the effect of RUNX3 on metastasis and angiogenesis in CRC, Kim et al., (2016) 
found that TNM staging in CRC was correlated with a decreased RUNX3 
expression, whereas RUNX3 over-expression inhibited CRC cell migration and 
invasion. They also demonstrated that the restoration of RUNX3 decreased 
vascular endothelial growth factor (VEGF) secretion and suppressed tube 
formation and endothelial cell growth in CRC cells. RUNX3 has also been 
implicated in recurrence risk in stage II-III colon cancer (Berg et al., 2015). 
Furthermore, promoter hypermethylation of RUNX3 in serum was found to be a 
sensitive marker for cancer detection (Tan et al., 2007) showing its promise as 
a biomarker.  
 
Less is known on the role of hypermethylated IGF2 in CRC. The gene is a 
member of the insulin/insulin-like growth factor (IGF) signalling pathway. Its 
receptors are integral membrane proteins and it is involved in the AKT and 
MAP kinase signalling pathways (Rogers et al., 2016). 
Loss of imprinting of IGF2 is an epigenetic change that is known to occur in 
some cancers. Under normal conditions, only one allele, either maternal or 
paternal, is expressed. Loss of imprinting of IGF2 refers to the aberrant bi-
allelic expression of the gene, resulting in its overexpression and subsequently 
in pro-mitogenic and growth promoting signals through binding to the insulin-
like growth factor receptor type 1 (IGF1R). IGF2 over-expression has been 
often associated with tumour proliferation, invasion and poor outcome in CRC 
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(Livingstone, 2013). Rogers et al., (2016) demonstrated an association 
between IGF2 and proliferation, adhesion and, to a limited extent, apoptosis in 
CRC cell lines. Similarly, Zhong and colleagues (2017) found that the over-
expression of IGF2, a consequence of the hypermethylation of its promoter 
region, acts as a major tumourigenic driver in a subset of CRC cell lines.  
Contrary to previous studies, Belharazem et al. (2016) have recently shown 
that LOI of IGF2 can occur independently of major pathogenic CRC routes 
(serrated vs. non-serrated), occur throughout the large intestine without 
predilection for the right colon, and may even constitute a distinct molecular 
subgroup. Additionally, IGF2 over-expression was associated with treatment 
resistance in certain CRC subgroups (Zanella et al., 2015) making it an 
important gene for further studies  
 
In summary, the hypermethylation of RUNX3 and IGF2 has a strong association 
with the initiation, progression and to a certain extent, treatment response of 
CRC cancer. Those two genes have mainly been looked at as part of the CIMP 
panel of CRC subsets. Larger cohorts are required to assess CIMP status in 
rectal cancer and the subgroups associated with different clinicopathological 
characteristics if any.  
 
 
4.6 Biological and cellular pathways in rectal cancer 
Our GO analysis revealed several pathways, both in the biological and cellular 
categories, that are involved in rectal cancer. In the cellular function category, 
several of the most significant pathways and DMRs annotated to genes, were 
associated with the ECM functions, such as IGFBP3, MMP13, MMP23B, FBN2, 
GPC6, COL4A2, NTNG1, ITGA4 and SPOCK1 amongst others (Table 3.16) 
(Simmer et al, 2012).  
The ECM is synonymous with the proteinaceous ECM and is part of the 
extracellular region (Section 3.3.7). Figure (3.13) represents this relationship 
through an ancestor chart. It is an elaborate meshwork of cross-linked proteins 
that provide architectural and structural support for cells. These proteins bind to 
growth factors, present them to cells and provide biochemical cues that are 
major regulators of cellular behaviour (Hynes, 2009). The ECM affects motility, 
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viability, adhesion and proliferation of cells and constitutes a major part of their 
environment. Subsequently, it is also a major component of a tumour’s 
microenvironment: it has the potential to support its survival and proliferation, 
sustain their growth, encourage the tumour cell’s seeding and invasion of 
nearby as well as distant sites (Cretu and Brooks, 2007). Therefore, 
deregulation of ECM pathways may play a role in the pathogenesis and 
progression of tumour cells.  
 
 
 
Figure 3.13. Ancestor chart for the ECM (GO:0031012). Adapted from the 
European Bioinformatics Institute (2018). 
 
 
Aberrant ECM environments have also been implicated in the ability of tumours 
to undergo epithelial mesenchymal transition (EMT) and metastasise. This is 
because cells lose cell-cell and cell-extracellular matrix adherence along with 
profound changes in their cytoskeleton architecture. DNA methylation induces 
silencing of ECM pathway regulatory genes (Yi et al., 2011). A recent study 
found that the methylation of ITGA4 and TFPI2 is an early and frequent event 
in precancerous and cancerous lesions of the rectum (Gerecke et al., 2015). 
The TFPI2 gene encodes a serine proteinase inhibitor that protects the ECM 
of cancer cells from degradation and inhibits in vitro colony formation and 
proliferation. Hypermethylation induced loss of TFPI2 function could 
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predispose cells toward a pro-invasive program in rectal cancer, an important 
event especially in later stages of carcinogenesis (Glockner et al. 2009, Hahn 
et al. 2008). 
The ITGA4 gene encodes the alpha-4 subunit of an integrin family member. 
Integrins are membranous receptor proteins which play important roles in 
extracellular control of cell survival and differentiation via cell–cell interactions 
and cell–matrix communication. ITGA4 therefore is able to control cell 
adhesion, making it a putative tumour suppressor (Ausch et al. 2009). A loss 
in function is shown to be an early event in carcinogenesis through aberrations 
of the ECM and cell-cell pathway integrity. 
 
Interestingly, it is also thought that the ECM has a potential to confer treatment 
resistance, by acting as a barrier to drug delivery. In a recent study on CRC cell 
lines, Stankevisius et al., (2016) established ECM-dependent pathways which 
may be feasible targets for anti-cancer therapies. Other studies however, 
demonstrated that inhibition of the stroma reorganisation and alignment through 
drugs or genetic engineering, accelerates tumour growth and decreases 
survival (Ozdemir et al., 2014; Rhim et al., 2014). This suggests that is a more 
complex role for the ECM in cancer homeostasis and progression. 
 
The idea that changes in ECM architecture may allow cancer development and 
progression is novel, and the possibility that these changes could be used as 
diagnostic or therapeutic tools in cancer treatment is still poorly investigated. 
We have demonstrated an association between deregulated ECM pathways 
though aberrant methylation of genes in rectal cancer. Further research is 
required to establish the role of ECM in rectal cancer and its potential as a 
therapeutic tool.  
We also observed that some of the top terms included in our GO biological 
analysis were related to cell-cell adhesion, plasma-membrane adhesion 
molecules regulation of transcription regulatory region DNA binding and cell fate 
commitment. This is consistent with the knowledge that defective function of cell 
cycle and cell proliferation regulators is a main cause for tumour development 
and progression. Cell adhesion molecules play a role in the progression of 
cancer and interactions of cancer cells with the endothelium determine the 
metastatic spread of tumours.  Additionally, direct tumour cell interactions with 
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platelets, leukocytes, extra and intracellular components contribute to cancer 
cell adhesion, extravasation and metastases (Bendas and Borsig, 2011).  
 
A hallmark of cancer is the alteration of cellular differentiation pathways during 
developmental processes. Mutations in the WNT pathway cause colon cancer 
through constitutive activation of the nuclear β-catenin/TCF transcription factor 
complex, identified in GO analysis. Many of the DMPs identified in this study are 
annotated to genes involved in the Wnt signalling pathway, including SFRP1, 
SFRP2 and DKK3. Recent research indicates that the Wnt and bone 
morphogenetic proteins (BMP) pathways, both of which were included in our top 
results, play a role in normal epithelial cell differentiation, and, if altered, may 
contribute to CRC tumourigenesis (Bertrand et al., 2012). The Wnt family 
consists of 19 glycoproteins that have been implicated in diverse biological 
processes, including cell fate specification, cell proliferation, cell migration, 
dorsal axis formation and asymmetric cell division. Wnt signalling is activated 
at the bottom of the intestinal crypts, which is crucial for stem cell maintenance 
and tissue homeostasis. Aberrant Wnt activation is frequently observed in CRC 
(Cancer Genome Atlas Network, 2012). The Wnt pathway is commonly divided 
into β-catenin dependent (canonical) and independent (non-canonical) 
signalling (Zhan et al., 2016). In the canonical pathway, Wnt ligands binds to the 
Frizzled receptor and the LRP5/6 co-receptor. This stabilises the gene and 
leads to cytoplasmic accumulation and nuclear translocation of β-catenin. 
Stabilised, free β-catenin that translocates to the nucleus associates with 
TCF/LEF to regulate transcription. The involvement of β-catenin defines the 
canonical Wnt signalling, compared with the Wnt/Frizzled signalling pathways 
which do not include β-catenin (Bertrand et al., 2012).  
Epigenetic silencing of Wnt inhibitors by DNA hypermethylation has been 
suggested as a mechanism for the aberrant activation of the Wnt pathway in 
CRC. Indeed, the epigenetic silencing of extracellular Wnt inhibitors SFRP1, 
SFRP2 and DKK3, have been reported in several studies (Qi et al., 2006, 
Rawson et al., 2011). The effect of aberrant canonical Wnt signalling is not only 
restricted to cancer cells, but can also dynamically interact with the 
microenvironment of cells and immune system. The non-canonical Wnt 
signalling also plays a role in the progression of tumours as it can mediate 
motility of cancer cells during metastasis (Bertrand et al., 2012). From a clinical 
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perspective, there are important implications to understanding the Wnt 
signalling mechanisms and role in rectal cancer. NSAIDs such as aspirin, 
indomethacin and celecoxib, have been shown to have some effect in inhibiting 
Wnt signalling (Gurpinar et al., 2013). These Cox-2 inhibitors are thought to 
inhibit Wnt by suppressing prostaglandin E2 (PGE2) production, since PGE2 
has been shown to promote Wnt signalling. This may prove valuable in the 
clinical treatment of rectal cancer and in identifying protective patient factors 
such as regular medications.  
 
BMPs are members of the TGF β superfamily, that bind to serine-threonine 
kinase receptors (the serine/threonine kinase signalling pathway was also 
included in our gene ontology findings) resulting in the activation and nuclear 
localisation of Smad4 (Bertrand et al., 2012). The loss of BMP signalling is 
associated with sporadic colon cancers and correlates with TRG. It is also 
thought to contribute to tumour progression and has been reported to promote 
the growth of colon carcinomas. Interestingly, there is increasing evidence that 
mutations affecting BMP pathways corroborate with activated Wnt to drive 
sporadic colon cancers, particularly in later stages of the disease (Hardwick et 
al., 2008).  Given the importance of these pathways in CRC and the potential 
for the development of pathway inhibitory mechanisms, they should be 
examined further to determine their role and therapeutic utility in rectal cancer.  
 
 
 
 
4.7 Concordance with previous rectal cancer studies 
In a recent epigenome wide analysis of 25 pairs of rectal cancer vs normal 
mucosa, Vymetalkova et al. (2016) used the lllumina Human Methylation 450 
BeadChip to assess DNA methylation. They identified the genes SND1, ITGA4, 
OPLAH, NPY, FLI1, TFPI2, ADHFE1, PRKAR1B, TRBJ2–6 annotated to their 
top ten hypermethylated CpG sites, and other differentially methylated genes 
including GPR85, GPR88, CHST2 and TLX1, associated with rectal cancer. 
Remarkably, our results included all of these genes- with the exception of 
TRBJ2-6- therefore supporting their findings.  
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Some of these genes are known to play a role in cancer, including SND1 
ADHFE1 and OPLAH which have been selected as part of a robustly 
methylated panel of genes in CRC and cross validated using data from the 
Cancer Genome Atlas (Naumov et al., 2013). 
Exploring these genes further, we learned that OPLAH 3′ UTR hypermethylation 
has been reported as a shared feature in some tumours (Xu et al., 2012) whilst 
the promoter hypermethylation of ADHFE1 is frequently present in CRC. A 
recent study found that alcohol induces methylation-mediated down expression 
of ADHFE1 and proliferation of CRC cells (Moon et al., 2014). Alcohol induced 
methylation changes could therefore be interesting to explore. The 
Staphylococcal nuclease homology domain 1 (SND1) is over-expressed in 
breast, prostate, colorectal and hepatocellular carcinomas (Jariwala et al., 
2015). Over-expression of SND1 is thought to occur at a very early stage in 
colon carcinogenesis and contribute to the regulation of key players in CRC 
including APC and β-catenin (Tsuchiya et al., 2007). 
Another important gene is PRKAR1B which appeared twice in our list of top ten 
DMPs, yet little is documented on the role of the gene in CRC. The protein 
encoded by PRKAR1B is a regulatory subunit of cyclic AMP dependent protein 
kinase A (PKA), which is involved in the signalling pathway of the second 
messenger cAMP. Studies have revealed that cAMP/PKA signalling pathway is 
altered in different cancers and may be used in cancer therapy and diagnosis 
(Naviglio et al., 2009). Further investigation of aberrant pathways induced by 
epigenetic changes in this gene may be rewarding. 
 
In another genome wide study, Wei et al. (2016) found 36 genes differentially  
methylated in rectal cancer, notably the gene GFRA1, which was also 
annotated to our list of top DMRs. They performed further analysis on this gene 
and demonstrated its suitability as a potential diagnostic biomarker for rectal 
cancer.  
Leong et al. (2011) in another study evaluated DNA methylation in sporadic 
rectal cancers treated by Radical TME to identify markers associated with local 
and distant metastasis. Methylation levels in cancer were analysed by MS-
MLOA and compared with methylation levels in adjacent tissue. 24 frequently 
methylated tumour suppressor genes were looked at. Five were found to be 
differentially methylated in cancer compared with normal controls. Two of those 
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genes, ESR1, CDH13, were included in our findings, further highlighting their 
presence in rectal cancer.  
 
In conclusion, we found large agreement between our results and previously 
published rectal cancer epigenetic studies, providing further validity to our 
findings.  
 
 
4.8 Clinical biomarkers for rectal cancer 
The discovery of clinical biomarkers for rectal cancer has been hampered by 
the lack of research addressing rectal cancer as a separate entity from colon 
cancer and the use of limited sets of genes in the majority of studies. We 
identified in our results several DMRs and DMPs annotated to genes that have 
promising potential as biomarkers. Some may be used in screening, staging 
and prognosis whilst others in predicting the response to therapeutic 
intervention. Ultimately the identification of DNA methylation signatures in 
easily-accessible peripheral tissues such as whole blood would be optimal for 
use as a diagnostic and prognostic biomarker. Future studies should aim to 
profile matched blood samples from the same individuals from whom 
mucosal/tumour samples have been assessed to explore the extent of 
methylomic covariation between tissues. 
 
Screening, staging and prognosis  
Two main methods are currently used for CRC screening: colonoscopy and 
faecal occult blood test (FOBT). Colonoscopy is the most accurate, however it 
is costly and is associated with poor patient compliance and procedure related 
complications. FOBT is a less costly and simple method, but it has low 
specificity and sensitivity (Smith et al., 2017). Accurate methods for early 
detection, staging and prognosis of primary and recurrent cancer are extremely  
important for increasing patient survival. 
A screening test for CRC performed via a blood sample is considered an 
inexpensive simple test that would encourage more patients to undergo 
screening. It could ultimately result in decreased mortality, cost savings to 
healthcare since more CRCs would be detected at an earlier stage (Warren et 
al., 2011). Lofton-Day et al. (2008) described molecular markers for CRC that 
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are shed from solid tumours into the blood stream. One of these markers is 
SEPT9, a differentially methylated gene in CRC tissues, which can be 
sensitively and specifically detected in blood plasma. The hypermethylated 
SEPT9 was annotated to one of our DMRs in rectal cancer vs normal mucosa. 
SEPT9 gene methylation has been implicated in CRC for over a decade, and 
used as a biomarker for over 8 years. In fact, the aberrantly methylated Sept9 in 
plasma has shown almost 70% sensitivity and 90% specificity for detection of 
CRC (Bingsheng Li ref 2016). A recent systematic review of the performance of 
SEPT9 gene methylation assay in CRC concluded that SEPT9 assay is 
satisfactory for the diagnosis and screening of CRC, with more research 
needed for treatment monitoring and prognosis prediction. In Europe and the 
Middle East, a blood based assay that detects methylated SEPT9 is already 
marketed as a colon cancer screening assay under the name Epi proColon 
(Song L, 2017). Whether SEPT9 will achieve similar promising results in rectal 
cancer specifically is yet to be tested, however the identification of this gene in 
our results shows a promising first step.  
 
Other aberrantly methylated genes have also shown promising results as future 
biomarkers. In a recent study assessing the potential of methylated DNA as 
biomarkers in CRC, Mitchell et al., (2014) selected 23 hypermethylated genes 
to assess. 11 of those genes had methylation levels detectable in white blood 
cell DNA therefore making them suitable for further evaluation as blood-based 
CRC diagnostic biomarkers. We described 7 of them in our rectal tumour 
DMRs: Col4A2, SDC2, DLX5, FGF5, FOXF1, IRF4, SOX21. The same study 
identified 6 genes that they considered candidate biomarkers for stool based 
assays. We identified 3 of them in our DMRs: SL6A15, SOX21 and NPY.  
Of note is the IRF4 gene, which belongs to the Interferon Regulatory Factor 
(IRF) family of transcription factors. the IRF family contributes to the regulation 
of the interferon signalling pathway (IFN), which has been found to play a role in 
rectal cancer (Slattery et al., 2011). 
Another potential biomarker identified in our results is SDC2, which is a cell 
surface receptor that appears to play a conflicting role in cancer literature: 
SDC2 over-expression has a poor prognostic factor in prostate cancer (Popović 
et al., 2010) whereas its downregulation was associated with poor prognosis in 
oesophageal squamous cell carcinoma (Huang et al., 2009). In addition to its 
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recognition in Mitchell’s study (2014), SDC2 was ranked second by Simmer and 
colleagues (2012) in a survey of genes methylated in CRC and its potential as a 
plasma biomarker was also demonstrated by Oh et al. (2013).  
 
Several other genes amongst our findings could act as potential biomarkers for 
rectal cancer screening, staging and prognosis, such as: AQP5, which is 
associated with metastasis in colon cancer (Kang et al., 2008) and with tumour 
TNM stage, lymph node and distant metastases in CRC (Shan et al., 2014); 
methylated C9orf50 which has been identified as a novel blood based DNA 
methylation biomarker for CRC early detection; FGF12, of the fibroblast growth 
factor (FGF) family, which is involved in broad mitogenic and cell survival 
activities and has recently been identified as a novel hypermethylated gene in 
CRC (Li et al., 2012); IKZF1 which is found to be methylated in several cancer 
types and has recently shown potential to be used as a blood biomarker in the 
detection of CRC recurrence (Pedersen et al., 2015); PHACTR3, a potentially 
suitable biomarker for CRC detection in stool (Bosch et al., 2012); EFS gene, 
associated with prediction of biochemical, local, and systemic recurrence of 
prostate cancer (Vanaja et al., 2009) and may be a promising  biomarker for 
rectal cancer as part of a specific DNA methylation signature (Vymetalkova et 
al., 2016); SFRP2 which has shown good potential for detection as a stool and 
serum biomarker in CRC patients (Nagaska at al., 2009, Tang et al., 2011); 
HIC1, a growth regulatory and tumour suppressor gene associated with CRC 
and detected in CRC stool samples in a hypermethylated state (Lenhard et al., 
2005); IRAK3, found to be frequently methylated in hepatocellular carcinoma 
tissues and associated with tumour stage and poor prognosis (Kuo et al., 2015); 
CDO1 methylated gene, which has recently been considered to play a role in 
the CRC and studies have shown it to be a promising biomarker for CRC 
detection (Yamashita et al., 2014, Vedeld et al., 2015) and the ITGA4 and 
GATA4 which were included in a recent systematic review looking at DNA 
based biomarkers in CRC detection and name as some of the most important, 
noteworthy and independently validated genes to study (Lam et al., 2016) 
 
Treatment response  
Response to therapeutic treatment in rectal cancer varies. Up to 15% of 
patients - in selected series of advanced disease in the UK and across cancer 
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networks- achieve a cCR (and radiological response) and another 10% of 
patients who undergo resection, achieve a pCR) with no evidence of tumour 
remaining in the specimen (Dalton et al., 2012, Renehan et al., 2016). These 
two groups make up to 25% of rectal cancer patients selected for CRT based 
upon MRI-stage. Patients who achieve complete response have a significantly 
improved 5-year survival (up to 85%-100%) compared with patients who show 
minimal response (55%-66%) (Park et al., 2011, Yeo et al., 2010).  
In many centres, without evidence of CRM involvement, CRT is avoided for 
early stage rectal tumours and surgery is offered as the sole treatment. This 
contrasts with the Habr-Gama group (2004) who offered CRT to all low rectal 
tumours and achieved higher rates of cCR. 
The molecular heterogeneity of colorectal and therefore rectal cancer is 
believed to be one of the factors responsible for the variability in treatment 
response among patients with the same stage of cancer (Buczacki and Davies, 
2014). Under the TNM staging (Section 1.2.4 and Section 1.4.4) and treatment 
guidelines, there is both over and under-treatment of rectal cancer patients.  
TME for early stage rectal cancer carries with it significant side effects, including 
bladder and bowel dysfunction. Up to 76% of patients undergoing sphincter 
preserving surgery will experience changes in bowel habit, the so called low 
anterior resection syndrome (LARS), which can last for months to years 
(Dulskas et al., 2016) and has a significant detrimental effect on patient quality 
of life. Preoperative RT is an additional risk factor for LARS. It also entails 
important morbidity related to the increased risk of anastomotic leak, tenesmus 
and neurological toxicity amongst others (Biondo et al., 2016). In addition, 
preoperative chemotherapy in advanced stage rectal cancer is associated with 
significant adverse effects, including faecal and urinary incontinence, delayed 
wound healing and sexual dysfunction (Williamson et al., 2015) as well as the 
specific side effects of the chemotherapy agents chosen in treatment.  
The challenge therefore is to identify patients who are likely to achieve complete 
response and spare them the morbidity of unnecessary treatment. 
Subsequently, an accurate method for predicting the response to CRT would 
allow for improved treatment choice with avoidance of unnecessary side effects: 
patients with chemoradiation-resistant disease would be spared the morbidity of 
this treatment. Equally, patients with a prediction of pCR may be spared radical 
surgery and its complications. 
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Studies into epigenetic silencing through aberrant DNA methylation have 
revealed novel insights into the response of tumours to chemotherapy and RT 
in a number of cancers including cervical, prostate, lung, oesophageal and CRC 
(Williamson et al., 2015). There are currently no available biomarkers for 
assessing treatment response in rectal cancer patients. We will discuss some of 
the interesting genes we identified in our results which have the potential to be 
investigated as therapeutic response biomarkers.  
 
Exner and colleagues (2015) have assessed DNA methylation differences in 
rectal cancer using targeted DNA microarray for 360 marker candidate genes. 
The ‘signature’ genes that differentiated tumours from adjacent normal mucosa 
comprised TWIST1 (Twist basic helix-loop-helix transcription factor 1) and 
PITX2 (paired like homeodomain 2). Both TWIST1 and PITX2 are 
hypermethylated in different cancers and have been suggested as potential 
biomarkers. PITX2 methylation has been well established as a prognostic 
biomarker for breast and prostate cancer (Mikeska et al., 2012). DNA 
methylation of PITX2 was also associated with prognosis for OS of patients with 
biliary tract cancers (Uhl et al., 2016). High expression of TWIST1 has pointed 
to high rates of metastasis, poor prognosis, EMT (a crucial event for 
dissemination of epithelial tumours) and chemotherapeutic resistance (Brabletz, 
2012, Eide et al., 2013, Qin et al., 2012). The potential for TWIST1 as a 
therapeutic target has recently been investigated. Studies showed that 
Doxycyline, Sirtuin SIRT6 and RNA-based inhibition of TWIST1 can target the 
gene in lung and breast cancer cells therefore reducing metastatic potential 
(Qin et al., 2015, Finlay et al., 2015, Han et al., 2014).  
Another important gene is TFPI2 (tissue factor pathway inhibitor 2), which 
belongs to a family of Kunitz type serine protease inhibitors. TFPI2 is implicated 
in tissue remodelling, is known to protect the ECM of cancer cells from 
degradation and to inhibit in vitro colony formation and proliferation (Wong et 
al., 2007). As discussed earlier, proteolytic degradation of the ECM is 
considered to be an essential step in tumour growth and metastasis. The loss of 
the TFPI2 function is thought to negatively regulate the activity of ECM 
associated enzymes that protect the ECM stability, therefore playing a role in 
carcinogenesis and its progression (Rao et al., 1998 and 2000). 
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As such, TFPI2 may act as a tumour suppressor gene and has been found 
methylated in different tumour types, including pancreatic, cervical, gastric and 
prostate carcinoma (Exner et al., 2015). Hibi et al. (2011) showed that in TFPI2 
plasma hypermethylation was present in 38 CRC patients preoperatively. The 
Hypermethylation in TFPI2 however was absent in patient who were curatively 
resected. This suggests that TFPI2 may act as a marker for complete response 
following treatment. Furthermore, Glockner et al. (2005) demonstrated the 
potential of TFPI2 as a biomarker by detecting TFPI2 methylation in stool DNA. 
TFPI2 was also suggested as a potential serum methylation biomarker in rectal 
cancer (Exner et al., 2015) 
 
Two other genes may be of interest in treatment response studies. First, the 
TFAP2A gene which is part of the AP2 transcription factor family. The TFAP2A 
family consists of five subtypes: AP2- α, β, χ, δ and ε. TFAP2A has been shown 
to modulate the Wnt signalling pathway and the APC protein, key pathways in 
CRC (Beggs et al., 2015). Interestingly, TFAP2E -a subtype of the AP2 
transcription factor family- was associated with chemoresistance to                  
5-fluorouracil in CRC (Ebert et al., 2012). Beggs et al. (2015) investigated this 
further, and concluded that it does play a role in chemoresistance but through 
more complex pathways than previously thought. The second gene is CYP1B1, 
a cytochrome P450 enzyme which is consistently over-expressed in certain 
cancers. CYP1B1 has been shown to be active within tumours and possesses 
the ability to metabolise a diverse range of anticancer drugs. CpG methylation 
of the CYP1B1 promoter region epigenetically regulates CYP1B1 expression in 
cancers including CRCs. Cancers with aberrant CYP1B1 expression might 
show altered response to chemotherapy in CRC (Habano et al., 2009) whilst in 
epithelial ovarian cancer cells, CYP1B1 enhanced the resistance of the cells to 
chemotherapy (Zhu et al., 2015). Interestingly, CYP1B1 methylation in the bone 
marrow of acute myeloid leukaemia patients changed during their 
chemotherapy treatment (Xia et al., 2016). 
 
We have included patients in our study that underwent nCRT with the aim of 
reinvestigating our findings in the future and looking at potential biomarkers for 
rectal cancer staging, prognosis and treatment response. We believe this is 
important for the continuation of this study, as available tissue for the 
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assessment of biomarkers in rectal cancer might be possible only after the 
neoadjuvant treatment.  
 
 
4.9 Summary  
In this study, we assessed genome wide patterns of DNA methylation in 30 
matched rectal tumour and adjacent normal mucosal samples using the Illumina 
Infinium 450K array platform. We found that there is global DNA 
hypomethylation associated with rectal cancer. We identified DMPs and DMRs 
annotated to genes associated with rectal tumours. Some of the genes we 
found are associated with the initiation and progression of the adenoma-
carcinoma sequence in CRC, such as CDH13, RUNX3, SFRP1, SFRP2, ESR1 
and ITGA4. Due to the limited size of our cohort and lack of prognostic 
information, we did not assess CIMP status in rectal tumours, but identified two 
genes differentially methylated in our results, RUNX3 and IGF2 which are part 
of the CIMP panel. We found good agreement with the few previous studies 
looking at genomic wide variations in rectal cancer with the panels of 
differentially methylated genes and implicated pathways. The pathways 
implicated in rectal cancer included Wnt signalling, BMP pathways and ECM 
involved pathways, in line with CRC aberrant pathways. We also found several 
genes that may be promising as biomarkers for detection, staging and 
prognosis of rectal cancer.  
 
 
4.10 Limitations 
Our study has some important limitations. We acknowledge that the number of 
samples profiled in this study is small, therefore replication in similar larger 
cohorts is required. 
We also recognise that it is a single institution study, of patients from or living in 
the Devon area in England, as such our sample is not fully representative. 
Additionally, we included all MRI staged clinical diagnosis of rectal cancer as 
histological samples taken were considered too superficial to be representative. 
A next step would be to segregate the rectal tissues into separate categories 
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(tumour, dysplasia, aberrant crypts) and comparatively assess the methylation 
levels at each step of the adenoma-carcinoma sequence.  
We performed stringent quality control on our processed samples using the 
450K array. Whilst the Illumina Human Methylation 450 BeadChip is one of the 
more advanced options for genome-wide DNA methylation analyses, there are 
some issues to consider when using this array. First, it interrogates 
approximately 1.7% of all CpG sites in the human genome (482 422 cytosines) 
which is substantially less than other methods. Second, the technology has 
preselected probes that only interrogate specific CpG sites previously identified 
in methylation-based assays, making the design biased. Third, it works on a co-
methylation assumption, which is the assumption that CpG sites located next to 
those interrogated by the probes will be similarly methylated or unmethylated.  
We discussed the methodology adopted in our study -  which is a common 
methodology for DNA methylation studies. We cannot rule out that the observed 
differences in DNA methylation were caused by carcinogenesis in tumour 
tissue, or by other confounding factors, such as age, environmental exposures 
or risk factors. Furthermore, we recognise that the mechanistic relevance of the 
differentially methylated genes in CRC as noted in our literature review, has not 
been demonstrated in all instances. It is feasible that many of the differences do 
not have a causal role in the oncogenetic process but are a consequence of the 
cancer. 
Yet, the site of effects and concordance with previous studies suggest that our 
methodology and findings are robust. Additionally, the study was robustly done, 
using stringent quality control measures and advanced statistical analyses. 
Importantly, it represents a unique experiment cohort, as it is one of the few 
studies to look at genome wide differential methylation between normal and 
tumour tissue in rectal cancer as a single entity, separate from the colon.  
Despite the limitations encountered, our data is consistent with previous 
findings in CRC and provides further support for the role of DNA methylation in 
rectal cancer. 
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4.11 Conclusion 
To this date, very few studies have looked at the genome wide changes in 
rectal cancer as a single entity using the latest sequencing technologies. Our 
study focused on the discovery of de novo epigenetic changes associated with 
rectal cancer. Epigenetic instability in rectal cancer appears to be manifested in 
global DNA hypomethylation and gene promoter hypermethylation in CpG 
islands, similar to CRC. We identified several novel DMPs, DMRs and 
molecular pathways differentiating rectal tumours from normal mucosa. 
The findings of this study are in line with the growing appreciation that aberrant 
epigenetic events are important in the process of cancer initiation, progression 
and response to treatment. Larger studies are now required to replicate these 
results.  
 
Future studies looking at the epigenetics of rectal cancer should assess 
genome wide and CpG site methylation across the different stages of rectal 
cancer, from aberrant crypt foci to advanced stage adenocarcinoma, address 
the relationship of age and DNA methylation, field cancerisation, environmental 
factors, perform network and pathway analyses and identify potential subgroups 
as well as biomarkers specific to the disease.  
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Appendix 1 – Good Clinical Practice Certificate 
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Appendix 2 – Application for samples from the tissue bank 
 
 
 
 
Application for Samples from the Royal Devon & Exeter Tissue Bank  
 
 
Your details 
 
 
Name of lead researcher: Professor Jon Mills 
 
Contact email:  
 
 
Contact telephone:  
 
 
Sample Details 
 
Type of sample required: 
 
• Matched benign and malignant rectal cancer samples 
 
Proposed analysis: 
 
 
• DNA methylation studies  
 
 
 
Numbers of samples and volumes required: 
(please provide details of power calculation overleaf) 
 
30 matched benign and malignant samples (60 in total)  
 
(see attached protocol for sample size details)  
 
Did you specifically request the RD&E Tissue Bank to collect these tissues?   
 
NO 
 
If YES please provide the CTB and STB codes allocated to the collection (found 
on steering committee approval letter): 
 
 
Do you require any of the following? (some of these services may be chargeable): 
Matched benign and malignant tissue X   
Extracted DNA  
Extracted RNA  
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Accurate histopathological analysis of adjacent tissue  
Peripheral blood samples   
 
 
Do you have prior ethical approval for this study? No 
If YES please state ethics number:  
If you have ethical approval from a REC to use these samples please provide a copy of your 
IRAS form and approval letter. 
 
Please provide the following information: 
See attached protocol for details requested below 
 
Lay Summary (explain in less than 300 words why this collection is important and how it will 
contribute to future improvements in patient care.) 
 
 
 
Scientific Justification (please provide a full scientific protocol justifying your research 
methods and outcome measures.)   
 
 
Statistics (please provide an explanation to justify the volumes and numbers of samples 
requested.) 
 
 
Funding and Expertise (please provide evidence of your expertise to undertake this 
project (CV) and details of where you expect to fund your analysis from.) 
 
 
 
Signature of Lead Researcher       
 
Date of application:  
 
Please submit completed application to: 
rde-tr.tissuebanks@nhs.net 
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Appendix 3 - Proposal template for use of samples from the 
RDTEB 
 
 
JMRD/Vs1/03/03/16 
 
Title:  Refining methods for obtaining rectal tumour cells for DNA 
methylation profiling in rectal cancer biopsies. 
 
Project team: 
Professor Jon Mill, Professor of Epigenetics, University of Exeter Medical 
School; J.Mill@exeter.ac.uk 
Mr Neil J Smart, Consultant Colorectal Surgeon RD&E NHS FT 
Dr Ian Chandler, Consultant Pathologist RD&E NHS FT 
Miss Rachel Dbeis, MRes Intercalating Medical Student 
Dr Bridget Knight, Nurse Manger, Exeter Tissue Bank/NIHR Exeter CRF 
 
Summary: 
 
There are approximately 15,000 new cases of rectal cancer each year in the 
UK. Surgery is the main treatment in early stage cancer however it carries 
significant risks and intermediate probability of recurrence rates in most 
patients. Tremendous advances have been made in understanding the 
molecular pathology of cancer, including rectal cancer. Recent focus has been 
on DNA sequence mutations and epigenetic variation in tumour cells, although 
work in this area is still in its infancy. 
 
Chemotherapy and radiotherapy are recommended prior to surgery in advanced 
stage rectal cancer1. Patients’ response to treatment is varied: some patients 
achieve complete clinical response while others do not. Chemotherapy and 
radiotherapy are both associated with significant adverse effects. Being able to 
predict which patients are likely to respond to therapy, or have a higher 
recurrence rate following surgery will spare patients avoidable morbidities, 
improve care and clinical decision making.  
 
 
Response to treatment, recurrence rates and prognosis may be dependent on 
many factors. Recent interest has focussed on the potential role of epigenetic 
variation in mediating underlying differences in treatment response given the fact 
that epigenetic dysfunction is known to play an important role in the aetiology, 
progression and metastasis of cancer2. 
 
A few studies have started to examine epigenetic variation in rectal cancer, yet a 
solid methodology for DNA methylation analysis in tumour cells obtained from 
patients is still to be defined. Of note, no study has aimed to identify genome-
wide patterns of differential methylation in rectal cancer, despite the successes 
of this approach in other types of cancer. 
 
This project aims to develop and validate methods for isolating tumour cells for 
DNA methylation analysis from rectal cancer tissue, and obtain preliminary data 
on genome-wide patterns of DNA methylation in rectal cancer.  
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This will enable future studies to identify epigenetic variation associated with 
response to treatment, recurrence rates and prognosis in rectal cancer. 
 
 
 
 
Lay summary: 
 
Rectal cancer is a common form of bowel cancer that usually needs an operation 
(surgery) to try to cure it. This can be complicated, risky and result in long-term 
complications. Before surgery a combination of chemotherapy and radiotherapy 
can be used to try and shrink the cancer but the results are variable: the cancer 
may shrink completely (and the person may potentially avoid surgery) or it will 
have no effect at all. At the moment we cannot tell how an individual will respond 
to this combination therapy. As the therapy itself can have adverse effects we 
need to find a way to identify those people who will respond very well to it and 
therefore safely avoid surgery.  
How a person responds may be controlled by their genes, but we are not sure 
how. Genes are the body’s instruction manual affecting the way you look and how 
your body works. We would like to look at the chemical switches that control the 
activity of the genes. Changes to these chemical switches have been seen in 
many different types of cancer and it may be that the pattern of these changes 
could help to identify how a person responds to treatment. However it is not 
always easy to get the right samples to look for these patterns. Our study wants 
to find a good reliable way of getting the rectal cancer cells we need to look at 
the chemical switches. This is an essential first step if we want to go on and study 
the possible effects of these pattern changes in rectal cancer.  
 
 
Background: 
 
Rectal cancer accounts for one third of all colorectal cancers. For patients with 
early disease, surgery - radical total mesorectal excision (TME) - is the mainstay 
of treatment3. Due to its anatomical location in the small confined pelvic area, 
surgical resection with clear margins is often difficult. Furthermore, surgery on the 
rectum comes with side effects, significant risk of complications, poor long-term 
function and reduced quality of life3. Additionally, most patients are found to have 
an intermediate probability of recurrence3. Current imaging modalities do not 
detect lymph node spread reliably, especially at a microscopic level. 
Consequently, in the absence of robust scientific evidence evaluating recurrence 
rates, the recommendation to undergo radical surgery in early stage rectal cancer 
is usually based on uncertainty.  
 
 
NICE recommends neaodjuvant chemo-radiotherapy (NAC) prior to surgical 
resection in patients with advanced stage rectal tumours or nodal disease1.  
The response to the treatment is varied. A complete eradication of tumour is 
achieved in some patients following NAC. Other patients however, see no 
improvement and rely solely on surgery. Chemotherapy and radiotherapy are 
both associated with significant adverse effects too, including delayed wound 
healing, urinary and faecal incontinence and sexual dysfunction. 
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Therefore, being able to identify the patients that will not respond to NAC will 
spare them the morbidity associated with the treatment. Equally, patients that 
achieve complete response from NAC alone will be spared surgery and its 
potential complications. 
 
There is considerable interest in the analysis of epigenetic modifications to the 
genome of cancer cells that do not involve a change in the nucleotide 
sequence. Epigenetic alterations are believed to be as important as genetic 
mutations in a cell’s transformation to cancer, and their manipulation holds great 
promise for cancer prevention, detection, and therapy2. A variety of epigenetic 
mechanisms have been shown to be involved in different types of cancer, 
particularly the silencing of tumour suppressor genes and the activation of 
oncogenes by altered DNA methylation patterns4. Several medications which 
directly influence epigenetic processes are now used in various types of cancer. 
 
 
Although considerable research has focused on epigenetic changes in colon 
cancer, especially DNA methylation differences between cancer cells and normal 
mucosal cells, the epigenetic and transcriptional changes specific to rectal cancer 
are poorly understood3,4. Methylomic variation in certain transcription genes and 
loci have been reported in rectal cancer and linked to recurrence rates and 
prognosis4. However, very few of the markers found have been replicated 
successfully in subsequent studies. Additionally, to our knowledge, there is no 
published genome-wide study looking at the differences in the epigenetic profile 
of rectal tumour tissue vs normal mucosa, or attempting to create an epigenetic 
profile for differentially methylated regions in rectal cancer.  
 
This paucity of information may be due to limitations in the current methodologies 
used for the extraction and processing of rectal tissue in molecular 
epidemiological work. The outputs are varied and not always adequate. For DNA 
methylation studies, high yield rectal tumour cells should be used for analysis 
where possible. Colorectal adenocarcinomas will vary in histopathological 
features depending on the microscopic levels of inflammatory cells, 
neuroendocrine scattered cells and necrotic debris found within the samples. 
Therefore, it is impossible to quantify the content of tumour cells within a rectal 
tumour sample without histological workup.  
 
 
Current Methodologies for tissue collection: 
 
Currently, there is no standardised method for DNA extraction and methylation 
analyses for rectal cancer tumours across the limited number of studies that 
have been performed in this field.  
 
A common method is DNA extraction from flash frozen cancer specimens 
collected from patients during surgery. In their methylation study, Leong et al 
used liquid nitrogen flash frozen rectal tumour samples3. However, the samples 
were not histologically assessed for heterogeneity, nor were the levels of 
tumour cells within the samples quantified. Therefore the discrepancy in the 
content of tumour cells in each sample may have subsequently affected the 
DNA methylation analyses.  
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Benard et al used formalin-fixed paraffin embedded specimens, identified as 
rectal cancer by a pathologist4. Those were subsequently micro dissected for 
tumour areas, although no threshold for tumour content within each specimen 
was determined or specified. 
 
Jo et al used rectal tumour samples that revealed a tumour cell content of at 
least 60% after histological workup5. The methodology used for estimation of 
tumour cell content however was not specified. Furthermore, the threshold of 
60% is deemed to be too low to produce reliable DNA methylation results.  
 
Our study therefore aims to develop and validate methods for isolating tumour 
cells for DNA methylation analysis from rectal cancer tissue, and obtain 
preliminary data on genome-wide patterns of DNA methylation in rectal cancer.  
 
 
 
Aims: 
 
To develop, and validate, methods for isolating tumour cells for DNA 
methylation analysis from rectal cancer tissue, and obtain preliminary data on 
genome-wide patterns of DNA methylation in rectal cancer.  
 
 
Objectives: 
 
• Obtain matching rectal tumour and non-tumour tissues from pre-existing 
collected samples stored in The Exeter Tissue Bank of the NIHR Exeter 
Clinical Research Facility. Assess the samples histologically for integrity 
and cellular heterogeneity  
• Dissect the samples histologically to obtain a high yield tumour DNA cells 
(optimally > 50% purity threshold) 
• Extract DNA from the paraffin embedded tissue samples 
• Perform quality control procedures to validate methodology 
• Perform DNA methylation analysis on the samples using microarray 
technology 
• Process the data using an optimised pipeline to identify patterns of 
differential DNA methylation in the tumour samples compared to non-
tumour samples. 
 
 
																								 203	
Methods: 
 
Study design:   
This is a methodological study utilising tissue samples currently held by the RD&E 
Tissue Bank (TB). Tissue remaining from this study will remain in the custody of 
the TB.   
 
Inclusion criteria for this study: 
Matched malignant, and benign, rectal cancer samples from the same individual.   
 
Availability of potential tissues:  
Preliminary discussions with the TB Management team have identified a 
sufficient number of samples would be available to facilitate this project.  
 
Procedure: 
This study aims to assess 30 matched pairs of tumour and non-tumour tissue (i.e. 
process 60 individual biopsies in total).  Matching samples consisting of rectal 
tumour tissue and unaffected mucosal tissue for each patient will be selected 
from the TB.  Sections of the flash frozen tissue received from the TB will be 
dissected and placed in formalin section. This will be paraffin stained and 
assessed histologically for integrity, heterogeneity and tumour cells content by 
an experienced histopathologist (Figure 1).  
 
 
Figure 1. Paraffin stained section from a rectal tumour sample as assessed 
histologically.  
 
The samples will then be dissected in order to obtain tumour tissue containing > 
50% tumour cells for further processing.  
 
Genomic DNA will be isolated from each paraffin embedded tissue sample using 
a method specifically designed for processing small numbers of fixed cells. DNA 
will be tested for quality and quantity and then treated with sodium bisulfite to 
convert unmethylated cytosines to uracil. DNA methylation will be quantified 
using the Illumina Infinium HumanMethylation 450K array, which generates a 
quantitative measurement of DNA methylation for >480,000 CpG sites spanning 
all annotated genes and other functional motifs across the genome. Data will 
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undergo stringent quality control and be analysed using a custom bioinformatics 
pipeline developed by Professor Mill’s group. Following methylomic profiling, 
specifically differentially methylated regions (DMRs) of interest will be validated 
and subsequently replicated in additional samples using bisulfite-
pyrosequencing. Each assay will be designed to span CpG regulatory regions 
likely to be affected by DNA methylation (e.g. transcption-factor binding sites). 
 
Data storage: 
All biological samples will be stored in line with the HTA6 and MRC guidelines7 
on the handling and storage of human tissues. 
 
All data in paper form will be kept in locked filing cabinets within the controlled 
access research facility.  
 
All other study data will be kept on a password protected study database on a 
network drive accessible only to the study team and under the guardianship of 
the CI. Prof Mill’s team has a dedicated secure server that will be used for data 
pre-processing and bioinformatics analysis after the DNA methylation arrays 
have been run. They routinely process samples from clinical patients and have 
secure data protection protocols in place. 
Tissue	Donor	Privacy	and	Confidentiality:	
 
Tissue and associated data obtained from the TB will be provided anonymised 
and identified only by original TB ID number. 
 
Data analysis: 
 
DNA methylation will be assessed using the Illumina Infinium Human Methylation 
450K array, which generates a quantitative measurement of DNA methylation for 
>480,000 CpG sites spanning all annotated genes and other functional motifs 
across the genome. Raw methylomic data will undergo stringent quality control 
assessment and be subsequently analysed using a specialized bioinformatic 
pipeline. Data normalisation and pre-processing will be undertaken using the 
WateRmelon package, developed by our group8 with non-specific probes and 
those known to overlap polymorphic SNPs removed from subsequent analyses. 
Cellular heterogeneity between samples will be controlled for using cell count 
data and in silico algorithms designed to determine cellular composition in 
aggregate samples9. Following methylomic profiling, specific differentially 
methylated regions (DMRs) of interest will be confirmed and further examined by 
targeted bisulfite-pyrosequencing to accurately quantify DNA methylation at 
specific CpG sites nominated by our genome-wide analyses. Professor Mill’s 
group has used these approaches extensively to characterise epigenetic 
variation in complex disease10, and all facilities and expertise is available locally. 
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Sample numbers and power calculation: 
 
We propose to use matched tumour and non-tumour tissue from 30 individuals in 
this study. This will provide sufficient power to address the aims of the study.  
 
For our differential DNA methylation analysis, the study will undertake intra-
individual paired analysis. Such an approach overcomes many of the 
confounders that can reduce power in molecular epidemiology as affected and 
unaffected samples are from the same donor (and thus are matched for 
genotype, age, sex, environmental exposures, etc.). This will represent the 
largest study yet undertaken in rectal cancer, and the first to take an unbiased 
genome-wide approach. Given the dramatic and widespread changes in the 
epigenome seen in cancer, we should have excellent power to identify tumour-
associated differences; a power calculation using control data generated in 
Professor Mill’s lab using the same Illumina 450K array platform that we propose 
to use demonstrates that our planned approach has excellent power to detect 
changes of the magnitude widely seen in other types of cancer – a 20% difference 
in DNA methylation (for which we have almost 100% power, see Figure below) 
would be considered a small change in this regard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Project development and user involvement: 
 
Clinical members of the research team have regular discussions with their 
patients on the importance of ensuring the right treatment for each individual. 
These discussions involve the need for continued research into improving 
treatment options. Patients have been supportive of “anything” that can improve 
their care and understand that to get to an end result that may improve their care 
on the front-line; it often needs these kinds of method development studies in the 
early stages. The samples obtained from the TB were donated by individuals also 
keen that:  “it may not help me, but could help someone else further down the 
line”  
 
 
Reporting adverse effects 
 
In the event of an adverse event being identified during the processing of the 
anonymised frozen tissue, laboratory protocols will be followed and the event 
reported to appropriate channels.  
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Timescale 
It is anticipated that the objectives identified above will be achieved within 3 
months as outlined below: 
• Obtain samples: (March 2016)  
• Assess techniques for obtaining tissue cells from all samples (March 2016)  
• Methylation studies (March 2016)  
• Data analysis (April 2016) 
• Prepare data and submit for peer-reviewed publication (April 2016) 
 
 
Budget Summary and Costings: 
 
This project will bring together NHS and UoE Medical School research staff and 
utilise existing NIHR infrastructure (RD&ETB) therefore research staff costs are 
covered.  
 
Funding for sample analysis (approx. £175 per sample) will be covered by 
existing funding to Professor Mill.	
 
 
Dissemination/implementation of research 
Results will be written up and submitted for publication in peer-reviewed journals. 
Abstracts will be submitted to relevant conferences. Results will be presented to 
clinical/academic colleagues at regular in-house meetings. 
 
Potential impact and benefit of the proposed research 
 
The potential impact of this project will be both short and long term: in the short 
term the project will allow the identification of a specific methodology for obtaining 
rectal tumour cells for DNA methylation in rectal cancer biospises. 
 
In the longer term, the availablity of a standard methodology for obtaining 
appropriate tissue samples will inform the development of future research 
projects looking at DNA methylation associated with rectal cancer, leading to an 
understanding of the epigenetic factors involved in rectal cancer.  
 
Justification of research 
 
The current research group have existing expertise in the fields of epigenetics 
and DNA methylation in several areas including tumour methylomic profiling,  
genome-wide analyse and epigenetic variation in complex disease and cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
   
 
 
 
End of Study 
The study will finish when tissue cell collection techniques have been assessed, 
and sample analysis undertaken on all samples as identified in the project 
timescale above. 
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A
ppendix 4 – Supplem
entary Tables 
 Supplem
entary Table 1. Age C
alculator results for all sam
ples. 
   Sam
ple	
Age	
DNA	Age	
Predicted	Gender	
Predicted	Tissue	
Tissue	
1	
49	
54.16994748	
m
ale	
Colon	
Blood	
2	
49	
74.92292768	
m
ale	
Colon	
Blood	
3	
71	
64.9085782	
fem
ale	
Colon	
Blood	
4	
71	
53.01152044	
fem
ale	
Colon	
Blood	
5	
75	
65.0955444	
fem
ale	
Colon	
Blood	
6	
75	
67.92234351	
fem
ale	
Colon	
Blood	
7	
76	
72.19747319	
fem
ale	
Colon	
Blood	
8	
76	
46.56578304	
m
ale	
Colon	
Blood	
9	
79	
71.75498177	
fem
ale	
Colon	
Blood	
10	
79	
59.93039255	
fem
ale	
Colon	
Blood	
11	
77	
67.4391369	
fem
ale	
Colon	
Blood	
12	
77	
59.72348624	
fem
ale	
Colon	
Blood	
13	
74	
58.42779004	
fem
ale	
Colon	
Blood	
14	
74	
56.67313195	
fem
ale	
Colon	
Blood	
15	
71	
63.85673321	
fem
ale	
Colon	
Blood	
16	
71	
53.7667642	
fem
ale	
Colon	
Blood	
17	
67	
68.43355106	
m
ale	
Colon	
Blood	
18	
67	
67.9124292	
m
ale	
Colon	
Blood	
19	
63	
55.4932901	
fem
ale	
Colon	
Blood	
20	
63	
48.42127721	
fem
ale	
Colon	
Blood	
21	
65	
56.90356746	
fem
ale	
Colon	
Blood	
22	
65	
42.72908983	
fem
ale	
Colon	
Blood	
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23	
79	
71.54005144	
m
ale	
Colon	
Blood	
24	
79	
52.87519815	
m
ale	
Colon	
Blood	
25	
56	
59.96906713	
m
ale	
Colon	
Blood	
26	
56	
24.84936953	
m
ale	
Colon	
Blood	
27	
72	
67.97555223	
m
ale	
Colon	
Blood	
28	
72	
50.03930671	
m
ale	
Colon	
Blood	
29	
78	
65.22639049	
m
ale	
Colon	
Blood	
30	
78	
53.58342956	
m
ale	
Colon	
Blood	
31	
45	
44.53594746	
m
ale	
Colon	
Blood	
32	
45	
44.7380869	
m
ale	
Colon	
Blood	
33	
49	
NA	
m
ale	
NA	
Blood	
34	
49	
38.49008452	
m
ale	
Colon	
Blood	
35	
66	
NA	
m
ale	
NA	
Blood	
36	
66	
NA	
m
ale	
NA	
Blood	
37	
62	
NA	
Unsure	
NA	
Blood	
38	
62	
81.7601887	
m
ale	
Colon	
Blood	
39	
54	
58.06056364	
m
ale	
Colon	
Blood	
40	
54	
10.02421202	
m
ale	
Colon	
Blood	
41	
62	
NA	
fem
ale	
NA	
Blood	
42	
62	
NA	
fem
ale	
NA	
Blood	
43	
59	
28.50444261	
fem
ale	
Colon	
Blood	
44	
59	
NA	
fem
ale	
NA	
Blood	
45	
90	
NA	
m
ale	
NA	
Blood	
46	
90	
127.285128	
fem
ale	
Bone	
Blood	
47	
77	
61.62673632	
fem
ale	
Colon	
Blood	
48	
77	
66.49283439	
fem
ale	
Colon	
Blood	
49	
80	
78.85047564	
fem
ale	
Colon	
Blood	
50	
80	
27.16244925	
fem
ale	
Buccal	
Blood	
51	
93	
57.23264818	
m
ale	
Colon	
Blood	
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52	
93	
NA	
m
ale	
NA	
Blood	
53	
65	
110.6556222	
m
ale	
Colon	
Blood	
54	
65	
60.13889438	
m
ale	
Colon	
Blood	
55	
70	
67.12283683	
m
ale	
Colon	
Blood	
56	
70	
116.1693726	
m
ale	
Colon	
Blood	
57	
73	
NA	
m
ale	
NA	
Blood	
58	
73	
60.38563593	
m
ale	
Colon	
Blood	
59	
67	
NA	
m
ale	
NA	
Blood	
60	
67	
NA	
Unsure	
NA	
Blood	
61	
83	
NA	
m
ale	
NA	
Blood	
62	
83	
NA	
m
ale	
NA	
Blood	
63	
77	
58.1125704	
fem
ale	
Colon	
Blood	
64	
77	
38.22529811	
fem
ale	
Colon	
Blood	
65	
79	
NA	
m
ale	
NA	
Blood	
66	
79	
NA	
m
ale	
NA	
Blood	
67	
69	
69.21559324	
Unsure	
Colon	
Blood	
68	
69	
47.3688346	
Unsure	
Colon	
Blood	
69	
81	
42.89876798	
m
ale	
Colon	
Blood	
70	
81	
12.68150801	
Unsure	
Colon	
Blood	
71	
80	
NA	
Unsure	
NA	
Blood	
72	
80	
NA	
Unsure	
NA	
Blood	
73	
79	
NA	
m
ale	
NA	
Blood	
74	
79	
9.17757191	
fem
ale	
Colon	
Blood	
75	
85	
NA	
Unsure	
NA	
Blood	
76	
85	
NA	
fem
ale	
NA	
Blood	
77	
44	
53.0678611	
fem
ale	
Colon	
Blood	
78	
44	
18.19440839	
fem
ale	
Saliva	
Blood	
79	
76	
NA	
Unsure	
NA	
Blood	
80	
76	
90.66549701	
Unsure	
Colon	
Blood	
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81	
61	
NA	
m
ale	
NA	
Blood	
82	
61	
4.227320802	
fem
ale	
Saliva	
Blood	
83	
56	
33.82796604	
m
ale	
Colon	
Blood	
84	
56	
49.11316433	
m
ale	
Colon	
Blood	
85	
54	
NA	
fem
ale	
NA	
Blood	
86	
54	
58.97562436	
fem
ale	
Colon	
Blood	
87	
67	
NA	
fem
ale	
NA	
Blood	
88	
67	
NA	
fem
ale	
NA	
Blood	
89	
45	
NA	
Unsure	
NA	
Blood	
90	
45	
NA	
fem
ale	
NA	
Blood	
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   Supplem
entary Table 2. List of all D
M
Ps 
   Probe	
Chr	
Chr	Location	
P.value	
Beta	effect	
M
ap	Location	
Gene	Nam
e	
Gene	Location	
cg02647878	
4	
47513	
3.66E-10	
0.449429809	
154681197	
RNF175;RNF175	
5'UTR;1stExon	
cg14650610	
5	
239524	
7.30E-10	
0.484972492	
136834492	
SPOCK1	
5'UTR	
cg13001868	
17	
211163	
1.58E-09	
0.451116562	
43339223	
C17orf46;LOC100133991
;LOC100133991	
Body;Body;TSS1500	
cg13895235	
7	
225738	
2.22E-09	
0.569170792	
752292	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B	
5'UTR;5'UTR;TSS200;	
5'UTR;	
5'UTR;5'UTR	
cg18538668	
14	
295626	
3.79E-09	
-0.19612723	
103839038	
	
 
cg03061682	
15	
54820	
4.83E-09	
0.41722365	
28352098	
	
 
cg24847829	
5	
382403	
6.29E-09	
0.396895297	
136834464	
SPOCK1	
5'UTR	
cg26034516	
17	
398674	
6.48E-09	
0.346216327	
76228121	
LOC283999	
Body	
cg03576469	
19	
63572	
6.83E-09	
0.290652294	
46917061	
CCDC8	
TSS200	
cg18601167	
7	
296508	
8.02E-09	
0.559808371	
752286	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B	
5'UTR;5'UTR;TSS200;5'UTR;	
5'UTR;5'UTR	
cg05447008	
6	
95009	
9.87E-09	
0.400432306	
73331114	
KCNQ
5;KCNQ
5;KCNQ
5;	
KCNQ
5;KCNQ
5	
TSS1500;TSS1500;TSS1500;	
TSS1500;TSS1500	
cg13356896	
2	
216007	
1.15E-08	
0.399185694	
198650987	
BOLL;BOLL	
TSS200;TSS1500	
cg09129067	
8	
154157	
1.29E-08	
-
0.348999594	
103750904	
	
 
cg23977631	
2	
369868	
1.30E-08	
0.456560177	
100938799	
LONRF2;LONRF2	
5'UTR;1stExon	
cg26238800	
20	
401750	
1.38E-08	
0.36683134	
45142206	
ZNF334;ZNF334	
TSS200;TSS200	
																								
213	
cg24685755	
19	
379961	
1.39E-08	
0.349845061	
53758031	
ZNF677	
5'UTR	
cg24820783	
10	
382004	
1.41E-08	
0.247143991	
26504969	
GAD2;GAD2	
TSS1500;TSS1500	
cg25480336	
20	
391254	
1.50E-08	
0.385016545	
50720908	
ZFP64	
Body	
cg16964348	
7	
273155	
1.65E-08	
0.390871674	
24323799	
NPY	
TSS200	
cg11328303	
10	
187365	
1.94E-08	
0.27109572	
26505440	
GAD2;GAD2;GAD2;GAD2	
5'UTR;1stExon;5'UTR;		
1stExon	
cg09734791	
8	
163406	
2.06E-08	
0.455869807	
72756155	
M
SC	
1stExon	
cg10224098	
1	
170996	
2.26E-08	
0.397396517	
44873229	
RNF220	
5'UTR	
cg04921989	
2	
86278	
2.32E-08	
0.368576617	
132183100	
	
 
cg26314722	
1	
402967	
2.36E-08	
-
0.238588868	
234867300	
	
 
cg04504205	
20	
79260	
2.42E-08	
-
0.323480149	
45946429	
ZM
YND8;LOC100131496;
ZM
YND8;ZM
YND8	
Body;TSS1500;	
Body;Body	
cg18324583	
5	
292503	
2.48E-08	
-
0.217418501	
142975083	
	
 
cg11220565	
20	
185731	
2.48E-08	
0.359207899	
47934802	
	
 
cg19752627	
7	
312333	
2.51E-08	
0.386976262	
98467380	
TM
EM
130;TM
EM
130;	
TM
EM
130	
Body;Body;Body	
cg03470088	
1	
61682	
2.52E-08	
0.025592041	
24513939	
IL28RA;IL28RA;IL28RA	
TSS200;TSS200;TSS200	
cg25884711	
7	
396613	
2.52E-08	
0.417868233	
24323840	
NPY;NPY	
5'UTR;1stExon	
cg06952671	
2	
119270	
2.55E-08	
0.472093568	
182322268	
ITGA4;ITGA4	
5'UTR;1stExon	
cg04377145	
6	
77167	
2.72E-08	
0.329003654	
73331191	
KCNQ
5;KCNQ
5;KCNQ
5;	
KCNQ
5;KCNQ
5	
TSS1500;TSS1500;TSS1500;	
TSS1500;TSS1500	
cg14168530	
2	
230764	
2.84E-08	
0.506333301	
45155991	
	
 
cg00859129	
1	
15911	
2.87E-08	
-
0.224919096	
109422184	
GPSM
2	
5'UTR	
cg26958524	
16	
412835	
2.90E-08	
0.337002486	
86613067	
FOXL1	
1stExon	
cg25024074	
2	
385025	
2.94E-08	
0.311479567	
182322501	
ITGA4	
1stExon	
cg26328335	
12	
403139	
3.26E-08	
0.446031402	
50354840	
AQ
P5	
TSS1500	
																								
214	
cg26020069	
6	
398471	
3.29E-08	
-
0.265475554	
52382441	
TRAM
2	
Body	
cg22434409	
4	
348028	
3.29E-08	
0.406457764	
21950722	
KCNIP4	
TSS1500	
cg08266366	
12	
140921	
3.38E-08	
0.375119199	
50354998	
AQ
P5	
TSS1500	
cg18607529	
7	
296589	
3.47E-08	
0.408805228	
50343869	
IKZF1	
TSS1500	
cg06319475	
8	
108631	
3.67E-08	
0.38253068	
145105829	
	
 
cg07589773	
7	
130039	
3.80E-08	
0.372646268	
50343883	
IKZF1	
TSS1500	
cg03020208	
12	
54057	
3.85E-08	
0.303956259	
50354962	
AQ
P5	
TSS1500	
cg11751707	
2	
193379	
3.85E-08	
0.273146429	
38302587	
CYP1B1	
5'UTR	
cg09220050	
20	
155496	
3.88E-08	
-
0.029897082	
48770642	
TM
EM
189;TM
EM
189;	
TM
EM
189;	TM
EM
189-
UBE2V1	
TSS1500;TSS1500;	
TSS1500;TSS1500	
cg20415809	
2	
321496	
3.92E-08	
0.386142582	
182321855	
ITGA4;ITGA4	
5'UTR;1stExon	
cg21938148	
13	
341900	
4.01E-08	
0.479457137	
110958977	
COL4A1;COL4A2	
Body;TSS1500	
cg13405887	
9	
216828	
4.37E-08	
0.424566454	
132382812	
C9orf50	
1stExon	
cg25340966	
1	
389226	
4.46E-08	
0.340306042	
119532195	
TBX15	
TSS200	
cg17200768	
13	
276563	
4.62E-08	
0.394516994	
28503373	
	
 
cg26415547	
12	
404524	
4.82E-08	
0.319863705	
66583048	
IRAK3;IRAK3;IRAK3;IRAK
3	
1stExon;1stExon;5'UTR;	
5'UTR	
cg07921384	
2	
135314	
4.84E-08	
0.332251121	
220299740	
SPEG	
1stExon	
cg10013343	
13	
167616	
4.86E-08	
0.502548779	
29106503	
	
 
cg12628196	
7	
206178	
4.87E-08	
0.403101986	
127672458	
SND1;LRRC4	
Body;TSS1500	
cg06072021	
11	
104977	
4.99E-08	
0.516435028	
128564106	
FLI1;FLI1;FLI1	
1stExon;5'UTR;5'UTR	
cg16674351	
1	
269065	
5.03E-08	
0.34913105	
121260892	
LOC647121	
TSS200	
cg17170568	
7	
276109	
5.05E-08	
0.17708847	
156433406	
C7orf13;RNF32;RNF32	
TSS200;1stExon;5'UTR	
cg24190603	
6	
373133	
5.05E-08	
0.355341561	
84418433	
SNAP91;SNAP91	
Body;5'UTR	
cg15336765	
12	
249239	
5.15E-08	
0.42949648	
50355307	
AQ
P5;AQ
P5	
1stExon;5'UTR	
cg25223771	
8	
387740	
5.45E-08	
0.376669909	
145105503	
	
 
cg00741836	
20	
13819	
5.50E-08	
0.447569313	
53092233	
DOK5	
TSS200	
																								
215	
cg02155398	
2	
38836	
5.53E-08	
0.364728517	
45160490	
	
 
cg25680916	
3	
393965	
5.76E-08	
-
0.028952666	
53916015	
ACTR8	
1stExon	
cg24924779	
20	
383575	
5.98E-08	
0.380071371	
49639998	
KCNG1	
TSS1500	
cg25773267	
20	
395264	
6.14E-08	
0.359460259	
61992187	
CHRNA4	
Body	
cg17393267	
3	
279350	
6.15E-08	
0.287395147	
192127356	
FGF12;FGF12	
TSS1500;Body	
cg12441126	
7	
203414	
6.21E-08	
0.414079829	
751962	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B	
5'UTR;5'UTR;5'UTR;5'UTR;5'U
TR;5'UTR	
cg13267264	
8	
214705	
6.29E-08	
0.428780876	
70983600	
PRDM
14	
TSS200	
cg11901272	
6	
195740	
6.34E-08	
0.379458459	
29760447	
HCG4	
Body	
cg02742906	
13	
49145	
6.39E-08	
0.340909118	
112758625	
	
 
cg11947981	
2	
196422	
6.39E-08	
0.394836421	
182322749	
ITGA4	
Body	
cg26718707	
10	
409118	
6.46E-08	
-
0.421586867	
518370	
DIP2C	
Body	
cg20381963	
7	
321042	
6.48E-08	
0.509017834	
752238	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B;	
PRKAR1B;PRKAR1B	
5'UTR;5'UTR;TSS200;5'UTR;5'
UTR;5'UTR	
cg20107395	
20	
317502	
6.60E-08	
0.496803783	
53092334	
DOK5;DOK5	
1stExon;5'UTR	
cg24242823	
7	
373759	
6.79E-08	
0.37208258	
24323675	
NPY	
TSS200	
cg11601252	
15	
191089	
6.92E-08	
0.350932645	
68122139	
LBXCOR1	
Body	
cg04366687	
8	
77006	
7.26E-08	
0.353103589	
145107199	
OPLAH	
Body	
cg18355902	
4	
292935	
7.28E-08	
0.401077083	
154681128	
RNF175;RNF175	
5'UTR;1stExon	
cg08206318	
5	
139920	
7.33E-08	
0.299706014	
134363637	
PITX1	
3'UTR	
cg13554086	
5	
219602	
7.39E-08	
0.389158636	
76507100	
PDE8B;PDE8B;PDE8B;	
PDE8B;PDE8B	
Body;Body;Body;Body;	Body	
cg25645268	
4	
393529	
7.81E-08	
0.305821609	
154710598	
SFRP2	
TSS1500	
cg17101450	
10	
275064	
7.85E-08	
0.377444704	
102900365	
	
 
																								
216	
cg00321614	
5	
5977	
7.88E-08	
-
0.174805125	
172856932	
	
 
cg14215472	
17	
231713	
7.91E-08	
0.350417461	
27940404	
ANKRD13B	
Body	
cg18335068	
19	
292663	
7.99E-08	
0.315843801	
53757910	
ZNF677	
5'UTR	
cg09296001	
7	
156745	
8.21E-08	
0.521700368	
127672564	
SND1	
Body	
cg03424342	
3	
60835	
8.35E-08	
0.279116055	
120169783	
FSTL1;FSTL1	
5'UTR;1stExon	
cg26593267	
13	
407219	
8.47E-08	
0.341347306	
113764871	
F7;F7	
Body;Body	
cg10120816	
6	
169297	
8.61E-08	
0.256360286	
99296305	
	
 
cg09871471	
1	
165522	
8.62E-08	
0.41166646	
121260900	
LOC647121	
TSS200	
cg03147907	
3	
56232	
9.20E-08	
-
0.336528803	
62926690	
	
 
cg10928466	
19	
181453	
9.24E-08	
0.108647309	
11353961	
DOCK6	
Body	
cg07719492	
8	
132095	
9.24E-08	
0.315052192	
70983348	
PRDM
14	
5'UTR	
cg21995919	
2	
342525	
9.27E-08	
0.414609207	
182322279	
ITGA4;ITGA4	
5'UTR;1stExon	
cg23383871	
20	
361615	
9.31E-08	
0.372836732	
47934987	
	
 
cg10770742	
7	
179135	
9.31E-08	
0.372960807	
151107285	
W
DR86	
TSS200	
cg04023150	
1	
71075	
9.33E-08	
0.447449018	
44873064	
RNF220	
5'UTR	
cg17228900	
6	
277000	
9.42E-08	
0.453670006	
391764	
IRF4;IRF4	
5'UTR;1stExon	
cg27532621	
1	
421231	
9.61E-08	
0.230813829	
164593763	
PBX1	
Body	
cg10065823	
9	
168383	
1.00E-07	
0.29923162	
96108467	
C9orf129;C9orf129	
1stExon;5'UTR	
cg11573679	
2	
190672	
1.03E-07	
0.475379695	
68546467	
CNRIP1;CNRIP1	
1stExon;1stExon	
cg23572908	
7	
364168	
1.05E-07	
0.370648121	
158937969	
VIPR2	
TSS1500	
cg01440841	
4	
26322	
1.06E-07	
0.351171663	
154681066	
RNF175;RNF175	
5'UTR;1stExon	
cg05946309	
16	
102971	
1.07E-07	
-
0.208488839	
85926085	
	
 
cg05288172	
8	
92328	
1.07E-07	
-0.26607755	
103751006	
	
 
cg18918321	
8	
300921	
1.08E-07	
0.2622105	
41424524	
	
 
cg02177231	
1	
39206	
1.09E-07	
0.333194537	
119529930	
TBX15	
5'UTR	
cg16437728	
11	
265286	
1.09E-07	
0.364624499	
7273046	
SYT9	
TSS200	
																								
217	
cg08957069	
6	
151718	
1.11E-07	
0.316843199	
28743700	
	
 
cg23934404	
13	
369192	
1.13E-07	
0.418802979	
112758491	
	
 
cg23933289	
1	
369171	
1.14E-07	
0.233664502	
178998656	
FAM
20B	
5'UTR	
cg11338643	
6	
187521	
1.16E-07	
0.409405033	
166580983	
T	
Body	
cg08750504	
2	
148450	
1.20E-07	
0.387758312	
172946193	
	
 
cg09073398	
5	
153372	
1.20E-07	
0.385215757	
168727762	
SLIT3;SLIT3	
5'UTR;1stExon	
cg14337134	
7	
233929	
1.21E-07	
0.176560163	
102920323	
DPY19L2P2;DPY19L2P2	
Body;Body	
cg21232488	
6	
332729	
1.23E-07	
-
0.279429477	
30079203	
TRIM
31	
Body	
cg16504626	
8	
266227	
1.25E-07	
0.384265106	
57070013	
	
 
cg01618245	
20	
29403	
1.29E-07	
-
0.237429382	
61990279	
CHRNA4	
Body	
cg14443519	
6	
235755	
1.30E-07	
0.433782606	
29760410	
HCG4	
Body	
cg27141850	
2	
415570	
1.30E-07	
0.379147268	
20869434	
GDF7	
Body	
cg14015706	
9	
228020	
1.30E-07	
0.502648076	
132382433	
C9orf50	
1stExon	
cg24171907	
2	
372892	
1.32E-07	
0.447022617	
68546579	
CNRIP1;CNRIP1;	
CNRIP1;CNRIP1	
1stExon;1stExon;5'UTR;	
5'UTR	
cg20652954	
20	
324617	
1.33E-07	
-
0.197332275	
61716293	
	
 
cg10210594	
1	
170794	
1.34E-07	
0.330872402	
208132787	
	
 
cg12433277	
7	
203284	
1.34E-07	
0.314504362	
151106990	
W
DR86;W
DR86	
5'UTR;1stExon	
cg02700626	
11	
48369	
1.35E-07	
0.240343059	
64739320	
	
 
cg20295442	
8	
319933	
1.37E-07	
0.477998364	
67344665	
ADHFE1	
TSS200	
cg08332074	
16	
142027	
1.37E-07	
0.309815416	
51189941	
	
 
cg21647227	
1	
338120	
1.37E-07	
0.363506599	
119527111	
TBX15	
5'UTR	
cg06401021	
6	
109895	
1.37E-07	
0.416252367	
55443868	
HM
GCLL1;HM
GCLL1;	
HM
GCLL1;HM
GCLL1	
1stExon;5'UTR;1stExon;	
5'UTR	
cg23641267	
11	
365125	
1.39E-07	
0.251295468	
58343791	
LPXN;LPXN	
Body;TSS1500	
cg23092823	
1	
357374	
1.39E-07	
0.245227874	
53528612	
PODN	
Body	
																								
218	
cg25771271	
1	
395231	
1.41E-07	
0.319163644	
119550191	
	
 
cg27341128	
20	
418487	
1.41E-07	
0.333202735	
53092259	
DOK5	
TSS200	
cg14595003	
3	
238570	
1.41E-07	
0.383497013	
129694156	
TRH	
5'UTR	
cg25189564	
7	
387224	
1.43E-07	
0.29061549	
158938051	
VIPR2	
TSS1500	
cg24645214	
8	
379359	
1.45E-07	
0.30076221	
54789978	
RGS20	
Body	
cg07878486	
19	
134591	
1.46E-07	
0.326438411	
58951885	
ZNF132	
TSS1500	
cg18303242	
17	
292176	
1.48E-07	
-
0.368987913	
25879250	
KSR1	
5'UTR	
cg12619536	
1	
206042	
1.49E-07	
0.41578936	
108508067	
VAV3	
TSS1500	
cg17892556	
19	
286136	
1.49E-07	
0.466224169	
12267464	
ZNF625;ZNF625	
1stExon;5'UTR	
cg04415599	
19	
77844	
1.49E-07	
0.239895854	
37464508	
	
 
cg08516516	
5	
144823	
1.50E-07	
0.300889602	
115152492	
CDO1	
TSS200	
cg02065637	
20	
37250	
1.51E-07	
0.363052106	
61809035	
M
IR124-3	
TSS1500	
cg08569799	
5	
145637	
1.52E-07	
0.294087308	
1886828	
	
 
cg17226446	
4	
276961	
1.53E-07	
0.139640018	
154408845	
KIAA0922;KIAA0922	
Body;Body	
cg25060829	
6	
385522	
1.56E-07	
0.309825561	
28367571	
ZSCAN12;ZSCAN12	
TSS200;TSS200	
cg19991022	
20	
315982	
1.56E-07	
0.545169429	
53091929	
DOK5	
TSS1500	
cg13850380	
1	
224969	
1.60E-07	
0.317619683	
1475143	
C1orf70	
Body	
cg15745900	
8	
255165	
1.62E-07	
0.381411419	
68864549	
PREX2;PREX2	
TSS200;TSS200	
cg27200446	
6	
416403	
1.62E-07	
0.57207624	
41606439	
M
DFI	
5'UTR	
cg07790085	
13	
133165	
1.64E-07	
-
0.253479546	
29597447	
M
TUS2	
TSS1500	
cg20912169	
8	
328051	
1.64E-07	
0.479902615	
67344720	
ADHFE1;ADHFE1	
5'UTR;1stExon	
cg00250422	
15	
4717	
1.65E-07	
0.415840996	
28352347	
	
 
cg09632907	
4	
161903	
1.68E-07	
0.242282767	
54969963	
	
 
cg18435449	
19	
294072	
1.70E-07	
0.331667026	
58095445	
ZIK1	
TSS200	
cg17371081	
11	
279020	
1.70E-07	
0.277851676	
20690957	
NELL1;NELL1	
TSS200;TSS200	
cg03064067	
12	
54860	
1.70E-07	
0.394769427	
85306916	
SLC6A15;SLC6A15;	
SLC6A15	
TSS1500;TSS1500;TSS1500	
																								
219	
cg12868067	
12	
209399	
1.71E-07	
0.379758435	
128752246	
TM
EM
132C	
Body	
cg13389502	
17	
216514	
1.72E-07	
0.161722774	
1961440	
HIC1;HIC1	
Body;Body	
cg06427779	
5	
110268	
1.73E-07	
0.319148477	
54180079	
	
 
cg27188703	
12	
416248	
1.76E-07	
0.329107422	
50297581	
FAIM
2;FAIM
2	
1stExon;5'UTR	
cg11903130	
10	
195775	
1.82E-07	
0.34806647	
26506751	
GAD2;GAD2	
Body;Body	
cg18921980	
2	
300977	
1.82E-07	
0.27771105	
175594943	
	
 
cg16306898	
1	
263170	
1.83E-07	
0.477786305	
1475675	
C1orf70	
1stExon	
cg02640612	
8	
47384	
1.84E-07	
0.282845368	
53853444	
NPBW
R1	
1stExon	
cg16366473	
3	
264117	
1.88E-07	
0.412447519	
192126849	
FGF12;FGF12	
TSS200;Body	
cg22862480	
10	
353888	
1.91E-07	
0.486456346	
7450355	
SFM
BT2	
5'UTR	
cg14658804	
5	
239677	
1.92E-07	
0.330784284	
168728213	
SLIT3	
TSS200	
cg23575688	
11	
364206	
1.93E-07	
-
0.206365044	
119486443	
	
 
cg21013866	
14	
329498	
1.95E-07	
0.357490982	
23834985	
EFS;EFS	
TSS200;TSS200	
cg24663256	
4	
379578	
1.96E-07	
0.382297975	
21950307	
KCNIP4;KCNIP4	
5'UTR;1stExon	
cg22663389	
17	
350997	
1.97E-07	
-
0.352405177	
57929274	
	
 
cg01046104	
19	
19396	
1.98E-07	
0.26295962	
58095588	
ZIK1	
TSS200	
cg04803843	
15	
84191	
1.99E-07	
0.423122961	
28351906	
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Supplem
entary Table 3 The 53 D
M
R
s annotated to genes also identified in the list of D
M
Ps. 
   Region	
Gene	
N.Probes	
P	Value	
Epigenetic/Cancer	Literature	
		
		
		
		
		
chr6:391114-
392131	
IRF4	
11	
1.72E-14	
Related	to	the	interferon	signalling	pathw
ay	IFN,	w
hich	has	been	found	to	
play	a	role	in	rectal	cancer	(M
artha	Slattery)	
chr8:67344553-
67345006	
ADHFE1	
9	
1.13E-15	
Prom
oter	hyperm
ethylation	frequently	present	in	CRC.	
chr11:128693677-
128694679	
FLI1	
9	
7.83E-07	
Prom
ising		biom
arker	for	rectal	cancer	as	part	of	a	specific	DNA	
m
ethylation	signature	(Vym
etalkova,V,	2016)	
chr1:25257505-
25258082	
RUNX3	
13	
3.86E-05	
Part	of	CIM
P	Panel	for	CRC		
chr1:108507078-
108508207	
VAV3;	
VAV3-AS1	
8	
9.67E-13	
Overexpressed	in	CRC	and	is	correlated	w
ith	tum
our	m
etastases	and	
invasion	(Yih-Huei)	
chr19:58095011-
58095659	
ZIK1	
9	
2.00E-14	
M
ethylated	in		azoxym
ethane	colon	cancer	m
odel	(Borinstein	SC,	2010)	
chr7:751830-
752456	
PRKAR1B	
9	
1.24E-19	
Included	in	Top	10	DM
Ps		
chr5:136833893-
136834492	
SPOCK1	
7	
1.05E-13	
Included	in	Top	10	DM
Ps		
chr4:154680808-
154681619	
RNF175	
8	
5.39E-12	
Included	in	Top	10	DM
Ps		
chr2:68546467-
68547256	
CNRIP1	
9	
4.37E-12	
Included	in	a	novel	com
bined	biom
arker	panel	for	detection	of	CRC	and	
prem
alignant	m
alinom
as	(Guro	E	Lind)(W
ang	Pei)	
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chr2:100938799-
100939477	
LONRF2	
6	
4.88E-09	
Hyperm
ethylation	thought	to	contribute	to	tum
ourigenesis	or	rectal	
cancer	(Hua	Y,	2017)	
chr7:24323128-
24323939	
NPY	
10	
1.82E-17	
hyperm
ethylated	in	CRC	and	prom
ising	biom
arker	(Roperch	Jean	PierrE)	
chr6:41606317-
41607326	
M
DFI	
8	
5.60E-15	
Hyperm
ethylated	in	CRC	(Lin	PC,2014)	
chr19:12267308-
12267796	
ZNF625;	
ZNF20	
6	
2.36E-09	
Hyperm
ethylated	in	CRC	(Lin	PC,		2015)	
chr10:26504950-
26505503	
GAD2	
9	
1.97E-13	
Hyperm
ethylated	in	CRC	(Hai	Li,	2012)	
chr17:1961109-
1961778	
HIC1	
5	
1.58E-07	
Hyperm
ethylated	in	CRC	(H	P	M
oham
ed)	
chr6:73331114-
73331680	
KCNQ
5	
7	
3.56E-13	
Hyperm
ethylated	in	CRC	(Ashktorab,	2016).	
chr5:168728076-
168728586	
SLIT3	
8	
1.67E-09	
Frequently	m
ethylated	in	CRC	and	significantly	associated	w
ith	TNM
	
stage,	lym
ph	node	m
etastasis	and	differentiation	(Tingting	huang)	
chr2:182321489-
182322841	
ITGA4	
11	
3.88E-18	
Frequently	m
ethylated	in	CRC	and	adenom
a	tissues	(Xie	Zhang).	
chr4:154710224-
154710961	
SFRP2	
17	
2.45E-12	
Frequently	m
ethylated	in	CRC	and	adenom
a	tissues	(Xie	Zhang).	
chr4:154713235-
154713789	
SFRP2	
6	
6.63E-07	
Frequently	m
ethylated	in	CRC	and	adenom
a	tissues	(Xie	Zhang).	
chr6:84419189-
84419360	
SNAP91	
9	
9.39E-09	
Dow
nregulated	due	to	prom
oter	hyperm
ethylation	in	around	60%
	of	
colorectal	cancer	and	m
ay	be	associated	w
ith	treatm
ent	resistance.	
(Andrew
	Beggs)	
chr5:115152019-
115152938	
CDO1	
12	
3.58E-10	
Considered	to	play	a	role	as	potential	biom
arker	for	CRC	detection.	
(Yam
ashita	K)	(Vedeld	HM
)	
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chr14:23834710-
23835212	
EFS	
9	
6.24E-13	
Associated	w
ith	prediction	of	biochem
ical,	local,	and	system
ic	recurrence	
of	prostate	cancer	(Vanaja	DK,	2009)	
chr3:129693370-
129694683	
TRH	
11	
7.14E-19	
_	
chr1:119526783-
119528848	
TBX15	
14	
8.02E-19	
_	
chr5:134362967-
134363973	
PITX1	
9	
2.38E-16	
_	
chr8:70982867-
70983760	
PRDM
14	
10	
3.32E-16	
_	
chr11:7272653-
7273735	
SYT9	
11	
8.23E-16	
_	
chr8:68864012-
68865187	
PREX2	
14	
4.04E-15	
_	
chr1:119531625-
119532925	
TBX15	
17	
9.24E-15	
_	
chr20:53091739-
53092984	
DOK5	
10	
2.18E-13	
_	
chr4:21949853-
21951046	
KCNIP4	
10	
3.38E-13	
_	
chr11:20690628-
20691429	
NELL1	
12	
6.23E-13	
_	
chr11:2160875-
2162510	
IGF2;		
41	
8.06E-13	
_	
INS-IGF2	
chr8:72755568-
72756341	
M
SC;		
6	
8.26E-13	
_	
M
SC-AS1	
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chr12:50297477-
50297945	
FAIM
2	
6	
1.41E-12	
_	
chr8:53852030-
53852661	
NPBW
R1	
8	
1.59E-12	
_	
chr3:192126584-
192126996	
FGF12	
7	
1.66E-12	
_	
chr20:61809348-
61809932	
M
IR124-3	
10	
1.70E-12	
_	
chr6:28367070-
28367898	
ZSCAN12	
10	
2.52E-12	
_	
chr20:45141911-
45142336	
ZNF334	
7	
7.55E-12	
_	
chr19:53757677-
53758609	
ZNF677	
9	
1.04E-11	
_	
chr7:151106990-
151107807	
W
DR86-
AS1;	
W
DR86	
7	
1.18E-11	
_	
chr6:166581929-
166582585	
T	
10	
5.90E-11	
_	
chr2:162283189-
162284206	
TBR1	
9	
7.61E-11	
_	
chr5:134366162-
134367394	
PITX1	
8	
1.18E-10	
_	
chr10:26506353-
26506933	
GAD2	
5	
1.83E-10	
_	
chr10:7453329-
7454063	
SFM
BT2	
9	
2.77E-10	
_	
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chr19:58951599-
58952249	
ZNF132	
9	
3.87E-10	
_	
chr6:166580460-
166581538	
T	
7	
4.13E-10	
_	
chr1:119521928-
119522855	
TBX15	
5	
7.62E-10	
_	
chr5:76506484-
76507680	
PDE8B	
8	
1.44E-09	
_	
chr3:192232468-
192233231	
FGF12	
5	
9.14E-09	
_	
chr1:164290179-
164290833	
PBX1	
8	
1.81E-08	
_	
chr12:128752040-
128752586	
TM
EM
132C	
5	
5.97E-08	
_	
chr10:7452242-
7452950	
SFM
BT2	
5	
1.02E-07	
_	
chr6:30080189-
30080782	
TRIM
31-
AS1;	
TRIM
31	
7	
2.02E-07	
_	
chr6:55443757-
55444488	
HM
GCLL1	
10	
2.41E-07	
_	
chr2:220299484-
220300242	
SPEG	
11	
1.83E-06	
_	
chr8:70946891-
70947440	
PRDM
14	
5	
1.20E-05	
_	
chr8:72756656-
72757004	
M
SC;	
8	
1.34E-05	
_	
M
SC-AS1	
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chr1:119530600-
119531122	
TBX15	
6	
2.82E-05	
_	
chr12:128850196-
128850696	
TM
EM
132C	
6	
3.02E-04	
_	
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Supplem
entary Table 4. List of All D
M
R
s. 
  CHR	
Start	
End	
N	of	
Probes	
Sildak	P	
Value	
Gene	Nam
e	
CpG	Island	
Extension	
Nam
e	
chr7	
751830	
752456	
9	
1.24E-19	
PRKAR1B	
CpG:	54	
chr3	
129693370	
129694683	
11	
7.14E-19	
TRH	
CpG:	155	
chr1	
119526783	
119528848	
14	
8.02E-19	
TBX15	
CpG:	35	
chr10	
118031632	
118033902	
24	
8.33E-19	
GFRA1	
CpG:	275	
chr2	
182321489	
182322841	
11	
3.88E-18	
ITGA4	
CpG:	119	
chr7	
24323128	
24323939	
10	
1.82E-17	
NPY	
CpG:	123	
chr8	
69243285	
69244734	
12	
1.66E-16	
C8orf34-AS1;C8orf34	
CpG:	83	
chr6	
133561224	
133562776	
41	
1.76E-16	
EYA4	
CpG:	138	
chr5	
134362967	
134363973	
9	
2.38E-16	
PITX1	
CpG:	174	
chr8	
70982867	
70983760	
10	
3.32E-16	
PRDM
14	
CpG:	253	
chr2	
45159504	
45160554	
10	
3.88E-16	
SIX3-AS1	
CpG:	18	
chr18	
12253749	
12254976	
20	
6.91E-16	
CIDEA	
CpG:	85	
chr11	
7272653	
7273735	
11	
8.23E-16	
SYT9	
CpG:	139	
chr15	
28351619	
28352558	
6	
8.77E-16	
HERC2	
CpG:	146	
chr8	
67344553	
67345006	
9	
1.13E-15	
ADHFE1	
CpG:	51	
chr13	
78492306	
78494462	
48	
1.13E-15	
EDNRB	
CpG:	70	
chr7	
93519220	
93520566	
20	
1.52E-15	
TFPI2;	LOC105375401	
CpG:	70	
chr8	
68864012	
68865187	
14	
4.04E-15	
PREX2	
CpG:	48	
chr6	
41606317	
41607326	
8	
5.60E-15	
M
DFI	
CpG:	168;	
CpG:	20	
																								
228	
chr16	
51183988	
51185772	
25	
7.59E-15	
SALL1	
CpG:	366	
chr1	
119531625	
119532925	
17	
9.24E-15	
TBX15	
CpG:	19	
chr6	
391114	
392131	
11	
1.72E-14	
IRF4	
CpG:	261	
chr19	
58095011	
58095659	
9	
2.00E-14	
ZIK1	
CpG:	88	
chr17	
32906991	
32908285	
12	
7.12E-14	
TM
EM
132E	
CpG:	276	
chr5	
87973439	
87974547	
12	
8.39E-14	
LINC00461	
CpG:	34	
chr2	
144694405	
144695257	
6	
8.72E-14	
LOC101928386	
CpG:	69	
chr5	
136833893	
136834492	
7	
1.05E-13	
SPOCK1	
CpG:	134	
chr3	
140769691	
140771372	
19	
1.48E-13	
SPSB4	
CpG:	103	
chr2	
45155201	
45156207	
9	
1.60E-13	
SIX3-AS1	
CpG:	177	
chr10	
26504950	
26505503	
9	
1.97E-13	
GAD2	
CpG:	242	
chr10	
129535138	
129535898	
9	
2.00E-13	
FOXI2	
CpG:	238	
chr20	
53091739	
53092984	
10	
2.18E-13	
DOK5	
CpG:	96	
chr12	
5018229	
5019482	
15	
2.67E-13	
KCNA1	
CpG:	202	
chr4	
4863678	
4864902	
11	
2.86E-13	
M
SX1	
CpG:	40	
chr4	
21949853	
21951046	
10	
3.38E-13	
KCNIP4	
CpG:	24;	
CpG:	36	
chr6	
73331114	
73331680	
7	
3.56E-13	
KCNQ
5	
CpG:	175	
chr7	
142494148	
142495098	
15	
4.29E-13	
PRSS3P2	
CpG:	68	
chr14	
100437951	
100438957	
7	
4.99E-13	
EM
L1	
CpG:	128	
chr1	
179711583	
179712740	
13	
5.60E-13	
FAM
163A	
CpG:	199	
chr12	
104697193	
104697631	
12	
5.63E-13	
TXNRD1;	TXNRD1;	EID3	
CpG:	56	
chr1	
111217194	
111218287	
12	
5.91E-13	
KCNA3	
CpG:	190	
chr11	
20690628	
20691429	
12	
6.23E-13	
NELL1	
CpG:	114	
chr14	
23834710	
23835212	
9	
6.24E-13	
EFS	
CpG:	131	
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chr11	
2160875	
2162510	
41	
8.06E-13	
IGF2;	INS-IGF2;	IGF2-AS;IGF2;IGF2	
CpG:	302	
chr8	
72755568	
72756341	
6	
8.26E-13	
M
SC;M
SC-AS1	
CpG:	88	
chr2	
56150255	
56151179	
12	
9.33E-13	
EFEM
P1	
CpG:	70	
chr1	
108507078	
108508207	
8	
9.67E-13	
VAV3;	VAV3-AS1	
CpG:	78	
chr2	
98962900	
98963768	
8	
1.17E-12	
CNGA3	
CpG:	114	
chr12	
50297477	
50297945	
6	
1.41E-12	
FAIM
2	
CpG:	40	
chr5	
178017260	
178018186	
13	
1.43E-12	
COL23A1	
CpG:	111	
chr20	
44746392	
44747006	
11	
1.44E-12	
CD40	
CpG:	18	
chr12	
85305219	
85307152	
18	
1.49E-12	
SLC6A15	
CpG:	17;	
CpG:	16;	
CpG:	44	
chr13	
28500882	
28501413	
5	
1.51E-12	
PDX1	
CpG:	23	
chr11	
128563483	
128564180	
9	
1.53E-12	
FLI1;	SENCR;	FLI1;FLI1	
CpG:	194	
chr4	
96470053	
96471143	
12	
1.54E-12	
UNC5C	
CpG:	94	
chr8	
53852030	
53852661	
8	
1.59E-12	
NPBW
R1	
CpG:	245	
chr10	
15760947	
15762312	
13	
1.62E-12	
ITGA8	
CpG:	77	
chr3	
192126584	
192126996	
7	
1.66E-12	
FGF12	
CpG:	176	
chr20	
61809348	
61809932	
10	
1.70E-12	
M
IR124-3	
CpG:	424	
chr4	
154710224	
154710961	
17	
2.45E-12	
SFRP2	
CpG:	112	
chr6	
28367070	
28367898	
10	
2.52E-12	
ZSCAN12	
CpG:	40	
chr20	
41818356	
41819125	
8	
2.74E-12	
PTPRT	
CpG:	177	
chr21	
27011139	
27012615	
12	
3.20E-12	
JAM
2	
CpG:	64	
chr15	
83775850	
83776446	
8	
3.40E-12	
TM
6SF1	
CpG:	115	
chr6	
31685392	
31685575	
7	
3.63E-12	
LY6G6D	
CpG:	26	
chr4	
110223040	
110224288	
19	
3.70E-12	
COL25A1	
CpG:	112	
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chr20	
25062254	
25063052	
10	
4.04E-12	
VSX1	
CpG:	116	
chr2	
68546467	
68547256	
9	
4.37E-12	
CNRIP1	
CpG:	75	
chr1	
119548527	
119549312	
6	
4.51E-12	
LOC105378933	
CpG:	176	
chr7	
38670412	
38671001	
8	
4.75E-12	
AM
PH	
CpG:	70	
chr6	
30078754	
30079662	
19	
4.93E-12	
TRIM
31-AS1;	TRIM
31;	TRIM
31	
CpG:	15	
chr4	
154680808	
154681619	
8	
5.39E-12	
RNF175	
CpG:	66	
chr4	
166794786	
166796183	
13	
6.92E-12	
TLL1	
CpG:	68	
chr20	
45141911	
45142336	
7	
7.55E-12	
ZNF334	
CpG:	36	
chr21	
38076709	
38077971	
9	
7.67E-12	
SIM
2	
CpG:	70	
chr12	
54392988	
54394212	
18	
7.90E-12	
HOXC9;		HOXC-AS1	
CpG:	118	
chr13	
95364510	
95364993	
11	
9.36E-12	
SOX21-AS1;	SOX21	
CpG:	276	
chr19	
53757677	
53758609	
9	
1.04E-11	
ZNF677	
CpG:	37	
chr8	
97172825	
97173722	
7	
1.08E-11	
GDF6	
CpG:	113	
chr20	
37302636	
37303484	
7	
1.14E-11	
ARHGAP40	
CpG:	59	
chr7	
151106990	
151107807	
7	
1.18E-11	
W
DR86-AS1;	W
DR86	
CpG:	157	
chr5	
140864020	
140864834	
8	
1.19E-11	
PCDHGA8;	PCDHGA1;	PCDHGB7;	PCDHGB5;	PCDHGC4;	
PCDHGA11;	PCDHGA12;	PCDHGA9;	PCDHGA7;	
PCDHGA10;	PCDHGA5;	PCDHGA2;	PCDHGA3;	PCDHGC3;	
PCDHGB6;	PCDHGB4;	PCDHGB3;	PCDHGB2;	PCDHGB1;	
PCDHGA6;	PCDHGA4	
CpG:	22	
chr3	
196065106	
196065688	
12	
1.66E-11	
TM
4SF19-TCTEX1D2;		TM
4SF19	
CpG:	87	
chr16	
77822083	
77823221	
12	
1.70E-11	
VAT1L	
CpG:	72	
chr6	
87646740	
87647644	
15	
2.14E-11	
HTR1E	
CpG:	43	
chr6	
30737007	
30737455	
6	
2.16E-11	
IER3	
CpG:	161	
																								
231	
chr10	
57389676	
57391271	
10	
2.43E-11	
M
TRNR2L5	
CpG:	75	
chr17	
43339040	
43339831	
12	
2.45E-11	
SPATA32;	M
AP3K14-AS1;	M
AP3K14-AS1	
CpG:	65	
chr5	
83678796	
83680326	
11	
2.53E-11	
EDIL3	
CpG:	111	
chr2	
223162666	
223163809	
14	
2.54E-11	
CCDC140;PAX3	
CpG:	75	
chr11	
18813191	
18813556	
5	
2.65E-11	
PTPN5	
CpG:	115	
chr16	
55689865	
55690564	
8	
2.77E-11	
SLC6A2	
CpG:	120	
chr17	
6616351	
6617580	
12	
3.15E-11	
SLC13A5	
CpG:	92	
chr11	
64739253	
64739852	
8	
3.23E-11	
C11orf85	
CpG:	70	
chr4	
17782643	
17783502	
12	
3.38E-11	
FAM
184B	
CpG:	94	
chr6	
10881782	
10882336	
11	
3.49E-11	
GCM
2	
CpG:	23	
chr8	
55370192	
55370579	
10	
5.00E-11	
SOX17	
CpG:	233	
chr6	
166581929	
166582585	
10	
5.90E-11	
T	
CpG:	270	
chr8	
143532613	
143533532	
7	
6.32E-11	
ADGRB1	
CpG:	331	
chr14	
97684772	
97686001	
11	
7.08E-11	
LOC101929241	
CpG:	74	
chr17	
6679254	
6679781	
12	
7.34E-11	
FBXO39	
CpG:	49	
chr13	
108518955	
108521062	
16	
7.35E-11	
FAM
155A	
CpG:	139	
chr2	
162283189	
162284206	
9	
7.61E-11	
TBR1	
CpG:	85	
chr5	
178367621	
178368620	
11	
7.75E-11	
ZNF454	
CpG:	91	
chr4	
184826215	
184827086	
12	
7.77E-11	
STOX2	
CpG:	197	
chr1	
221067662	
221069136	
9	
7.88E-11	
HLX	
CpG:	66;	
CpG:	31	
chr14	
85995655	
85996873	
15	
7.94E-11	
FLRT2	
CpG:	45	
chr3	
11033866	
11035357	
12	
8.43E-11	
SLC6A1	
CpG:	87	
chr17	
33775295	
33776554	
13	
8.45E-11	
SLFN13	
CpG:	40;	
CpG:	28	
																								
232	
chr7	
130130478	
130131887	
33	
8.92E-11	
M
EST;	M
ESTIT1;	M
EST	
CpG:	177	
chr10	
91294781	
91295855	
14	
9.01E-11	
SLC16A12	
CpG:	100	
chr1	
119549626	
119550484	
5	
9.02E-11	
LOC105378933	
CpG:	176	
chr3	
134369339	
134370241	
13	
9.65E-11	
KY	
CpG:	79	
chr21	
34397654	
34398532	
11	
9.92E-11	
OLIG2	
CpG:	348	
chr6	
125283726	
125284659	
11	
1.04E-10	
RNF217-AS1;	RNF217	
CpG:	128	
chr8	
41166530	
41167278	
8	
1.04E-10	
SFRP1	
CpG:	147	
chr2	
119602212	
119603969	
13	
1.10E-10	
EN1	
CpG:	128	
chr5	
134366162	
134367394	
8	
1.18E-10	
PITX1	
CpG:	51	
chr13	
79169714	
79171469	
15	
1.27E-10	
RNF219-AS1	
CpG:	95	
chr21	
38080526	
38081976	
8	
1.33E-10	
SIM
2	
CpG:	153	
chr4	
5052795	
5053596	
8	
1.33E-10	
STK32B	
CpG:	97	
chr2	
120281354	
120281999	
6	
1.35E-10	
SCTR	
CpG:	67	
chr6	
29594830	
29595661	
15	
1.40E-10	
GABBR1	
CpG:	39	
chr4	
111533267	
111533951	
7	
1.41E-10	
PITX2	
CpG:	59	
chr13	
88323940	
88324879	
9	
1.44E-10	
SLITRK5	
CpG:	92	
chr11	
105480771	
105481863	
15	
1.51E-10	
GRIA4	
CpG:	31	
chr8	
89339404	
89340750	
11	
1.51E-10	
M
M
P16	
CpG:	37	
chr7	
127672152	
127672658	
7	
1.53E-10	
SND1	
CpG:	156	
chr4	
1397664	
1398798	
6	
1.62E-10	
NKX1-1	
CpG:	534	
chr7	
43151828	
43152542	
8	
1.76E-10	
HECW
1	
CpG:	124	
chr7	
19156621	
19158747	
30	
1.82E-10	
TW
IST1	
CpG:	152	
chr10	
26506353	
26506933	
5	
1.83E-10	
GAD2	
CpG:	242	
chr2	
467799	
468413	
5	
1.89E-10	
FAM
150B	
CpG:	79	
																								
233	
chr20	
61638149	
61638588	
8	
1.98E-10	
BHLHE23	
CpG:	272	
chr21	
36042170	
36042752	
5	
1.99E-10	
CLIC6	
CpG:	204	
chr11	
44330903	
44333192	
46	
2.11E-10	
ALX4	
CpG:	111;	
CpG:	36	
chr6	
29759947	
29761044	
19	
2.20E-10	
LOC554223;	HCG4	
CpG:	78	
chr18	
44337664	
44338147	
6	
2.20E-10	
ST8SIA5	
CpG:	47	
chr19	
37464066	
37464633	
5	
2.22E-10	
ZNF568	
CpG:	46	
chr1	
20878540	
20879813	
11	
2.28E-10	
FAM
43B	
CpG:	188	
chr2	
74742309	
74743243	
6	
2.28E-10	
TLX2	
CpG:	288	
chr2	
154727907	
154728468	
7	
2.41E-10	
GALNT13	
CpG:	37	
chr1	
91184290	
91185749	
11	
2.45E-10	
BARHL2	
CpG:	36;	
CpG:	124	
chr4	
778924	
779880	
7	
2.53E-10	
CPLX1	
CpG:	172	
chr6	
117086479	
117087083	
9	
2.56E-10	
FAM
162B	
CpG:	112	
chr15	
79382548	
79383560	
10	
2.68E-10	
RASGRF1	
CpG:	195	
chr10	
7453329	
7454063	
9	
2.77E-10	
SFM
BT2	
CpG:	418	
chr1	
77333749	
77334256	
7	
2.86E-10	
ST6GALNAC5	
CpG:	112	
chr2	
38302230	
38302892	
5	
3.07E-10	
CYP1B1	
CpG:	300	
chr5	
115152019	
115152938	
12	
3.58E-10	
CDO1	
CpG:	122	
chr19	
58951599	
58952249	
9	
3.87E-10	
ZNF132	
CpG:	81	
chr6	
166580460	
166581538	
7	
4.13E-10	
T	
CpG:	270	
chr19	
56879207	
56879994	
13	
4.30E-10	
ZNF542P	
CpG:	57	
chr4	
4859772	
4860698	
20	
4.39E-10	
M
SX1	
CpG:	41	
chr6	
99295470	
99296305	
5	
4.52E-10	
POU3F2	
CpG:	51	
chr14	
102247610	
102248253	
5	
4.66E-10	
PPP2R5C	
CpG:	64	
																								
234	
chr2	
115919785	
115920612	
6	
4.68E-10	
DPP10	
CpG:	203	
chr4	
157996959	
157997750	
13	
5.38E-10	
GLRB	
CpG:	62	
chr2	
139537544	
139537845	
5	
5.46E-10	
NXPH2	
CpG:	100	
chr14	
52535758	
52536436	
11	
5.56E-10	
NID2	
CpG:	160	
chr18	
5894665	
5895539	
6	
5.64E-10	
TM
EM
200C	
CpG:	120	
chr20	
37352612	
37353158	
9	
5.67E-10	
SLC32A1	
CpG:	380	
chr7	
121940216	
121940992	
7	
5.73E-10	
FEZF1	
CpG:	53	
chr2	
106681831	
106682640	
8	
5.74E-10	
C2orf40	
CpG:	48	
chr7	
155166205	
155167511	
10	
5.78E-10	
BLACE	
CpG:	277	
chr10	
106399877	
106400880	
11	
5.88E-10	
SORCS3	
CpG:	295	
chr1	
942161	
942696	
9	
5.97E-10	
ISG15	
CpG:	413	
chr19	
44952417	
44952808	
9	
6.19E-10	
ZNF229	
CpG:	37	
chr1	
110610899	
110612044	
8	
6.59E-10	
ALX3	
CpG:	264	
chr8	
65710790	
65711916	
12	
6.96E-10	
CYP7B1	
CpG:	70	
chr10	
134900906	
134902278	
13	
7.54E-10	
ADGRA1	
CpG:	155	
chr16	
10276081	
10277317	
13	
7.59E-10	
GRIN2A	
CpG:	278	
chr1	
119521928	
119522855	
5	
7.62E-10	
TBX15	
CpG:	36	
chr8	
75896720	
75897310	
8	
8.20E-10	
CRISPLD1	
CpG:	60	
chr10	
102279330	
102279954	
10	
8.37E-10	
SEC31B	
CpG:	66	
chr2	
29337946	
29338636	
11	
8.41E-10	
CLIP4	
CpG:	103	
chr6	
62995876	
62996299	
9	
9.15E-10	
KHDRBS2	
CpG:	45	
chr2	
119599189	
119600002	
7	
9.52E-10	
EN1	
CpG:	103;	
CpG:	20	
chr14	
29235904	
29236535	
13	
1.13E-09	
FOXG1	
CpG:	77	
chr3	
142839578	
142840240	
6	
1.37E-09	
CHST2	
CpG:	303	
																								
235	
chr13	
51417469	
51418053	
9	
1.42E-09	
DLEU7-AS1;	DLEU7	
CpG:	69	
chr5	
76506484	
76507680	
8	
1.44E-09	
PDE8B	
CpG:	117	
chr3	
68981852	
68982098	
9	
1.49E-09	
FAM
19A4	
CpG:	105	
chr7	
1272255	
1272710	
9	
1.49E-09	
UNCX	
CpG:	923	
chr1	
16084445	
16085642	
9	
1.50E-09	
FBLIM
1	
CpG:	76	
chr6	
100911240	
100912168	
13	
1.64E-09	
SIM
1	
CpG:	109	
chr6	
1390361	
1391265	
6	
1.66E-09	
FOXF2;	M
IR6720	
CpG:	184	
chr5	
168728076	
168728586	
8	
1.67E-09	
SLIT3	
CpG:	96	
chr4	
156587884	
156589291	
12	
1.82E-09	
GUCY1A3	
CpG:	89	
chr6	
133563342	
133564066	
7	
1.99E-09	
EYA4	
CpG:	138;	
CpG:	16	
chr19	
12267308	
12267796	
6	
2.36E-09	
ZNF625;	ZNF625;ZNF625-ZNF20	
CpG:	58	
chr13	
23734299	
23734763	
5	
2.38E-09	
SGCG	
CpG:	93	
chr8	
77594595	
77595359	
7	
2.49E-09	
ZFHX4-AS1;	ZFHX4	
CpG:	50	
chr2	
95690821	
95692010	
8	
2.54E-09	
M
AL	
CpG:	116	
chr4	
122301573	
122302331	
11	
2.59E-09	
Q
RFPR	
CpG:	67	
chr6	
5994235	
5995371	
9	
2.63E-09	
NRN1	
CpG:	20	
chr2	
209271164	
209272057	
10	
2.81E-09	
PTH2R	
CpG:	70	
chr6	
108488335	
108489292	
7	
2.92E-09	
NR2E1	
CpG:	318	
chr5	
78985425	
78986160	
12	
2.96E-09	
CM
YA5	
CpG:	35	
chr6	
32187918	
32189558	
12	
3.03E-09	
NOTCH4	
CpG:	92	
chr4	
5709858	
5710411	
9	
3.18E-09	
EVC2	
CpG:	56	
chr21	
22369802	
22370864	
9	
3.19E-09	
NCAM
2	
CpG:	92	
chr6	
85473773	
85474595	
11	
3.27E-09	
TBX18	
CpG:	129	
																								
236	
chr13	
102068989	
102069556	
9	
3.28E-09	
NALCN	
CpG:	99	
chr1	
200007403	
200008026	
5	
3.39E-09	
NR5A2	
CpG:	72	
chr5	
5139334	
5140029	
16	
3.40E-09	
CTD-2297D10.2	
CpG:	140	
chr12	
103351855	
103352694	
9	
4.02E-09	
ASCL1	
CpG:	105	
chr1	
91301204	
91301962	
6	
4.36E-09	
LOC105378853	
CpG:	86	
chr22	
19137874	
19138475	
6	
4.52E-09	
GSC2	
CpG:	202	
chr20	
3218145	
3218905	
11	
4.53E-09	
SLC4A11	
CpG:	247	
chr1	
22140769	
22141400	
7	
4.65E-09	
LDLRAD2	
CpG:	49	
chr11	
111410935	
111411381	
9	
4.66E-09	
LAYN	
CpG:	110	
chr2	
100938799	
100939477	
6	
4.88E-09	
LONRF2	
CpG:	153	
chr11	
94134015	
94135029	
12	
5.26E-09	
GPR83	
CpG:	64	
chr13	
96204493	
96204873	
8	
5.30E-09	
CLDN10	
CpG:	68	
chr20	
23029640	
23030343	
5	
5.35E-09	
THBD	
CpG:	312	
chr1	
98510865	
98511792	
9	
5.59E-09	
M
IR137HG;	M
IR137;	M
IR2682	
CpG:	73	
chr16	
86598792	
86599976	
9	
5.71E-09	
FOXC2-AS1	
CpG:	283	
chr6	
29520698	
29521803	
38	
5.99E-09	
UBD	
CpG:	80	
chr6	
72130209	
72131020	
12	
6.25E-09	
LINC00472;	LINC01626	
CpG:	138	
chr8	
67874858	
67875646	
5	
6.41E-09	
TCF24	
CpG:	209	
chr4	
155662795	
155664311	
12	
6.43E-09	
LRAT	
CpG:	38	
chr10	
125732373	
125732842	
5	
6.74E-09	
CHST15	
CpG:	53	
chr6	
28411030	
28411423	
9	
6.99E-09	
ZSCAN23	
CpG:	40	
chr1	
207818395	
207818493	
5	
7.11E-09	
CR1L	
CpG:	53	
chr13	
36871646	
	36872346	
								13	
			7.97E-09	
CCDC169;	CCDC169;	CCDC169-SOHLH2	
CpG:	33	
chr19	
58570419	
58570995	
8	
7.99E-09	
ZNF135	
CpG:	118	
chr7	
43153023	
43153595	
6	
8.13E-09	
HECW
1	
CpG:	124	
																								
237	
chr4	
62066211	
62067393	
7	
8.47E-09	
M
IR548AG1	
CpG:	212	
chr12	
114846849	
114847641	
8	
8.55E-09	
TBX5-AS1	
CpG:	119	
chr6	
108485837	
108487506	
13	
8.72E-09	
NR2E1	
CpG:	318	
chr18	
18822579	
18823509	
8	
9.09E-09	
GREB1L	
CpG:	195	
chr3	
192232468	
192233231	
5	
9.14E-09	
FGF12	
CpG:	92	
chr13	
37004536	
37005582	
27	
9.24E-09	
CCNA1	
CpG:	103	
chr16	
49311483	
49312560	
10	
9.39E-09	
CBLN1	
CpG:	61	
chr6	
84419189	
84419360	
9	
9.39E-09	
SNAP91	
CpG:	185	
chr1	
75600124	
75601276	
10	
9.62E-09	
LHX8	
CpG:	55	
chr10	
49731375	
49732003	
5	
9.67E-09	
ARHGAP22	
CpG:	112	
chr13	
93878969	
93879769	
9	
1.01E-08	
GPC6	
CpG:	133	
chr10	
22541995	
22542726	
5	
1.05E-08	
LOC100130992	
CpG:	184	
chr20	
57089933	
57090317	
9	
1.10E-08	
APCDD1L	
CpG:	71	
chr8	
49647579	
49648297	
9	
1.15E-08	
EFCAB1	
CpG:	37	
chr5	
1875611	
1876397	
7	
1.15E-08	
IRX4	
CpG:	306	
chr20	
61050885	
61051915	
24	
1.16E-08	
GATA5	
CpG:	247	
chr18	
7117680	
7118122	
5	
1.21E-08	
LAM
A1	
CpG:	136	
chr1	
67217673	
67218505	
13	
1.23E-08	
TCTEX1D1	
CpG:	23	
chr1	
58715499	
58716033	
7	
1.26E-08	
DAB1	
CpG:	87	
chr6	
32115964	
32116591	
13	
1.27E-08	
PRRT1	
CpG:	56	
chr19	
56904442	
56905152	
12	
1.40E-08	
ZNF582;	ZNF582;	ZNF582-AS1	
CpG:	69	
chr8	
53477881	
53478102	
5	
1.43E-08	
FAM
150A	
CpG:	119	
chr5	
37838290	
37838871	
6	
1.45E-08	
GDNF	
CpG:	308	
chr20	
37434158	
37434552	
8	
1.48E-08	
PPP1R16B	
CpG:	126	
chr20	
58179847	
58180616	
5	
1.52E-08	
PHACTR3	
CpG:	98	
																								
238	
chr11	
104034227	
104035204	
9	
1.55E-08	
PDGFD	
CpG:	54	
chr14	
60975811	
60976285	
8	
1.61E-08	
SIX6	
CpG:	178	
chr1	
147782116	
147782558	
5	
1.63E-08	
NBPF8	
CpG:	32	
chr4	
134070039	
134070819	
10	
1.64E-08	
LOC101927359;	PCDH10;	PCDH10	
CpG:	90	
chr2	
220361467	
220362242	
7	
1.66E-08	
LOC100996693	
CpG:	141	
chr6	
33131745	
33134078	
32	
1.78E-08	
COL11A2	
CpG:	47	
chr1	
164290179	
164290833	
8	
1.81E-08	
PBX1	
CpG:	34	
chr19	
11784246	
11785248	
12	
1.90E-08	
ZNF833P	
CpG:	20	
chr14	
24803679	
24804342	
10	
1.98E-08	
ADCY4	
CpG:	59	
chr12	
106978920	
106979874	
9	
2.00E-08	
LOC100287944;	RFX4	
CpG:	140	
chr1	
119542159	
119542629	
6	
2.02E-08	
LOC105378933	
CpG:	32	
chr7	
28997403	
28998540	
11	
2.02E-08	
TRIL	
CpG:	318	
chr1	
217309568	
217310572	
7	
2.07E-08	
ESRRG	
CpG:	46	
chr1	
75138964	
75139958	
11	
2.16E-08	
ERICH3	
CpG:	40	
chr19	
15580310	
15580721	
6	
2.28E-08	
PGLYRP2	
CpG:	60	
chr13	
43148017	
43149043	
9	
2.28E-08	
TNFSF11	
CpG:	83	
chr1	
108023249	
108023482	
5	
2.35E-08	
NTNG1	
CpG:	22	
chr3	
62363466	
62364390	
8	
2.36E-08	
FEZF2	
CpG:	23	
chr7	
96625955	
96627253	
8	
2.43E-08	
DLX6-AS1	
CpG:	30	
chr13	
37248078	
37248838	
6	
2.53E-08	
SERTM
1	
CpG:	60	
chr10	
134755862	
134756707	
8	
2.59E-08	
CFAP46	
CpG:	112	
chr8	
109095264	
109096151	
12	
2.67E-08	
RSPO2	
CpG:	118	
chr18	
25757202	
25757710	
5	
2.79E-08	
CDH2	
CpG:	223	
chr2	
145274874	
145275441	
7	
2.82E-08	
ZEB2	
CpG:	148	
chr2	
185462269	
185463218	
11	
2.95E-08	
ZNF804A	
CpG:	38	
																								
239	
chr10	
100993553	
100994143	
11	
2.96E-08	
HPSE2	
CpG:	38	
chr6	
10390039	
10390961	
6	
2.96E-08	
TFAP2A	
CpG:	16;	
CpG:	40	
chr6	
72595944	
72596748	
10	
3.04E-08	
RIM
S1	
CpG:	33	
chr16	
215410	
216450	
10	
3.07E-08	
HBM
	
CpG:	198	
chr5	
169930535	
169931363	
9	
3.12E-08	
KCNIP1	
CpG:	50	
chr3	
62358234	
62358980	
6	
3.23E-08	
FEZF2	
CpG:	162	
chr8	
17270604	
17271535	
10	
3.26E-08	
M
TM
R7	
CpG:	64	
chr4	
96468962	
96469634	
9	
3.26E-08	
UNC5C	
CpG:	20	
chr16	
22825621	
22826243	
7	
3.31E-08	
HS3ST2	
CpG:	187	
chr10	
110671609	
110672231	
5	
3.33E-08	
LINC01435	
CpG:	43	
chr19	
54023732	
54024834	
15	
3.54E-08	
ZNF331	
CpG:	45;	
CpG:	20	
chr14	
57274550	
57275413	
8	
3.59E-08	
OTX2	
CpG:	176	
chr6	
127440000	
127441199	
10	
3.61E-08	
RSPO3	
CpG:	152	
chr16	
82659960	
82660873	
15	
3.78E-08	
CDH13	
CpG:	99	
chr4	
144621898	
144621971	
5	
3.86E-08	
FREM
3	
CpG:	123	
chr4	
111554966	
111555503	
5	
4.00E-08	
PITX2	
CpG:	46	
chr5	
113391125	
113392117	
9	
4.09E-08	
KCNN2	
CpG:	76	
chr17	
27044169	
27044745	
5	
4.12E-08	
RAB34;	NARR;	RAB34	
CpG:	95	
chr6	
10398494	
10399046	
5	
4.24E-08	
TFAP2A	
CpG:	19	
chr5	
1882520	
1883514	
10	
4.35E-08	
IRX4	
CpG:	470	
chr1	
2983926	
2984869	
11	
4.36E-08	
LINC00982	
CpG:	406	
chr2	
213401195	
213402433	
7	
4.50E-08	
ERBB4	
CpG:	132	
chr4	
156680007	
156681047	
9	
4.90E-08	
GUCY1B3	
CpG:	119	
chr20	
37434950	
37435716	
5	
5.01E-08	
PPP1R16B	
CpG:	126	
																								
240	
chr5	
1445354	
1445593	
6	
5.01E-08	
SLC6A3	
CpG:	206	
chr6	
108495385	
108495985	
5	
5.02E-08	
NR2E1	
CpG:	27	
chr7	
112726089	
112726869	
11	
5.13E-08	
GPR85	
CpG:	44	
chr10	
93392399	
93393238	
13	
5.24E-08	
PPP1R3C	
CpG:	49	
chr8	
97157453	
97158052	
6	
5.38E-08	
GDF6	
CpG:	106	
chr3	
185911208	
185911885	
6	
5.44E-08	
DGKG	
CpG:	69	
chr19	
37997294	
37998171	
13	
5.46E-08	
ZNF793-AS1;	ZNF793	
CpG:	26	
chr1	
91300215	
91300559	
7	
5.47E-08	
LOC105378853	
CpG:	86	
chr10	
102419209	
102419617	
6	
5.48E-08	
PAX2	
CpG:	46	
chr3	
6902337	
6903327	
8	
5.61E-08	
GRM
7	
CpG:	77	
chr5	
146257347	
146258785	
19	
5.61E-08	
PPP2R2B	
CpG:	97	
chr8	
72470352	
72471153	
6	
5.77E-08	
EYA1	
CpG:	82	
chr4	
122686038	
122686667	
10	
5.90E-08	
TM
EM
155;	PP12613;	TM
EM
155	
CpG:	83	
chr12	
128752040	
128752586	
5	
5.97E-08	
TM
EM
132C	
CpG:	184	
chr5	
45695241	
45696455	
7	
6.24E-08	
HCN1	
CpG:	98	
chr14	
95234658	
95235489	
9	
6.35E-08	
GSC	
CpG:	191	
chr1	
114696350	
114697113	
11	
6.54E-08	
SYT6	
CpG:	155;	
CpG:	25	
chr7	
30721797	
30722643	
11	
6.63E-08	
CRHR2	
CpG:	107	
chr6	
33943520	
33943929	
5	
6.86E-08	
M
IR1275	
CpG:	33	
chr2	
87017419	
87018104	
6	
7.25E-08	
CD8A	
CpG:	170	
chr19	
21657529	
21658001	
6	
7.33E-08	
LINC00664	
CpG:	39	
chr7	
44143774	
44144434	
6	
7.49E-08	
AEBP1	
CpG:	24	
chr10	
118892211	
118893430	
9	
7.66E-08	
VAX1	
CpG:	36	
chr7	
49815117	
49815751	
6	
7.72E-08	
VW
C2	
CpG:	251	
																								
241	
chr4	
5712581	
5713100	
8	
8.90E-08	
EVC	
CpG:	63	
chr5	
16179633	
16180419	
15	
9.10E-08	
M
ar-11	
CpG:	134	
chr7	
45961078	
45961569	
16	
9.17E-08	
IGFBP3	
CpG:	139	
chr19	
15343786	
15344364	
5	
9.39E-08	
EPHX3	
CpG:	33	
chr16	
28074384	
28075289	
9	
9.40E-08	
GSG1L	
CpG:	145	
chr15	
83348985	
83349864	
7	
9.50E-08	
AP3B2;	CPEB1-AS1	
CpG:	87	
chr1	
46951291	
46951683	
6	
9.52E-08	
DM
BX1	
CpG:	48	
chr18	
35145983	
35147532	
28	
9.75E-08	
CELF4	
CpG:	196	
chr10	
102483843	
102484499	
6	
9.84E-08	
PAX2	
CpG:	30	
chr10	
7452242	
7452950	
5	
1.02E-07	
SFM
BT2	
CpG:	418	
chr7	
96649956	
96650668	
8	
1.03E-07	
DLX5	
CpG:	109	
chr5	
54518469	
54519307	
7	
1.05E-07	
M
CIDAS	
CpG:	54	
chr6	
110678920	
110679566	
5	
1.05E-07	
M
ETTL24	
CpG:	45;	
CpG:	25	
chr18	
11148510	
11149068	
9	
1.07E-07	
PIEZO2	
CpG:	164	
chr14	
60952097	
60952945	
8	
1.08E-07	
C14orf39	
CpG:	77	
chr3	
69591633	
69592090	
6	
1.08E-07	
FRM
D4B	
CpG:	99	
chr8	
31496644	
31497082	
5	
1.11E-07	
NRG1	
CpG:	143	
chr12	
72665282	
72665880	
5	
1.15E-07	
TRHDE-AS1	
CpG:	175	
chr10	
125650957	
125651621	
9	
1.17E-07	
CPXM
2	
CpG:	55	
chr17	
42733527	
42733994	
9	
1.18E-07	
M
EIOC	
CpG:	101	
chr1	
91192162	
91192803	
6	
1.21E-07	
BARHL2	
CpG:	147	
chr6	
110797233	
110798022	
6	
1.29E-07	
SLC22A16	
CpG:	97	
chr22	
19511707	
19512320	
6	
1.32E-07	
CLDN5	
CpG:	147	
chr19	
12203029	
12203644	
6	
1.32E-07	
ZNF788	
CpG:	41	
chr1	
150254280	
150255241	
10	
1.36E-07	
CIART	
CpG:	22	
																								
242	
chr14	
62583787	
62584600	
12	
1.40E-07	
LINC00643	
CpG:	54	
chr5	
63257499	
63257941	
10	
1.44E-07	
HTR1A	
CpG:	100	
chr8	
54164051	
54164442	
8	
1.46E-07	
OPRK1	
CpG:	114	
chr12	
72666976	
72667707	
10	
1.46E-07	
TRHDE;	TRHDE-AS1	
CpG:	175	
chr8	
99961376	
99962347	
7	
1.51E-07	
OSR2	
CpG:	73	
chr12	
120032374	
120033155	
5	
1.51E-07	
TM
EM
233	
CpG:	118	
chr14	
57263993	
57264919	
7	
1.56E-07	
OTX2	
CpG:	83	
chr17	
1961109	
1961778	
5	
1.58E-07	
HIC1	
CpG:	764	
chr10	
28034669	
28035208	
9	
1.63E-07	
M
KX;	M
KX-AS1	
CpG:	398	
chr19	
15121204	
15121596	
8	
1.64E-07	
CCDC105;	SLC1A6	
CpG:	69	
chr11	
71954982	
71955599	
11	
1.65E-07	
PHOX2A	
CpG:	89	
chr19	
52900882	
52901307	
11	
1.73E-07	
ZNF528;	ZNF528-AS1	
CpG:	24;	
CpG:	15	
chr19	
34112229	
34113010	
9	
1.81E-07	
CHST8	
CpG:	232	
chr10	
104170217	
104170718	
5	
1.84E-07	
PSD	
CpG:	55	
chr11	
65600739	
65601427	
14	
1.87E-07	
SNX32	
CpG:	53	
chr2	
5835853	
5836366	
6	
1.97E-07	
SOX11	
CpG:	138	
chr6	
30080189	
30080782	
7	
2.02E-07	
TRIM
31-AS1;	TRIM
31;	TRIM
31	
CpG:	15	
chr11	
123300839	
123301171	
5	
2.03E-07	
M
IR4493	
CpG:	108	
chr13	
26625089	
26625396	
7	
2.04E-07	
SHISA2	
CpG:	192	
chr3	
132756721	
132757741	
14	
2.05E-07	
TM
EM
108	
CpG:	83	
chr1	
14925078	
14925524	
6	
2.08E-07	
KAZN	
CpG:	119	
chr2	
71126606	
71128191	
24	
2.10E-07	
VAX2	
CpG:	185	
chr2	
137522211	
137522960	
5	
2.12E-07	
THSD7B	
CpG:	107	
chr6	
168078772	
168079427	
6	
2.17E-07	
LOC401286	
CpG:	19	
																								
243	
chr13	
112760898	
112761184	
5	
2.21E-07	
LINC00403	
CpG:	23	
chr19	
45737483	
45738115	
9	
2.31E-07	
EXOC3L2	
CpG:	87	
chr5	
170735754	
170736572	
11	
2.34E-07	
TLX3	
CpG:	411	
chr6	
55443757	
55444488	
10	
2.41E-07	
HM
GCLL1	
CpG:	36	
chr14	
70316621	
70317239	
7	
2.41E-07	
SM
OC1	
CpG:	32	
chr4	
55991418	
55992458	
10	
2.46E-07	
KDR	
CpG:	71	
chr6	
30227729	
30228254	
16	
2.65E-07	
HLA-L;	HCG17	
CpG:	83	
chr11	
31839314	
31839947	
9	
2.65E-07	
PAX6;	DKFZp686K1684	
CpG:	35	
chr7	
19812327	
19813149	
11	
2.65E-07	
TM
EM
196	
CpG:	29	
chr9	
970297	
971046	
6	
2.71E-07	
DM
RT1	
CpG:	260	
chr16	
67977865	
67978450	
8	
2.71E-07	
SLC12A4;	LCAT	
CpG:	93	
chr10	
131758112	
131758786	
6	
2.73E-07	
EBF3	
CpG:	181	
chr5	
63986130	
63987010	
6	
2.79E-07	
FAM
159B	
CpG:	78	
chr4	
174439478	
174440103	
6	
2.83E-07	
HAND2	
CpG:	36	
chr11	
32454718	
32455735	
12	
2.93E-07	
W
T1	
CpG:	188	
chr11	
133938676	
133939265	
7	
2.97E-07	
JAM
3	
CpG:	77	
chr1	
77332991	
77333229	
8	
2.97E-07	
ST6GALNAC5	
CpG:	112	
chr20	
31780882	
31781697	
8	
3.13E-07	
BPIFA4P	
CpG:	30	
chr1	
99470550	
99470801	
5	
3.18E-07	
LOC100129620	
CpG:	95	
chr7	
120968877	
120969174	
8	
3.19E-07	
W
NT16	
CpG:	81	
chr15	
48937856	
48938775	
7	
3.27E-07	
FBN1	
CpG:	174	
chr5	
32712623	
32713723	
6	
3.31E-07	
NPR3	
CpG:	298	
chr3	
172165696	
172166517	
7	
3.44E-07	
GHSR	
CpG:	107	
chr1	
37500195	
37500790	
6	
3.60E-07	
GRIK3	
CpG:	232	
																								
244	
chr3	
126113640	
126114064	
9	
3.62E-07	
CFAP100;	CCDC37-AS1	
CpG:	47	
chr18	
5543271	
5544169	
10	
3.66E-07	
EPB41L3	
CpG:	82	
chr19	
13616871	
13617584	
9	
3.87E-07	
CACNA1A	
CpG:	56	
chr13	
110960177	
110960563	
5	
4.09E-07	
COL4A2	
CpG:	185	
chr14	
26674046	
26674563	
7	
4.16E-07	
NOVA1	
CpG:	30	
chr22	
33453893	
33454632	
11	
4.41E-07	
SYN3	
CpG:	68	
chr22	
45404843	
45406130	
15	
4.89E-07	
PHF21B	
CpG:	273	
chr1	
228651848	
228652581	
7	
5.01E-07	
M
IR4666A	
CpG:	84	
chr1	
18958084	
18958924	
6	
5.12E-07	
PAX7	
CpG:	205	
chr8	
57358590	
57359414	
9	
5.18E-07	
LOC101929415;	PENK	
CpG:	138	
chr10	
1779432	
1780003	
9	
5.20E-07	
ADARB2	
CpG:	95	
chr13	
36705446	
36705622	
5	
5.35E-07	
DCLK1	
CpG:	65	
chr5	
1886828	
1887583	
5	
5.40E-07	
CTD-2194D22.4;	IRX4	
CpG:	470	
chr5	
135265753	
135266135	
6	
5.73E-07	
FBXL21	
CpG:	80	
chr6	
151814892	
151815526	
7	
5.76E-07	
CCDC170	
CpG:	64	
chr18	
904851	
905611	
14	
5.88E-07	
ADCYAP1	
CpG:	330	
chr7	
155260310	
155261295	
6	
5.90E-07	
EN2	
CpG:	196	
chr19	
37406932	
37407486	
12	
6.04E-07	
ZNF829;	ZNF568	
CpG:	48	
chr12	
41085901	
41086308	
8	
6.14E-07	
CNTN1	
CpG:	47	
chr3	
45077254	
45078075	
8	
6.19E-07	
CLEC3B	
CpG:	54	
chr6	
28602543	
28603230	
29	
6.25E-07	
LINC00533	
CpG:	32	
chr7	
116962950	
116963802	
7	
6.33E-07	
W
NT2	
CpG:	148	
chr11	
115630531	
115631452	
12	
6.36E-07	
LINC00900	
CpG:	68	
chr7	
101005832	
101006573	
11	
6.54E-07	
COL26A1	
CpG:	153	
																								
245	
chr1	
181287301	
181287967	
7	
6.56E-07	
GM
140	
CpG:	52	
chr8	
85094437	
85094923	
5	
6.62E-07	
RALYL	
CpG:	49	
chr4	
154713235	
154713789	
6	
6.63E-07	
SFRP2	
CpG:	52	
chr8	
65291287	
65292321	
12	
6.71E-07	
M
IR124-2HG	
CpG:	68	
chr14	
42075406	
42075975	
7	
6.80E-07	
LRFN5	
CpG:	58	
chr6	
99272559	
99273679	
13	
6.92E-07	
POU3F2	
CpG:	50	
chr15	
79724517	
79724802	
6	
7.07E-07	
KIAA1024	
CpG:	165	
chr6	
32063991	
32064258	
12	
7.08E-07	
TNXB	
CpG:	150	
chr7	
35294430	
35295198	
6	
7.27E-07	
TBX20	
CpG:	124	
chr1	
170630397	
170630734	
5	
7.34E-07	
PRRX1	
CpG:	38	
chr3	
184301211	
184301826	
5	
7.40E-07	
EPHB3	
CpG:	92	
chr10	
125425583	
125426048	
6	
7.44E-07	
GPR26	
CpG:	126	
chr6	
27647713	
27648605	
9	
7.77E-07	
LINC01012	
CpG:	19	
chr7	
79081791	
79083056	
11	
7.78E-07	
M
AGI2-AS3;	M
AGI2	
CpG:	26;	
CpG:	70;	
CpG:	20	
chr11	
128693677	
128694679	
9	
7.83E-07	
FLI1	
CpG:	56	
chr19	
57862242	
57862713	
10	
7.83E-07	
ZNF304	
CpG:	58	
chr5	
1885174	
1885950	
6	
7.89E-07	
IRX4	
CpG:	470	
chr2	
164592477	
164592854	
6	
7.94E-07	
FIGN	
CpG:	57	
chr8	
79427993	
79428725	
8	
8.08E-07	
PKIA	
CpG:	46	
chr13	
25620954	
25621735	
6	
8.16E-07	
PABPC3	
CpG:	52	
chr1	
217310887	
217311177	
6	
8.29E-07	
ESRRG	
CpG:	46	
chr2	
1748112	
1748876	
6	
8.37E-07	
PXDN	
CpG:	198	
																								
246	
chr15	
83316223	
83316911	
6	
8.82E-07	
CPEB1-AS1;	CPEB1;	CPEB1	
CpG:	218	
chr7	
601283	
601828	
5	
8.97E-07	
LOC101927000;	PRKAR1B	
CpG:	49	
chr1	
177139876	
177140680	
9	
9.29E-07	
BRINP2	
CpG:	23	
chr12	
81471311	
81472177	
13	
9.34E-07	
ACSS3	
CpG:	43	
chr11	
101454317	
101454823	
8	
9.58E-07	
TRPC6	
CpG:	114	
chr7	
155174508	
155175340	
6	
9.69E-07	
BLACE	
CpG:	78	
chr5	
115298511	
115299088	
5	
9.74E-07	
LVRN	
CpG:	72	
chr18	
43913147	
43914264	
10	
9.86E-07	
RNF165	
CpG:	103	
chr2	
31456741	
31457287	
12	
1.01E-06	
EHD3	
CpG:	79	
chr1	
242688081	
242688681	
7	
1.01E-06	
PLD5	
CpG:	60	
chr5	
127873283	
127873980	
5	
1.03E-06	
FBN2	
CpG:	186	
chr6	
30418508	
30419493	
18	
1.03E-06	
HLA-E	
CpG:	54	
chr12	
66122804	
66123380	
5	
1.05E-06	
RPSAP52	
CpG:	56	
chr6	
137816475	
137817512	
7	
1.10E-06	
OLIG3	
CpG:	61	
chr20	
54579814	
54580196	
5	
1.13E-06	
CBLN4	
CpG:	173	
chr4	
66535145	
66535732	
9	
1.14E-06	
EPHA5-AS1;	EPHA5;	EPHA5	
CpG:	36	
chr11	
8102450	
8103101	
6	
1.21E-06	
TUB	
CpG:	62	
chr7	
49812836	
49813111	
7	
1.22E-06	
VW
C2	
CpG:	251	
chr17	
27038664	
27039132	
8	
1.29E-06	
PROCA1	
CpG:	79	
chr3	
27770852	
27772201	
12	
1.33E-06	
EOM
ES	
CpG:	24	
chr17	
50235737	
50236765	
7	
1.35E-06	
CA10	
CpG:	109	
chr5	
92931173	
92932120	
7	
1.35E-06	
M
IR548AO	
CpG:	27	
chr7	
136553243	
136553884	
12	
1.42E-06	
CHRM
2	
CpG:	154	
chr21	
31311797	
31312643	
7	
1.46E-06	
GRIK1	
CpG:	61	
																								
247	
chr6	
10422139	
10422636	
5	
1.48E-06	
TFAP2A	
CpG:	26	
chr7	
92237896	
92238364	
6	
1.49E-06	
CDK6	
CpG:	77	
chr3	
170302640	
170303721	
9	
1.52E-06	
SLC7A14	
CpG:	21;	
CpG:	24	
chr6	
31733799	
31734580	
18	
1.57E-06	
VW
A7	
CpG:	68	
chr6	
152128024	
152129036	
21	
1.58E-06	
ESR1	
CpG:	89	
chr2	
45170725	
45171818	
7	
1.60E-06	
SIX3	
CpG:	171	
chr3	
148415443	
148416019	
6	
1.61E-06	
AGTR1	
CpG:	56	
chr17	
35296481	
35297309	
5	
1.65E-06	
LHX1	
CpG:	597	
chr3	
96533258	
96534005	
9	
1.67E-06	
EPHA6	
CpG:	174	
chr19	
57018614	
57019373	
9	
1.75E-06	
ZNF471	
CpG:	77	
chr2	
220299484	
220300242	
11	
1.83E-06	
SPEG	
CpG:	77	
chr15	
89910632	
89911298	
6	
1.85E-06	
M
IR9-3HG;	M
IR9-3	
CpG:	131	
chr2	
229045958	
229046785	
7	
1.85E-06	
SPHKAP	
CpG:	45	
chr5	
115297488	
115298079	
6	
1.87E-06	
LVRN	
CpG:	33	
chr2	
119916431	
119916686	
7	
1.90E-06	
C1Q
L2	
CpG:	229	
chr15	
74421523	
74421935	
12	
1.90E-06	
LOC283731;	ISLR2	
CpG:	216	
chr7	
37488162	
37489005	
15	
1.93E-06	
ELM
O1	
CpG:	135	
chr5	
33936171	
33936752	
13	
1.95E-06	
RXFP3	
CpG:	166	
chr12	
41086680	
41087252	
6	
1.98E-06	
CNTN1	
CpG:	47	
chr11	
69631981	
69633313	
9	
1.99E-06	
FGF3	
CpG:	263	
chr8	
15397637	
15398333	
8	
2.01E-06	
TUSC3	
CpG:	67	
chr5	
174158984	
174159705	
5	
2.09E-06	
M
SX2	
CpG:	88	
chr4	
156128904	
156130016	
11	
2.10E-06	
NPY2R	
CpG:	67	
chr10	
134599783	
134600600	
20	
2.12E-06	
NKX6-2	
CpG:	569	
chr21	
28339262	
28339907	
7	
2.13E-06	
ADAM
TS5	
CpG:	193	
																								
248	
chr1	
63795279	
63795934	
6	
2.20E-06	
M
IR6068	
CpG:	66	
chr8	
42623686	
42623946	
6	
2.21E-06	
CHRNA6	
CpG:	55	
chr17	
73583839	
73584617	
9	
2.29E-06	
M
YO15B	
CpG:	221	
chr4	
111549880	
111550666	
6	
2.38E-06	
PITX2	
CpG:	22	
chr8	
97505391	
97505868	
8	
2.43E-06	
SDC2	
CpG:	165	
chr1	
91190005	
91190891	
8	
2.44E-06	
BARHL2	
CpG:	147	
chr10	
102893925	
102894639	
6	
2.46E-06	
TLX1NB;	TLX1	
CpG:	110	
chr2	
30144152	
30144838	
8	
2.57E-06	
ALK	
CpG:	147	
chr2	
119600348	
119600627	
5	
2.58E-06	
EN1	
CpG:	103	
chr3	
63263752	
63264335	
8	
2.59E-06	
SYNPR	
CpG:	20	
chr20	
39995539	
39996039	
8	
2.71E-06	
EM
ILIN3	
CpG:	131	
chr11	
30038286	
30039113	
14	
2.71E-06	
KCNA4	
CpG:	32;	
CpG:	16	
chrX	
130191788	
130192734	
12	
2.71E-06	
LINC01201;	ARHGAP36	
CpG:	55	
chr5	
79330669	
79331135	
7	
2.72E-06	
THBS4	
CpG:	57	
chr10	
122216848	
122217376	
5	
2.73E-06	
PLPP4	
CpG:	118	
chr4	
41258560	
41259283	
7	
2.85E-06	
UCHL1;	UCHL1-AS1	
CpG:	123	
chr8	
97169764	
97170666	
6	
2.86E-06	
GDF6	
CpG:	56	
chr5	
131592959	
131593287	
9	
2.86E-06	
PDLIM
4	
CpG:	64	
chr10	
23983496	
23983990	
7	
2.87E-06	
KIAA1217	
CpG:	139	
chr7	
21582444	
21582834	
6	
3.11E-06	
DNAH11	
CpG:	84	
chr18	
31020418	
31021065	
8	
3.22E-06	
CCDC178	
CpG:	41	
chr20	
21378045	
21378560	
10	
3.33E-06	
NKX2-4	
CpG:	213	
chr8	
109094032	
109094880	
7	
3.70E-06	
RSPO2	
CpG:	118	
chr5	
177412586	
177413021	
5	
3.82E-06	
PROP1	
CpG:	17	
																								
249	
chr3	
121902442	
121902622	
7	
3.83E-06	
CASR	
CpG:	75	
chr3	
13323567	
13324132	
6	
3.84E-06	
NUP210	
CpG:	136	
chr5	
76249502	
76250351	
5	
3.87E-06	
CRHBP	
CpG:	104	
chr1	
221054201	
221055097	
7	
3.96E-06	
HLX	
CpG:	24	
chr17	
35300448	
35300874	
5	
3.99E-06	
LHX1	
CpG:	597	
chr8	
16884197	
16884576	
6	
4.06E-06	
M
ICU3	
CpG:	103	
chr7	
155164995	
155165891	
6	
4.11E-06	
BLACE	
CpG:	277	
chr3	
13114570	
13115406	
8	
4.30E-06	
IQ
SEC1	
CpG:	70	
chr11	
69633659	
69634334	
6	
4.34E-06	
FGF3	
CpG:	263	
chr3	
26663805	
26664741	
9	
4.43E-06	
LRRC3B	
CpG:	71	
chr5	
137474700	
137475288	
7	
4.47E-06	
NM
E5	
CpG:	23	
chr8	
97507561	
97507958	
5	
4.56E-06	
SDC2	
CpG:	165	
chr2	
240168836	
240169280	
6	
4.57E-06	
HDAC4	
CpG:	22	
chr13	
38443634	
38444227	
9	
4.65E-06	
TRPC4	
CpG:	45	
chr5	
146889027	
146889701	
6	
4.69E-06	
DPYSL3	
CpG:	102	
chr12	
54333179	
54333823	
6	
4.70E-06	
HOXC13;	HOXC13-AS	
CpG:	88	
chr7	
96647021	
96647483	
6	
4.75E-06	
DLX5	
CpG:	60	
chr11	
17740887	
17741243	
5	
4.79E-06	
M
YOD1	
CpG:	233	
chr1	
49242359	
49242934	
8	
4.82E-06	
BEND5;	AGBL4;BEND5	
CpG:	38	
chr2	
127413363	
127414108	
8	
4.89E-06	
GYPC	
CpG:	54	
chr14	
42076492	
42077327	
6	
5.11E-06	
LRFN5	
CpG:	58	
chr10	
134598908	
134599372	
5	
5.33E-06	
NKX6-2	
CpG:	569	
chr8	
132052702	
132052942	
6	
5.42E-06	
ADCY8	
CpG:	208	
chr2	
115419537	
115420260	
6	
5.42E-06	
DPP10	
CpG:	51	
chrX	
153637261	
153637827	
10	
5.43E-06	
DNASE1L1	
CpG:	93	
																								
250	
chr7	
30951272	
30951801	
11	
5.47E-06	
AQ
P1	
CpG:	64	
chr5	
155108085	
155109126	
6	
5.58E-06	
SGCD	
CpG:	138	
chr5	
38258007	
38258884	
11	
5.73E-06	
EGFLAM
	
CpG:	108	
chr7	
84815088	
84815543	
5	
5.75E-06	
SEM
A3D	
CpG:	94	
chr12	
103889166	
103890274	
13	
5.97E-06	
C12orf42;	C12orf42;	LOC105369945	
CpG:	79	
chr4	
5891833	
5892628	
7	
6.19E-06	
CRM
P1	
CpG:	35	
chr9	
124461008	
124461640	
5	
6.22E-06	
DAB2IP	
CpG:	38	
chr20	
42544648	
42545099	
10	
6.46E-06	
TOX2	
CpG:	172	
chr8	
26722496	
26722965	
5	
6.55E-06	
ADRA1A	
CpG:	202	
chr11	
32452038	
32452839	
8	
6.60E-06	
W
T1	
CpG:	53	
chr7	
100463206	
100463759	
5	
6.61E-06	
SLC12A9	
CpG:	32	
chr4	
7194841	
7195466	
5	
6.62E-06	
SORCS2	
CpG:	99	
chr5	
59189375	
59189934	
10	
6.74E-06	
PDE4D	
CpG:	68	
chr6	
36808207	
36808894	
5	
6.87E-06	
CPNE5	
CpG:	80	
chr6	
85484287	
85484863	
5	
6.91E-06	
TBX18	
CpG:	188	
chr8	
23567310	
23567941	
7	
6.99E-06	
NKX2-6	
CpG:	43	
chr5	
128300696	
128301488	
12	
7.13E-06	
SLC27A6	
CpG:	44	
chr13	
100623942	
100624293	
8	
7.24E-06	
ZIC5	
CpG:	391	
chr5	
140857474	
140858107	
8	
7.30E-06	
PCDHGA8;	PCDHGA1;	PCDHGB7;	PCDHGC3;	PCDHGA11;	
PCDHGB5;	PCDHGA9;	PCDHGA7;	PCDHGA10;	PCDHGA5;	
PCDHGA2;	PCDHGA3;	PCDHGA12;	PCDHGB6;	PCDHGB4;	
PCDHGB3;	PCDHGB2;	PCDHGB1;	PCDHGA6;	PCDHGA4	
CpG:	19	
chr11	
43602845	
43603214	
8	
7.42E-06	
M
IR129-2	
CpG:	61	
chr1	
203044677	
203045229	
5	
7.42E-06	
PPFIA4	
CpG:	67	
chr3	
6903921	
6904640	
5	
7.61E-06	
GRM
7	
CpG:	40	
chr8	
11561283	
11561724	
10	
7.69E-06	
GATA4	
CpG:	221	
																								
251	
chr3	
159756648	
159757071	
6	
7.73E-06	
IL12A-AS1	
CpG:	35	
chr5	
127874463	
127874825	
5	
7.84E-06	
FBN2	
CpG:	186	
chr16	
56228114	
56228901	
12	
8.17E-06	
GNAO1;	DKFZP434H168	
CpG:	91	
chr1	
53308654	
53309261	
5	
8.35E-06	
ZYG11A	
CpG:	112	
chr1	
13910555	
13910796	
6	
8.49E-06	
PDPN	
CpG:	59	
chr5	
145713607	
145714097	
7	
8.54E-06	
POU4F3	
CpG:	22	
chr15	
84115433	
84116151	
12	
8.70E-06	
SH3GL3	
CpG:	95	
chr5	
1931251	
1931781	
5	
8.76E-06	
CTD-2194D22.4	
CpG:	110	
chr16	
875410	
876216	
7	
8.92E-06	
PRR25	
CpG:	37	
chr6	
28641704	
28642394	
11	
9.25E-06	
LINC00533	
CpG:	32	
chr1	
53098630	
53099352	
7	
9.29E-06	
FAM
159A	
CpG:	70	
chr6	
55039232	
55039622	
5	
9.30E-06	
HCRTR2	
CpG:	15	
chr18	
44777736	
44778236	
5	
9.36E-06	
SKOR2	
CpG:	45	
chr11	
12030088	
12030289	
6	
9.40E-06	
DKK3	
CpG:	103	
chr2	
54086854	
54087552	
13	
9.59E-06	
GPR75;GPR75-ASB3	
CpG:	60	
chr10	
102821427	
102821848	
6	
9.68E-06	
KAZALD1	
CpG:	173	
chr9	
122131895	
122132261	
6	
1.03E-05	
BRINP1	
CpG:	104	
chr14	
95239381	
95239751	
5	
1.03E-05	
GSC	
CpG:	35	
chr2	
45028604	
45030072	
11	
1.06E-05	
CAM
KM
T	
CpG:	32;	
CpG:	38	
chr20	
61885850	
61886313	
7	
1.06E-05	
NKAIN4;	FLJ16779	
CpG:	156	
chr7	
3341524	
3342048	
6	
1.09E-05	
SDK1	
CpG:	24	
chr4	
81106663	
81107185	
5	
1.11E-05	
PRDM
8	
CpG:	65	
chr8	
70946891	
70947440	
5	
1.20E-05	
PRDM
14	
CpG:	39	
chr5	
82767297	
82767968	
7	
1.23E-05	
VCAN	
CpG:	63	
chr15	
47476133	
47476482	
6	
1.27E-05	
SEM
A6D	
CpG:	95	
																								
252	
chr16	
54968727	
54969146	
6	
1.28E-05	
IRX5	
CpG:	453	
chr6	
31894990	
31895598	
7	
1.29E-05	
C2	
CpG:	124	
chr6	
123317124	
123317714	
9	
1.29E-05	
CLVS2	
CpG:	59	
chr8	
91803357	
91804110	
8	
1.32E-05	
NECAB1	
CpG:	48	
chr10	
102896102	
102896869	
6	
1.32E-05	
TLX1;	TLX1NB	
CpG:	30	
chr7	
79083408	
79083509	
5	
1.33E-05	
M
AGI2-AS3	
CpG:	70	
chr8	
72756656	
72757004	
8	
1.34E-05	
M
SC;	M
SC-AS1	
CpG:	88	
chr3	
147136904	
147137503	
7	
1.36E-05	
LOC440982	
CpG:	37	
chr2	
182548750	
182549408	
7	
1.37E-05	
NEUROD1	
CpG:	94	
chr13	
103046499	
103047287	
7	
1.39E-05	
FGF14;FGF14-AS2;	FGF14-IT1	
CpG:	60	
chr6	
100050506	
100051339	
8	
1.39E-05	
PRDM
13	
CpG:	83	
chr11	
31825605	
31825969	
5	
1.40E-05	
PAX6	
CpG:	81	
chr18	
76740088	
76740284	
7	
1.42E-05	
SALL3	
CpG:	338	
chr11	
65360123	
65360509	
5	
1.45E-05	
KCNK7	
CpG:	114	
chr17	
27369780	
27370117	
5	
1.51E-05	
PIPOX	
CpG:	34	
chr1	
12123262	
12123936	
9	
1.57E-05	
TNFRSF8	
CpG:	63	
chr8	
9760869	
9761454	
7	
1.61E-05	
M
IR124-1	
CpG:	70	
chr8	
85096835	
85097429	
9	
1.66E-05	
RALYL	
CpG:	49	
chr13	
107028903	
107029443	
5	
1.75E-05	
LINC00460	
CpG:	30	
chr3	
141516232	
141516705	
6	
1.76E-05	
GRK7	
CpG:	43	
chr2	
233924713	
233925275	
9	
1.88E-05	
INPP5D	
CpG:	18	
chr13	
95655083	
95655579	
5	
1.90E-05	
ABCC4	
CpG:	46	
chr14	
77737495	
77738080	
7	
1.91E-05	
NGB	
CpG:	116	
chr6	
85472949	
85473344	
5	
1.95E-05	
TBX18	
CpG:	129	
chr17	
72352968	
72353536	
5	
1.96E-05	
BTBD17	
CpG:	129	
																								
253	
chr17	
37365885	
37366501	
5	
2.07E-05	
STAC2	
CpG:	54	
chr2	
27530670	
27531360	
11	
2.09E-05	
UCN	
CpG:	180	
chr4	
107956955	
107957430	
5	
2.11E-05	
DKK2	
CpG:	62	
chr11	
111385338	
111385778	
6	
2.20E-05	
C11orf88	
CpG:	31	
chr17	
75368750	
75369657	
10	
2.21E-05	
Septin9	
CpG:	138	
chr16	
66612955	
66613582	
12	
2.21E-05	
CKLF-CM
TM
1;	CM
TM
2;	CM
TM
1	
CpG:	70	
chr15	
35046610	
35047203	
7	
2.23E-05	
GJD2	
CpG:	106	
chr19	
36909326	
36909913	
6	
2.28E-05	
ZFP82	
CpG:	66	
chr7	
54609587	
54610320	
11	
2.34E-05	
VSTM
2A	
CpG:	39	
chr17	
8770908	
8771331	
7	
2.36E-05	
PIK3R6	
CpG:	35	
chr7	
94284380	
94285004	
24	
2.40E-05	
SGCE	
CpG:	112	
chr8	
58906736	
58907387	
7	
2.49E-05	
FAM
110B	
CpG:	95	
chr10	
82116203	
82116571	
9	
2.60E-05	
DYDC2;	DYDC2;	DYDC2;	DYDC1	
CpG:	93	
chr1	
3567109	
3567550	
7	
2.73E-05	
W
RAP73	
CpG:	284	
chr16	
3238937	
3239638	
5	
2.75E-05	
OR1F1	
CpG:	51	
chr1	
119530600	
119531122	
6	
2.82E-05	
TBX15	
CpG:	84	
chr3	
238048	
238618	
8	
2.92E-05	
CHL1	
CpG:	171	
chr3	
62354878	
62355525	
7	
2.94E-05	
FEZF2	
CpG:	16;	
CpG:	59	
chr1	
229543009	
229543603	
5	
2.99E-05	
ACTA1	
CpG:	69	
chr5	
170743459	
170744027	
5	
3.01E-05	
TLX3	
CpG:	72	
chr10	
22634038	
22634602	
11	
3.29E-05	
SPAG6	
CpG:	102	
chr3	
32859099	
32859587	
8	
3.35E-05	
TRIM
71	
CpG:	251	
chr10	
8077830	
8078357	
7	
3.36E-05	
GATA3-AS1	
CpG:	41	
chr5	
40841298	
40841590	
5	
3.41E-05	
CARD6	
CpG:	53	
																								
254	
chr2	
70995349	
70995459	
5	
3.46E-05	
ADD2	
CpG:	88	
chr12	
33591899	
33592642	
5	
3.58E-05	
SYT10	
CpG:	129	
chr2	
394115	
394572	
5	
3.61E-05	
FAM
150B	
CpG:	116	
chr8	
9763033	
9763739	
7	
3.62E-05	
M
IR124-1	
CpG:	170	
chr6	
166422182	
166422741	
5	
3.70E-05	
LINC00602	
CpG:	37	
chr10	
102997782	
102998117	
6	
3.73E-05	
LBX1-AS1	
CpG:	40	
chr1	
25257505	
25258082	
13	
3.86E-05	
RUNX3	
CpG:	311	
chr12	
104850321	
104850767	
9	
3.91E-05	
CHST11	
CpG:	184	
chr6	
10385320	
10386160	
7	
3.91E-05	
TFAP2A	
CpG:	49	
chr2	
242794854	
242795282	
6	
4.05E-05	
PDCD1	
CpG:	19	
chr6	
10882927	
10883376	
5	
4.14E-05	
GCM
2	
CpG:	21	
chr1	
221057558	
221057808	
5	
4.25E-05	
HLX	
CpG:	24	
chr12	
132663428	
132663883	
8	
4.34E-05	
GALNT9	
CpG:	32	
chr3	
238931	
239733	
7	
4.40E-05	
CHL1	
CpG:	171	
chr11	
32456759	
32457386	
10	
4.44E-05	
W
T1-AS;	W
T1	
CpG:	188	
chr2	
119615496	
119616242	
5	
4.47E-05	
EN1	
CpG:	173;	
CpG:	48	
chr19	
53635967	
53636398	
7	
4.53E-05	
ZNF415	
CpG:	45	
chr3	
157155088	
157155476	
5	
4.62E-05	
VEPH1;	PTX3	
CpG:	67	
chrX	
133305793	
133306382	
5	
4.73E-05	
M
IR106A	
CpG:	111	
chr14	
60977856	
60978275	
5	
4.73E-05	
SIX6	
CpG:	178	
chr12	
95942761	
95943114	
5	
4.83E-05	
USP44	
CpG:	134	
chr15	
83952345	
83952875	
7	
4.84E-05	
BNC1	
CpG:	188	
chr6	
101846779	
101847541	
13	
4.90E-05	
GRIK2	
CpG:	27	
chr13	
102068234	
102068650	
5	
4.96E-05	
NALCN	
CpG:	99	
chr19	
9473565	
9474128	
11	
5.02E-05	
ZNF177;	ZNF559-ZNF177	
CpG:	31	
																								
255	
chr3	
44626029	
44626860	
11	
5.07E-05	
ZNF660	
CpG:	35	
chr19	
49249932	
49250561	
7	
5.11E-05	
IZUM
O1	
CpG:	44	
chr11	
119293385	
119293869	
5	
5.34E-05	
THY1	USP2-AS1;THY1	
CpG:	48	
chr11	
79149704	
79150593	
6	
5.45E-05	
TENM
4	
CpG:	300	
chr5	
50685201	
50685716	
5	
5.46E-05	
ISL1	
CpG:	53	
chr3	
170137240	
170137871	
5	
5.55E-05	
CLDN11	
CpG:	132	
chr4	
13536409	
13537318	
8	
5.66E-05	
LINC01097	
CpG:	27	
chr1	
208083913	
208084415	
6	
5.68E-05	
CD34	
CpG:	36	
chr4	
20255061	
20255343	
5	
5.68E-05	
SLIT2	
CpG:	291	
chr8	
101117949	
101118548	
9	
5.70E-05	
RGS22	
CpG:	88	
chr6	
30720080	
30720491	
8	
5.74E-05	
IER3	
CpG:	161	
chr14	
60973462	
60974039	
6	
5.88E-05	
SIX6	
CpG:	32	
chr1	
78956845	
78957253	
5	
6.09E-05	
PTGFR	
CpG:	70	
chr7	
96651915	
96652481	
10	
6.21E-05	
DLX5	
CpG:	20	
chr6	
124124620	
124125371	
7	
6.22E-05	
NKAIN2	
CpG:	117	
chr2	
207506975	
207507528	
7	
6.27E-05	
LOC200726	
CpG:	53	
chr6	
50817157	
50817674	
6	
6.30E-05	
TFAP2B	
CpG:	39	
chr6	
50803820	
50804174	
6	
6.50E-05	
TFAP2B	
CpG:	29	
chr1	
10732063	
10733030	
11	
6.52E-05	
CASZ1	
CpG:	36	
chr6	
6004207	
6004897	
8	
6.52E-05	
NRN1	
CpG:	191	
chr10	
7708670	
7709073	
7	
6.71E-05	
ITIH5	
CpG:	21	
chr3	
44039204	
44040206	
8	
6.80E-05	
M
IR138-1	
CpG:	344	
chr2	
234847554	
234848156	
5	
7.20E-05	
TRPM
8	
CpG:	19	
chr2	
154729622	
154730157	
5	
7.34E-05	
GALNT13	
CpG:	23	
chr3	
147142102	
147142415	
5	
7.97E-05	
LOC440982	
CpG:	18	
																								
256	
chr20	
21494547	
21494831	
8	
8.00E-05	
NKX2-2	
CpG:	671	
chrX	
101905837	
101906288	
5	
8.21E-05	
ARM
CX5-GPRASP2	
CpG:	89	
chr1	
101004472	
101005121	
5	
8.40E-05	
GPR88	
CpG:	134	
chr19	
2251764	
2252432	
6	
8.47E-05	
JSRP1;	AM
H	
CpG:	330	
chr15	
27111435	
27112430	
21	
8.48E-05	
GABRA5	
CpG:	159	
chrX	
107979401	
107980144	
7	
8.56E-05	
IRS4;	LOC101928358	
CpG:	160	
chr11	
109292789	
109293216	
7	
9.03E-05	
C11orf87	
CpG:	102	
chr3	
172167445	
172167810	
5	
9.10E-05	
GHSR	
CpG:	26	
chr12	
129338484	
129338939	
5	
9.77E-05	
GLT1D1	
CpG:	93	
chr10	
102995987	
102996798	
8	
0.0001009	
LBX1-AS1	
CpG:	40	
chr8	
97171668	
97172219	
5	
0.0001012	
GDF6	
CpG:	24	
chr16	
1030166	
1030619	
9	
0.0001013	
LM
F1	
CpG:	437	
chr20	
30060822	
30061044	
5	
0.0001092	
DEFB124	
CpG:	27	
chr19	
21646329	
21646781	
5	
0.0001138	
LINC00664	
CpG:	18	
chr8	
141248582	
141249094	
6	
0.0001142	
TRAPPC9	
CpG:	32	
chr3	
62359390	
62360240	
9	
0.0001158	
FEZF2	
CpG:	162	
chr3	
128719999	
128720433	
6	
0.0001163	
EFCC1	
CpG:	139	
chr11	
122850140	
122850741	
6	
0.0001171	
BSX	
CpG:	86	
chr8	
23563572	
23564294	
10	
0.0001181	
NKX2-6	
CpG:	187	
chr6	
118228382	
118228871	
8	
0.0001236	
SLC35F1	
CpG:	166	
chr4	
93225933	
93226540	
6	
0.0001274	
GRID2	
CpG:	63	
chr4	
41882564	
41883172	
9	
0.0001286	
LINC00682	
CpG:	34	
chr2	
223166909	
223167463	
6	
0.0001295	
CCDC140	
CpG:	25	
chr11	
31819148	
31819678	
7	
0.0001449	
PAX6	
CpG:	98	
chr19	
54926277	
54926805	
7	
0.000146	
TTYH1	
CpG:	35	
																								
257	
chr5	
26669320	
26669882	
5	
0.0001464	
CDH9	
CpG:	28	
chr6	
33135753	
33136511	
9	
0.0001517	
COL11A2	
CpG:	47	
chr12	
99139301	
99139867	
6	
0.000156	
ANKS1B	
CpG:	42	
chr12	
104851909	
104852446	
6	
0.0001586	
CHST11	
CpG:	184	
chr10	
94825257	
94825848	
5	
0.0001712	
CYP26C1	
CpG:	64	
chr19	
51071294	
51071328	
5	
0.0001716	
LRRC4B	
CpG:	20	
chr13	
103052362	
103052943	
5	
0.0001722	
FGF14	
CpG:	51	
chr18	
11149435	
11150043	
5	
0.0001736	
PIEZO2	
CpG:	164	
chr20	
45279830	
45280414	
7	
0.0001767	
SLC13A3	
CpG:	40	
chr12	
114846162	
114846503	
8	
0.0001773	
TBX5-AS1;	TBX5	
CpG:	119	
chr11	
66188019	
66188745	
6	
0.0001852	
NPAS4	
CpG:	102	
chr19	
52956622	
52957180	
10	
0.0001927	
ZNF578	
CpG:	47	
chr17	
78152051	
78152466	
5	
0.0001931	
CARD14	
CpG:	15	
chr11	
45376874	
45377324	
5	
0.0002003	
LOC101928812	
CpG:	25	
chr16	
54972573	
54973385	
6	
0.0002086	
IRX5	
CpG:	179	
chr10	
125852693	
125853232	
6	
0.0002089	
CHST15	
CpG:	209	
chr1	
3331987	
3332264	
6	
0.0002108	
PRDM
16	
CpG:	19	
chr5	
77268331	
77268888	
5	
0.0002117	
LOC101929154	
CpG:	44	
chr18	
59001158	
59001726	
5	
0.0002172	
CDH20	
CpG:	101	
chr16	
66637919	
66638702	
12	
0.0002207	
CM
TM
3	
CpG:	126	
chr12	
3600019	
3600317	
6	
0.0002248	
THCAT155;	PRM
T8	
CpG:	212	
chr12	
4918848	
4919230	
5	
0.0002308	
KCNA6	
CpG:	138	
chr7	
27142200	
27143046	
15	
0.0002344	
HOXA2	
CpG:	24	
chr17	
21280740	
21281318	
5	
0.0002443	
KCNJ12	
CpG:	187	
chr1	
1566687	
1567257	
5	
0.0002511	
M
M
P23B	
CpG:	470	
chr8	
144240945	
144241434	
5	
0.0002568	
LY6H	
CpG:	132	
																								
258	
chr4	
185942086	
185942746	
7	
0.0002626	
HELT	
CpG:	256	
chr20	
61885249	
61885291	
5	
0.0002648	
NKAIN4	
CpG:	156	
chr15	
88799300	
88799999	
7	
0.0002651	
NTRK3-AS1;	NTRK3;	NTRK3	
CpG:	119	
chr13	
36919344	
36919960	
7	
0.000273	
SPG20	
CpG:	121	
chr17	
4689640	
4689893	
6	
0.0002878	
VM
O1	
CpG:	75	
chr12	
128850196	
128850696	
6	
0.0003024	
TM
EM
132C	
CpG:	17	
chr11	
123301490	
123302099	
6	
0.0003047	
M
IR4493	
CpG:	108	
chr4	
185940923	
185941625	
6	
0.0003057	
HELT	
CpG:	256	
chr6	
10883834	
10884314	
6	
0.000311	
GCM
2	
CpG:	21	
chr5	
87968118	
87968658	
5	
0.0003147	
LINC00461	
CpG:	24	
chr7	
19146032	
19146555	
5	
0.0003232	
TW
IST1	
CpG:	34	
chr11	
3239953	
3240399	
6	
0.0003282	
M
RGPRG;	M
RGPRG-AS1	
CpG:	66	
chr12	
15475116	
15475767	
8	
0.0003309	
PTPRO	
CpG:	61	
chr17	
74944775	
74945219	
5	
0.0003334	
M
GAT5B	
CpG:	17	
chr7	
142966	
143220	
5	
0.0003355	
LOC102723672	
CpG:	49	
chr12	
82153008	
82153464	
9	
0.0003366	
PPFIA2	
CpG:	34	
chr10	
1778529	
1779033	
5	
0.0003429	
ADARB2	
CpG:	95	
chr1	
2980038	
2980598	
6	
0.0003437	
LINC00982	
CpG:	126	
chr7	
88388555	
88388646	
5	
0.0003533	
ZNF804B	
CpG:	71	
chr7	
45613410	
45613825	
5	
0.0003668	
ADCY1	
CpG:	151	
chr4	
172733760	
172734347	
5	
0.0003677	
LOC441052	
CpG:	117	
chr15	
89951787	
89952499	
5	
0.0003712	
M
IR9-3HG	
CpG:	58	
chr10	
119000638	
119001529	
8	
0.000375	
SLC18A2	
CpG:	123	
chr5	
161274540	
161275138	
6	
0.0003787	
GABRA1	
CpG:	68	
chr17	
74868561	
74869001	
5	
0.0003822	
M
GAT5B	
CpG:	218	
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chr3	
147125712	
147126244	
13	
0.0004167	
ZIC1	
CpG:	180	
chr13	
112547459	
112548065	
5	
0.0004431	
LINC00354	
CpG:	53	
chr21	
32930938	
32931935	
6	
0.0004478	
TIAM
1	
CpG:	249	
chr6	
85482946	
85483800	
5	
0.0004663	
TBX18	
CpG:	188	
chr11	
19367501	
19368112	
6	
0.0005057	
NAV2	
CpG:	116	
chr14	
23821149	
23822017	
7	
0.0005071	
SLC22A17	
CpG:	92	
chr4	
134069236	
134069670	
6	
0.0005101	
LOC101927359	
CpG:	90	
chr3	
85008587	
85008991	
5	
0.0005216	
CADM
2	
CpG:	48	
chr17	
43974804	
43975063	
5	
0.0005542	
M
APT-IT1;	M
APT	
CpG:	302	
chrX	
30327423	
30327819	
12	
0.0005624	
NR0B1	
CpG:	116	
chr3	
27765232	
27765546	
5	
0.0005948	
EOM
ES	
CpG:	40	
chr14	
104690040	
104690244	
5	
0.0006521	
KIF26A	
CpG:	18	
chr10	
28035631	
28035822	
5	
0.0006524	
M
KX-AS1	
CpG:	398	
chr1	
34630518	
34631450	
8	
0.0007154	
CSM
D2	
CpG:	169	
chr10	
25465171	
25465352	
6	
0.0007992	
GPR158;	GPR158-AS1	
CpG:	166	
chr1	
236849653	
236850232	
5	
0.0008241	
ACTN2	
CpG:	84	
chr20	
24451428	
24452036	
6	
0.0008448	
SYNDIG1	
CpG:	173	
chr7	
70597458	
70597921	
7	
0.0008857	
W
BSCR17	
CpG:	232	
chr3	
42306385	
42306974	
5	
0.0009454	
CCK	
CpG:	94	
chr4	
81187601	
81187906	
5	
0.001249	
FGF5	
CpG:	43	
chr12	
45444203	
45445023	
7	
0.001305	
DBX2	
CpG:	115	
chr10	
130338781	
130339186	
5	
0.001393	
LINC01163	
CpG:	28	
chr20	
30062696	
30063249	
7	
0.001405	
REM
1	
CpG:	27	
chr11	
134145889	
134146324	
9	
0.001533	
GLB1L3	
CpG:	152	
chr10	
94820892	
94821085	
7	
0.001618	
CYP26C1	
CpG:	255	
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chr15	
74422275	
74422761	
11	
0.001873	
ISLR2	
CpG:	216	
chr4	
175750280	
175750666	
9	
0.002116	
GLRA3	
CpG:	26	
chr11	
20181725	
20182324	
9	
0.002204	
DBX1	
CpG:	87	
chr10	
99790170	
99790596	
5	
0.00222	
CRTAC1	
CpG:	160	
chr11	
109293945	
109294233	
6	
0.002269	
C11orf87	
CpG:	102	
chr6	
152957910	
152958173	
7	
0.00227	
SYNE1	
CpG:	60	
chr5	
180017623	
180018201	
5	
0.002534	
SCGB3A1	
CpG:	176	
chr17	
8868669	
8869213	
8	
0.002554	
PIK3R5	
CpG:	87	
chr1	
116380946	
116381475	
6	
0.002677	
NHLH2	
CpG:	209	
chrX	
66765795	
66766334	
6	
0.0029	
AR	
CpG:	27	
chr11	
94501461	
94502008	
5	
0.003172	
AM
OTL1	
CpG:	114	
chr2	
124782586	
124782885	
5	
0.003638	
CNTNAP5	
CpG:	71	
chr8	
72917147	
72917695	
5	
0.003748	
M
SC-AS1	
CpG:	29	
chr2	
200334558	
200335148	
7	
0.004256	
SATB2;	SATB2-AS1	
CpG:	74	
chr5	
119800143	
119800972	
5	
0.004356	
PRR16	
CpG:	52;	
CpG:	15	
chr2	
63283806	
63284132	
5	
0.004399	
OTX1	
CpG:	26	
chr20	
24449734	
24449916	
5	
0.004702	
SYNDIG1	
CpG:	173	
chr3	
181441571	
181442137	
5	
0.004754	
SOX2-OT	
CpG:	47	
chr8	
37823979	
37824529	
7	
0.005035	
ADRB3	
CpG:	137	
chr2	
161127261	
161127827	
5	
0.005904	
LOC100505984	
CpG:	39	
chrX	
142723112	
142723713	
5	
0.00617	
SLITRK4	
CpG:	135	
chr2	
163695776	
163696000	
5	
0.006657	
KCNH7	
CpG:	46	
chr6	
71666682	
71666858	
5	
0.007235	
B3GAT2	
CpG:	181	
chr2	
63274615	
63275178	
5	
0.008145	
LOC100132215	
CpG:	354	
chr1	
107683532	
107684059	
6	
0.008488	
NTNG1	
CpG:	134	
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chr14	
92790097	
92790711	
5	
0.01163	
SLC24A4	
CpG:	131	
chr16	
86546785	
86547386	
6	
0.01236	
FOXF1	
CpG:	21	
chr11	
637032	
637175	
5	
0.01455	
DRD4	
CpG:	278	
chr7	
32110145	
32110650	
5	
0.01587	
PDE1C	
CpG:	84	
chr1	
13910138	
13910224	
6	
0.01677	
PDPN	
CpG:	59	
chr15	
92936818	
92937360	
5	
0.01742	
ST8SIA2	
CpG:	177	
chr2	
88751621	
88752322	
7	
0.01812	
FOXI3	
CpG:	120	
chr2	
121223740	
121224009	
6	
0.01835	
LINC01101	
CpG:	34	
chr4	
126237371	
126237597	
6	
0.02693	
FAT4	
CpG:	230	
chr12	
96883202	
96883596	
5	
0.036	
CFAP54	
CpG:	45	
chr10	
128994030	
128994644	
6	
0.04364	
FAM
196A;	DOCK1	
CpG:	172	
chr15	
92937735	
92938295	
5	
0.04917	
ST8SIA2	
CpG:	177	
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Supplem
entary Table 5. G
O
 enrichm
ent analysis – Biological category 
 		Term
	
P	value	
Adjusted	P	value	
em
bryonic	m
orphogenesis	(GO:0048598)	
1.7132E-17	
5.72552E-14	
behaviour	(GO:0007610)	
4.80146E-15	
8.02324E-12	
pattern	specification	process	(GO:0007389)	
1.02545E-14	
1.14235E-11	
synaptic	transm
ission	(GO:0007268)	
2.04466E-13	
1.13888E-10	
cell-cell	adhesion	(GO:0098609)	
5.09521E-14	
3.40564E-11	
cell-cell	adhesion	via	plasm
a-m
em
brane	adhesion	m
olecules	(GO:0098742)	
4.44464E-14	
3.40564E-11	
regulation	of	neuron	differentiation	(GO:0045664)	
2.62233E-12	
1.09548E-09	
neuron	differentiation	(GO:0030182)	
2.43946E-12	
1.09548E-09	
hom
ophilic	cell	adhesion	via	plasm
a	m
em
brane	adhesion	m
olecules	(GO:0007156)	
3.94219E-12	
1.46387E-09	
single-organism
	behaviour	(GO:0044708)	
3.60916E-11	
1.20618E-08	
regionalization	(GO:0003002)	
1.37505E-10	
4.17766E-08	
organ	m
orphogenesis	(GO:0009887)	
8.93567E-10	
1.99087E-07	
central	nervous	system
	neuron	differentiation	(GO:0021953)	
4.8044E-10	
1.33803E-07	
em
bryonic	organ	m
orphogenesis	(GO:0048562)	
6.33846E-10	
1.62947E-07	
locom
otory	behaviour	(GO:0007626)	
3.00094E-09	
6.26821E-07	
cell	fate	specification	(GO:0001708)	
8.08533E-10	
1.93008E-07	
tissue	m
orphogenesis	(GO:0048729)	
8.93821E-09	
1.65953E-06	
forelim
b	m
orphogenesis	(GO:0035136)	
1.76139E-08	
2.67572E-06	
negative	regulation	of	cell	developm
ent	(GO:0010721)	
1.17763E-08	
2.07138E-06	
neuron	m
igration	(GO:0001764)	
7.58469E-09	
1.49106E-06	
cell	fate	com
m
itm
ent	(GO:0045165)	
1.6157E-08	
2.57127E-06	
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appendage	m
orphogenesis	(GO:0035107)	
2.29374E-08	
3.19403E-06	
lim
b	m
orphogenesis	(GO:0035108)	
2.29374E-08	
3.19403E-06	
behavioural	fear	response	(GO:0001662)	
1.22961E-07	
1.3256E-05	
behavioural	defense	response	(GO:0002209)	
1.22961E-07	
1.3256E-05	
negative	regulation	of	nervous	system
	developm
ent	(GO:0051961)	
4.47994E-08	
5.98878E-06	
m
ulticellular	organism
al	response	to	stress	(GO:0033555)	
1.39448E-08	
2.33017E-06	
hindlim
b	m
orphogenesis	(GO:0035137)	
8.15769E-08	
1.04858E-05	
m
orphogenesis	of	an	epithelium
	(GO:0002009)	
9.38606E-08	
1.157E-05	
anterior/posterior	pattern	specification	(GO:0009952)	
9.69364E-08	
1.157E-05	
negative	regulation	of	neurogenesis	(GO:0050768)	
1.05065E-07	
1.21079E-05	
fear	response	(GO:0042596)	
3.92016E-07	
3.44768E-05	
positive	regulation	of	nervous	system
	developm
ent	(GO:0051962)	
2.98233E-07	
3.05004E-05	
cell	fate	determ
ination	(GO:0001709)	
3.11388E-07	
3.05004E-05	
signal	transduction	involved	in	regulation	of	gene	expression	(GO:0023019)	
6.02994E-07	
4.79811E-05	
em
bryonic	appendage	m
orphogenesis	(GO:0035113)	
3.37677E-07	
3.05004E-05	
em
bryonic	lim
b	m
orphogenesis	(GO:0030326)	
3.37677E-07	
3.05004E-05	
m
orphogenesis	of	a	branching	epithelium
	(GO:0061138)	
3.21392E-07	
3.05004E-05	
adenylate	cyclase-m
odulating	G-protein	coupled	receptor	signaling	pathw
ay	(GO:0007188)	
3.19789E-07	
3.05004E-05	
adult	behaviour	(GO:0030534)	
5.97081E-07	
4.79811E-05	
em
bryonic	forelim
b	m
orphogenesis	(GO:0035115)	
1.7115E-06	
0.000111787	
m
orphogenesis	of	a	branching	structure	(GO:0001763)	
6.73236E-07	
5.23245E-05	
palate	developm
ent	(GO:0060021)	
5.43109E-07	
4.65403E-05	
branching	m
orphogenesis	of	an	epithelial	tube	(GO:0048754)	
5.97081E-07	
4.79811E-05	
extracellular	m
atrix	organization	(GO:0030198)	
1.73936E-06	
0.000111787	
negative	regulation	of	neuron	differentiation	(GO:0045665)	
1.0751E-06	
7.81085E-05	
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tube	developm
ent	(GO:0035295)	
1.40714E-06	
9.40533E-05	
extracellular	structure	organization	(GO:0043062)	
1.83937E-06	
0.000115984	
neuron	developm
ent	(GO:0048666)	
1.1828E-06	
8.41048E-05	
em
bryonic	skeletal	system
	m
orphogenesis	(GO:0048704)	
8.27848E-07	
6.28788E-05	
nervous	system
	developm
ent	(GO:0007399)	
2.03006E-06	
0.000123354	
m
uscle	organ	developm
ent	(GO:0007517)	
9.28862E-07	
6.89835E-05	
sensory	perception	(GO:0007600)	
2.70182E-06	
0.000161241	
G-protein	coupled	receptor	signaling	pathw
ay,	coupled	to	cyclic	nucleotide	second	
m
essenger	(GO:0007187)	
1.8803E-06	
0.000116369	
m
uscle	structure	developm
ent	(GO:0061061)	
1.31039E-06	
9.09979E-05	
cell	differentiation	in	spinal	cord	(GO:0021515)	
3.99096E-06	
0.000229962	
neurogenesis	(GO:0022008)	
4.86299E-06	
0.00027546	
adenylate	cyclase-inhibiting	G-protein	coupled	receptor	signaling	pathw
ay	(GO:0007193)	
1.3342E-06	
9.09979E-05	
em
bryonic	hindlim
b	m
orphogenesis	(GO:0035116)	
4.96874E-06	
0.000276759	
axon	guidance	(GO:0007411)	
6.90918E-06	
0.000360789	
neuron	projection	guidance	(GO:0097485)	
6.90918E-06	
0.000360789	
regulation	of	organ	m
orphogenesis	(GO:2000027)	
5.13471E-06	
0.000281315	
sym
pathetic	nervous	system
	developm
ent	(GO:0048485)	
7.88033E-06	
0.00040517	
positive	regulation	of	neurogenesis	(GO:0050769)	
8.2482E-06	
0.000417659	
positive	regulation	of	cell	developm
ent	(GO:0010720)	
1.09239E-05	
0.000536875	
neuron	fate	specification	(GO:0048665)	
6.86565E-06	
0.000360789	
skeletal	system
	m
orphogenesis	(GO:0048705)	
3.91051E-06	
0.000229279	
adult	locom
otory	behaviour	(GO:0008344)	
9.18401E-06	
0.000458104	
neural	crest	cell	m
igration	(GO:0001755)	
1.42802E-05	
0.000681778	
regulation	of	cell	m
orphogenesis	involved	in	differentiation	(GO:0010769)	
2.11006E-05	
0.000979418	
regulation	of	m
em
brane	potential	(GO:0042391)	
2.24333E-05	
0.001027017	
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skeletal	system
	developm
ent	(GO:0001501)	
1.3918E-05	
0.000674116	
epithelial	cell	differentiation	(GO:0030855)	
2.54267E-05	
0.001133014	
regulation	of	organ	form
ation	(GO:0003156)	
2.80573E-05	
0.001186931	
pituitary	gland	developm
ent	(GO:0021983)	
2.80573E-05	
0.001186931	
cellular	com
ponent	m
orphogenesis	(GO:0032989)	
3.28287E-05	
0.001371418	
regulation	of	transm
em
brane	receptor	protein	serine/threonine	kinase	signaling	pathw
ay	
(GO:0090092)	
2.63132E-05	
0.001142405	
positive	regulation	of	neuron	differentiation	(GO:0045666)	
2.42282E-05	
0.001094197	
cranial	nerve	developm
ent	(GO:0021545)	
4.19925E-05	
0.001690832	
regulation	of	neuron	projection	developm
ent	(GO:0010975)	
3.73187E-05	
0.001520964	
feeding	behaviour	(GO:0007631)	
3.44487E-05	
0.001421328	
neuron-neuron	synaptic	transm
ission	(GO:0007270)	
1.99371E-05	
0.000938449	
inner	ear	m
orphogenesis	(GO:0042472)	
2.63211E-05	
0.001142405	
regulation	of	developm
ental	grow
th	(GO:0048638)	
4.98756E-05	
0.001984335	
m
iddle	ear	m
orphogenesis	(GO:0042474)	
5.31752E-05	
0.002090725	
response	to	steroid	horm
one	(GO:0048545)	
0.000105577	
0.003675392	
regulation	of	transm
em
brane	transport	(GO:0034762)	
8.52796E-05	
0.003131916	
gland	developm
ent	(GO:0048732)	
8.20531E-05	
0.00307709	
epithelium
	developm
ent	(GO:0060429)	
8.9379E-05	
0.003211878	
am
eboidal-type	cell	m
igration	(GO:0001667)	
7.41025E-05	
0.00281421	
cell	m
orphogenesis	(GO:0000902)	
8.62213E-05	
0.003132081	
positive	regulation	of	heart	grow
th	(GO:0060421)	
8.2866E-05	
0.00307709	
regulation	of	ion	transm
em
brane	transport	(GO:0034765)	
0.000110179	
0.003796065	
positive	regulation	of	organ	grow
th	(GO:0046622)	
0.000104421	
0.003673436	
central	nervous	system
	developm
ent	(GO:0007417)	
7.08495E-05	
0.002721596	
dorsal/ventral	pattern	form
ation	(GO:0009953)	
5.71215E-05	
0.002219767	
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regulation	of	stem
	cell	proliferation	(GO:0072091)	
0.000123508	
0.004211872	
grow
th	(GO:0040007)	
0.000219614	
0.006924069	
regulation	of	BM
P	signaling	pathw
ay	(GO:0030510)	
0.000128105	
0.004324526	
positive	regulation	of	developm
ental	grow
th	(GO:0048639)	
0.000102682	
0.003650664	
positive	regulation	of	grow
th	(GO:0045927)	
0.000266953	
0.008078519	
kidney	epithelium
	developm
ent	(GO:0072073)	
0.000157199	
0.005253601	
potassium
	ion	transport	(GO:0006813)	
0.00019337	
0.006397681	
regulation	of	DNA	binding	(GO:0051101)	
0.000195287	
0.006397681	
kidney	developm
ent	(GO:0001822)	
0.000227967	
0.007054305	
regulation	of	peptide	secretion	(GO:0002791)	
0.000318379	
0.009252382	
positive	regulation	of	cardiac	m
uscle	cell	proliferation	(GO:0060045)	
0.000197176	
0.006397681	
neurom
uscular	process	(GO:0050905)	
0.000238779	
0.007321108	
axis	specification	(GO:0009798)	
0.000216109	
0.00687845	
negative	regulation	of	W
nt	signaling	pathw
ay	(GO:0030178)	
0.000308412	
0.00904134	
regulation	of	W
nt	signaling	pathw
ay	(GO:0030111)	
0.00041175	
0.010835193	
digestive	tract	developm
ent	(GO:0048565)	
0.000268317	
0.008078519	
cellular	response	to	lipid	(GO:0071396)	
0.000617915	
0.014048116	
nerve	developm
ent	(GO:0021675)	
0.000494563	
0.011890863	
regulation	of	neural	precursor	cell	proliferation	(GO:2000177)	
0.000221816	
0.006928117	
regulation	of	cell	m
orphogenesis	(GO:0022604)	
0.000506993	
0.01210265	
m
idbrain	developm
ent	(GO:0030901)	
0.000307993	
0.00904134	
positive	regulation	of	DNA	binding	(GO:0043388)	
0.000362491	
0.010266472	
positive	regulation	of	am
ine	transport	(GO:0051954)	
0.000372959	
0.010386915	
cardiac	ventricle	m
orphogenesis	(GO:0003208)	
0.000452905	
0.011174413	
branching	involved	in	ureteric	bud	m
orphogenesis	(GO:0001658)	
0.000349106	
0.010057851	
tube	form
ation	(GO:0035148)	
0.000399616	
0.010599347	
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cell	m
orphogenesis	involved	in	differentiation	(GO:0000904)	
0.000438756	
0.011174413	
visual	perception	(GO:0007601)	
0.000378209	
0.010425362	
positive	regulation	of	cardiac	m
uscle	tissue	grow
th	(GO:0055023)	
0.000304483	
0.00904134	
regulation	of	axonogenesis	(GO:0050770)	
0.000399616	
0.010599347	
potassium
	ion	transm
em
brane	transport	(GO:0071805)	
0.000383698	
0.010425362	
m
etanephros	developm
ent	(GO:0001656)	
0.000494563	
0.011890863	
spinal	cord	m
otor	neuron	differentiation	(GO:0021522)	
0.000372959	
0.010386915	
cellular	potassium
	ion	transport	(GO:0071804)	
0.000383698	
0.010425362	
neuron	fate	com
m
itm
ent	(GO:0048663)	
0.000424441	
0.011046489	
sensory	perception	of	light	stim
ulus	(GO:0050953)	
0.000447556	
0.011174413	
positive	regulation	of	cell	adhesion	(GO:0045785)	
0.000687152	
0.015009551	
neuropeptide	signaling	pathw
ay	(GO:0007218)	
0.000399616	
0.010599347	
blood	vessel	m
orphogenesis	(GO:0048514)	
0.000562137	
0.013046261	
regulation	of	em
bryonic	developm
ent	(GO:0045995)	
0.000473637	
0.011553966	
regulation	of	peptide	horm
one	secretion	(GO:0090276)	
0.000713541	
0.015384866	
fluid	transport	(GO:0042044)	
0.000454734	
0.011174413	
regulation	of	transcription	regulatory	region	DNA	binding	(GO:2000677)	
0.000452905	
0.011174413	
cellular	response	to	steroid	horm
one	stim
ulus	(GO:0071383)	
0.000770084	
0.015502591	
regulation	of	system
	process	(GO:0044057)	
0.001178409	
0.02030022	
regulation	of	horm
one	secretion	(GO:0046883)	
0.000925567	
0.017761122	
negative	regulation	of	transm
em
brane	receptor	protein	serine/threonine	kinase	signaling	
pathw
ay	(GO:0090101)	
0.0007565	
0.015502591	
cyclic	nucleotide	m
etabolic	process	(GO:0009187)	
0.000429696	
0.011046489	
regulation	of	osteoblast	differentiation	(GO:0045667)	
0.000701398	
0.015221254	
response	to	corticosteroid	(GO:0031960)	
0.000808587	
0.016085111	
neuron	projection	m
orphogenesis	(GO:0048812)	
0.000863438	
0.016874914	
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positive	regulation	of	epithelial	cell	proliferation	(GO:0050679)	
0.001039532	
0.019300641	
regulation	of	postsynaptic	m
em
brane	potential	(GO:0060078)	
0.000429696	
0.011046489	
regulation	of	cell	projection	organization	(GO:0031344)	
0.001170177	
0.020262856	
regulation	of	am
ine	transport	(GO:0051952)	
0.000536256	
0.012532632	
cardiac	cham
ber	m
orphogenesis	(GO:0003206)	
0.000774666	
0.015502591	
ionotropic	glutam
ate	receptor	signaling	pathw
ay	(GO:0035235)	
0.000452905	
0.011174413	
stem
	cell	differentiation	(GO:0048863)	
0.000663563	
0.014686276	
cell	differentiation	in	hindbrain	(GO:0021533)	
0.000652383	
0.014632651	
negative	regulation	of	cAM
P	m
etabolic	process	(GO:0030815)	
0.000573611	
0.013130187	
regulation	of	epithelial	cell	proliferation	(GO:0050678)	
0.001412474	
0.023139651	
synaptic	transm
ission,	glutam
atergic	(GO:0035249)	
0.000573611	
0.013130187	
neural	tube	closure	(GO:0001843)	
0.000678503	
0.01491814	
regulation	of	striated	m
uscle	tissue	developm
ent	(GO:0016202)	
0.001089263	
0.019627288	
positive	regulation	of	em
bryonic	developm
ent	(GO:0040019)	
0.000652383	
0.014632651	
developm
ental	grow
th	(GO:0048589)	
0.001166756	
0.020262856	
negative	regulation	of	cyclic	nucleotide	m
etabolic	process	(GO:0030800)	
0.000662376	
0.014686276	
regulation	of	m
uscle	tissue	developm
ent	(GO:1901861)	
0.001168599	
0.020262856	
tube	closure	(GO:0060606)	
0.000743739	
0.015465269	
regulation	of	binding	(GO:0051098)	
0.001255902	
0.02119811	
circulatory	system
	process	(GO:0003013)	
0.001228283	
0.020943484	
developm
ental	grow
th	involved	in	m
orphogenesis	(GO:0060560)	
0.000889742	
0.017287893	
positive	regulation	of	stem
	cell	proliferation	(GO:2000648)	
0.00081454	
0.01610764	
m
uscle	tissue	developm
ent	(GO:0060537)	
0.001142905	
0.020103095	
regulation	of	m
uscle	organ	developm
ent	(GO:0048634)	
0.001252667	
0.02119811	
adult	w
alking	behaviour	(GO:0007628)	
0.000761688	
0.015502591	
regulation	of	sm
oothened	signalling	pathw
ay	(GO:0008589)	
0.000735901	
0.015465269	
																								
269	
gonad	developm
ent	(GO:0008406)	
0.001089263	
0.019627288	
outflow
	tract	m
orphogenesis	(GO:0003151)	
0.000995443	
0.018689718	
aging	(GO:0007568)	
0.001548017	
0.02487246	
response	to	glucocorticoid	(GO:0051384)	
0.001228283	
0.020943484	
phospholipase	C-activating	G-protein	coupled	receptor	signaling	pathw
ay	(GO:0007200)	
0.000935355	
0.017761122	
colum
nar/cuboidal	epithelial	cell	differentiation	(GO:0002065)	
0.000835104	
0.016417164	
developm
ental	induction	(GO:0031128)	
0.000774666	
0.015502591	
brain	developm
ent	(GO:0007420)	
0.00163934	
0.025842799	
endoderm
	form
ation	(GO:0001706)	
0.000354722	
0.010132304	
glutam
ate	receptor	signaling	pathw
ay	(GO:0007215)	
0.000995443	
0.018689718	
cognition	(GO:0050890)	
0.001907182	
0.028771434	
cell-cell	signaling	involved	in	cell	fate	com
m
itm
ent	(GO:0045168)	
0.000913913	
0.017654905	
striated	m
uscle	tissue	developm
ent	(GO:0014706)	
0.001474646	
0.023808056	
em
bryonic	cranial	skeleton	m
orphogenesis	(GO:0048701)	
0.001071651	
0.019570814	
regulation	of	excitatory	postsynaptic	m
em
brane	potential	(GO:0060079)	
0.000935355	
0.017761122	
regulation	of	peptide	transport	(GO:0090087)	
0.002277122	
0.032203671	
second-m
essenger-m
ediated	signaling	(GO:0019932)	
0.001579397	
0.025255237	
regulation	of	ossification	(GO:0030278)	
0.002008912	
0.029972243	
regulation	of	gliogenesis	(GO:0014013)	
0.001092363	
0.019627288	
neurotransm
itter	transport	(GO:0006836)	
0.001329004	
0.022319255	
positive	regulation	of	cardiac	m
uscle	tissue	developm
ent	(GO:0055025)	
0.001071651	
0.019570814	
regulation	of	heart	grow
th	(GO:0060420)	
0.001131718	
0.020011651	
response	to	alcohol	(GO:0097305)	
0.002724808	
0.0359769	
cardiac	septum
	m
orphogenesis	(GO:0060411)	
0.001447895	
0.023506985	
regulation	of	cardiac	m
uscle	cell	proliferation	(GO:0060043)	
0.001071651	
0.019570814	
regulation	of	cell	adhesion	(GO:0030155)	
0.002925203	
0.037600107	
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calcium
	ion	hom
eostasis	(GO:0055074)	
0.002724808	
0.0359769	
enteric	nervous	system
	developm
ent	(GO:0048484)	
0.000199755	
0.006419059	
negative	regulation	of	cell	m
orphogenesis	involved	in	differentiation	(GO:0010771)	
0.001866844	
0.028359051	
negative	regulation	of	transport	(GO:0051051)	
0.003401837	
0.042901664	
regulation	of	gastrulation	(GO:0010470)	
0.001448964	
0.023506985	
regulation	of	vasculature	developm
ent	(GO:1901342)	
0.002671431	
0.0359769	
m
em
brane	depolarization	(GO:0051899)	
0.002186163	
0.03188907	
regulation	of	angiogenesis	(GO:0045765)	
0.00272243	
0.0359769	
learning	or	m
em
ory	(GO:0007611)	
0.002799177	
0.036149633	
m
esonephric	tubule	developm
ent	(GO:0072164)	
0.001629824	
0.025814558	
signal	release	(GO:0023061)	
0.002403624	
0.033610503	
negative	regulation	of	canonical	W
nt	signaling	pathw
ay	(GO:0090090)	
0.002339284	
0.032848266	
negative	regulation	of	purine	nucleotide	m
etabolic	process	(GO:1900543)	
0.001721906	
0.026518939	
positive	regulation	of	cell-substrate	adhesion	(GO:0010811)	
0.002704379	
0.0359769	
m
esonephric	epithelium
	developm
ent	(GO:0072163)	
0.001829047	
0.027911756	
axonogenesis	(GO:0007409)	
0.002669987	
0.0359769	
negative	regulation	of	gliogenesis	(GO:0014014)	
0.001671845	
0.02586715	
regulation	of	cell	grow
th	(GO:0001558)	
0.003647827	
0.045151991	
neurotransm
itter	secretion	(GO:0007269)	
0.00159062	
0.025313588	
positive	regulation	of	ion	transport	(GO:0043270)	
0.00380721	
0.046606949	
response	to	pain	(GO:0048265)	
0.001671845	
0.02586715	
regulation	of	synaptic	transm
ission	(GO:0050804)	
0.004078595	
0.049386465	
response	to	fibroblast	grow
th	factor	(GO:0071774)	
0.003987647	
0.048460788	
positive	regulation	of	m
uscle	organ	developm
ent	(GO:0048636)	
0.002046649	
0.030131728	
negative	regulation	of	nucleotide	m
etabolic	process	(GO:0045980)	
0.002221102	
0.031973599	
positive	regulation	of	striated	m
uscle	tissue	developm
ent	(GO:0045844)	
0.002046649	
0.030131728	
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cellular	response	to	organic	cyclic	com
pound	(GO:0071407)	
0.005115282	
0.057754304	
cyclic	purine	nucleotide	m
etabolic	process	(GO:0052652)	
0.001919817	
0.028771434	
negative	regulation	of	cAM
P	biosynthetic	process	(GO:0030818)	
0.001671845	
0.02586715	
nitric	oxide	m
ediated	signal	transduction	(GO:0007263)	
0.000738126	
0.015465269	
regulation	of	synaptic	transm
ission,	glutam
atergic	(GO:0051966)	
0.002283743	
0.032203671	
response	to	alkaloid	(GO:0043279)	
0.003038036	
0.038900826	
cellular	response	to	horm
one	stim
ulus	(GO:0032870)	
0.005493761	
0.060000484	
cyclic	nucleotide	biosynthetic	process	(GO:0009190)	
0.00219464	
0.03188907	
positive	regulation	of	m
uscle	tissue	developm
ent	(GO:1901863)	
0.002283743	
0.032203671	
negative	regulation	of	cyclic	nucleotide	biosynthetic	process	(GO:0030803)	
0.001919817	
0.028771434	
activation	of	protein	kinase	A	activity	(GO:0034199)	
0.000738126	
0.015465269	
rhythm
ic	process	(GO:0048511)	
0.005347711	
0.058789639	
form
ation	of	prim
ary	germ
	layer	(GO:0001704)	
0.002046649	
0.030131728	
negative	regulation	of	secretion	(GO:0051048)	
0.004340393	
0.051427935	
divalent	inorganic	cation	hom
eostasis	(GO:0072507)	
0.005115282	
0.057754304	
regulation	of	canonical	W
nt	signaling	pathw
ay	(GO:0060828)	
0.004340393	
0.051427935	
response	to	cocaine	(GO:0042220)	
0.00219464	
0.03188907	
regulation	of	cardiac	m
uscle	tissue	developm
ent	(GO:0055024)	
0.002541464	
0.034667648	
stem
	cell	proliferation	(GO:0072089)	
0.002541464	
0.034667648	
digestive	tract	m
orphogenesis	(GO:0048546)	
0.00112612	
0.020011651	
cell-m
atrix	adhesion	(GO:0007160)	
0.004354909	
0.051427935	
negative	regulation	of	nucleotide	biosynthetic	process	(GO:0030809)	
0.002498102	
0.034356618	
negative	regulation	of	purine	nucleotide	biosynthetic	process	(GO:1900372)	
0.002498102	
0.034356618	
W
nt	signaling	pathw
ay	(GO:0016055)	
0.005731808	
0.062193834	
neural	crest	cell	developm
ent	(GO:0014032)	
0.00112612	
0.020011651	
regulation	of	cardiac	m
uscle	tissue	grow
th	(GO:0055021)	
0.002498102	
0.034356618	
																								
272	
anion	transm
em
brane	transport	(GO:0098656)	
0.00472011	
0.054963786	
m
uscle	cell	differentiation	(GO:0042692)	
0.004938096	
0.057104216	
single	organism
al	cell-cell	adhesion	(GO:0016337)	
0.005958903	
0.063991171	
sensory	perception	of	pain	(GO:0019233)	
0.003123444	
0.039690302	
positive	regulation	of	angiogenesis	(GO:0045766)	
0.004644407	
0.054271353	
sensory	organ	developm
ent	(GO:0007423)	
0.005268696	
0.058593999	
regulation	of	lipase	activity	(GO:0060191)	
0.005855247	
0.063327621	
regulation	of	glial	cell	differentiation	(GO:0045685)	
0.003123444	
0.039690302	
single	organism
	cell	adhesion	(GO:0098602)	
0.006923424	
0.069068901	
positive	regulation	of	peptide	secretion	(GO:0002793)	
0.003955147	
0.048241249	
regulation	of	heart	m
orphogenesis	(GO:2000826)	
0.001368616	
0.022531595	
cellular	response	to	estradiol	stim
ulus	(GO:0071392)	
0.001368616	
0.022531595	
cell-substrate	adhesion	(GO:0031589)	
0.00591971	
0.063818288	
em
bryonic	digestive	tract	m
orphogenesis	(GO:0048557)	
0.00164753	
0.025849978	
cAM
P	m
etabolic	process	(GO:0046058)	
0.002498102	
0.034356618	
cellular	response	to	fibroblast	grow
th	factor	stim
ulus	(GO:0044344)	
0.007748532	
0.075718114	
sensory	perception	of	sound	(GO:0007605)	
0.006537663	
0.068065011	
reproductive	structure	developm
ent	(GO:0048608)	
0.008556455	
0.081936029	
cell	grow
th	(GO:0016049)	
0.006326206	
0.066276425	
response	to	cAM
P	(GO:0051591)	
0.006677545	
0.068665713	
regulation	of	synapse	assem
bly	(GO:0051963)	
0.005023774	
0.057301888	
response	to	drug	(GO:0042493)	
0.010060453	
0.090870364	
positive	regulation	of	lipase	activity	(GO:0060193)	
0.006677545	
0.068665713	
sensory	perception	of	m
echanical	stim
ulus	(GO:0050954)	
0.007676419	
0.075233405	
renal	system
	process	(GO:0003014)	
0.005435766	
0.059561743	
cell	projection	m
orphogenesis	(GO:0048858)	
0.009712379	
0.088443512	
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m
em
ory	(GO:0007613)	
0.006677545	
0.068665713	
em
bryonic	digit	m
orphogenesis	(GO:0042733)	
0.005022791	
0.057301888	
regulation	of	cell-substrate	adhesion	(GO:0010810)	
0.009216165	
0.084849655	
heart	developm
ent	(GO:0007507)	
0.008868558	
0.083254838	
regulation	of	neurotransm
itter	levels	(GO:0001505)	
0.006677545	
0.068665713	
negative	regulation	of	BM
P	signaling	pathw
ay	(GO:0030514)	
0.004509519	
0.052880045	
m
esenchym
e	developm
ent	(GO:0060485)	
0.005022791	
0.057301888	
ureteric	bud	developm
ent	(GO:0001657)	
0.004509519	
0.052880045	
response	to	purine-containing	com
pound	(GO:0014074)	
0.009911005	
0.090007005	
regulation	of	insulin	secretion	(GO:0050796)	
0.009681595	
0.088404072	
w
ater	transport	(GO:0006833)	
0.005023774	
0.057301888	
m
esenchym
al	cell	developm
ent	(GO:0014031)	
0.00273433	
0.0359769	
horm
one-m
ediated	signaling	pathw
ay	(GO:0009755)	
0.008082202	
0.078519532	
adrenal	gland	developm
ent	(GO:0030325)	
0.00273433	
0.0359769	
regulation	of	sequence-specific	DNA	binding	transcription	factor	activity	(GO:0051090)	
0.011779369	
0.098911187	
regulation	of	cAM
P	m
etabolic	process	(GO:0030814)	
0.009434234	
0.086618713	
regulation	of	organ	grow
th	(GO:0046620)	
0.006798634	
0.069068901	
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Supplem
entary Table 6 G
O
 enrichm
ent analysis – C
ellular category 
   Term
	
P	value	
					Adjusted	P	value	
synapse	part	(GO:0044456)	
1.9776E-09	
6.24921E-07	
integral	com
ponent	of	plasm
a	m
em
brane	(GO:0005887)	
3.36109E-08	
5.31052E-06	
extracellular	m
atrix	(GO:0031012)	
7.55151E-08	
7.95426E-06	
dendrite	(GO:0030425)	
1.09876E-06	
8.57239E-05	
proteinaceous	extracellular	m
atrix	(GO:0005578)	
1.35639E-06	
8.57239E-05	
ion	channel	com
plex	(GO:0034702)	
1.38185E-05	
0.000727772	
postsynaptic	m
em
brane	(GO:0045211)	
2.01469E-05	
0.000909487	
transm
em
brane	transporter	com
plex	(GO:1902495)	
2.42697E-05	
0.000958654	
transporter	com
plex	(GO:1990351)	
3.16854E-05	
0.00111251	
synaptic	m
em
brane	(GO:0097060)	
5.41966E-05	
0.001712611	
axon	part	(GO:0033267)	
8.26454E-05	
0.002374176	
synapse	(GO:0045202)	
0.000125062	
0.00329329	
receptor	com
plex	(GO:0043235)	
0.000209504	
0.00509256	
transcription	factor	com
plex	(GO:0005667)	
0.000430107	
0.009263376	
extracellular	region	(GO:0005576)	
0.001272455	
0.022338662	
axon	(GO:0030424)	
0.000554144	
0.01094434	
ionotropic	glutam
ate	receptor	com
plex	(GO:0008328)	
0.000439717	
0.009263376	
presynaptic	m
em
brane	(GO:0042734)	
0.001143319	
0.021252288	
extracellular	m
atrix	part	(GO:0044420)	
0.001732199	
0.028809205	
neuronal	cell	body	(GO:0043025)	
0.002542347	
0.040169085	
cell	body	(GO:0044297)	
0.002842581	
0.040829795	
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basem
ent	m
em
brane	(GO:0005604)	
0.005881631	
0.071484435	
postsynaptic	density	(GO:0014069)	
0.007459839	
0.084189613	
perikaryon	(GO:0043204)	
0.007427013	
0.084189613	
synaptic	vesicle	(GO:0008021)	
0.010616733	
0.104840238	
chloride	channel	com
plex	(GO:0034707)	
0.008851019	
0.091158777	
axon	term
inus	(GO:0043679)	
0.007806262	
0.085061341	
extracellular	space	(GO:0005615)	
0.015357726	
0.138658327	
interstitial	m
atrix	(GO:0005614)	
0.002767292	
0.040829795	
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